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ABSTRACT 
The risk of autoimmune disorders such as multiple sclerosis (MS) may be influenced by 
environmental factors early in life. This epidemiological thesis provides new knowledge 
on the role of early life environmental factors in MS in particular, for which the specific 
aetiology is unknown. 
Two main potential environmental determinants of MS, ultraviolet radiation (UVR) and 
infections, are explored through an analysis of their timing of action in the life course 
and a consideration of their possible protective effects. Other organ-specific 
autoimmune disorders whose aetiology is also unknown , including type 1 diabetes and 
rheumatoid arthritis (RA), are also assessed for links with UVR for comparison with MS. 
Two existing national Australian datasets provided the outcome data for the analyses. 
The 1995 Australian National Health Survey (NHS) provided summary prevalence 
estimates for ecological (population-level) analysis of four immune disorders other than 
MS. The 1981 Australian MS Survey, used for the largest part of the thesis , provided 
individual-level MS-case data for 1981 throughout Australia, and was further modified 
to construct a longitudinal MS-rates study dataset for analysis of timing of birth. 
Ecological analysis of the 1995 NHS data showed that geographic latitude was 
positively associated , and regional ambient UVR inversely associated , with the 
prevalence of type 1 diabetes in Australia. Ambient UVR exposure may thus be a 
protective factor against such disease at the population level. The association supports 
previous ecological findings for MS in Australia and adds to the evidence that UVR 
exposure might be a modifiable determinant for autoimmune disease generally. 
Longitudinal analysis of the reconstructed 1981 Australian MS Survey dataset showed 
that increased MS risk of around 30% was evident in Australians born in November to 
December (southern hemisphere early summer) compared with those born in May to 
June (early winter) . This MS-risk pattern , indicating environmental factor(s) acting 
around the time of birth , mirrored (seasonally) that seen for MS in the northern 
hemisphere, suggesting globally similar perinatal environmental determinants 
modifying the risk of MS onset. Most importantly, this Australian pattern was found to 
be fully accounted for by individual , regional (state) and seasonal ambient UVR levels 
specific to the prenatal period seven to eight months before birth . Low ambient 
(maternal) UVR exposure in the first trimester of pregnancy thus appears to be 
associated with a higher risk of MS in the offspring. 
lV 
Birth-order analysis of cases in the 1981 MS Survey further showed that early birth 
order was independently associated with MS risk , MS cases being more likely to be 
one of the older siblings in their sibships . Consistent with the hygiene hypothesis, this 
result suggests that a lack of microbial exposure in early childhood may increase MS 
risk later in life. 
Population health implications of these findings are discussed. In particular, safe sun 
exposure and/or vitamin D supplementation during early pregnancy may help prevent 
subsequent onset of high-morbidity, long-duration and presently incurable autoimmune 
disorders such as MS in the offspring. 
V 
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PROLOGUE 
Focus of this thesis 
'The ultimate goal of epidemiologic research is the elaboration of causes that 
can explain patterns of disease occurrence' 
Rothman and Greenland (1998) [1] 
Organ-specific autoimmune disorders, such as multiple sclerosis (MS), type 1 diabetes 
mellitus and rheumatoid arthritis (RA), are a significant public health problem, 
particularly in the Western world, yet their aetiology remains unknown. Some 5 to 20% 
of the world's population are affected [2] and the morbidity burden contributes markedly 
to public health costs because of their often long duration; as yet, however, no cures 
are known. The incidence of autoimmune disorders is increasing worldwide [3], the rate 
over three decades indicating environmental influences rather than genetic change [4]. 
Epidemiological studies have indicated that a multifactorial aetiology of MS and other 
such autoimmune disorders Is likely, several putative, possibly sequential, 
environmental risk factors having been proposed. Further study is required to 
determine the significance of these candidate risk factors, and in particular their timing 
of action in the life course before disease onset. Any one such environmental factor 
may then be amenable to intervention to prevent eventual onset of autoimmune 
disease [1 ]. This thesis focuses largely on MS, with additional consideration of type 1 
diabetes and RA where applicable. 
Autoimmune diseases such as MS have long been observed to be distributed along 
geographic latitude gradients , particularly among Caucasian populations , with the 
prevalence of disease increasing with increase In latitude. These gradients are not 
easily explained by the postulated infectious aetiology for autoimmune disease, 
wherein autoimmunity is thought to be triggered by early life exposure to viral or 
bacterial antigens mimicking 'self' tissues [5]. In 1997, McMichael and Hall 
hypothesised that the latitude gradient may reflect direct suppression of autoimmune 
activity by ultraviolet radiation (UVR) in sunlight, rather than resulting directly from 
infective agents, diet or possibly disease susceptibility genes as previously thought. 
This new hypothesis proposed that, for MS in particular, as latitude was inversely 
proportional to solar UVR, 'the level of UVR exposure influences aspects of immune 
functioning involved in the pathogenesis of MS' and that 'UVR-induced suppression of 
immune function, maximal at low latitudes, attenuates the [infection-related] 
1 
autoimmune process that underlies MS' [5] . To test this hypothesis, McMichael and 
Hall stressed there was a need, first , 'to show that there is an association between 
UVR and MS at the individual level' and, second , to answer the question 'Does UVR 
act early in life?', the latter emphasising the probable importance of timing of this (and 
other such factors) in the aetiology of MS [6]. These questions and this hypothesis are 
the inspiration and basis for this thesis . 
Therefore, the two main, possibly protective, environmental factors explored in this 
thesis are UVR in sunlight, and infections. Both factors are tested at the individual level 
for MS, and UVR is also investigated at the population level for some immune 
disorders other than MS. Moreover, these factors at the individual level are considered 
particularly with regard to their time of action during the life course (prior to disease 
onset), because timing can help identify the nature of determinant factors [7] . The 
timing of infections-for example , whether early or late in childhood/adolescence-can 
also determine whether they are ultimately protective or directly causal [3, 8]. 
The overall aim of this thesis is to explore the distribution (in place and time), and thus 
identify possible environmental determinants, of organ-specific autoimmune disorders 
in Australia, focusing particularly on MS. As specific aims, the following hypotheses will 
be explored: 
1. Prevalence of autoimmune disorders other than MS, such as type 1 diabetes 
and RA, exhibits an inverse UVR gradient within Australia (as already shown for 
MS in Australia in 2001) [9]. 
2. lmmunosuppressive UVR in sunlight acts near the time of birth to protect 
against subsequent MS risk . 
3. Infection or other microbial exposure acts in early childhood to protect against 
subsequent MS risk. 
To test the first hypothesis , an ecological analysis of geographic latitude, regional 
ambient UVR and prevalence of four immune disorders other than MS, including type 1 
diabetes and RA, is conducted at the population level. Such an inverse UVR grad ient 
for autoimmune disorders other than MS was one of McMichael and Hall 's specific 
predictions to test their UVR hypothesis [5] ; this information was unknown at the 
commencement of this thesis , particularly in the southern hemisphere. The broad 
latitude range and resulting wide range of ambient UVR levels over the Australian 
continent are a further advantage for this study (results published as Staples et al. , 
2003, Appendix I). 
2 
For the second specific hypothesis, a timing (month)-of-birth (i .e. seasonal) pattern is 
initially investigated at the individual level, to determine whether an environmental 
factor such as UVR (or infection or diet or other climatic factor) might be influencing MS 
risk at this possibly critical life-course period . A further question of whether such a 
timing-of-birth pattern varies over the latitudinal breadth of Australia is also posed , 
given that the latitude (and UVR) range is ideal for studying this question. Few studies 
on timing of birth of MS had been published in the northern hemisphere prior to the 
commencement of this thesis, and such information was unknown in the southern 
hemisphere. Finally, for this specific hypothesis, a direct regional (birthplace) and 
seasonal UVR exposure factor during prenatal development is independently and 
prospectively explored at the individual level, to contribute specific information on the 
nature of this possible determinant and particularly its prenatal timing, which had not 
been studied previously. This prenatal UVR study is unique, suggesting important new 
information for risk of MS (published as Staples et al., 2010, Appendix II). 
To test the third specific hypothesis for MS, that early childhood infection(s) may 
influence MS risk protectively (also known as the 'hygiene hypothesis' , see Chapter 3), 
an independent analysis using the proxy factor of early birth order is conducted at the 
individual level. Few studies on sibship characteristics of MS cases in the southern 
hemisphere had been published prior to this thesis and the findings from the northern 
hemisphere are inconsistent. 
The research questions for this thesis are: 
1. Are lower UVR (and higher latitude) associated with prevalence of type 1 
diabetes and RA (and other selected immune disorders) in Australia? 
2a. Do MS cases show a timing (month)-of-birth pattern in Australia? 
b. Does this pattern vary by (individual) birthplace region over Australia? 
c. Is (individual) perinatal ambient UVR associated with MS risk? Can perinatal 
ambient UVR explain a timing-of-birth pattern? 
3. Do MS cases show a birth-order pattern at the individual level in Australia? 
Specifically, are MS cases more likely to be one of the older siblings (i .e. early 
born) in their sibships? 
Finally, both major candidate factors for MS (UVR and infections) are considered and 
discussed as part of a possible sequential 'cascade model ' of disease determinants in 
order to identify where (and when) population health interventions to prevent MS might 
possibly be instigated. 
3 
Datasets 
Secondary analyses of existing datasets are a well-established method for addressing 
research questions that are important and difficult to answer directly, particularly for 
rare disease conditions such as MS with a long latency period, for which new 
prospective cohort studies would be both time-consuming and expensive [10, 11 ]. The 
use of good quality, national datasets can mean less wastage of available, already 
well-collected information, and can also reduce the likelihood of bias in primary studies 
due to , for example, recall, non-response and even the effect on the diagnostic process 
of attention caused by the research question [12]. The relatively large size of national 
datasets, and the number of relevant measures, can also ensure population 
representativeness, making statistical inference more straightforward and enabling a 
generalisable answer to a high-impact question [11 ]. 
This thesis makes use of two existing national Australian datasets, one (for the first 
hypothesis) comprising summary estimates of several health conditions of the 
Australian population in 1995, as sampled by the Australian Bureau of Statistics (ABS), 
and the other (for the second and third hypotheses) comprising original individual-level 
data on most MS cases in Australia in 1981, as sampled comprehensively by noted MS 
researcher and neurologist Professor J. McLeod, his team at the University of Sydney, 
Australia, and his Australian colleagues. 
The 1995 National Health Survey (NHS) is part of a comprehensive three to five-yearly 
health survey by the national statistical organisation in Australia , ABS , that is also 
responsible for conducting the five-yearly Census of Population and Housing. Like the 
United States (US) National Health Interview Survey (NHIS), the NHS is conducted by 
personal interview in households using stratified multi-stage probability design and 
targeting the civilian , non-institutionalised population of all ages residing in Australia . 
Good supporting documentation and statistical advice for use of this survey and a high 
response rate achieved by the ABS (see Chapter 4) make this dataset reliable for valid 
secondary analysis of selected disorders. The standardised design and interview 
questionnaire, where obvious errors and biases have been noted and rectified , also 
contributes to validity; for example , partial-response bias has been accounted for in the 
1995 NHS by drawing on previous analysis experience [13]. 
The 1981 MS Survey, kindly made available for this thesis by Professor McLeod , is 
used for the largest part of this thesis (see Chapters 5 to 8). This population-based 
cross-sectional survey Is based on comprehensive and state-standardised 
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ascertainment of MS cases in Australia on 30 June 1981, the date chosen to coincide 
with an ABS national Census of Population and Housing. MS cases were ascertained 
widely from a number of national and state sources, and potential cases then generally 
individually interviewed by the study neurologists, diagnosed, and these diagnoses 
independently validated. The well-coordinated nature of this unique survey contributes 
to overall validity and usefulness of this dataset. Several internationally recognised 
peer-reviewed publications on the epidemiology of MS in Australia, based solely on this 
dataset, resulted between 1987 and 2011 (see Chapter 5, Table 5.1 ), making this 
dataset a valuable resource for the purposes of this thesis. Access to original clinical 
files of the cases further aided this candidate's familiarity with the primary interviews 
conducted and subsequent treatment of data. 
However, challenges in using this 'prevalence' dataset for timing-of-birth analysis 
included necessary derivation of suitable denominators and adjustment of these to 
account for original sampling limitations. This existing Australian survey of MS cases 
was then utilised essentially as a longitudinal dataset suitable for such analysis, 
enabling a complete comparison of timing of birth between MS cases and a relevant 
reference population in a 1920 to 1950 Australia-born 'cohort', rather than simply a 
disease prevalence study. 
Thus, there are issues to be noted that are inherent in using existing datasets: for 
example , for secondary analysis to be appropriate , the dataset must be adequate to 
answer the particular research question(s). While the secondary analyst does not have 
control over design and sample size, the sample should both reflect the population of 
interest and be large enough to detect a clinically meaningful effect [1 OJ . Familiarity 
with the dataset and access to information related to the purpose, content, population 
representation , and previously conducted studies relating to the existing data, provide 
the information required to assess the quality and hence the reliability and validity of 
the data [14]. Checks for the extent of missing observations , accuracy of coding and 
appropriateness of measures available to answer the research questions are also 
needed [10, 12], as is confirmation of data integrity after transference or other 
mathematical manipulation by the secondary analyst. These issues, where applicable , 
are discussed in the relevant chapters of this thesis , together with strategies used to 
overcome inevitable data limitations. Identification of these limitations here should also 
inform future studies. A range of different methodological and statistical approaches is 
applied in the analyses of these two datasets for testing the above hypotheses in this 
thesis . 
5 
Chapter structure 
Chapter 1 presents an overview of autoimmune disease, including mechanisms 
involved in the maintenance and breakdown of immunological self-tolerance leading to 
such disease. The clinical features and immuno-pathogenesis of MS are described . 
Chapters 2 and 3 review the epidemiological evidence for autoimmune disease 
determinants, particularly environmental factors , and mechanisms for their action , 
focusing mainly on MS. Chapter 2 considers evidence for sunlight as UVR and/or 
vitamin D and its possible early life timing of action . Chapter 3 reviews evidence for 
infections and other possible environmental determinants, and then considers the 
overall life-course timing of these determinants together. 
Chapter 4 focuses on the ecological analysis of the 1995 NHS and reports findings on 
associations between latitude, regional ambient UVR and prevalence of four immune 
disorders, including type 1 diabetes and RA. 
Chapters 5, 6 and 7 cover analysis of prenatal UVR and timing-of-birth risk patterns of 
MS in Australia , including specific methodology for this purpose. Chapter 5 focuses on 
the 1981 MS Survey data, to be used as numerators for subsequent analysis , and 
reports on cleaning , verification and comparison of these data with those of prior 
publications. 
Chapter 6 describes derivation of reference-population denominators from the 1981 
census and supplementary births-registration sources for construction of the required 
dataset, together with necessary final adjustment of these denominators. Preliminary 
prevalence relationships are reported as a validity check of the constructed longitudinal 
dataset to be used for subsequent timing-of-birth analysis . 
Chapter 7 presents and discusses results of the main statistical analys is of timing of 
birth of MS cases in Australia. Prenatal UVR as a prospective regional and seasonal 
exposure factor is also considered as an independent determinant fo r MS, and the 
findings discussed in relation to the timing-of-birth pattern . 
Chapter 8 focuses on the original unit-record 1981 MS Survey dataset and analyses 
the association between birth order of MS cases and MS risk in Austral ia. Specific 
methodology for this purpose is included. 
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The final chapter, Chapter 9, summarises the key findings of this thes is and discusses 
their implications for future research directions and population health policy. 
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CHAPTER 1 
PATHOGENESIS OF MS AND OTHER ORGAN-SPECIFIC AUTOIMMUNE 
DISORDERS: IMMUNE MECHANISMS 
'The organism possesses certain contrivances by means of which the immunity 
reaction ... is prevented from acting against the organism's own elements and so 
giving rise to auto toxins ... so that one might be justified in speaking of a 'horror 
autotoxicus' of the organism' 
Dr Paul Ehrlich, Nobel Laureate, the 'father' and founder of modern immunology, 1897 
[15] 
1.1 Introduction-autoimmunity and disease 
When Paul Ehrlich, a leading German medical scientist working on disease toxins 
(such as diphtheria), antitoxins and immunity at the turn of the last century, published 
his 'Side-chain Theory of Antibody Formation' in 1897 and 'On Immunity with Special 
Reference to Cell Life' [16, 17], he helped establish the science of immunology and 
introduced a radically new way of thinking about the immune system. His original 
concept was that the immune system was able to recognise foreign antigens , for 
example, from pathogens, before they were actually encountered in the body. This was 
achieved by having a 'repertoire ' of pre-existing cell-surface receptors , ready to 
specifically bind any foreign antigen. On encountering the antigen , these cells 
(lymphocytes) would then be stimulated to produce more specific receptors and 
secrete them into the extracellular fluid as antibodies . Today, Ehrlich 's idea is a 
principal feature of the lymphocyte clonal-selection theory that is the basis of modern 
immunology; this was further developed by Niels Jerne [18] , MacFarlane Burnet [19] 
and other immunologists some 60 years later [20] . In addition to identifying 
lymphocytes, the white-blood-cell mediators of immunity, Ehrlich 's experiments on 
specific receptors and antibodies led him to conclude that immunity was exclusively 
directed to foreign materials or antigens, and that normally there was no reactivity 
towards 'self'. That is, the body tolerated 'self' and scrupulously avoided an immune 
attack on itself (that is, 'horror autotoxicus' or avoidance of autoimmunity) . 
In fact, we now know that some level of self-reactivity does occur and , indeed , is crucial 
for the immune system to function optimally [2, 21-23]. Response to self-antigens is 
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required in the system to ensure that pathogenic microbes that have invaded host cells 
intracellularly, or have been 'internalised ' by the host's phagocytic cells (macrophages) 
during a non-specific, innate inflammatory response , are also recognised as foreign 
and killed. This is part of the less rapid but antigen-specific adaptive immune system of 
higher animals [24], summarised in Figure 1.1 and the accompanying legend , and 
further discussed in Section 1.3.2. 
Therefore, the notion of a controlled response to self-antigens and no over-abiding or 
persistent pathological self-reactivity is still current. Thus, we should here differentiate 
between the terms 'autoimmunity' or 'autoimmune responses ', both of which define a 
necessary physiologic level of self-reactivity, and the term 'autoimmune disease', which 
defines a pathological state [2, 23]. 
Autoimmune disease may be said to result when healthy self-tolerance fails and the 
immune system acts inappropriately [25, 26], or persistently [23 , 27] or, in certain 
micro-environments, such as in the presence of inflammatory cytokines [2] , attacks 
self-tissues. 
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Figure 1.1: Development and role of T and B lymphocytes in antigen-specific (adaptive) immunity; for example, to microbial infection. 
Both T (thymus) and B (bone marrow) lymphocyte cells originate in bone marrow, but T cells migrate to thymus at early stage as 
thymocytes. Both cell types undergo random rearrangement of DNA segments, forming a 'repertoire' of antigen-specific receptors on 
the cell surface that is sufficient for all pathogens likely to be encountered in life. Na"ive B cells encounter microbial antigen in 
secondary lymphoid organs (SLO, e.g. lymph nodes, spleen) and are activated to become plasma cells secreting 
neutralising/opsonising antibodies, either assisted by, or independently of, T-helper (Th) cells. Na"ive T cells encounter antigen-
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presenting cells (e.g. dendritic cells) in SLO; antigen is presented as microbial peptide complexed with self-MHC (major 
histocompatibility complex) molecule, either class I (leading to *COB+ [cytotoxic] T cells recognising endogenous antigen, e.g. viral) 
or class II (*CD4+ [helper] T cells recognising exogenous bacteria); co-stimulation, for example, via cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4) (on DCs), is also necessary. Antigen-activated T cells proliferate (clonal expansion) and differentiate 
into effector T-helper cell subsets, producing soluble cytokines that effect both the eradication of pathogen and (downstream) 
control of tissue damage; most effectors migrate to the site of inflammation but a few remain in SLO as memory T cells for future 
responses. (Figure from Parkin and Cohen, 2001 [24].) (*CD cell-surface markers defined in footnote 2, Section 1.2.1) 
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Three such organ-specific autoimmune diseases are MS, type 1 (insulin-dependent) 
diabetes mellitis (also known as juvenile diabetes or insulin-dependent diabetes mellitis 
[IDDM]) and RA. The autoimmune targets for these three different disorders are 
thought to be, respectively, the myelin-producing cells in the central nervous system 
(MS), the insulin-producing islet beta-cells in the pancreas (type 1 diabetes) and the 
collagen-producing cells in the synovia of bone joints (RA) [25]. Some 5 to 20% of the 
world's population is affected by these or other known autoimmune conditions, 
particularly in Western countries [2]; at least 0.1 % of children and adolescents ( <20 
years) are affected by type 1 diabetes [26, 28]. While 60 to 75% of patients are female 
in MS and RA, a relatively equal risk between males and females is seen in childhood 
onset type 1 diabetes. There are also notable differences in the age distribution among 
autoimmune diseases; for example, the mean or median age of onset for type 1 
diabetes, MS and RA is, respectively, 10, 32 and 58 years [28, 301 ]. 
Autoimmune diseases are among the leading causes of death among young and 
middle-aged women (aged <65 years) in the US [29]; almost all autoimmune diseases 
(except type 1 diabetes) disproportionately affect women [28]. Given that such 
diseases are typically of long duration, they also constitute a significant morbidity 
burden [22], and contribute markedly to the costs of public health. For example, type 1 
diabetes has been estimated to have average lifetime medical support costs of 
approximately $1.3 million in the US per person [30]. Yet, despite much intensive 
research , the aetiology of these diseases remains unknown , their pathogenesis 
obscure and cures presently unattainable; therapy must therefore be directed at 
modifying the autoimmune response , since the self-antigens themselves cannot be 
eliminated from the body. 
Autoimmune disease is usually manifested as chronic inflammation , in the absence of 
ongoing infection or any other discernible cause. The self-targeted autoimmune 
response is thought to be mediated largely by self-reactive T-cell lymphocytes (i.e . eel/-
mediated immune response) , although auto-antibodies produced by B cells are also 
often involved [2 , 27, 31] . The Th1 subtype of T-helper cells 1 was for many years 
considered to be the self-reactive T cell most important in mediation of autoimmune 
disease, by virtue of its secreted pro-inflammatory cytokines , including interleukin 2 (IL-
2), interferon-y (IFN-y) and tumour necrosis factor-a (TNF-a). Polarisation of immune 
1 T-helper cells are effector T cells of the adaptive immune system , ass isting cytotoxic T ce lls to perform 
their cell-to-cell function by secretion of immunoregulatory cytokines (chemica l mediato rs) [24] . 
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responses towards the production of Th 1 cytokines, relative to other T-cell types, was 
thought to be the essential basis of the autoimmune reaction in MS, type 1 diabetes 
and RA [25, 26]. However, the 'immune deviation' paradigm of just a decade ago, 
based on a simple balance between Th 1 and Th2 cytokines (the latter secreting anti-
inflammatory IL-4, IL-5 and IL-13) [25], has since been superseded by T-cell mediation 
theories of increasing complexity. For example, pro-inflammatory I L-17-producing T 
cells have been recently credited with causing and sustaining tissue damage in organ-
specific autoimmune disorders in the brain, synovium, intestine and other tissues, and 
now appear to play a major role in immune-mediated tissue injury as well as Th1 cells 
[31-35]. 
In addition, the identification of distinct lineages of immunosuppressive 'regulatory T 
cells' with wide effects on many immune cells has shifted the emphasis from specific 
effector T-cell types to less specific, but crucial, regulatory mechanisms to control 
responses to pathogens and to prevent autoimmune disease. That is, a resurgence of 
interest in a special subgroup of T cells with 'suppressor' properties has occurred in the 
last 15 years, and these re-named 'regulatory T cells' have now been found to be of 
critical importance in limiting inflammation and maintaining a state of dominant self-
tolerance in the immunological system [36-39]. 
Thus, a dynamic homeostatic balance between regulatory and self-reactive T cells is 
now considered to be the dominant factor in the avoidance of autoimmune disease; 
these regulatory T cells will be explored further in Section 1.3.1. Therefore , 
autoimmune disease can be described as a breakdown in homeostatic self-tolerance 
mechanisms that can occur in a number of different ways [21 , 40 , 41]. Thus , the T-cell-
mediated inflammatory response , if over-expressed or insufficiently regulated , may 
contribute to autoimmune disease because of a breakdown in tolerance of self-
antigens. 
In this chapter, the immunological mechanisms for maintaining self-tolerance, and the 
general conditions possibly leading to the breakdown of this tolerance , will be reviewed 
by focusing on recent human studies as much as possible , supplemented by studies in 
various organ-specific disease models in mammals (mainly mice, for example , 
experimental allergic/autoimmune encephalomyelitis [EAE, 'mouse MS']) , in which 
much experimental work has necessarily been conducted . The history, clinical features 
and immuno-pathogenesis of MS as a particular example of human organ-specific 
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autoimmune disease will then be discussed in the final section (see Section 1.5, 
together with a brief introduction to EAE in Section 1.5.4 ). 
1.2 Immunological self and tolerance 
'An extraordinarily precise mechanism of self-recognition holds us back from the 
brink of autoimmune disease' 
Sir Gustav Nossal [22] 
Immunological (self-)tolerance may be defined as a functional state in which there is 
either no apparent immune response to self-antigens found naturally in the body, or in 
which an anti-self immune response exists but does not lead to tissue damage [27]. 
The maintenance of immunological tolerance to self-antigens in the body, while still 
retaining the ability to respond rapidly and effectively to invading non-self potential 
pathogens, is the crux of the immune system's functional homeostasis. Mechanisms 
that allow the immune system to mount a protective response towards pathogen-
derived foreign antigens, while avoiding a pathological response to self-antigens at the 
same time, have evolved in a necessarily complex manner. 
Immunological tolerance, the system by which the body does not normally over-
respond to self-antigens, can be thought of as being generated at two levels , 'central ' 
tolerance, developing primarily in foetal and neonatal life , and 'peripheral ' tolerance, 
developing postnatally for the control of self-reactivity outside the thymus [26 , 27] . 
1.2.1 Central T-cell tolerance 
The central lymphoid organs where early life lymphopoiesis takes place comprise the 
thymus and bone marrow [26]. Although both T (thymus) cells and B (bone marrow, 
antibody-producing) cells (Figure 1.1) are involved in most immunity processes (and 
the terms 'central' and 'peripheral ' apply equally to both kinds of lymphocytes) , T cells 
appear to play a dominant role in immune tolerance and autoimmunity [2 1, 42] . 
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The chief mechanism of T-cell self-tolerance is the initial selection , sorting and then 
deletion by apoptosis (programmed cell death) of most of the self-reactive T cells in the 
thymus. In the thymus, immature T cells (thymocytes) encounter circulating peptides 
derived from endogenous (self) proteins that are presented to them bound to major 
histocompatibility complex (MHC, self) molecules. Depending on the binding affinity 
between the T-cell antigen receptors (TCRs) and the peptides, only a few of these (self) 
T-cell complexes eventually survive the process of 'negative selection ' or 'clonal 
deletion ', and are then able to migrate to the body's peripheral systems where foreign 
antigens may be encountered . The exiting na"fve (i.e. having not yet encountered their 
specific foreign antigen) T cells , either T-helpers (bearing the CD4+ cell surface 
marker)2 or cytotoxic T cells (CDS+ marker) , are self-tolerant but able to recognise 
foreign antigen when presented to them with self-MHC in the periphery [24] (see Figure 
1.1 ). Self-recognising regulatory T cells (mostly CD4+) are now known to also be 
produced in the thymus and emerge at this early stage [43, 44] (to be discussed in 
detail in Section 1.3.1 ). Thus, more than 98% of the self-reacting cell complexes are 
deleted , or purged , centrally from the immune system in the thymus [20 , 45] , as was 
postulated originally by immunologists such as MacFarlane Burnet in 1957 [19]. 
That is, the centrally located selection mechanisms are not completely effective in 
removing self-reactive cell complexes , nor are they meant to be (in contrast to earlier 
thinking). Some, indeed many, auto-reactive cells are necessarily part of the peripheral 
T-cell repertoire of healthy individuals-the survival of na"fve T and B cells in the 
periphery requires continuous exposure to auto-antigens [2 , 22] . For example , both T 
and B cells recognising insulin or myelin basic protein (MBP) can be isolated from 
persons without type 1 diabetes or MS [21 , 42 , 46] . Therefore , rather than central 
tolerance being thought of as a 'leaky' process [26] with these escapee lymphocytes 
requ iring constant surveillance and elimination , the ongoing presence in the peri phery 
of, for example , myelin-reactive T cells in unaffected persons , is now known to be an 
essential feature of the immunological tolerance system. However, mechan isms to 
maintain th is state of self-tolerance in the periphery are then requ ired . 
2 Many of the funct ional ly important ce ll surface molecu les and their receptors are descri bed by the cluster 
of differentiation (CD) nomenclature, based on the ir identifi ca tion by characteri sed monoclonal antibod ies 
[26] . 
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1.2.2 Peripheral T-cell tolerance 
A number of different peripheral tolerance mechanisms contributing to the prevention of 
immune pathology have been known for some years , including passive mechanisms 
such as immunologic ignorance (T-cell unresponsiveness) and sequestration of 
antigens (for example , isolating self-antigens behind cellular or vascular barriers) , and 
active mechanisms such as antigen-induced T-cell apoptosis and T-cell anergy 
(induced unresponsiveness) [47]. Further, antigen-presenting cells , and particularly 
dendritic cells, have increasingly been recognised as crucial to the overall process of 
achieving peripheral self-tolerance. 
Tolerogenic dendritic cells 
Dendritic cells (DCs) can be described as 'professional' specialised antigen-presenting 
cells (APCs) in that they have a unique ability to first-activate nai"ve T cells , as opposed 
to 'non-professional' APCs (e.g. B cells, monocytes, macrophages and endothelial cells) 
capable of stimulating mainly memory (i.e. antigen-experienced) T cells [48]. That is, 
DCs are particularly specialised for acquiring, processing and presenting both self- and 
non-self-antigens to na·fve T cells so that effector T-cell responses to invading 
pathogens or tissue damage in peripheral tissues can be instigated (see Figure 1.1 ). 
Thus, they have been termed 'the sentinels of the immune system ' because they are 
strategically located at all pathogen entry sites of the body. There , DCs respond to 
environmental 'danger' signals , including pro-inflammatory cytokines IL-1 , TNF-a and 
IL-6, prostaglandins and pathogen products such as lipopolysaccharide (LPS) , and , 
once activated , migrate from peripheral tissues into SLO (such as lymph nodes) where 
they mature and most effectively induce and regulate effector T-cell responses to 
infection [49-51 ]. Their up-regulated expression of co-stimulatory molecules, and 
production of soluble pro-inflammatory cytokines such as IL-1 , TNF-a and IL-12 , then 
promotes the differentiation of the responder ( effector) T cells and ampl ifies the effector 
T-cell response [47] . 
However, DC function has more recently been found to vary with their state of 
differentiation-that Is , whether immature or mature [27] . It is now evident that 
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immature myeloid 3 DCs have a very different and pivotal role in the induction and 
maintenance of peripheral tolerance by being able to differentiate into either 
immunogenic DCs, as described , or into 'tolerogenic' DCs, which can induce T-cell 
tolerance and thus modulate immune responses [50 , 52] . Tolerogenic DCs induce T-
cell tolerance by a variety of mechanisms, ranging from production of anti-inflammatory 
cytokines with broad attenuating effects, to the induction of antigen-specific T-cell 
responses resulting , on the one hand , in anergy or deletion of effector T cells or, 
alternatively, stimulation of suppressive regulatory T cells [50] (Figure 1.2). 
Suppressive cytok,nes 
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Figure 1.2: Functional plasticity of immature/resting DCs. Highly sensitive to 
stimulatory and suppressive agents, immature myeloid DCs are accessible to 
activating and inhibitory factors that favour their immunogenic or tolerogenic 
function, respectively. lmmunosuppressive agents, such as IL-10 or TGF-J3 , 
irreversibly convert immature DCs into tolerogenic DCs with locked 
immunosuppressive function. Tolerogenicity can also be induced in immature 
DCs by activated regulatory T cells or immunosuppressive drugs. In contrast, 
pro-inflammatory cytokines (i.e. IL-1, IL-6, TNF-a), microbial products (toll-like 
receptor [TLR] ligands) and the crosstalk with activated effector T cells induce 
the terminal differentiation of immature DCs into immunogenic DCs, 
insusceptible to cellular or soluble tolerating signals. (Figure from Steinbrink et 
al., 2009 [50].) 
3 DCs are classified into two cel l types: myeloid DCs are the most well characterised and are found 
throughout the body as interstitial ce lls or as Langerhans cells (LCs) in the skin ; they can become either 
immunogenic (producing IL-12 and efficiently priming na"fve T ce lls) or tolerogenic. Plasmacytoid DCs are 
less well characterised , are found in the bone marrow and secrete IFN-~ in response to viruses and other 
pathogens; they may be cons idered naturally occurri ng tolerogen ic DCs [31, 52, 53]. 
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This modulation by tolerogenic DCs occurs primarily constitutively (that is , in the 
normal , steady, non-inflammatory state when self-antigens are the main antigens being 
presented in the tissues) , but can also occur at the end of an inflammatory process 
caused by pathogens, in order to control established immune responses and prevent 
chronic autoimmune disease [27 , 49]. That is , in the absence of inflammation and 
disease, tolerogenic DCs constantly present innocuous self- and non-self-antigens in a 
way that promotes self-tolerance, and this occurs, in large part, by control of regulatory 
T cells [49, 54]. 
In turn, regulatory T cells (considered next section) are able to affect DC development, 
preventing differentiation into immunogenic DCs and even inducing production of 
immunosuppressive cytokines such as IL-10 by (tolerogenic) DCs. Thus , there is a 
mutual interaction between DCs and regulatory T cells for maintaining immune 
homeostasis: tolerogenic DCs induce and enhance regulatory T cells and, inversely, 
regulatory T cells assist DCs to become immunosuppressive, in a vital two-way 
relationship [54]. DCs are instrumental in maintaining a balance between the activities 
of effector T cells and regulatory T cells in the immune system. 
In humans, the incidence of the autoimmune disease systemic lupus erythematosus 
(SLE) is correlated with a chronically activated DC phenotype [54]. DCs with an altered 
phenotype, as well as dysfunctional interactions between DCs and regulatory T cells , 
have been described also in animal models of autoimmune disease (for example, 
'mouse MS' [EAE]) and in MS patients (reviewed by Zozulya and Wiendl , 2008 [55]). 
Conversely, towards tolerance , in vitro generated immature (self) antigen-pulsed DCs 
have been shown to induce antigen-specific T-cell tolerance in vivo in human 
volunteers , by induction of antigen-specific regulatory T cells [50]. More evidence of 
modulation by DCs has come from autoimmune disease therapy. For example , IFN-~ 
treatment in MS up-regulates a tolerogenic molecule on DCs related to apoptosis 
(programmed cell death) [56] , and reputedly also has a role in inducing regulatory T 
cells via interactions between them and DCs [55] . Further drug treatments shown to 
promote induction of tolerogenic DCs include the glucocorticosteroids (discussed with 
respect to MS therapy in Section 1.5.5) ; these impair DC maturation and inhibit co-
stimulatory expression and pro-inflammatory IL-12 production by DCs, leading to 
decreased allo- (non-self) stimulatory capacity. Indeed , many anti-inflammatory and 
immunosuppressive drugs appear to act via induction of such DCs with tolerogen ic 
properties (reviewed by Adorini and Penna, 2009 [52]). 
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Thus, self-tolerance comprises central tolerance mechanisms, wherein immature 
lymphocytes recognising self-antigens in bone marrow or thymus are removed by 
apoptosis, and peripheral (or adaptive) tolerance 1 where mature lymphocytes 
encounter self-antigens in peripheral tissues and are killed, shut down or otherwise 
controlled (57]. Peripheral tolerance mechanisms include anergy or deletion (apoptotic 
cell death) of effector T cells , modulation by tolerogenic DCs and, most essentially, 
suppression by regulatory T cells, discussed next. 
1.3 Maintenance of tolerance 
1.3.1 Regulatory T cells 
There has been increasing recognition of specific T-cell populations with 
suppressive/regulatory properties that are dedicated to the maintenance of tolerance in 
both humans and experimental animals (36-38, 42 , 48, 58-60]. T-cell populations that 
are able to inhibit the response of other (effector) T cells, and thus suppress the 
autoimmune response, were described in humans and other mammals several 
decades ago and have been 'revived' in importance only relatively recently. These 
regulatory T cells playing a key role in the control of both reactivity to self-antigens and 
to non-self (such as in graft transplantation) have, appropriately, been receiving much 
recent attention because they offer hope as use for possible future therapies for 
autoimmune disorders (61-65] . 
'Suppressor T cells ' were initially defined in the 1970s when Gershon and Kondo 
described a population of T cells that suppressed the immune response of mice to 
foreign antigens (66], but the concept was not developed further during the next two 
decades. It was later found that a variety of autoimmune diseases developed in mice 
whose thymus was removed soon after birth , clearly indicating the presence of thym ic 
cells that were capable of suppressing autoimmunity. The subsequent discovery of a 
subpopulation of T cells that could critically control auto-reactive T cells of mice in vivo 
revived the original concept of regulatory cells that were suppressive in action (58]. 
These now-termed 'regulatory T cells ' were found to have potent inhibitory effects on 
immune responses to foreign antigens and on the development of autoimmune disease. 
That is, autoimmune disease in multiple organs could be spontaneously produced in 
normal rodents by removal of these regulatory T cells , but not by general reduction of 
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T-helper cells. Organ-specific autoimmune disease induction was dependent on the 
genetic strain , suggesting an autoimmune mechanism that may be common to each 
disease but is target-modified by genetics [67]. Moreover, in 'adoptive transfer' 
experiments ( discussed further in Section 1.5.4) in mice (reviewed by Sakaguchi et al. , 
2006 [68] and Roncarolo and Battaglia , 2007 [64]) , these regulatory T cells could block 
the development of autoimmune disease even in thymectomised mice [20]. 
Further studies identifying the presence of regulatory T cells in human peripheral blood , 
and their ability to suppress T-cell proliferation in vitro, followed [69-71 ]. Both 
endogenous 'natural ' regulatory T cells (nTreg), produced and fully differentiated in the 
thymus, and 'induced ' regulatory T cells , obtained by administration of exogenous 
antigen in the periphery, have now been identified , most being of the original CD4+ T-
helper type [37] (Figure 1.3). It has been suggested that the thymic-derived regulatory 
T cells , such as natural nTreg (considered next), have a central homeostatic function to 
regulate T-cell proliferation in lymphoid organs , while peripheral antigen-induced 
regulatory T cells , such as Tr1 (considered in the following subsection) have anti-
inflammatory capacity and infiltrate injured tissues to control inflammation and tissue 
destruction locally [72] 
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Figure 1.3: Differentiation of CD4+ T cells into regulatory or effector T cells. 
Cytokines and transcription factors (such as Foxp3) that promote the 
differentiation of na'i've T cells into regulatory (induced iTreg), or effector T cells 
(Th1, Th2, Th17) for specific conditions, are shown. (Figure adapted from 
Sakaguchi et al., 2008 [37].) 
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Naturally occurring thymic regulatory T cells 
nTreg (Foxp3+ CD4+ CD25+) 
Natural regulatory CD4+ T cells (nTreg)4 co-expressing the CD25 alpha chain of the IL-
2 receptor (identified in mice by Sakaguchi and colleagues in 1995 and in humans in 
2001 by several groups) and additionally expressing the Foxp3 transcription factor 
(Forkhead Box P3 protein, identified in regulatory T cells in 2003, see Figure 1.3) have 
now been demonstrated in the peripheral blood of human subjects by many workers 
[37]. These cells can suppress the activation, proliferation and effector functions-such 
as cytokine production-of a wide range of immune cells, including T cells, B cells and 
APCs, including DCs. This unique ability to control immune responses makes nTreg 
central in the prevention of autoimmune disease, immunopathology and allergy, as well 
as in the maintenance of allograft tolerance and foetal-maternal tolerance during 
pregnancy [74]. nTreg were found to be occurring naturally in uninfected healthy 
individuals and to have differentiated and matured fully in the thymus, making up 2 to 
10% of the total CD4+ cells detectable in the thymus and SLO. In humans, thymic T-
cell development, including nTreg cells, takes place in utero; fully functional nTreg are 
detectable relatively early in foetal development and form ~ 7% of mature CD4+ 
thymocytes by the fourteenth week [74] . 
nTreg cells appear to have a unique ability to suppress neighbouring T cells in an 
antigen-specific and cell contact-dependent way, inhibiting proliferation and IL-2 
production by either CD4+ or CDS+ T cells in vitro [48 , 59 , 64 , 72 , 75] . Contact-
dependent suppression may act via direct cytolytic effects on target cells (leading to 
apoptosis) or by 'metabolic disruption ' (i.e. inducing release of adenosine nucleosides 
in or from target) [76]. As discussed in the previous section , nTreg may also inhibit by 
repressing maturation and/or function of DCs and , therefore , the priming of effector T 
cells (see Figure 1.1) [39, 54] . 
nTreg may also inhibit via production of soluble anti-inflammatory factors , such as 
TGF-f3 (transforming growth factor-f3) and IL-10 (these generally inhibitory cytokines 
discussed in more detail later in this section) . For example , IL-10 produced by nTreg is 
4 Given the currently accepted importance of naturally-occurring thymic regu latory T cells in 
immunomodulation , some publications in the literature refer to these regulatory T cells simply as 'Treg '; 
however, to avoid confus ion and to be consistent with major publicat ions , the term 'nTreg ' will be used 
here. The term 'iTreg ' will then be reserved for antigen-induced Foxp3+ regulatory T ce lls [37 , 73 , 74] (as 
Figure 1.3), and not include other inducible regulatory T cel ls such as Tr1 and Th3 , which are more often , 
but not always, classified as Foxp3-. 
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known to be essential for immune regulation at mucosal surfaces such as the intestines, 
lungs and skin [73]; TGF-~ is required for maintenance of Foxp3+ expression [77]. That 
is, there appear to be a multitude of potential mechanisms constituting the nTreg 
arsenal-some may be involved in key regulatory functions, such as homeostasis and 
'homing ' (to particular tissues in vivo), and others in, for example , suppression in 
different tissues (e.g. mucosal versus lymphoid tissue) or in different diseases (e.g. 
autoimmune versus inflammatory). However, many of the exact mechanisms by which 
nTreg cells exert suppression in vitro and in vivo still remain to be determined [7 4]. 
Overall, nTreg are vital to the prevention of autoimmune disorders in both humans and 
experimental animals. The importance of T-cell regulation in human disease is 
highlighted by the severe inflammation and autoimmune disorders in people with IPEX 
(immunodysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome, who 
completely lack nTreg cells as a result of a mutation in the Foxp3 gene. These 
individuals develop a broad range of auto-antibodies, insulin-dependent diabetes, 
thyroiditis, eczema, haemolytic anaemia and irritable bowel disease and, in the 
absence of a bone marrow transplant, die at an early age [78]. 
In MS, also, Viglietta and co-workers found that the functional activity of these unique 
nTreg cells correlated inversely with MS disease activity; importantly, these data 
demonstrated alterations in function , rather than numbers, of these T cells from 
patients with the most common form of MS, relapsing-remitting MS (RRMS) [79]. More 
recently, the same research group confirmed that natural nTreg , and not induced iTreg , 
were functionally less suppressive in patients with MS [80] . Several groups have now 
shown that nTreg are functionally impaired or have deficits in their maturation or in their 
thymic emigration in patients with MS [81-83], while Venken and colleagues 
demonstrated impaired nTreg function together with decreased Foxp3 expression in 
RRMS [84]. Huan and colleagues also showed lower levels of Foxp3 messenger 
ribonucleic acid (RNA) and protein expression in MS patients than in healthy people 
[85]. Another study by Venken and co-workers confirmed altered generation of nTreg 
cells, pointing to disturbed thymic development and function in MS patients [86] . 
However, whether such nTreg cell dysfunction has a causal role in MS, or whether this 
cell dysfunction represents a more general defect within the immunoregulatory system 
that can be associated with any autoimmune disorder, is yet to be determined [87]. 
Cvetanovich and Hafler further caution that many earlier studies have used less 
defined human regulatory T-cell populations (and therefore impure or heterogeneous 
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populations, in terms of CD and Foxp3 expression, that might obscure results). 
Nevertheless, they conclude that nTreg show multiple differences in RRMS patients, 
compared with healthy controls, that are likely to play roles in the complex 
pathogenesis of RRMS, including reduced thymic output and various nTreg cell 
impairments [88]. 
Defective suppressor function has also been found in vitro in these regulatory T cells 
from patients with type 1 diabetes [89]. A recent study showed that the same regulatory 
T cells from patients with type 1 diabetes had a reduced capacity to respond to IL-2, 
this defect in IL-2-induced signalling being correlated with a loss of Foxp3 expression 
[90] . Other recent studies on type 1 diabetes patients' regulatory T cells also showed 
ineffective suppression [91, 92]. Indeed, such dysfunction in autoimmune disorders 
such as type 1 diabetes may be due, in part, to resistance of effector T cells in these 
type 1 diabetic patients to nTreg suppression [78, 92]. 
Data demonstrating that Foxp3+ regulatory T cells are functionally compromised in RA 
patients have also been published [93], the impaired function linked to reduced 
expression of CTLA-4 [94]. These data further indicated that this suppressive function 
could be restored by anti-TNF-a, which, rather than reversing the CTLA-4 defect, 
induced a novel regulatory T-cell population with potent suppressive properties [94] 
and has been of some therapeutic value in RA [95]. In RA, further, IL-17-producing T-
helper cells were resistant to suppression by these regulatory T cells, making this 
inflammatory condition complex to treat [94]. 
Interestingly, recent studies (reviewed by Bettini and Vignali, 2009 [96] and Campbell 
and Koch, 2011 [73]) have shown that different, specialised subsets of nTreg cells are 
able to restrain the different types of CD4+ effector T-cell responses (i.e. by Th1 , Th2 , 
or Th 17 T cells) by using the corresponding nuclear transcription factors 5 that are 
required for initial differentiation of these effector T cells. That is , nTreg utilise different 
transcriptional 'programmes' depending on the T-helper subset they are attempting to 
suppress, in order to maintain or restore immune homeostasis. For example , 'T-bet' , 
which is the master transcription factor controlling the differentiation , migration and 
function of IFNy-producing Th1 cells (see Figure 1.3), is also expressed by a subset of 
nTreg cells and is now found to be required for nTreg cell homeostasis and function 
5 The functional specialisation of the various CD4+ T-cell subsets is due to the differential expression of 
'master' transcription factors in the cell nucleus, which are activated by signals transduced from the bound 
antigen on the cell surface to the nucleus and which then turn on distinct programmes of gene expression 
that control T-cell proliferation , function and migration [24 , 73] . 
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during Th1-type pro-inflammatory responses [97]. Possibly T-helper cells and nTreg 
cells have co-evolved in tandem [96], such that pro-inflammatory immune responses 
that are necessary in an infection can also be regulated to ensure that host tissues are 
not harmed after pathogen eradication. 
NKT cells 
Another unique 'natural ', thymus-derived , self-recognising , regulatory T-cell population 
comprises 'NKT' cells. These are a subset of T cells expressing receptors found on 
both CD4+ T cells and natural killer (NK)6 cells . NKT cells can both respond rapidly to 
invading pathogens (as innate immune cells do) and produce both Th1 and Th2-type 
cytokines adaptively (Figure 1.4 ); thus, they are said to bridge the innate and adaptive 
(i.e . antigen-responding) immune systems. NKT cells have been shown to mediate 
both protective and regulatory immune functions , including tumour rejection , protection 
against infectious microbes, maintenance of transplant tolerance and inhibition of 
autoimmune disease development, their immunomodulatory functions being linked , at 
least in part, to generation of tolerogenic DCs [98]. 
NKT cells have been recently functionally linked with amelioration of EAE via Th 17 
cells in the gut [99]. A selective reduction in NKT cell numbers has also been shown in 
human patients with autoimmune diseases, including RA, type1 diabetes and MS 
(reviewed by Balato et al. , 2009 [98]) . For example , decreased numbers of both NKT 
and nTreg cells were demonstrated in the peripheral blood of type 1 diabetes patients , 
suggesting possible thymic dysfunction and/or broad T-cell defects [100] . 
6 NK cells are a wh ite blood cell type of the innate immune system with both cytolytic and potent cytokine-
producing properties [24] . 
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Figure 1.4: Differentiation of (CD4+ CDS+) T cells (in thymus) into CD4+ subsets, 
CDS+ T cells (CDS+ discussed further in Section 1.5.4), NKT.cells and activation 
of NKT cells by APCs. Activated NKT cells produce Th1 or Th2 cytokines and 
have direct cytotoxicity activity leading to apoptosis of the target cell. (Figure 
adapted from Salato et al., 2009 [98].) 
Antigen-induced regulatory T cells 
Antigen-induced regulatory T cells are adaptive T cells produced in SLO in the 
periphery of the body (i .e. outside the central thymus and bone marrow, in the lymph 
nodes and spleen). They are phenotypically diverse and induced by antigenic signals in 
the presence of immunosuppressive cytokines , and often in special circumstances, 
such as after mucosa! administration of antigen or in chron ic viral infections [101 ]. In 
older adult humans, the induced regu latory T cells may play a greater role , compared 
with nTreg cells , in maintaining immune homeostasis because thym ic output in humans 
is decreased following puberty and fewer natural nTreg cells subsequently emerge 
from the thymus [73]. 
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iTreg (Foxp3+ CD4+ CD25+) 
Foxp3+ CD4+ CD25+ regulatory T cells were originally considered to be a 
homogeneous population of naturally occurring , thymus-derived T cells (i.e. nTreg). 
However, similar Foxp3+ regulatory T cells ('iTreg ') can be induced from CD25-
precursors in vivo , and ex vivo with IL-2 and TGF-~ [77] . Both populations express 
Foxp3 and suppress immune responses through contact-dependent mechanisms and 
the production of soluble factors, including the cytokines TGF-~, IL-10 and (in mice) IL-
35 [78]. 
iTreg are induced in the periphery from a CD4+ CD25- Foxp3- (na·1ve) T-cell population 
following T-cell receptor (TCR) stimulation (by antigen) in the presence of cytokines 
TGF-~ and IL-2 (see Figure 1.3). That is, iTreg differ in their antigen specificity (i.e. 
TCR repertoire) compared with nTreg (which are thought to be largely self-reactive, 
see Figure 1.5) and in their TCR signal strength and co-stimulatory requirements 
needed for their generation ; however, whether they have any unique function in vivo 
has been unclear. It is possible that nTreg and iTreg have different roles in the adaptive 
immune response ; for example , whereas nTreg (in mice) can be converted to Th 17-
type cells by IL-6 under some conditions, induced iTreg are resistant to this cytokine 
and thus might retain suppressive function at inflammatory sites [77]. Other reviewers 
take this concept of separate roles further and propose that nTreg and iTreg cells may 
synergise to achieve optimal regulation. For example, Curotto de Lataille and Lataille 
(2009) consider that there is a division of labour between nTreg and iTreg cells , based 
on the different TCR repertoires of both regulatory T-cell populations (Figure 1.5). That 
is , although iTreg seem tailored to respond to foreign antigens and neo-antigens (e.g . 
tumour antigens) , it is likely that iTreg can also be generated in response to self-
antigens and can then synergise with nTreg cells in the control of autoimmune 
inflammation [102]. 
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Figure 1.5: Thymic and peripheral generation of Foxp3+ regulatory T cells. 
Natural nTreg cells differentiate in the thymus and migrate to peripheral tissues. 
Induced Foxp3+ iTreg cells differentiate in SLO and tissues. The peripheral 
population of Foxp3+ regulatory T cells comprises both nTreg and iTreg cells. 
nTreg and Foxp3+ iTreg cells likely differ in their TCR repertoire, because the 
iTreg cell repertoire is drawn from na·ive conventional CD4+ T cells that have 
survived negative selection (for self-antigens) in the thymus. Conversely, nTreg 
cells are selected (positively for self-antigens) by high-avidity interactions in the 
thymus (Treg, Foxp3- regulatory T cell). (Figure adapted from Curotto de Lataille 
and Lataille, 2009 [102].) 
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Other inducible regulatory T cells 
Other inducible regulatory T cells , including Tr1 (T-regulatory type 1) and Th3 (T-helper 
type 3) , appear to derive from the CD25- [48] and Foxp3- [102] T-cell subtype in the 
periphery (Figure 1.5); Tr1 and Th3 rely on cytokines such as IL-10 and TGF-~ to effect 
suppression. Both these types of induced regulatory T cells and their cytokines have 
potent modulatory properties. 
Type 1 regulatory cells (Tr1) have been more studied and appear to play an 
important role in self-tolerance induction; self-reactive Tr1 cells have been isolated 
from healthy human donors [103], indicating that auto-reactive T cells circulate in 
healthy people and that regulatory T cells actively suppress their function [64] . Tr1 cells 
do not have a unique cell marker but are identified by their high production of IL-10 and 
not pro-inflammatory cytokines [78]. Human Tr1 cells down-regulate immune 
responses through the release of both of the anti-inflammatory cytokines IL-10 and 
TGF-~, and regulate the function of na·fve and memory Th 1-type or Th2 responses. 
They also display a memory phenotype, and down-regulate the expression of co-
stimulatory molecules and pro-inflammatory cytokines by APCs [64]. 
Further, Tr1 cells enhance the production of antibodies lgD, lgA and lgG by B 
lymphocytes. Importantly, Tr1 cells are inducible , antigen specific and need to be 
activated through their TCRs to exert their suppressive functions. However, once 
activated , they mediate suppression in an antigen non-specific manner [104] . For 
human Tr1-cell generation , IL-10 is necessary but probably not sufficient; other 
necessary factors include the presence of APCs, which provide , in addition to IL-10, 
other solub:e and surface molecules crucial for Tr1-cell differentiation [64]. 
Human Tr1 cells appear to migrate to peripheral sites to directly regulate the 
inflammation of injured tissues and to maintain tolerance at mucosa! surfaces. This 
suggests that the suppressive effect of regulatory Tr1 cells occurs locally and 
selectively in peripheral inflamed tissues [72]. Interestingly, and in support of th is, an 
EAE experimental model has shown that Tr1 cells prevent encephalomyel itis only if the 
specific myelin antigen is administered in the brain and not systemically [105], 
suggesting that regulation of the pathogenic autoimmune response by Tr1 is localised 
in the inflamed environment. Indeed, in the human immune response to certain 
infectious agents, pathogen-specific Tr1 cells can be generated in vivo during the 
course of bacterial , viral , fungal or parasitic infections; the major purpose of these cells 
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here is to control inflammation and collateral tissue damage, thereby preventing 
chronic infectious states that may otherwise result if this mechanism is subverted by 
the pathogen [38] . 
In human autoimmune disorders, impaired Tr1 function in MS patients has been 
demonstrated, lower amounts of IL-10 being produced by these cells [106 , 107]. 
Further, CD4+ T cells from MS patients were more resistant to suppression by IL-10 
because the IL-10 signalling cascade was defective in MS patients [107]. 
T-helper 3 (Th3) cells are another antigen-specific regulatory cell population that 
originates in the periphery; Th3 cells mediate suppression through the secretion of 
TGF-~ and , similar to Tr1 cells, they do not have a unique cell-surface marker [78]. Th3 
cells were originally propagated from animals that became tolerant to orally 
administered protein antigen . They provide help for lgA synthesis and display 
suppressive properties for both Th 1 and Th2 cells [108]. Th3 cells specific for myelin 
antigens have been shown to suppress autoimmunity in animal models of autoimmune 
encephalitis [109]. However, at least some Th3 cells appear to be TGF-~-induced 
Foxp3+ iTreg [37] . Relevant to this finding, Carrier and co-workers, using a TGF-~-
transgenic mouse model , showed that TGF-~-dependent induction of antigen-specific 
Th3 cells in the periphery effected , in turn , the generation of antigen-specific Foxp3+ 
regulatory cells (i .e. iTreg) by producing required TGF-~. Th3 cells may thereby play a 
crucial role in inducing and maintaining peripheral tolerance , by driving the 
differentiation of antigen-specific Foxp3+ iTregs in the periphery [11 O]. 
Thus, both of these peripherally produced , induced regulatory T-cell types act in a 
down-regulating , anti-inflammatory way. Interestingly, some peripheral regulatory T 
cells exhibit antigen specificity while others appear to have lost such specificity. 
Initiation of regulation appears to be antigen-dependent, whereas , as regulation 
expands both quantitatively and qualitatively, antigen dependency appears to be lost 
and the production of more non-specific immunosuppressive cytokines , such as IL-1 O 
and TGF-beta , appears to be the result [111 ]. 
CDB+ regulatory T cells of a variety of types, induced in association with MHC class I 
(self) antigens, have also been reported . One type appears to play a prominent role in 
protection from MBP-stimulated EAE in mice [38] ; another type appears to resemble 
CD4+ Tr1 cells because their suppressive effects are primarily mediated by IL-10. A 
further type, characterised as CD28-, also expresses Foxp3 messenger RNA and can 
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render APCs tolerogenic [38] . Importantly, in humans, CDS+ T cells prevalent in MS 
lesions may have a regulatory function by direct effects on CD4+ cells [31 , 55] . 
lmmunomodulatory cytokines 
The interrelations between nTreg , DCs, iTreg, Tr1 and Th3 cells, and the role of 
cytokines in the suppressive effects mediated by the different populations of regulatory 
T cells , are yet to be fully defined. Possibly, all types of regulatory T cells co-operate in 
vivo to prevent autoimmune reactions [48]. However, both TGF-f3 and IL-10 cytokines 
appear consistently as mediators of these generally immunosuppressive processes. 
IL-10 
IL-10 is a maJor immunomodulatory (down-regulating) cytokine that can inhibit the 
activation and effector function of many kinds of immune cells , playing a crucial role in 
preventing inflammatory and autoimmune disorders. This cytokine was originally 
described as a T-helper 2 (Th2)-type cytokine, and later associated with regulatory T 
cells such as Tr1 [104] . It is now known that IL-10 is much more broadly expressed by 
many cells of both the adaptive immune system (e.g. Th1 , Th2 , Th17 , Tr1 , CDS+ T 
cells and 8 cells) and the innate immune system (e.g. DCs, macrophages, mast cells , 
NK cells , eosinophils and neutrophils), affirming its role as a feedback regulator of 
diverse immune responses . 
IL-10 exhibits broad anti-inflammatory properties by its suppression of both 
macrophage and DC function , including APC function and suppression of pro-
inflammatory cytokine production. Thus, IL-10 has a primary role in limiting the immune 
and inflammatory responses to pathogens in order to prevent damage to the host [112]. 
Indeed, although IL-10-deficient mice can clear certain intracel lular pathogens more 
efficiently than normal , this efficient dispensing of pathogens is often accompanied by 
immunopathology that can be lethal to the host [113] . 
IL-10 inhibits the development of Th1- and Th17-type responses by act ing on DCs and 
macrophages, but also suppresses Th2 and allerg ic responses. As well , because IL-1 0 
can be produced by Th1 , Th2 and Th17 cells , an additional feedback loop effectively 
limits the innate effector functions of macrophages and DCs and their subsequent 
activation of T cells [114]. However, IL-10 also up-regulates the differentiation of IL-10-
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secreting regulatory T cells, forming a positive regulatory loop for its induction [104]. 
This cytokine can also activate mast cells and enhance the functions of CDS+ T cells, 
NK cells and B cells in some situations; thus, IL-10 has important effects on the 
development of an immune response, and a central role in the induction of tolerance 
and maintenance of immunological homeostasis in humans and other mammals. 
The key in vivo role of IL-10 has been demonstrated in several experimental animal 
models. For example, IL-10 'knock-out' mice (that is, a genetic strain in which IL-10 
production is down-regulated) develop EAE induced by a myelin protein (myelin 
oligodendrocyte glycoprotein [MOG]) [115] and spontaneously develop inflammatory 
bowel disease [112, 116]. These genetically modified mice are also more susceptible to 
RA [117] . IL-10 has also been administered prophylactically to various animal models 
and mostly shown to be effective in the prevention of inflammatory and organ-specific 
autoimmune disorders such as EAE, diabetes mellitus and arthritis (reviewed by 
Asadullah et al., 2003 [118]). 
However, some data are conflicting, and the therapeutic action of IL-10 may differ 
depending on the local micro-environment, the disease stage and the IL-10 
concentration. Nevertheless, clinical trials in humans are in progress using recombinant 
IL-10 in immune-mediated inflammatory diseases such as psoriasis, Crohn's disease 
and RA, with varying results (reviewed by O'Garra et al. , 2008 [112]). 
TGF-/3 
TGF-~ has been found to be essential in the adaptive (peripheral) immune system, 
affecting most immune-cell types as shown by the broad distribution of the relevant 
receptor. TGF-~ initiates 'signalling ' events in target cells that affect cell-fate decisions, 
proliferation and survival by modifying cellular transcriptional programmes. Using more 
recent genetic targeting approaches, TGF-~ signalling has been implicated in the 
inhibition of cytolytic and Th 1-cell differentiation , proliferation and apoptosis in 
particular. This direct role was confirmed when aggressive autoimmune lesions 
resulted after abrogation of TGF-~ signalling in mice [119] . A further direct role for TGF-
~ in the differentiation of pro-inflammatory IL-17-producing Th17 cells has also been 
recently uncovered: TGF-~ in the presence of IL-6 determines the generation of this 
distinct cell lineage rather than iTreg (see Figure 1.3). 
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The essential role of TGF-~ (together with IL-2) in Foxp3+ iTreg development has 
already been noted ; in this role, TGF-~ also requires CTLA-4 in order to induce 
activated CD4+ cells to express Foxp3. In addition, TGF-~ is required to maintain 
Foxp3 expression in both iTreg and nTreg. It has also been reported that Foxp3+ 
regulatory T cells can secrete active TGF-~ and express this cytokine on their cell 
surface; membrane-bound TGF-~ seems to have stronger regulatory effects on other 
immune cells than soluble TGF-~ and may thus have an important role in the functional 
properties of both activated nTreg and iTreg [77]. Therefore, TGF-~ has both a direct 
role-in determining T effector cell functions-and an indirect role-in inducing and 
maintaining peripheral Foxp3+ regulatory cells-in the overall maintenance of immune 
homeostasis [96, 119]. 
TGF-~ derived from Foxp3+ regulatory cells may further be involved in inducing 
immature DCs to become tolerogenic, since DCs are principal targets of Foxp3+ 
regulatory cells and , as discussed earlier, are prevented from maturing into 
immunogenic DC by them. Further, tolerogenic DCs can produce latent TGF-~ and 
convert this precursor molecule to biologically active TGF-~ [77]. TGF-~ is also 
produced by both of the peripherally antigen-induced Th3 and Tr1 cells (particularly 
Th3) , and has generally down-regulatory effects. 
In humans, T-cell cultures derived from patients with active MS produced less TGF-~ 
compared to T cells from patients with stable disease [120]. MBP-specific T-cell clones 
from MS patients also produced less TGF-~ compared with MBP-specific T-cell clones 
from healthy individuals , when the frequencies of MBP-specific T cells were similar in 
patients and non-patients [121]. Thus, TGF-~ levels appear to be associated with 
appearance of symptoms in MS [122]. 
IL-2 
IL-2 is a maJor cytokine thought to control regulatory T-cell homeostasis , and 
particularly iTreg generation and homeostasis. Indeed , Foxp3+ regulatory T cells were 
initially identified based on their constitutive expression of the high-affinity IL-2 receptor 
component CD25 , and IL-2 is required for TGF-~ induction of Foxp3 transcription and 
suppressor activity [102]. IL-2 seems to have an essential and non-redundant role in 
controlling nTreg and iTreg function in the periphery, as shown by the development of 
lymphoproliferative disease and colitis in mice that are deficient in either IL-2 or CD25. 
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However, the precise way in which IL-2 influences regulatory T-cell function is unknown 
[73] . 
In summary, both central and peripheral mechanisms for maintaining tolerance are 
required for immunologic homeostasis. Now that the importance of the centrally-
derived Foxp3+ (CD4+ CD25+) regulatory T cells (nTreg) in several autoimmune 
diseases in humans has been recognised [79 , 89, 95], the thymic central tolerance 
system can be thought of as producing not one, but two, initial repertoires of 
tolerogenic cells (see Figure 1.5) that appear to balance each other. One repertoire is 
formed by deleting potentially aggressive T cells with high specificity for self-antigens-
the original clonal deletion model known since the days of Ehrlich and Burnet [19]; the 
other repertoire is formed by positive selection of Foxp3+ nTreg and NKT cells that do 
recognise self-antigens, with the express purpose of suppressing T-cell-mediated 
interactions and maintaining tolerance. Added to this are now the peripheral tolerance 
systems, including the induced iTreg, Tr1 and Th3 regulatory T cells, and the 
specialised antigen-presenting DCs that are responsible for much of the 'dialogue' in 
the system. Therefore, rather than a simple decision of T-cell clonal deletion or survival , 
as envisaged several decades ago, subsequent research has shown that individual T 
(and B) lymphocytes must pass a remarkably complex series of self-reactivity 
checkpoints before they form part of the combined immune repertoire and potentially 
become large clones of either effector or regulatory immune cells . 
So we may ask now two questions: (1) how is such heavily-regulated immune 
tolerance temporarily overcome in order to fight potentially pathogenic invaders? and (2) 
how is self-tolerance more permanently 'broken ', resulting in overt autoimmune disease? 
1.3.2 Overcoming tolerance to respond to infection 
In order to be able to mount an effective response to infection in the face of such 
immune regulation, both the adaptive and innate immune responses work together to 
overcome the suppressive properties of regulatory T cells . That is, cells of the innate 
immune system first produce cytokines in response to pathogen recognition and these 
initiate the inflammatory response , which is then subsequently amplified by products of 
the adaptive immune response. For example, microbial induction of toll-like receptors 
34 
(TLRs) 7 on DCs via microbial LPS can overcome regulatory T-cell-mediated 
suppression and allow the generation of an antigen-specific adaptive immune response 
[123, 124]. The suppressive activities of regulatory T cells may also be overcome by 
enhanced signalling, especially via co-stimulatory CD28, as might arise following the 
innate response of DCs to infection [125]. In general, high levels of cytokines such as 
IL-2, IL-4 or IL-15, or IL-6, may cause proliferation of both natural and induced 
regulatory T cells and temporarily overcome their cell-to-cell or cytokine-mediated 
suppressive abilities, until the concentration of growth factor falls again and the 
regulatory T cells stop proliferating. It seems that when the immune system has 
eradicated the infection, the regulatory T cells then recover their suppressive function 
[65] as pictured schematically in Figure 1.6. 
It has also been recently observed that Foxp3+ regulatory T cells may not initially be 
activated or induced in highly inflammatory environments in acute infection; that is, 
Th1-type or Th2-polarising cytokines can interfere with the induction of Foxp3+ 
regulatory T cells in mice [126]. In addition, cytokines such as IL-6, IL-1 and IL-12 can 
down-regulate Foxp3 expression and even convert either iTreg or nTreg to 
conventional pro-inflammatory effector T cells in vivo [73]. 
Thus, it seems that the steady-state regulatory process can be temporarily subverted to 
allow induction of an antigen-specific effector response to infection; then, mechanisms 
appear to be in place in order to prevent ongoing induction of this response and to limit 
pathogenic anti-self immune responses that might occur at inflammatory sites. For 
example , both TNF-a and IFN-y, considered archetypal pro-inflammatory cytokines , are 
now known to trigger regulatory processes, such as production of anti-inflammatory IL-
10, at the same time as they carry out their primary effector role. This means that they 
can trigger key immunoregulatory pathways 'downstream', for control of an established 
immune response, to prevent ongoing inflammation [27]. Anti-inflammatory TGF-~ 
production is also often associated with the downstream effects of inflammatory 
responses [126] , while other pro-inflammatory cytokines , such as IL-6 and IL-4, can 
also have both positive and negative effects on regulatory T-cell activity [73]. 
7 TLRs on innate immune cells are highly evolutionarily conserved receptors that recognize pathogen-associated molecular patterns. Once recogn ised , the innate cell can process the pathogen ic antigen and present as peptide to antigen-specific (i .e. antigen-recognis ing) T cells for further action (i .e. adaptive 
response) [24 , 31] . 
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Figure 1.6: Schematic model of response to infection, based on stability of the 
suppressor phenotype. Regulatory T cells suppress the response of auto-
reactive (red) cells to self-antigens in the steady state by ensuring that they do 
not reach the threshold for activation (hatched line). Their ability to suppress 
responses can be overcome in the face of infection, as a result of TLR ligation or 
increasing levels of co-stimulation and cytokines secreted in response to 
infection. This might permit localised activation of some auto-reactive (green) 
cells through bystander activation or molecular mimicry (discussed in Section 
1.4.2). However, their expansion will be prevented by clonal competition from 
cells specific for antigens carried by the infectious agent. Available evidence 
suggests that regulatory T cells retain their suppressive capacity and will thus 
continue to suppress the response to self-antigens when the infection has been 
cleared. (Figure adapted from Wraith et al., 2004 [65].) 
What, then , might go wrong in the immunoregulatory system, where self-tolerance 
should be maintained or at least reverted to after temporary infection , to initiate full-
scale , persistent autoimmune disease? 
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1.4 Breakdown of tolerance 
As described, immune self-tolerance is a process that eliminates or neutralises self-
reactive cells in a continuous ongoing way. The initiation of autoimmune disease then 
occurs when tolerance to self-antigens is broken-a phenomenon that has long 
fascinated immunologists-yet the actual initiating immunogens for this process are still 
unclear [127]. It appears that both intrinsic factors and external precipitating events 
probably contribute to eventual autoimmune disease. The intrinsic factors involve 
immunogenetic determinants and initial repertoire formation, and thus are involved 
largely with central tolerance mechanisms set up in early life (see Section 1.2.1 ); as 
discussed next, these may 'set the stage' for susceptibility to autoimmune disease. The 
eventual precipitating events (introduced subsequently) then appear to relate more to 
peripheral tolerance mechanisms (see Section 1.2.2), and these events, acting alone 
or in synergy, may finally lead to clinically established autoimmune disease. 
The primary genetic determinants of autoimmune disease are not reviewed here but 
are discussed briefly in relation to specific environmental factors detailed in Chapter 2. 
1.4.1 lmmunogenetic factors and faulty tolerance induction 
At a first level, the MHC (genetic self) haplotype (e.g. human leucocyte antigen [HLA] 
subtypes) can influence susceptibility to autoimmune disease. For example, this can be 
achieved by enhancing the presentation of antigens in the periphery, resulting in 
increased T-cell activation , or by ineffective presentation of self-antigens in the thymus , 
leading to more aggressive effector T cells or fewer numbers of regulatory T cells [127]. 
At a second level , various polymorphisms in genes involved in establishing self-
tolerance and immune regulation can occur. For example , expression of the human 
'autoimmune regulator' (AIRE) is vital to thymic negative selection and thus to the 
prevention of organ-specific autoimmune disease [128 , 129]; humans deficient in the 
AIRE gene develop a severe multi-organ autoimmune disease characterised by 
variable combinations of autoimmune endocrine diseases, including type 1 diabetes. 
AIRE is primarily expressed by epithelial cells in the thymic medulla and induces the 
transcription of a large number of tissue-specific self-antigens that would otherwise be 
sequestered in the periphery. Thus , AIRE ensures developing thymocytes are exposed 
to a comprehensive view of 'self', permitting early deletion of auto-reactive T cells 
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before acquisition of effector functions (see Section 1.2.1) [128 , 130]. It is therefore 
apparent that in the absence of AIRE expression, the establishment of central self-
tolerance is incomplete, resulting in an auto-aggressive reaction towards several self-
antigens [127]. 
Another example of aberrant tolerance induction is seen in the murine EAE model of 
human MS, in which a genetic variant of the self-protein , proteolipid protein (PLP) , 
expressed in thymic epithelial cells, results in the particular auto-reactive T-cell 
repertoire responsible for the EAE disorder [131 ]. This antigen-lacking variant may 
prevent proper presentation of the self-protein to T cells in the thymus, leading to poor 
self-tolerance induction and autoimmune disease susceptibility. 
Tolerance may also be compromised and autoimmune disease may develop as a 
consequence of altered balance between regulatory T cells and self-reactive 
conventional T cells. That is, any genetic anomalies that tip the balance toward self-
reactive conventional T cells could cause or predispose to autoimmune disease. As 
discussed , mutations in the Foxp3 gene result in IPEX syndrome, which is an nTreg-
specific immunodeficiency in humans (see Section 1.3.1 ). In addition , polymorphisms 
of several genes controlled by Foxp3 in nTreg cells , such as those encoding CTLA-4, 
IL-2 and CD25 , are associated with susceptibility to common autoimmune diseases 
(including type 1 diabetes) in humans and rodents . For example , 112 and Ctla4 are main 
susceptibility genes for type 1 diabetes in the diabetes-prone 'non-obese diabetic' 
(NOD) mouse model , and both IL-2 and CTLA-4 molecules seem to be important in 
maintaining the balance between Foxp3+ T-regulatory cells and self-reactive T cells 
[39] . In humans, a single nucleotide difference in Ctla4 alleles has been identified as 
being differentially expressed between people with autoimmune Grave 's disease and 
those without, and type 1 diabetes may also be linked to the same locus of th is Ctla4 
gene [132] , further highlighting the importance of this CTLA-4 'key negative immune 
regulator' in autoimmune disease susceptibility generally. 
Other genetic polymorphisms may occur, for example , in apoptos is genes, wh ich may 
lead to excess in effector T cells over regulatory T ce lls [27] . The importance of normal 
apoptotic processes for eradicating self-antigen activated lymphocytes in humans is 
illustrated by a finding that in type 1 diabetes patients , auto-reactive T cel ls are high ly 
anergic and resistant to apoptosis , requiring 20 to 100 times lower levels of IL-2 than 
non-diabetic T cells to escape apoptos is [133]. Genes controll ing the production of 
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cytokines such as TNF-a or IL-1 or IL-10 may also show polymorphisms; these too 
have been associated with susceptibility to autoimmune diseases [27, 134]. 
1.4.2 External events-autoimmune disease determinants 
Even in a genetically predisposed person, some precipitating event-an environmental 
exposure or a change in the internal environment-is likely to be required for frank 
auto-reactivity. However, in the case of most autoimmune diseases the actual factor is 
unknown [2]. External factors may act at an early stage in the life course and interact 
with both genetic and immunological mechanisms to set the initial conditions for later 
precipitation of autoimmune disease. This possibility, and some of the factors 
potentially involved, will be considered in more detail in Chapters 2 and 3. In the 
present section, the external factors that may be involved in initial activation of self-
antigen-specific T cells will be briefly considered, this being the critical early event in 
the induction of autoimmune disease [135]. 
Microbial agents 
Microbial antigens have the potential to initiate auto-reactivity through a number of 
different possible mechanisms. Infections are prime candidates for initiating 
autoimmune disease in predisposed persons, because they frequently induce strong 
inflammatory responses in various organs and can attract many potentially auto-
aggressive lymphocytes to the site of infection. 
Microbial infections can cause massive host inflammatory responses producing 
cytokines that polyclonally activate 'bystander' T cells at the site of infection in a non-
antigen-specific way. In this case , the sum of all non-specifically activated cells , rather 
than a few specific cells , causes collateral damage [127] . For example , the 
enhancement of type 1 diabetes in a strain of transgenic NOD mice by a Coxsackie B 
virus infection (this virus having been associated many times with human autoimmune 
diabetes [136]) has been shown to be a direct result of local infection leading to 
inflammation , tissue damage and the release of sequestered islet antigens , in turn 
resulting in the stimulation or re-stimulation of resting bystander auto-reactive T cells 
[137]. 
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There are several other examples of microbes triggering autoimmune disease in 
susceptible humans or animals by similar adjuvant effects (reviewed by Verhasselt and 
Goldman, 2001 [23] and discussed in more detail in Chapter 3). For example , work by 
Shevach and colleagues on EAE showed that pre-existing auto-reactive T cells stay in 
a quiescent state unless microbial products such as LPS are present; the presence of 
these microbial factors allows the development of effector Th1 cells and the induction 
of EAE through the stimulation of IL-12 production. DCs have been shown to produce 
IL-12 in response to various microbial products and to be the major source of this 
cytokine following infection. LPS might also act by interfering with the induction of 
peripheral T-cell death [23]. 
Another study showed that self-tolerance could be broken and spontaneous EAE 
produced by activation of TLRs on APCs, demonstrating response by the innate 
immune system to microbial products, even in the genetically resistant transgenic 
murine strain used [138]. Similarly, induction of EAE by (microbial) pertussis toxin was 
shown to be dependent on innate TLR4 and involved recruitment of leucocytes and T 
cells to the cerebrovascular endothelium; this suggests that infectious agents may have 
a role in the interaction between T cells and the blood-brain barrier (BBB)8 in central 
nervous system (CNS) disorders such as MS, by up-regulating adhesion molecules 
important for permeability of the CNS to immune cells [140]. 
Another pathway by which microbial agents can break self-tolerance may be v,a 
'antigenic (or 'molecular') mimicry' (discussed in more detail in Chapter 3)-this is the 
hypothesised 'mistaken identity' situation in which auto-reactive cells in the host are 
activated by microbes presenting antigens that are cross-reactive with (host) 'self'. In 
this process, the anti-foreign immune response causes collateral autoimmune damage 
by mistake [22]. In MS patients , for example, T cells react with a peptide from the auto-
antigen MBP, but also cross-react with peptides from Epstein-Barr virus (EBV), 
influenzavirus type A and human papillomavirus [141 ]. In type 1 diabetes, human T 
cells recognise both an auto-antigen peptide and an analogous peptide from a 
Coxsackie B virus protein [142]. RA also appears to have an infectious aetiological 
association , with Proteus bacterial species [143] or with other infectious agents such as 
viruses. 
8 The BBB is an important physical and physiologica l 'dividing line' between the immune system and the 
CNS and is also the locale, and condu it, for interactions between these two systems . It is a dynamic 
system that maintains brain homeostasis and limits CNS penetration via interactions of transmembrane 
and intracellular proteins. Thus , the BBB restricts unregulated mixing of immune substances in the blood 
with those in the CNS, directly transports neuroimmune-active substances between the blood and CNS 
and itself secretes neuroimmune substances [139] . 
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Although microbial agents have been associated with several autoimmune diseases, 
including MS, type 1 diabetes and RA (discussed further in Chapter 3), attempts to 
establish a direct epidemiological association between specific microbial infections and 
various autoimmune disorders have been difficult. Part of the problem in establishing 
this link is that most humans encounter a multitude of infections during their lifetime 
and most infections are cleared by the time of autoimmune disease diagnosis. Thus, 
precise 'footprints' documenting an individual's history of viral and bacterial infections 
are difficult to find . 
In addition, several sequential events may be necessary to precipitate autoimmune 
disease, each event accelerating an already pre-existing autoimmune condition rather 
than being an initiator [127]. Thus, microbial events are good candidates as part of a 
suite of factors for initiating autoimmune disease, given recent information that such 
events can initiate or strengthen allergic inflammation. For example, pathogen-derived 
products induce the expression of various members of the I L-1-cytokine family which 
have been shown to enhance and alter Th17 , Th1 and Th2 responses [144]. 
Finally, the observation that some infections, particularly those in early life , might 
protect an individual from autoimmune disease rather than enhance it-that is, the 
'hygiene hypothesis'-appears paradoxical to an infectious aetiology and further 
complicates the issue of whether infectious agents can be initiators and/or accelerators 
of autoimmune disease. For example , multiple infections during the first year of life are 
associated with a significant reduction in the risk of type 1 diabetes [145]. This means 
that microbes may be capable not only of triggering autoimmune disease but also may 
provide protection against such disease under different conditions. This hypothesis will 
be explored further in Chapters 3 and 8. 
Other determinants 
As discussed , to break self-tolerance microbial infections could combine a non-specific 
bystander activation component provided by local inflammation, and a cross-reacting 
antigen-specific element that directs the activated immune system to specifically target 
particular host proteins. However, such a 'perfect' combination can also be achieved by 
exposure to drugs or other chemical agents that modify self-components , resulting in 
the formation of 'neo-antigens' to which no previous tolerance could have been 
established by the host [127]. For example , metabolism of drugs such as procainamide 
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can cause antigenic modification of self-components, alteration of the immune 
repertoire and induction of the autoimmune 'lupus' disorder SLE. Some heavy metals 
such as mercury can also be immunotoxic in susceptible individuals. 
Other external factors that have been linked to CNS disorders such as MS, perhaps via 
perturbation of the BBB, include prior head injury and psychological stress (reviewed 
by Goodin et al. , 1999 [146]). In addition , several autoimmune disorders, including MS 
and RA, are more common in women than in men [14 7], indicating the importance of 
the internal environment, including hormones. Foreign substances, such as penicillins , 
or gliadin (from wheat gluten) may also act as haptens and render auto-antigens 
immunogenic [2] . Other possible environmental factors , including those related to the 
physical environment (e.g. climate), may also help determine autoimmune disease. For 
example , low exposure to sunlight and UVR have been implicated by epidemiological 
evidence; these will be considered in detail in Chapter 2. 
Thus, while internal and external determinants of MS and other organ-specific 
autoimmune diseases have been briefly introduced here, external factors , in particular, 
will be reviewed fully in chapters 2 and 3. In addition , the epidemiological parameters of 
MS, particularly those concerning incidence and prevalence and pertaining to the 
distribution of disease frequency-that is , variation in 'person , place and time'-will be 
discussed in detail in Chapter 2, together with those of type 1 diabetes and RA where 
appropriate. 
In conclusion , the breakdown of tolerance and the consequent initiation and final 
precipitation of autoimmune disease appears to be a multifactorial and complex 
process, requiring both immunogenetic components and a probable sequence of 
environmental events. During normal autoimmune responses , a del icate ba lance 
between activation and elimination of self-reactive lymphocytes is required to avoid 
tissue damage, and access of lymphocytes to intact tissues must also be lim ited [23]. 
In the words of noted Australian immunologist Sir Gustav Nossal [22] : 
'We are all constantly teetering on the brink of autoimmune disease ' 
'Our lymphocytes are not truly resting; rather they are integrating a 
wealth of positive and negative signals that arise from their antigen 
receptors and from many other signal-transducing molecules ... [and] 
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minor defects or insults can perturb the equilibrium, with disastrous 
results' 
On the one hand, this 'immunological self' complexity and precise mechanism of self-
recognition is to our advantage because it is not actually easy to break tolerance to 
auto-antigens and override the normal regulatory balances [127]. Conversely, however, 
the complexity makes the task of unravelling the aetiology of autoimmune disorders, 
such as MS, all the more difficult, and so the development of more specific therapeutic 
approaches for such autoimmune disease continues to be an ongoing process. 
In this setting of breakdown of immunological tolerance and consequent development 
of autoimmune disease, the clinical and immuno-pathogenic aspects of the specific 
disorder of MS, in particular, can now be considered. 
1.5 MS (sc/erose en plaques disseminees) 
1.5.1 General features 
MS is the most common chronic disabling disease of the CNS in young adults in 
Western countries, with 1 in 1000 people affected [148]. Noseworthy and colleagues 
describe the disease as an 'enigmatic, relapsing, and often eventually progressive 
disorder . . . [that] continues to challenge investigators trying to understand the 
pathogenesis of the disease and prevent its progression ' [149, 150]. 
MS was described more than a century ago by a French neurologist now honoured as 
the 'founder of modern neurology', Jean Martin Charcot, while noting the accumulation 
of inflammatory cells within the brain and spinal cord white matter of patients with 
intermittent episodes of neurologic dysfunction [135]. This led to the term sclerose en 
plaques disseminees (patches of scarring) , or MS [151 ]. This name conveys the MS 
pathological hallmark of the demyelinated 'plaque' (i .e. hardened sclerotic lesion) , 
leading to neurologic dysfunction due to interference in nerve transmission , which then 
becomes 'disseminated in space and time' at multiple sites within the brain and spinal 
cord of the CNS [150]. Kabat and colleagues further noted immunoglobulins 
(antibodies) in the cerebrospinal fluid (CSF) of MS patients in 1948, indicative of an 
inflammatory disease [152] 
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1.5.2 Natural history and clinical features 
As a chronic disease typically beginning in the second or third decade of life, MS can 
take different forms. The most frequent form is RRMS, characterised by bouts of 
disease followed by complete or incomplete remissions ; this form has a female 
predominance of approximately 2: 1 [150]. After several years , this relapsing disease 
can transform into secondary progressive MS (SPMS), defined by a slow clinical 
deterioration. Up to twenty per cent of MS patients have a primary progressive MS 
(PPMS) at onset, characterised by gradual progression from onset with no remissions ; 
this form has similar incidence in men and women [150, 301 ]. 
MS is a chronic inflammatory disease of the CNS, associated with the formation of 
large confluent plaques of demyelination in the brain and spinal cord [153]. Nerve 
axons are also injured and destroyed in the demyelinated areas and the loss of these 
axons appears to result in permanent neurological deficit [154]. In addition to focal 
demyelinating plaques, there is diffuse damage in the 'normal ' white matter and the 
cortex; this diffuse, global brain injury is most evident in patients with primary 
progressive or secondary progressive forms of MS. Functionally, the clinical symptoms 
of MS reflect disturbances in the electrical signal transmission in the CNS due to 
damage to the myelin sheath and associated axonal and neuronal grey matter injury 
[155] . 
1.5.3 Diagnosis of MS 
MS is diagnosed by a careful clinical process to demonstrate findings consistent with 
MS and to rule out other causes with similar symptoms. The basic criteria for 
diagnosing MS currently, known as the 'McDonald criteria ', are based on 
recommendations by an international panel convened in 2001 [156], which were 
revised in 2005 [157] . As in previously used criteria [158 , 159] , these recommendations 
focus on the objective demonstration of dissemination of lesions in both time and space, 
and now include magnetic resonance imaging (MRI) integrated with cl inica l and other 
paraclinical diagnostic methods, such as analys is of CSF (for evidence of immune 
inflammation) and visual evoked potentials (electrical nerve-transmiss ion tests). The 
clinical examination would include history and tests of function . An extensive review of 
mental , emotional and language functions , movement and coordination , vis ion , balance 
and the functions of the five senses would be covered. Birthplace, family history, age at 
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first symptoms and sex would also be taken into consideration [156] ('MS Australia ' 
website www.msaustralia.org.au , accessed March 2011 ). 
1.5.4 Pathology and immunopathology 
The composition of the inflammatory infiltrate in acute MS lesions, together with the 
local expression of various cytokines and other immune-associated molecules , 
suggests that the inflammatory response is based on a T-cell-mediated immunological 
process [160] . Thus, MS is generally agreed to be essentially an autoimmune disease, 
at least in the acute phase of RRMS [161, 162]. 
In the early 1930s, an autoimmune, and at times demyelinating, disease was 
demonstrated in mammals by repeatedly injecting rabbit brain and spinal cord into 
primates. This disease, known as experimental 'allergic' (later, 'autoimmune') 
encephalomyelitis, EAE, and now studied mainly in mice, led to the mostly accepted 
hypothesis that MS was similarly secondary to an autoimmune response to the (self-) 
proteins of the myelin nerve sheaths in a genetically susceptible host [135]. 
For the induction of EAE, injecting a rat or mouse with myelin protein in an adjuvant 
leads to the development of an inflammatory CNS process manifested by paralysis , 
after which most of these animals recover. Re-injection of myelin in the recovered 
animals produces no disease, because they have developed immunological memory 
and have acquired tolerance to future exposures to the myelin antigens. However, 
injection of cells isolated from sick animals into na"i"ve animals elicits EAE (a 
phenomenon known as adoptive , or passive , transfer of the disease). This suggests 
that EAE, and presumably MS, are largely cell-mediated diseases (rather than antibody 
mediated) [155] , although auto-antibodies are clearly also involved in human MS. It is 
likely that the human MS disease also exhibits immunological mechanisms add itional 
to those mediated by CD4+ Th 1 and Th 17 cells in EAE; these include CDS+ T cells 
found in MS lesions, B cells that can present antigen and interact with T cells and 
produce both pro-inflammatory and regulatory cytokines [31 ], as well as a 
neurodegenerative component in the target neural tissue, particularly in later disease 
stages [154, 160, 161 , 163]. Nevertheless, EAE disease models have been a crucial 
tool for attempting to understand this devastating human disorder (reviewed by Gold et 
al., 2006 [ 163]). 
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Such heterogeneity in human MS is supported by evidence of MS lesions varying in 
their patterns of demyelination, even though all share an inflammatory reaction 
dominated by T cells and macrophages [164] . Further, these patterns have been found 
to be heterogeneous among patients but homogeneous within active plaques from the 
same patient [160, 165]. In some lesions, the presence of immunoglobulins (e.g. lgG) 
and products of complement activation indicate that demyelinating antibodies also have 
a pathogenic role. In others, oligodendrocytes (the primary myelinating cells of the CNS) 
appear to be the main target for destruction. Thus , it has been suggested by a number 
of researchers that MS may be a series of syndromes with different pathogenic 
mechanisms and causes, characterised by: (1) T-cell-mediated immune injury, or T-cell 
plus complement- and antibody-mediated injury (both these types being characteristic 
of EAE animal models) and/or (2) primary oligodendrocyte dystrophy (this type less 
seen in EAE-type models and reminiscent of virus- or toxin-induced demyelination 
rather than autoimmunity) [135 , 162, 165-167]. 
Therefore, MS may be a much more complex and heterogeneous disease than was 
previously thought, and the pathogenetic mechanisms and targets of demyelination 
may be fundamentally different in distinct subgroups or stages of the disease. A now 
widely accepted , but relatively recent, concept is that MS is initiated by an autoimmune 
inflammatory process , but later develops a neurodegenerative component, which might 
progress independently from inflammation [161 , 162]. 
Possible immuno-pathogenesis and progression of MS 
Based on recent findings in humans [31 , 55, 135, 150, 155, 160-162, 167-169], the 
possible immuno-pathogenesis and progression of MS can be described as follows 
(refer to Figures 1.7 and 1.8): 
Breakdown in self-tolerance and lack of regulation 
Underlying immunoregulatory defects, such as functional decrease in nTreg cells in the 
circulation , may lead to disturbance in physiological mechanisms controlling T-cell 
homeostasis (i.e. faulty tolerance) and allow pathologic activation of auto-reactive T 
cells in the peripheral blood . 
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Activation of myelin-reactive T cells 
Antigen-presenting DCs are activated, possibly by microbial agents or other 
metabolites, leading to the consequent activation of myelin- or other 'MS-antigen'-
specific, auto-reactive T lymphocytes (Figure 1.7). That is, CD4+ T cells (Th1 and/or 
Th17) are reactive to one or more of several putative self-myelin and non-myelin 'MS 
antigens', including antigens of astrocytic and neuronal origin. Activation also triggers 
secretion of cytokines and chemokines that modify the local micro-environment. 
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Figure 1.7: Immunological processes during early steps in the development of 
MS lesions. These processes include opening of the BBB, cell adhesion to 
cerebrovascular endothelial cells and local reactivation of infiltrating T H1 or T H17 
cells (T H17 [CD4] presented here). (Adhesion molecules: ICAM, intercellular 
adhesion molecule; LFA-1, lymphocyte function-associated antigen 1 [integrin 
a1J32]; VCAM, vascular cell-adhesion molecule; VLA4, very late antigen 4 [integrin 
a4J31]. MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor). 
(Figure adapted from McFarland and Martin, 2007 [162].) 
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Disruption of BBB and entry into CNS 
Once activated, the CD4+ T cells proliferate, circulate in the peripheral blood and 
express a variety of cell-surface adhesion molecules, such as VLA4, which links with its 
ligand, vascular cell-adhesion molecule (VCAM) (Figure 1.7). The activated T cells 
adhere to the luminal surface of endothelial cells in CNS venules and migrate into the 
CNS through disruption of the 888, aided by enzymes such as matrix 
metalloproteinase (MMP) (Figure 1. 7). In the CNS, local factors may up-regulate the 
expression of various endothelial adhesion molecules, further facilitating the entry of T 
cells into the CNS. Th17 cells, in particular, have been shown to promote disruption of 
the 888 and 'trafficking' of self-reactive T cells from the systemic compartment into the 
CNS. 
Recognition and amplification of antigen 
Once in the CNS, the myelin-reactive T cells recognise the various MS antigens 
presented by microglia (i.e. local APCs), are re-activated and an inflammatory cascade 
triggered (Figure 1.8). Pro-inflammatory cytokines, such as IL-12 and IFN-y, as well as 
IL-6 and IL-23, result in proliferation of pro-inflammatory Th 1 and Th 17 cells , and can 
also up-regulate the expression of the myelin antigens on neighbouring lymphocytes 
and DCs/microglia, thus amplifying the immune response. Ingestion of myelin by 
macrophages, aided by antibodies, can further activate CNS microglia (Figure 1.8). 
Therefore, the initial damage by self-antigen-specific T cells is a strong stimulus for 
further 'bystander' recruitment of macrophages and microglia. 
Expansion of Th1 and Th17 
Pro-inflammatory Th1 and Th17 cells (secreting IFN-y and IL-2 , and IL-17, respectively) 
and CDS+ cytotoxic T cells proliferate and ultimately result in immune-mediated injury 
to myelin, oligodendrocytes and axons. The pro-inflammatory cytokine , osteopontin , 
expressed at high levels within lesions , promotes the survival of activated T cells . 
Cytokines such as IL-6 may inhibit the suppressive action of regulatory T cells (Figure 
1.8). 
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Auto-antibodies 
Anti-myelin or anti-oligodendrocyte antibodies may also gain access to the CNS 
through the disruption of the BBB as a consequence of the T-cell initiated inflammatory 
response (Figure 1.8). These antibodies can cause demyelination directly, possibly 
through the activation of complement, or assist other cell types such as macrophages. 
Myelin injury 
Activated macrophages and microglia further produce damaging soluble factors , 
including nitric oxide, reactive oxygen radicals and excito-toxins such as glutamate; 
sodium- and calcium-ion channels in the axons are also altered deleteriously (Figure 
1.8). Thus, multiple mechanisms of immune-mediated injury of myelin have been 
postulated: (a) cytokine-mediated injury of oligodendrocytes and myelin ; (b) digestion 
of surface myelin antigens by macrophages, assisted by auto-antibodies ; (c) 
complement-mediated injury and (d) direct injury of oligodendrocytes by CD4+ and 
CDS+ cytotoxic T cells (Figure 1.8). 
Immune regulation, remission and myelin repair 
The regulation of initiated autoimmune responses may involve both natural and 
induced regulatory T cells accessing the perivascular space of the CNS (F igure 1.8). 
Regulatory T cells in the CNS can directly suppress encephalitogenic T cells through 
anti-inflammatory cytokine secretion (IL-10 and TGF-~) and cell-cell interaction , the 
latter focusing primarily on Th17 cells , but they can also regulate Th1 /Th2 cells. 
Regulatory T cells also act on local DCs, thereby rendering them tolerogenic; the 
tolerogenic DCs in turn can enhance regulatory T-cell expansion or suppressive 
function that contributes to the suppression of ongoing auto immune CNS inflammation 
(see Sections 1.2.2 and 1.3.1 ). Despite the evident existence and importance of such 
immuno-modulation in MS, it is not yet known whether regulatory T cells can be 
generated in the brain parenchyma or whether they funct ion primarily in the periphery. 
CDS+ T cells found in lesions may also have a regulatory funct ion under some 
conditions. 
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Figure 1.8: Effector mechanisms (T H17 [CD4] cells shown here) leading to CNS 
tissue destruction. This includes antibody- and complement-mediated damage, 
formation of oxygen radicals, glutamate-mediated excito-toxicity, pro-
inflammatory cytokine secretion and cell-mediated damage, either through CD8+ 
T cells or by means of antibody receptors and monocytes, macrophages (MCI>) 
and microglia (NO, nitric oxide; C', complement). (Figure adapted from 
McFarland and Martin, 2007 [162].) 
The regenerational capacity of the CNS, including axons, has also been appreciated 
only recently. There are several possible mechanisms of repair of the myelin 
membrane, including resolution of the inflammatory response followed by spontaneous 
re-myelination, repair-enhancing antibody-producing B cells and re-myelination 
resulting from the proliferation , migration and differentiation of resident oligodendrocyte 
precursor cells. Recent evidence shows that neurotrophins such as brain-derived 
neurotrophic factor (BDNF) , produced by activated T cells , B cells and monocytes, may 
play a role in re-myelination as well as in protection of axons and neurons. 
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In summation, it is apparent that although CD4+ T cells are considered central to 
initiating CNS inflammation , the actual extent and specificity of tissue injury in MS 
reflects the whole array of adaptive (including CDS+ T cells and antibody) and innate 
(microglia/macrophages) immune constituents found in acute MS lesions [167] . Further, 
accumulating neurological deficit reflects the balance between injury and repair, the 
latter being affected also by inflammatory processes (i.e. rate of clearance of myelin 
tissue debris by macrophages). However, the lesions associated with the late 
progressive phases of MS seem more dominated by inflammatory 
microglia/macrophage response than by lymphocytic (T-cell) infiltrates. In progressive 
MS, such inflammation might become trapped in the CNS behind a closed or repaired 
BBB, and the disorder then increasingly refractory to immunological or anti-
inflammatory therapy [161 ]. 
1.5.5 Current treatment and prognosis 
The main aims of drug therapy for MS are to shorten the duration of attacks or relapses , 
ease specific symptoms and slow the progression of disease by reducing the rate of 
the attacks. Figure 1.9 provides an overview of basic inductor and effector mechanisms 
in MS, or EAE, as already described , and indicates possible sites for therapeutic 
intervention. 
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Figure 1.9: Inductor and effector stages of the immune reaction in EAE/MS (T H1 
shown here) and possible sites for therapeutic manipulation. Therapeutic 
intervention is indicated by black bars (C', complement; GA, glatiramer acetate; 
M<l>, macrophage; Treg, regulatory T cells). (Figure from Gold et al., 2006 [163].) 
Glucocorticosteroids have been used as adjunctive therapy to ease inflammation in 
RRMS for some years [163], acting at several potential sites (Figure 1.9); it is now 
known that glucocorticosteroids, in common with several other immunosuppressive and 
anti-inflammatory drugs, act by inducing tolerogenic DCs [52] (see Section 1.2.2). 
Among a number of immuno-therapeutic products, which are used mainly for RRMS, 
glatiramer acetate (GA, Figure 1.9) is an injected antigen-targeted therapy that appears 
to mimic the myelin protein and thus block myelin-specific autoimmune responses ; it is 
used for treatment of relapses and reduction of lesions in RRMS [164]. GA is also 
credited with increasing the suppressive potential of Foxp3+ regulatory T cells , as well 
as being able to induce COB+ regulatory T cells with enhanced suppressive ability, in 
MS patients [55]. 
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Injected beta-interferons (I FN-~ 1 a, b) are used for treatment of relapses and reduction 
of lesions in RRMS to slow progression and they may also have some cognitive benefit 
[164]. Beta-interferons have been shown to restore the numbers of Foxp3+ regulatory 
T cells in MS patients [55], as well as affect BBB 'trafficking ' by reducing the migration 
of monocytes and T cells through human brain endothelial cells [167] (Figure 1.9). 
However, recent work suggests that beta-interferons may be more effective for Th 1 
than for Th17 cells, and this might explain the lack of response to beta-interferons in 
some patients [170]. 
Compounds blocking adhesion molecules have also been approved for use, including 
the monoclonal antibody anti-VLA4 (Figure 1.9), also known as natalizumab. However, 
this drug currently requires careful and very controlled use because of rare fatalities 
('MS Australia' website, www.msaustralia.org.au, March 2011) [171 ]. A number of other 
immunotherapies are also under evaluation; these now tend to be less focused on 
CD4+ Th 1 cells and instead target other components of the MS immune system. For 
example , alemtuzumab appears to be able to influence production of regulatory T cells 
and may shift the unbalanced regulatory/effector T-cell ratio in MS back into 
homeostasis by removing lympho-mononuclear cells (CD4+ and CDS+) generally [31, 
162]. 
Some of the clinical trials have helped to further understand the still evolving immuno-
pathogenesis of MS. For example, a successful trial of rituximab targeting a marker on 
B cells indicated the involvement of B cells in acute MS lesions [162]. Further support 
for a role for B cells in disease pathogenesis also comes from a recent trial of 
ocrelizumab that depleted B cells and reduced RRMS lesion activity [172] . 
Recently, oral fingolimod has been proven effective for MS in clinical trials and is now 
available in Australia ; this compound targets a protein critical for egress of T cells from 
lymph nodes and acts to down-regulate T cells moving from lymphoid tissues into the 
CNS [173] . Two clinical trials of fingolimod have shown halved relapse rates and 
reduced lesion activity in RRMS , and a third trial with oral cladribine has shown similar 
reductions (reviewed by Bermel and Cohen , 2011 [171 ]). Addit ional effective oral 
treatments for MS are now likely, such as teriflunomide , which has long been used in 
rheumatic diseases and has now proven efficacious in reducing MS relapses [174]. 
Immune suppressants such as methotrexate or mitoxantrone may also be given , 
especially for progressive forms of MS for which there are few clinical treatments. 
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However, recent trials of (a patient's own) mesenchymal stem cells show potential in 
neurorepair, or at least neuroprotection, in progressive MS [175, 176] . 
Although life expectancy in MS appears to be only moderately affected [177, 178], the 
overall prognosis means that irreversible limitation in ambulation occurs after a median 
time of eight years progression, a unilateral aid is required for walking after 20 years 
and patients become wheelchair-bound after a median time of 30 years [179]. 
In synopsis, recent observations of immuno-pathogenesis in MS patients have helped 
to reveal a remarkably complex and still evolving picture of the induction and 
progression of MS disease. The data suggest that many different T-cell populations 
can be involved in the induction, propagation and modulation of the disease and that 
the same cells, which are potentially encephalitogenic, can also provide a proper 
environment for re-myelination and repair [154] . B cells may also be involved. 
Cytokines such as TNF-a and IFN-y, originally considered to be typically pro-
inflammatory, are now known to also stimulate immunomodulatory processes as a 
second , and different, function [27, 163]. Thus, MS is a disorder in which many different 
components of the immune system interact to break self-tolerance and induce disease . 
Importantly, there are many points in the immuno-pathogenetic sequence where both 
internal and external factors may possibly affect the initiation , precipitation and 
progression of MS. Relevant to this thesis , there may be a number of possible time 
points over the life course (discussed in Chapters 2 and 3) where environmental factors 
may influence disease induction through their effects on immuno-pathogenesis. By 
attempting to discern these critical points, we can begin to achieve the overall aim of 
understanding , and perhaps ultimately preventing , autoimmune disorders such as MS. 
1.6 Conclusion 
Organ-specific autoimmune disorders, such as MS, type 1 (insulin-dependent) diabetes 
and RA, constitute a significant public health problem in the Western world , yet their 
aetiology remains unknown. The concept of immunological self, and maintenance of 
immunologic tolerance to 'self' while retaining the ability to react to 'non-self' , appears 
to be key to understanding the mechanisms of autoimmunity and disease. Several 
newly recognised, specialised groups of immune regulatory cells constitute a major 
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homeostatic mechanism whereby the tolerant state 1s maintained and auto immune 
disease is avoided in the long term. 
Loss , or breakdown, of tolerance to self-antigens appears to be a critical component in 
the pathogenesis of autoimmune disease. In genetically susceptible people , both 
intrinsic and extrinsic environmental factors may contribute to the initiation of 
autoimmune disease. However, still unknown is the nature of the trigger(s) initiating 
disease. 
MS, a particularly disabling neurological autoimmune disorder, is heterogeneous in 
nature and its immuno-pathogenesis accordingly complex. Experimental animal models 
such as EAE, on which much prior work has been based , may represent only part of 
the spectrum of human MS disease. MS appears to be a largely autoimmune disease 
but a neurodegenerative component within the target tissue may also contribute to the 
initiation and propagation of disease. 
No cure exists for MS or any of the major autoimmune diseases, and therapy-
particularly immune therapy-is still somewhat developmental , or targeted towards the 
resulting organ damage rather than towards the underlying cellular mechanisms. A 
multifactorial aetiology is probable for MS as well as other organ-specific autoimmune 
disorders , a number of genetic, immunological and environmental factors possibly co-
contributing , in a sequential way, to the final 'tipping of the balance ' towards 
established disease. 
The next chapter will review the epidemiological evidence for organ-specific 
autoimmune disorders, particularly MS, focusing on the nature of extrinsic 
environmental factors possibly involved in aetiology and their timing of action leading 
up to diagnosis of disease. 
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CHAPTER 2 
DETERMINANTS AND THEIR TIMING IN MS AND OTHER ORGAN-SPECIFIC 
AUTOIMMUNE DISORDERS: EVIDENCE FOR GENETICS, ENVIRONMENT AND 
SUNLIGHT 
2.0 Preface 
A widely-used definition of the discipline of epidemiology is that of MacMahon and 
Pugh (1970) , namely, 'the study of the distribution and determinants of disease 
frequency in human populations' [1 ], the ultimate goal being to identify and optimise 
ways of reducing the incidence and severity of disease in those populations. The 
purpose of this chapter is to summarise the current relevant epidemiological literature 
on specific organ-specific autoimmune disorders in terms of 'person , place and time', 
this conceptual framework allowing organisation of the possible determinants with 
which disease frequency can be associated [180]. Discussion will be restricted mainly 
to MS, because this is the main autoimmune disorder explored in this thesis . However, 
type 1 diabetes and RA will also be considered for comparison where appropriate . It 
will then be possible to identify where current knowledge is lacking, particularly for the 
southern hemisphere, in order to formulate the overarching research questions for this 
thesis , keeping in mind the primary aim of determination of possible causes of such 
autoimmune disorders. 
This chapter will briefly consider first the genetic contribution to autoimmune disease , 
before focusing on the environmental factors and their likely immunologica l 
mechanisms that may contribute to the aetiology of MS, type 1 diabetes and RA. In this 
chapter, sunlight, in particular, will be discussed as a major candidate disease 
determinant for these autoimmune disorders. Chapter 3 will then continue the 
discussion of putative environmental factors , focus ing on infections and other factors 
possibly contributing to such disease. 
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2.1 Genetic basis of autoimmune disease 
Family pedigrees of disease phenotype provide one assessment of the contribution of 
genetic factors to disease susceptibility. In MS, for example , first-degree relatives 
(parents, children, siblings) of persons with MS have a 3 to 5% chance (i.e. absolute 
risk) of also developing the disease, this risk being 15 to 25 times the risk in the 
general background population (data from the Canadian Collaborative Project on 
Genetic Susceptibility to MS [CCPGSMS] [181 ]). Similar results were found also in the 
United Kingdom (UK) and Belgium [182, 183]. Since family micro-environmental factors 
can also produce familial disease, a study of adoptees was required to show that non-
related family members had no increased risk over that of the general population [184]. 
A further study of half-siblings showed the same risk to each half-sibling whether they 
were raised together or separately [185], all indicating that the familial risk was more 
likely due to gene-sharing rather than to the family micro-environment. To further 
illustrate the disease complexity, though, the risk to a half-sibling (half-sibs sharing 25% 
of their DNA genetic material) was about one-third the risk to a full sibling (who share 
50% of their DNA), rather than an expected risk of about one-half if only one gene was 
involved . This risk then decreased in more distant relationships , suggesting a 
multigene model of family inheritance [186]. More detailed genome-wide studies of MS 
over the past decade have supported the multigene concept [187 , 188]; however, such 
studies have identified only about half of the genetic risk in terms of specific 
chromosome or gene associations [189, 190]. 
Autoimmune disorders are also more evident in some particular genetic populations 
[150, 191-194]. In MS, for example, risk is highest in those of Scottish ancestry and this 
appears to be due largely to genetic factors [195]. In general , MS is much more 
common (prevalence >50 per 100,000 population) in northern European populations 
(and in southern countries colonised by the same Europeans) and is least common (<5 
per 100,000) in indigenous populations in the same areas and in Asia [196]. This 
variation in terms of 'person ' is exemplified by another population with unusually high 
MS risk , the Sardinians, who have been shown to be one of the most intact and ancient 
human lineages; interestingly, the Sardinians also show high type 1 diabetes risk [4] . 
For RA, the highest frequency of this condition is found amongst Native American 
peoples rather than in Europeans [194] , this being a further example of an autoimmune 
disorder linked to a particular genetic population . 
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The most important genes contributing generally to human autoimmune disease 
susceptibility are located in the HLA class 11 region of the MHC on the short arm of 
chromosome 6 [197, 198]. MHC class II molecules are central to adaptive immune 
responses against invading pathogens and to maintenance of tolerance to self-
antigens (see Chapter 1 ). Because MHC class II molecules are 'self' molecules 
involved in (non-self) antigen presentation to CD4+ T cells (see Chapter 1 ), it is not 
surprising that this gene region holds the largest number of, and the longest recognised, 
associations with autoimmune disease of any similar-sized region across the genome 
[197]. Genes HLA-DR, HLA-DQ, or both (specific HLA-DR/DQ haplotypes involved in 
MS, type 1 diabetes and RA) encode key molecules in antigen presentation and T-cell 
repertoire determination [199], and thus genetic variations, and/or levels of gene 
expression, in this region have a comparatively large effect on susceptibility to such 
disease. Although the functional basis for the observed HLA class 11 associations in 
autoimmune disease remains incompletely understood, a breakdown in immunological 
tolerance to self-antigens through compromised regulatory processes (see Chapter 1) 
is a current view [197]. 
To estimate the effect of genetic factors on the cause of a disease, population-based 
twin studies can be used as a powerful tool to assess genetic and non-genetic factors 
in multifactorial immune-mediated diseases [200]. While the concordance rate for MS 
in fraternal twins in the large Canadian CCPGSMS study was approximately 4% (much 
the same as for regular siblings who shared the same amount, i.e. 50%, of their DNA) , 
the pair-wise concordance rate in identical twins, sharing 100% of their DNA, was only 
38% [201 ]. A later analysis of longitudinal twin data by the same research group 
showed that the proband-wise concordance among female monozygotic (i.e. identical) 
twins approached only 25.3% (SE + 4.4 ), despite 100% sharing of genetic material 
[202]. In the UK, the monozygotic twin concordance rate was similarly only 25% [203]. 
Such twin concordance studies for MS in both Canada and the UK suggest the 
additional involvement of factors other than genetic. 
Type 1 diabetes similarly shows a concordance rate in monozygotic twins of only 40 to 
50% in several studies [204-206], leaving some 50 to 60% to be accounted for by non-
genetic means; however, other studies found the monozygotic twin concordance rate 
for type 1 diabetes to be only around 20% [207 , 208], leaving an even higher margin for 
environmental effects. RA also shows a particularly low monozygotic twin concordance 
rate of 12% [194, 209]. Thus, for all three of these organ-specific autoimmune diseases, 
concordance rates in dizygotic twins of only 2 to 4% that are less than half of those of 
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monozygotic twins, suggest that the disorders are affected by a number of genes, each 
with a moderate effect, rather than by a single dominant or higher-effect gene. 
The evident multigene, non-Mendelian nature of these complex autoimmune diseases 
[41 , 21 O] means that several genetic factors can occasionally combine in one individual 
to crucially affect their immunoregulatory tolerance mechanisms, predisposing that 
individual , in certain environmental contexts, to an autoimmune disease state. In MS, 
for example, a recent collaborative genome-wide association study of 9,772 MS cases 
from 15 countries revealed more than 20 previously suggested and another 29 novel 
risk loci for this disorder that, importantly, were all immune-related (though together 
having much less effect than the HLA genes [211 ]). These genetic loci particularly 
implicated T-helper-cell differentiation and thus immune dysregulation in the 
pathogenesis of MS [212]. 
Hafler (2004) gives an interesting evolutionary reasoning for the multigene concept in 
terms of microbes encountered by early humans coming out of Africa 30,000 to 50 ,000 
years ago. Presuming that several different microbe-resistance genes were needed to 
provide maximal disease resistance at the population level , when these genes 
randomly (and rarely) came to be expressed together In an individual , a hyper-
responsive immune system and subsequent autoimmune disease may have resulted 
[135]-this may have been the price that that rare individual paid for protection of the 
whole population [22 , 135]. 
In synopsis, the curious , but well-established , identical-twin low disease concordance 
finding in many populations-that is, of two individuals having the same genetic 
background and same family environment, but both being concordant for MS or type 1 
diabetes in less than half of these twin pairs-strongly suggests the importance of 
other non-genetic, non-shared environmental triggers , as well as 'chance ' or other 
contributory random , stochastic events in the aetiology of such autoimmune disease 
[186]. Indeed , even in a recent , very 'deep' genomic analys is of monozygotic twins 
discordant for MS, no genetic differences in their T-helper immune ce lls (CD4+ T 
lymphocytes involved in pathophysiology of MS, see Chapter 1) that rr1 ight definitively 
cause MS were found. Additionally , no epigenetic differences-that is , chemical 
modifications to ONA that effect gene expression but not nucleotide sequence-in the 
twins' T-helper cells were found , and nor were there any transcriptome differences 
(messenger RNA expression levels) in these cells [213] . Although only a few twin pairs 
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were analysed, such studies underline the maJor importance of the environment In 
autoimmune disease causation. 
Further discussion of specific individual genes associated with increased disease risk is 
beyond the scope of this thesis; however, appropriate reference will be made 
particularly to gene-environment interactions that appear to be of primary importance in 
influencing the risk of developing autoimmune disease. 
2.2 Interaction between genetics and environment 
'Nature versus nurture' arguments about the pathogenesis of autoimmune disorders 
such as MS have now given way to evidence that both genetics and environment are 
important. Indeed, susceptibility is likely to be mediated by direct interactions between 
the environment and genes [189, 214]. How might such interaction occur? Rioux and 
Abbas (2005) [57] and others [215] suggest that the environment actively interacts with 
the multiple genetic factors, or genotypes, to orchestrate the developing immune 
system , producing the conditions required for subsequent autoimmune disease to be 
initiated or triggered by later environmental factors and/or random events (Figure 2.1 ). 
In part (b) of Figure 2.1, the environmental factors may be extrinsic, for example , 
exposure to pathogens or to a climatic variable(s), while intrinsic variables may be 
hormones, such as during pregnancy, or from the mother during the foetal period. 
Importantly, this concept expresses that an individual 's functional immunological 
repertoire of specific antigen receptors (B-cell receptors and TCRs) is likely to be a 
product of the interaction between their genetic repertoire and the environment [57]. 
Indeed, differences in selection of TCRs after antigen stimulation between monozygotic 
twins discordant for MS have been shown [216]. 
A similar concept to explain (adult) phenotypic differences in genetically identical 
individuals is the 'early origins hypothesis ' or the 'foetal basis of adult disease' 
promoted by D.J.P. Barker. This hypothesis postulates that nutrition and other 
environmental factors during foetal and early neonatal development alter susceptibility 
to several chronic disease conditions in later adult life [217-220]. A similar hypothesis 
of prenatal 'imprinting ' was proposed particularly for vitamin D by J. McGrath in 2001 
[221 ]. There is now much evidence for intra-uterine environmental imprinting , which 
occurs when developmentally plastic cellular pathways are affected during gestation , 
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enabling a single genotype to produce a broad range of adult phenotypes [222]. Recent 
work has shown that gene expression can be altered thus by environmental exposure 
at the epigenetic level , that is, literally 'above the genome', where heritable changes in 
gene expression occur in the absence of changes to the DNA sequence itself [223]. In 
MS, for example, the risk associated with the major MS HLA susceptibility locus has 
changed between successive generations, strongly implicating gene-environment 
interactions mediated by epigenetic changes [224]. 
Consistent with early life effects , a study by CCPGSMS showed that half-sibs with a 
maternal parent in common had an almost doubled half-sib risk of MS compared with 
half-sibs with a paternal parent in common ; this suggests a significant maternal effect 
in MS occurrence [225] . These authors propose that environmental factors may have a 
substantial role in such an effect, and that 'parental imprinting remains a possible 
candidate '. Subsequent studies by the same group have confirmed this maternal 
parent-of-origin effect [226] , and further identify gender-specific (i.e. female) epigenetic 
interactions as mediating this effect [227]. The possible importance of the maternal 
uterine environment is further suggested [228] by the excess concordance (two-fold) of 
MS for dizygotic (fraternal) twins compared to non-twin sibling pairs in the Canadian 
data, although these data did not reach statistical significance [202] . 
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Figure 2.1: Comparison of (a) single gene disorders; for example, autoimmune 
polyendocrine syndrome (APS-1) caused by mutation of the autoimmune 
regulator (AIRE) gene (see Chapter 1, Section 1.4.1 ); and (b) complex traits where 
the disease state results from interactions between multiple genotypes and the 
environment. Individual genotypes can affect one or more components of the 
adaptive or innate immune systems; together these lead to an altered immune 
response to self-antigens. (Figure adapted from Rioux and Abbas, 2005 [57].) 
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Causation of autoimmune disorders such as MS and type 1 diabetes almost certa inly 
involves a combination of genetic and environmental exposure factors . This may be 
considered in the context of Rothman and Greenland's 'component cause model ' of 
disease causation [1], wherein 'sufficient cause' for a disease to occur is defined as a 
'set of minimal conditions and events that finally produce disease'. Each 'sufficient 
cause' comprises a set, or series, of 'component causes', the latter being defined as 
'an antecedent event, condition or characteristic that is necessary for occurrence of 
disease, but which may not be sufficient by itself to produce disease' (see Figure 2.2). 
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Figure 2.2: Component cause model of disease causation. Three sufficient 
causes of a disease characterised by component causes A, B, E and a 
ubiquitous component U. (Figure from Rothman and Greenland, 1998 [1].) 
In Figure 2.2, the component causes , A, B and E, where only two of these three 
components are necessary for disease, act together with a ubiquitous component 
cause, U, to produce three possible sufficient causes. That is, these component causes 
acting together in the same sufficient cause may be thought of as interacting 
biologically to produce disease. In other words, 'biological interaction ' may be defined 
as 'participation of two ( or more) component causes in the same sufficient cause ' [1 ]. 
Further, this interaction or 'joint action ' need not be simultaneous: one component 
cause may act many years before the other, the condit ion being that the first 
component cause leaves some effect that interacts with the later component [1]. Figure 
2.3 shows a possible 'life-course' sufficient-cause scena rio for an example 
multifactorial disease with four successive component causes, three components being 
environmental and the first being genetic. 
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Figure 2.3: Life-course disease causation model for a multifactorial disorder with 
genetic (G) and environmental (E1 to E3) component causes. 
Such a concept of an immune disorder such as MS or type 1 diabetes being 'a disease 
waiting to happen', wherein a combination of genetic and environmental factors must 
reach a sufficient level, or threshold, before the critical transition is made to clinical 
disease, is gaining support. For example, for MS, the critical factors, both genetic and 
environmental, may occur over 'a critical window of time', giving rise to persons with an 
'MS trait' [228]. The 'MS trait' notion, which evolved from observations such as the low 
concordance rate in monozygotic twins, postulates that in some genetically susceptible 
individuals, a primary challenge, which may or may not be immunological, may cause 
damage to the BBB, but that this is insufficient to result in formation of demyelination 
plaques (see Chapter 1, Section 1.5). A second immunological challenge may then 
make the already-vulnerable BBB less resistant to subsequent events. There may also 
be other subtle changes within the CNS as part of the MS trait [228]. Such an individual 
then, over time, may or may not develop either subclinical or clinical MS depending on 
other, presumably environmental, factors. A similar sequential concept is Goodin 's 
(2009) 'multi-hit causal cascade' hypothesis for MS [229] , discussed in more detail in 
Chapter 3. 
An analogous hypothesis for type 1 diabetes induction has been suggested , wherein 
genetic predisposition appears to determine almost entirely whether a person will 
develop immune reactivity against insulin-producing beta-cells in the pancreas, but 
environmental factors have a major effect on whether type 1 diabetes manifests itself 
clinically, this occurring after 80 to 90% of the beta-cells have been destroyed [230]. 
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Such a possible life-course model for MS, or other autoimmune disorders such as type 
1 diabetes or RA, is depicted in Figure 2.4, showing environmental factors acting at 
various 'critical windows of time'. The effect of environmental events in early life in 
particular will be discussed further at the end of this chapter in Section 2.6. 
Timeline of Life Through Course of Disease 
Genetic 
Susceptibility 
(Conception) r 
r r r 
Multiple Environmental 
Exposures from Foetal 
Period to Critical Age 
of Sufficient Exposure 
Latency period 
Autoimmune 
Disease (MS, 
Type 1 diabetes, 
RAJ 
Environmental factors may act at different 
times, beginning prior to and after birth , to 
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Figure 2.4: Aetiology of autoimmune disorders such as MS, type 1 diabetes and 
RA: a possible life-course model of timing of genetic and environmental 
component causes. 
Summing up this section , a substantial contributory role for environmental factors in the 
aetiology of these organ-specific autoimmune disorders is suggested. Genetic ('person ') 
factors are necessary, but not sufficient, to cause disease for most ind ividuals. 
Environmental factors should be considered to both interact with genetic factors and 
may act alone at several possible time points over the life course lead ing to onset of 
disease (Figures 2.3 and 2.4 ). Such factors are of particular interest if they are 
modifiable, or even preventable, and if they also trigger disease exacerbations, such as 
seen in MS [231 ]. From a public health point of view, it is important to note that if there 
are a number of component causes involved in a sufficient cause for any disorder, 
intervention on only one of these (environmental) components may be all that is 
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required to prevent disease. The remainder of this chapter, and the next, will therefore 
focus on the environmental factors that may possibly be involved in aetiology of MS, 
type 1 diabetes and RA, and the 'place' and 'time' associations of these factors with 
disease occurrence. 
2.3 Epidemiological evidence for environmental determinants 
Ecological studies and candidate environmental determinants 
Ecological studies, focused on group- or population-level disease determinants and 
disease occurrence, can inform about possible aetiological roles and assist in 
formulation of hypotheses to be tested at the individual level , or in screening of existing 
hypotheses [1 ]. Further, it is increasingly being recognised that such studies are 
valuable in their own right and that factors at the population level beyond those of 
individuals are often important to health [232]. For example , the well-known concept of 
herd immunity in infectious diseases implies that an individual 's likelihood of 
contracting an infectious disease depends partly on the level of immunity in the 
person 's population. Ecological studies allow the basic descriptive characteristics of a 
disease to be determined in relation to the parameters of 'person ', 'place' and 'time '. 
That is , of basic interest in these studies is : 
• Person: 'Who is getting the disease?', including age, sex and race . 
• Place: 'Where are the rates of disease highest and lowest? ', including 
country, geographic region within country (e.g. latitude gradient). For this 
parameter, studies of migrants provide hypotheses of possible relative roles 
of genetics and environment. 
• Time: 'When does the disease occur commonly or rarely? ', 'Is the frequency 
of the disease different now from the past? ' and 'Is there a cyclic or other 
pattern of the disease?' [233] . 
Despite ecological studies using data averaged over individuals , and sometimes proxy 
measures for exposure , together with often uncontrolled confounding factors , such 
studies can also be useful for detecting associations that signal the presence of effects 
that may be further investigated at the individual level [1 ]. An ecological approach is 
used in Chapter 4 of this thesis , for a number of immune disorders including type 1 
diabetes. 
66 
From ecological studies, a range of factors have been variously associated with MS, 
including those in the geographic or physical category (e.g . latitude, altitude, 
temperature , UVR, toxins) , biological factors (e.g . infections, diet, stress , hormones, 
smoking) and cultural factors such as socio-economic status (SES) [231 , 234-236] . The 
least equivocal associations were found with low temperature , non-specific infections 
[235] and , more recently , low UVR and/or low vitamin D [6 , 234, 237] , EBV and 
smoking [238, 239] . For type 1 diabetes, the environmental factors most impl icated 
include infections (e.g. enteroviruses), lack of breastfeeding , diet (e.g . cow's milk) , low 
temperature , toxins [192 , 240, 241] and , more recently , low vitamin D and/or UVR [242]. 
Environmental risk factors for RA lie mainly in the biological category and include 
infections, hormonal factors, adverse pregnancy outcomes, smoking , obesity, diet [194] 
and low vitamin D and/or UVR [25]. 
However, as shown by the component cause model of disease causation (see Figure 
2.2) , any of these factors as determined by ecological studies may be involved in any 
combination in the sequential determination , initiation (or induction) or final precipitation 
(triggering) of disease onset. They may contribute at different times to disease 
acquisition , as well as to the modification of its subsequent course [234] . 
Analytical epidemiology 
A useful technique here is an analytical epidemiological approach , where each factor is 
carefully assessed at the individual level to determine whether the exposure factor is 
acting as an antecedent cause , a directly causal exposure , an intermediate , a 
confounder, an effect modifier, or as a consequence of disease. 
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Table 2.1: Framework for the interpretation of an epidemiological study 
(Hennekens and Suring, 1987 [233]) 
Is there a valid statistical association? 
Is the association likely to be due to chance? 
Is the association likely to be due to bias? 
Is the association likely to be due to confounding? 
Can this valid statistical association be judged as cause and effect? 
Is there a strong association? 
Is there biological credibility to the hypothesis? 
Is there consistency with other studies? 
Is the time sequence compatible? 
Is there evidence of a dose-response relationship? 
While a number of criteria (based on those first proposed by Hill , 1965) car. be used to 
assess a valid statistical exposure-disease association for evidence of causality [233] 
(Table 2.1 ), Rothman and Greenland caution that only the criterion of temporality is 
strictly necessary to define causality (i .e. Is the time sequence compatible? In particular, 
does the exposure precede disease?), the other criteria assisting interpretation but not 
being exclusively required [1 ]. Additionally , whether an exposure factor is a true 
confounder of the association between exposure and disease , or is intermediate on the 
causal pathway between the exposure and disease (see Figure 2.5) , must be 
distinguished. As shown in Figure 2.5 , a confounder is a variable that is associated with 
the exposure and , independent of that exposure , is a risk factor for the disease. If, 
however, one mechanism of action of the exposure is to alter the level of the potential 
confounder, which in turn itself affects disease risk , then that factor is not a confounder 
but rather an intermediate step in the causal cha in between the exposure and disease 
[233] . 
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Figure 2.5: Interrelationship between an exposure (E), a confounding factor (C) 
and disease (D) (top of diagram), and an exposure (E), disease (D) and an 
intermediate factor (I), which is on the causal pathway and thus not a confounder 
(lower part of diagram). 
Effect modification, conversely, may be present when the magnitude of the association 
between the exposure and disease varies by levels of a third factor [233]. To 
distinguish such relationships between exposure factor(s) and disease, individual-level 
epidemiological studies, such as randomised controlled trials (RCTs), cohort studies, or 
case-control studies, are required. While the effects of confounding can often be 
controlled in the design phase of analytical epidemiological studies (i.e. by 
randomisation, restriction or matching), the specific analytic techniques of data 
stratification and multivariate analysis can also be used to both control confounding 
and determine and describe effect modification (this is discussed further with respect to 
data analysis in Chapter 7). This thesis will use an individual-level observational 
epidemiological approach for Chapters 5 to 7 (timing of birth of MS cases) and Chapter 
8 (order of birth of MS cases), aiming to determine the possible nature of 
environmental factors influencing MS risk from their life-course timing. 
A review of analytical epidemiological studies of sunlight exposure (UVR and vitamin D) 
and effects on MS, type 1 diabetes and RA is given in Section 2.6 of this chapter. 
However, such individual-level analytical studies on specific, potentially causal factors 
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can be guided by information from ecological studies of disease occurrence in terms of 
person , place and time. Examples are longer-term changes in disease incidence 
(variation in time) , geographic gradients in prevalence or incidence (variation in place) 
and seasonal or other cyclical changes in incidence (variation in time) . These will now 
be considered in turn for MS and type 1 diabetes. 
2.3.1 Increasing incidence of organ-specific autoimmune disorders 
Variation in 'time' 
One of the most convincing indications of the contribution of environmental factors to 
aetiology of autoimmune disorders is their increasing incidence over the last three 
decades in developed countries [3], such increases being faster than population-level 
genetic change would suggest or allow [4 , 193, 240]. Although ascertainment of 
disease cases would undoubtedly have also improved over the same period , these 
increases in incidence do appear to be, mostly, real and thus suggest environmental 
causation [4 , 240]. A substantial increase in MS incidence, for example, has been 
reported from high prevalence areas such as Norway, Finland and Sardinia in the 
northern hemisphere [243-245] and from Australia in the southern hemisphere [246, 
247]. 
In Newcastle, New South Wales (NSW) , Australia , where three different decades over 
the period 1950 to 1996 were compared using comparable diagnostic criteria and 
methods for each decade, average annual MS incidence rate doubled from 1.2 to 2.4 
per 100,000 population over the 35-year study period . The largest increases were seen 
in females and in the older age groups. Prevalence also increased markedly from 19.6 
to 59.1 per 100,000 of population over the same period. Although such trends in MS 
prevalence and incidence had been observed in the northern hemisphere, particularly 
in Europe (summarised in Tab le 2.2 ), th is was the first such study to show a 
longitudinal increase in prevalence and incidence in the southern hemisphere over a 
period of this duration [246]. Consistent with these results , another (and longer) MS 
study in Tasmania (TAS) , Australia showed a three-fold increase in age-standard ised 
prevalence and a nearly two-fold increase in incidence over the period 1951 to 2009, 
part of the prevalence increase being attributed to increased longevity, decreased 
mortality and increased incidence [24 7]. 
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Table 2.2: Increasing MS prevalence and crude incidence rates over time within areas in selected European countries 
Country Area 
Norway North Norway 
(Troms/Finnmark) 
Oslo 
(South Norway) 
SW Norway 
(Hordaland Co.) 
Prevalence 
(mean/105) (Year) 
21 (1973) 
73 (1993) 
86* (1983) 
120 (1995) 
? 
151 (2003) 
Reference 
[248] 
[249] 
[250] 
[251] 
[252] 
Incidence [95% Cl] 
(per 105/yr) (Years) 
2.6 [1.7 , 3.7] (1974-78) 
3.0 [2 .1, 4.2] (1979- 83) 
3.5 [2.5 , 4.8] (1984-88) 
4.3 [3 .0, 5.9] (1989- 92) 
3.6 [2 .2, 6.0] (1972- 76) 
4.4 [2.8 , 6.9] (1977- 81) 
4.9 [3.1 , 7.6] (1982-86) 
7.2 [5.0 , 10.2] (1987- 91) 
8. 7 [6 .3, 11.9] (1992-96) 
1.8 (1953- 57) 
4.1 [2 .1, 6.1] (1973- 77) 
4.7 [2 .4, 7.0] (1978- 82) 
3.2 [0.6 , 5.8] (1983- 87) 
6.0 (1993- 97) 
Reference 
[249] :t: 
' ' 
' ' 
' ' 
[251] 
[2511:t: 
' ' 
' ' 
[251] 
[252] 
[253] 
' ' 
' ' 
[252] 
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Country Area 
Finland 
Central Norway 
(Nord-Trondelag) 
Central Finland 
Western Finland 
(Seinajoki) 
Sweden North Sweden 
(Vasterbotten Co.) 
Denmark Denmark 
UK NE Scotland 
Prevalence 
(mean/105) (Year) 
? 
164 (2000) 
59 (1993) 
105 (2000) 
119(1983) 
202 (1993) 
125 (1990) 
154 (1997) 
59 (1950) 
112 ( 1990) 
Reference 
[254] 
[255] 
' ' 
[256] 
' ' 
[253] 
' ' 
[257] 
[258] 
154 (2005) [257] 
127 (1970) 
178 (1980) 
[259] 
' ' 
Incidence [95% Cl] 
(per 105/yr) (Years) 
3. 9 ( 1 9 7 4-7 5) 
5.6 (1998-99) 
3.8 (1979-93) 
9.2 (1994-98) 
9.4 [7.7, 11.2] (1979-86) 
11.6 [10.1, 13.8] (1987-93) 
2.6# [2.2, 3.0] (197 4-88) 
5.2 [4.4, 6.2] (1988-97) 
4.1 [3 .9, 4.3] (1970-79) 
5.0 [4 .8, 5.2] (1980-89) 
6.0 (1968-70) 
7.2 (1977-80) 
Reference 
[254] 
' ' 
[255] 
' ' 
[256] 
' ' 
[253] 
' ' 
[258] 
' ' 
[259] 
' ' 
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Country Area 
France 
Italy 
SE Scotland 
Nthn Ireland 
NE Nthn Ireland 
Wales 
Lorraine 
France 
North Sardinia 
(Sassari) 
Prevalence 
(mean/105) (Year) 
203 (1995) 
51 (1951) 
80 (1961) 
138 (1986) 
168 (1996) 
200 (2004) 
101 (1985) 
146 (2005) 
120 (2004) 
95 (2004) 
103 (1991) 
144 (1997) 
Reference 
[195] 
[26or 
' ' 
[261r 
[263r 
[262] 
[264] 
' ' 
[265] 
[266] 
[244] 
' ' 
Incidence [95% Cl] 
(per 105/yr) (Years) 
Reference 
12.2 [10.8 , 13.7] (1992-95) [195] 
2.7 (1937-51) [26or 
4.4 (1952-61) ' ' 
9.3 (1996-96) [262] 
4.2 [2.6, 6.9] (1985-85) [264] 
9.6 [7.1 , 13.1] (2007-07) 
5.5 [4 .4, 6.6] (1990-02) 
7.5 [7 .3, 7.6] (2003-04) 
1.2 [0 .8, 1.8] (1965-69) 
4.9 [4.0 , 6.0] (1980-84) 
6.1 [5 .1, 7.2] (1995-99) 
' ' 
[265] 
[266] 
[267] 
' ' 
' ' 
73 
Country Area 
Central Sardinia 
(Nuoro) 
Prevalence 
(mean/105) (Year) 
~100 (1985) 
152 (1994) 
*Vestfold County , Norway (near Oslo ). 
#Goteborg , southern Sweden . 
Reference 
[268] 
' ' 
Incidence [95% Cl] 
(per 105/yr) (Years) 
1.9 [1 .3, 2.9] (1955-59) 
4.8 (1975-79) 
6.4 [5.2 , 7.8] (1990-96) 
Reference 
[268] 
' ' 
' ' 
+cited by Sundstrom et al. , 2003 [253] . 
+Cited by Gray et al ., 2008 [262] . 
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In type 1 diabetes also, a marked increase in the incidence of this childhood immune 
disorder has been reported from Europe, North America , Norway, Sweden , Hungary, 
Finland, Austria, Israel, England and Switzerland in the northern hemisphere [269-285] . 
For example , in Switzerland, incidence increased from 4.5 to 10.5 per 100,000 of 
population over the 1965 to 2000 period, all of this increase being in children under five 
years of age, and most of the increase having occurred in the last 10 years [282]. 
Similarly in Finland, where incidence is highest worldwide, incidence increased from 
31.4 to 64.2 per 100,000 per year from 1980 to 2005; again the highest rate of increase 
(4.7% per year) was in the Oto 4 year-old age group [275]. For Europe (17 countries), 
the overall annual increase between 1989 and 2003 was 3.9% (95% Cl 3.6, 4.2) [280]. 
In the southern hemisphere, a 3 to 6% increase in type 1 diabetes per year has been 
recorded in Australia [286, 287] and in New Zealand (NZ) [288] and Peru [277, 279] , 
and the overall global increase in incidence, in 27 countries over three decades, has 
been estimated as 3% (95% Cl 2.6, 3.3) per year [279]. 
2.3.2 Latitude gradients in prevalence or incidence 
Variation in 'place' 
Another of the more significant epidemiological features of organ-specific autoimmune 
disorders is a gradient of increasing prevalence with increase in geographical latitude. 
That is , there is a general , global increase in prevalence of both MS and type 1 
diabetes away from the equator and towards Earth's poles , particularly in the northern 
hemisphere, where these diseases have been most studied (see Figure 2.6). Indeed , in 
MS, for example , while the effect of the environment is not necessarily mediated by a 
single factor, latitude demonstrates the strongest association [214 ]. Prevalence of MS 
in 2007/2008 varied globally from almost zero at the equator to greater than 100 (per 
100,000) at some temperate latitudes [289] ; these more recent estimates for MS are 
shown for Europe in Figure 2. 7 (Multiple Sclerosis International Federation Atlas of MS 
database, http://www.atlasofms.org/index.aspx , accessed February 2011 ). 
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Figure 2.6: (a) The north-south gradient in prevalence of MS (based on data from 
Kurtzke, 2000 [290]) and (b) the gradient in incidence of type 1 diabetes (based 
on data from Green and Patterson, 2001 [291]) in Europe, as given by Bach (2002) 
[3]. 
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Figure 2.7: Prevalence of MS in Europe by country, 2008. (Data map from Atlas of 
MS database.) 
RA also exhibits geographic variations suggestive of a similar north-south grad ient in 
both prevalence and incidence in Europe and North America [194 , 292]. 
76 
Although there are some local exceptions to the general pattern (e.g. for MS: Sardinia 
[Italy], and Scotland and Northern Ireland [UK] are higher than expected , and Sarni 
[northern ethnic group] areas in Norway lower than expected , see Figure 2.8) , the 
general global distribution of these three autoimmune diseases suggests the action of 
environment shaping such disease occurrence. 
MS 
In Figures 2.8 and 2.9, I have collated data from recent reviews to show the prevalence 
and incidence of MS in Europe in more detail. In Figure 2.8, mean prevalence is plotted 
against the latitude of the capital city of each country, using prevalence data over 1986 
to 2001 from Pugliatti et al. (2006) [293], supplemented by data for Scotland from 
Rothwell and Charlton (1998) [195]. 
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Figure 2.8: MS prevalence rates in Europe by latitude of country (rates shown 
adjusted for the standard European population, or crude where adjusted rates 
not available). Adjusted rates for Sardinia, Scotland and northern (Sam i-
populated) areas of Norway are shown separately. (Data from Pugliatti et al., 
2006 [293] and Rothwell and Charlton, 1998 [195].) 
MS incidence estimates over periods up to 15 years to 2001 show a simi lar pattern of 
increase with northern latitude of the capital cities (Figure 2.9). 
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Figure 2.9: MS incidence rates in Europe by latitude of country. Crude rates for 
Sardinia, Scotland and northern (Sarni-populated) areas of Norway are shown 
separately. (Data from Pugliatti et al., 2006 [293].) 
For both MS and type 1 diabetes, other factors possibly confounding this latitude 
gradient in Europe include disease ascertainment differences between northern and 
southern Europe [196, 293, 294], and a socio-economic gradient. The latter is shown 
by a positive correlation between the gross national product in 12 European countries 
and the incidence of both MS and type 1 diabetes, as well as asthma [3] . In addition , 
the contribution of ethnic ancestry to these gradients has been more recently defined in 
both Europe and North America for MS [4 , 193]. Nevertheless, as indicated by these 
gradients, environmental factors are generally agreed to be important in modifying 
genetic susceptibility and thus influencing disease distribution [193] . Within-country 
gradients are also marked in the UK [293] and France [189] for MS. 
In North America , a large prospective study for MS (the Nurses' Health Study) 
compared women born in two different periods (1920 to 1946 and 194 7 to 1964) in the 
US. A strong north-south latitude gradient was shown for the earl ier cohort , though th is 
appeared to have attenuated somewhat in the later cohort; a concomitant change in a 
causal environmental factor was, however, suggested [295]. Later work has shown the 
attenuation in the gradient to be mainly after 1980 [296] and particu larly in the US, 
where decreased time outdoors because of a modern urban lifestyle , and thus 
decreased UVR exposure, was postulated to be one contributing factor [297] . 
78 
In the southern hemisphere, the first epidemiological study of MS in Australia by 
Acheson in 1961 was based on mortality data , and found that MS mortality showed a 
close positive relationship with southern latitude [298]. This early study also showed 
that MS mortality was considerably lower than that in the UK [299]; this and later 
prevalence studies, such as that of Miller and colleagues (1990) , suggested that the 
antipodean environment was protective for northern Europeans for MS [300] . 
A comprehensive set of surveys of nine areas of Australia and NZ by McLeod, 
Hammond and colleagues in the 1980s were the first prevalence studies in these 
climes. This research group showed a marked latitude gradient in MS prevalence for 
Australasia, a seven-fold increase in prevalence existing from subtropical North 
Queensland (latitude 19 °S), to temperate Hobart, TAS (latitude 43°S), and NZ (latitude 
34 to 47°S) [301, 302]. 
While the more appreciable MS gradient in NZ has more recently been attributed 
partially to both higher numbers of Scottish migrants in the south and higher 
proportions of genetically resistant indigenous Maori people in the north [4 , 193], the 
still almost seven-fold gradient in Australia persists unexplained and cannot be easily 
attributed to differences in either SES or genetics [4, 301 , 303]. Further, the latitude 
gradient in MS prevalence was also evident among British and Irish migrants to 
Australia [304]. 
A recent prospective study in Australia ('Ausimmune' study) on the incidence rate of 
'first demyelinating events ' (FOE, a highly predictive pre-diagnostic event for MS) has 
also established a four-fold latitudinal gradient from Brisbane (27°S) to TAS ( 43°S) 
[305] , further suggesting environmental effects on MS-related disease. Australia is thus 
an ideal location for further MS study, as detailed in Chapters 5 to 7. 
Age-related migration (variation in 'time' and 'place') 
Studies of migrant populations moving between areas of differing prevalence rates 
have been used to help answer the 'genetics or environment' question , particularly for 
MS. In addition , by determining whether age at migration alters these prevalence 
patterns, the timing of important environmental exposures can be indicated . That is, 
even though such studies have many poss ible sources of error (rev iewed by Gale and 
Martyn, 1995) [306, 307], migrants moving from a high-(MS) risk region to a low-risk 
region (e.g. UK/Europe to Asia or Africa) generally have a lower than expected risk of 
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disease, particularly if migration occurs before the age of 15 years. However, migration 
from a low-risk to a high-risk region tends to result in retention of the low risk of the 
home country and not show any clear age-at-migration effect [8, 306]. More recent 
studies are largely consistent with these findings [308-311 ], including a re-analysis of 
an earlier Australian migration study that had previously reported a 'critical ' migration 
age well into adulthood [304] and that now supports the age-15 'limit' [312]. Thus , MS 
risk appears strongly associated with place of residence in early life. 
Type 1 diabetes 
In the northern hemisphere, the first globally-standardised incidence measures for type 
1 diabetes over 15 countries were achieved in the early 1980s. These showed the 
average annual age-adjusted incidence for those under 15 years of age to decrease 
approximately seven-fold from Finland to France in western Europe, and eight-fold 
from Michigan in the northern US to California in the southern US [313]. An update on 
the worldwide incidence in 40 countries by the World Health Organization (WHO) 
DiaMond group in 1993 showed the highest incidences and the greatest intra-
continental variation to be in Europe, where there was an eight-fold gradient from 
Finland to northern Greece [314]. In China, also, as part of the same WHO project, a 
strong north-south latitude gradient was shown , a doubled incidence being seen in the 
northern half of the country compared to the south , even though type 1 diabetes 
incidence overall was , globally, the lowest ever reported [315]. A further update by the 
WHO DiaMond group for 51 regions in 1990 to 1994 reported an overall 350-fold 
variation in annual incidence from 0.1/100,000 in China and Venezuela to 37 /100,000 
in Sardinia and Finland [316]. Subsequent analysis of these 1990 to 1994 data by 
latitude established an association between latitude and type 1 diabetes risk over all 51 
regions [317]. Records over the next decade showed even higher incidences in 
northern Europe [291], and a north-south gradient as pictured in Figure 2.6b. Some of 
the incidence variation was shown to be due to ethnicity [313 , 315], but a similar 
gradient was shown even within the genetically homogeneous country of Sweden [318]. 
Generally, southern hemisphere countries showed lower type 1 diabetes incidences 
than the northern hemisphere, and the lowest incidences overall were found in Asia 
(China) and South America [314 , 316] . However, few latitude-gradient studies have 
been conducted in the southern hemisphere on this important ch ildhood immune 
disorder, despite the average annual incidence being at least 10/100,000 in Australia 
and NZ [279, 288]. 
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Migration studies also support the geographic differences for type 1 diabetes. For 
example, Japanese children in Hawaii show a four-fold risk compared to those in Japan , 
and Samoan children in NZ show similar differences. There is an overall trend for 
immigrant populations from low-incidence countries to quickly adopt the type 1 
diabetes risk prevalent in the new environment [30]. 
Latitude as proxy environmental factor 
It is important to note that geographic latitude is essentially a proxy for several putative 
environmental factors. Increasing northern, or southern, latitude is inversely associated 
with decrease in both of the climatic variables, temperature and solar radiation, the 
latter including UVR. For example, both temperature and UVR decrease towards 
Earth's poles, the rate of decrease in both of these physical variables being greater at 
certain times of the year (e.g. winter). In Australia, the decrease in annual averaged 
ambient UVR is 1 kJm-2 per 10° increase in latitude [319]. Geographic latitude may also 
be indirectly associated with diet and biological factors, such as infectious agents, 
through their more obvious association with climate, and again in particularly cold, or 
wet, seasons. 
2.3.3 Seasonal variation 
Cyclic variation in 'time' 
Supporting the latitude-gradient evidence for the action of environmental factors on MS 
and type 1 diabetes, and perhaps even more strongly suggestive of this action , is 
evidence of seasonal changes in these disorders. Several of the aforementioned 
factors, including temperature, UVR and infections, vary seasonally as well as 
geographically, particularly at the higher latitudes. Possible associations of these with 
variations in disease parameters may give clues to the nature of these factors. 
For MS, for example, clustering (in time rather than in space) can occur in the time of 
birth (within the year) of persons who later develop MS, in the time of onset of disease, 
in the timing of disease relapses (in RRMS) , and in the timing of CNS lesion activity. 
Alternatively, or as well, a relative paucity of any of these MS parameters may occur at 
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any time of the year, since an environmental influence may be protective rather than 
adverse. 
MS 
Timing of MS births in the northern hemisphere has exhibited mainly a spring excess 
(relative to those in the general population), as seen in Denmark, Sweden and British 
Columbia (Canada) [7, 320-322]. An autumn excess in Sicily [323] has also been 
reported. More recently, a significant excess in MS births in May (northern spring) as 
well as a significant MS-births deficit in November (northern autumn) has been 
reported in a large, pooled Canadian, British, Danish and Swedish study [324]. A 
seasonal cycle in the month of birth of persons with MS may indicate a causal (or 
protective) environmental factor acting around the time of birth, which may be a critical 
time 'window' for such effects [7]. This is evaluated further in Chapters 5 to 7. Prior to 
this thesis, no published season- or month-of-birth data were available for MS in the 
southern hemisphere. 
The time of onset of disease can also be influenced directly by seasonally varying 
environmental factors. MS onset, and onset of monosymptomatic optic neuritis (MON, 
closely related to MS), were studied in a meta-analysis of 21 northern hemisphere 
studies; both conditions showed highest frequencies in spring, and lowest in winter 
[325]. 
Relapses or progression of MS can also show analogous changes with season. In the 
northern hemisphere MS meta-analysis, MS exacerbations showed highest 
frequencies in spring and lowest frequencies in winter, similar to both MS and MON 
onset [325]. A more recent meta-analysis in both hemispheres showed similar relapse 
onset peaks in early spring but troughs in autumn , April being the peak month in the 
northern hemisphere and October the peak in the southern hemisphere [326]. In 
southern hemisphere TAS , Australia , lower MS relapse rates at the population level 
were observed in late summer (February) compared with the rest of the year; these 
were associated with both upper respiratory tract infections (positively) and erythemal 
UVR (inversely) 1.5 months prior [327]. 
Additionally, the activity of MS lesions detected by MRI in southern German MS 
patients was shown to exhibit a 'sinusoidal' seasonal pattern with an excess in spring 
and early summer and an autumn deficit [328]; in a further ecological extension of this 
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study, this pattern was shown to be inversely correlated with the circulating vitamin D 
(25(OH)D) levels two months prior, indicating a time-lagged relationship with this 
largely environmentally determined factor [329]. While another larger MRI study of MS 
lesional activity in patients from Europe and Canada did not find significant seasonal 
variation [330], a recent intensive MRI study in the US reported increased disease 
activity, based on new lesions, in spring and summer, consistent with the previous 
findings [331]. 
Type 1 diabetes 
Seasonal variation in month of birth in type 1 diabetes has been reported in high-
incidence areas, such as the UK, the Netherlands, Sweden, Sardinia and Slovenia, 
with excess births in spring or summer [332-336], but a seasonal pattern was not found 
in subsequent analyses of other European regions [337, 338]. More recently, however, 
Vaiserman and colleagues showed spring excesses in type 1 diabetes births in Ukraine 
that were more pronounced than elsewhere in high-incidence Europe [339]. Laron and 
colleagues also showed spring excesses in type 1 diabetes births in the high-incidence 
Jewish population in Israel, but not in the low-incidence Arab population [340]. In low-
incidence Japan, no seasonal variation in either month of birth or month of onset was 
observed [341 ]. However, a recent, large study in the US has supported the spring 
excess in type 1 diabetes births in both sexes and in three racial groups, but only in the 
northern latitudes (Colorado, western Washington State and southern Ohio) , no birth-
month effect being seen in more southern locations [342]. In the southern hemisphere, 
a spring or summer peak in month of birth was seen in Canterbury, NZ, consistent with 
the northern hemisphere spring-summer findings [343 , 344], whereas Laron and 
colleagues reported a lack of any season-of-birth pattern in a more heterogeneous 
Australian (Sydney) population [343] . 
The onset of diabetes disease , however, as measured by the time of diagnosis, has 
been more often studied in both hemispheres and does appear to show clear seasonal 
variation [240 , 334, 345 , 346] . Several studies from as early as the 1980s report higher 
occurrence during the cold autumn and winter months than during the warmer spring 
and summer months [347] , thus mirroring the spring-summer seasonal variation in birth 
month [192]. 
In Melbourne, Australia, there were more new cases in late autumn and winter also 
[348] and in winter in NSW, Australia [349], and NZ [344] ; however, a study in Victoria 
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(VIC), Australia , showed no significant variation [350]. A more recent national study in 
Australia showed significantly higher diagnosis rates in winter, but no apparent season-
of-birth effect [351 ]. The autumn/winter pattern of onset has, in some studies, been 
associated with a preceding, perhaps precipitating, infection [352] or with both cold 
temperature and low sunshine hours [273]. Nevertheless, as indicated by Karvonen 
and colleagues, many physiological parameters, such as blood glucose, blood lipids, 
blood pressure and body weight, and health habits such as diet and physical activity , 
have a seasonal pattern. The seasonality in the diagnosis of type 1 diabetes may not 
be related only to causal factors that trigger the disease, but also with the expression of 
symptoms in people who are already at an advanced stage in developing the disease 
[34 7]. 
In synopsis, increasing incidence of autoimmune disease, latitude gradients in disease 
prevalence (or incidence) , changes in risk in migrant populations and seasonal 
clustering in month of birth, month of onset or times of disease progression all suggest 
the action of environmental factors in causation of disorders such as MS and type 1 
diabetes. Key factors may be involved either at the initiation stage of such diseases, or 
in subsequent precipitation of the clinical disorder, and even in the promotion of 
disease once precipitated. These factors vary spatially with geographic latitude and 
temporally throughout the year, as well as also possibly varying over a longer period-
that is, from year to year. Therefore, the likely factors include: temperature , solar 
radiation including visible light and UVR and , less directly, climate-associated infections, 
and possibly diet. 
2.4 Sunlight-a candidate determinant of disease 
The more sunlight, the less autoimmune disease? 
In 1960, an early ecological study reported that the North American gradient in MS 
prevalence by latitude of birth was 'explained ' largely by the decrease in winter so lar 
radiation [353]. This early study compared as exposures several cl imatic variables-
midwinter solar radiation , latitude, average annual 'so lar rad iation ' (measured by 
number of sunshine hours), a winter-severity index, a summer-temperatu re index and 
rainfall. Midwinter solar radiation , latitude, average annual sunshine hours and winter 
severity were , in decreasing order of magn itude, all significantly correlated with MS 
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prevalence by birthplace, whereas midsummer temperature and rainfall were non-
significant. While the correlation coefficient for latitude (and winter severity) was 
positive, the coefficient for solar radiation was negative and of strong magnitude, 
indicating an inverse relationship with this climatic variable. Solar radiation itself, or 
some other factor indirectly associated with sunlight [353], appeared to be the most 
beneficial in preventing this autoimmune disease. Importantly, these and other early 
workers [354] showed that the protective influence of sunlight appeared to be 
independent of latitude [355]. However, the possibility that both latitude and solar 
radiation are markers for some other geographically variant factor still exists [6]. 
lmmunosuppressant effects of sunlight have been suggested to explain such findings , 
these acting either through UVR [5, 6], and/or vitamin D [356-358] or through melatonin 
suppression by the visible-light portion of the sunlight spectrum [355] . Current 
knowledge of mechanisms of immunosuppression by UVR and vitamin D, in particular, 
giving plausibility to these hypotheses, are reviewed in Sections 2.4.1 and 2.4.2. 
In Australia, an ecological analysis has shown that the well-accepted latitude gradient 
for MS prevalence [301] is inversely associated with regional ambient UVR (r=-0.91 , 
p=0.01 ). This inverse association with MS was shown to be stronger than the positive 
association with melanoma skin cancer in Australia, and suggests a protective effect of 
higher UVR in northern Australia reducing MS prevalence in those regions [9]. A more 
recent geospatial analysis in North America also showed a strong inverse association 
between UVR and MS distribution, with a concomitant increase in MS risk in low 
ultraviolet (UV) areas [359]. Indeed , a global meta-analysis of MS prevalence in 54 
studies over the previous 10 years has shown a lack of UVR to outweigh other MS risk 
factors by at least 20-fold in univariate regression analyses [360]. Moreover, in 
Australia , the recent prospective 'Ausimmune ' study on FOE not only established an 
incidence gradient for this early precursor to MS [305] , but showed that the incidence 
gradient was partly accounted for by decrease in past sun exposure and vitam in D 
status over these reg ions [361] . 
For type 1 diabetes, fewer population stud ies have been conducted , but an ecolog ica l 
analysis in the northern hemisphere has shown that the factors temperature and 
latitude, although collinear with each other, together accounted for approximately 40% 
of the variation in type 1 diabetes risk worldwide [313] . In the southern hemisphere , no 
corresponding studies on latitude and type 1 diabetes had been conducted prior to th is 
thesis study (see Chapter 4 ). Subsequently, however, a further ecological study of 
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ambient UVR (of latitude of residence) and type 1 diabetes in Australia reported 
equivocal results: UVR was inversely associated with incidence at low population 
densities but was positively associated at high densities [351] . 
Thus, the ecological studies indicate that factors associated with latitude, and 
particularly UVR and/or vitamin D, are possible influences on the development of MS 
and other organ-specific autoimmune diseases such as type 1 diabetes, and that 
analytical studies are warranted . Although prior to this thesis few studies had been 
undertaken in the southern hemisphere, one advantage of Australia is that, unlike the 
large northern continents, its population is relatively genetically homogeneous and 
thereby suited to individual-level study to investigate the roles of 'place' and 'time'. That 
is, the 'person ' (or ethnic group) factor can be held more constant than in some settings , 
and latitude or seasonal variation then constitutes variation in only 'place' or 'time', 
respectively. 
Therefore , sun exposure , and thus UVR exposure , is a strong contender as an 
environmental factor influencing organ-specific diseases such as MS in a beneficial , 
protective way, even though the ecological studies do not discount other confounding , 
or directly causal , factors such as infections and even diet. As McMichael and Hall 
(2001) indicated , what are needed are individual-level studies on both kinds of factors , 
for example , UVR and infections, and then a focus on their mechanism(s) and at what 
age they might act [6]. 
The remainder of this section will focus on the immunosuppressive mechanisms of 
both UVR (see Section 2.4.1) and vitamin D (see Section 2.4.2 ) from sunlight for 
biological plausibility (i .e. how these factors might work). Then , the analytical 
epidemiological evidence for action of either of these factors in preventing , delaying or 
otherwise modulating MS, type 1 diabetes and RA is cons idered (Section 2.5). 
2.4.1 Ultraviolet radiation-mechanisms of UVR immunosuppression 
The effects of UVR from sunlight may be direct, as cons idered in this section , or 
indirect via production of vitam in D (cons idered in Section 2.4.2). Failure or breakdown 
of self-tolerance (i.e. failure of tolerance of one's own potentially antigen ic substances) 
appears to be the fundamental cause of autoimmune disease (see Chapter 1 ). That is, 
autoimmune diseases develop when self-reactive lymphocytes are activated and 
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normal regulatory mechanisms are somehow compromised. How might an 
environmental factor like UVR in sunlight contribute to the maintenance of 
immunological tolerance? 
While carcinogenic effects of solar radiation have been known for a century, it is only 
within the last 30 years that the profound immunological effect of exposing the skin to 
sunlight has been realised. This has given rise to the relatively recent science of 
photoimmunology, concerned with the effects of UVR on immunological processes. 
Exposure to UVR in sunlight is now known to induce a suppression of immune 
responses that plays a critical role in skin cancer induction [362]. Supporting this 
concept, data associating UV-induced immune suppression and skin cancer induction 
have come from both skin cancer patients and immunosuppressed renal transplant 
patients, as well as experimental animals. From both human and animal studies, UVR 
is found to induce changes that trigger a cascade of inflammatory events , leading 
ultimately to antigen-specific, systemic (as well as local) , T-cell-mediated 
immunosuppression [363-366]. Key components of this cascade are epidermal 
cytokines, which modulate the immune response to antigens and divert the response 
toward a state of specific immunosuppression ; this means that UVR can redirect the 
immune response from an effector to a suppressor pathway [366] . It is also important 
to note again that these effects are immediate and not mediated by vitamin D. 
That UVR has any effect on the immune system at all is both unexpected and 
remarkable , given that UV does not penetrate deeply into the skin and that human life 
has evolved in an environment containing UVR. However, the essential role of UVR in 
the production of vitamin D, necessary for bone growth , has long been known . While 
systemic immunosuppression by UVR could have negative implications, for example, 
for responses to either tumours or invading pathogens, down-regulation of key 
immunological processes can also have important positive benefits in preventing over-
expressed autoimmunity and consequent autoimmune disease. 
UVR, in the non-visible portion of the solar radiat ion spectrum , covers the wavelength 
range from 200 to 400 nanometers (nm) , visible light being in the 400 to 700nm range . 
UVC (200 to 290nm) is mostly absorbed by the atmosphere , leaving ~10% of the UVB 
(290 to 320nm) and most of the UVA (320 to 400nm) to reach the ground 's surface. 
UVB, in particular, has been associated most often with risk of skin cancer, whereas 
photo-ageing has been attributed to the longer-wavelength and deeper penetrating 
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UVA [367]. Importantly, the UVB component of the spectrum also catalyses the vital 
endogenous production of vitamin D. 
Most work on immunological effects of UVR has been conducted on UVB. The first 
step in the cascade of events leading ultimately to systemic immune suppression is the 
transformation of the electromagnetic energy of UVB into a biological signal in the skin. 
This is achieved by one of three possible chromophores , urocanic acid , DNA or lipid 
membranes, a major initiator identified being DNA damage in epidermal Langerhans 
cells (LCs) [362 , 368-371 ]. The immune suppressive signal must next be transmitted to 
the immune system-this appears to be achieved by a number of immunoregulatory 
mechanisms, discussed next. 
lmmunomodulatory effects of UVR 
Direct UVB effects on APCs 
Direct UVB irradiation of the skin alters the antigen-presenting function of LCs (i.e. 
epidermal DCs), making them tolerogenic rather than immunogenic (see Chapter 1, 
Section 1.2.2). That is , UV-irradiated LCs do not efficiently stimulate effector T cells 
[369 , 370] , which are also rendered unresponsive (i.e. anergic or tolerant, see Chapter 
1, Section 1.3.1) by means of IL-10 produced by UV-irradiated keratinocytes in the 
epidermis and/or mast cells in the dermis. The result is a shift away from effector T-cell 
immune responses , and tolerance induction [362 , 368 , 371 ], mean ing a decrease in 
inflammatory autoimmune processes. 
Of note, recent studies of patients with polymorphic light eruption (a dermatolog ical 
condition with clinical onset in the teenage or adult years that man ifests as an eczema-
like eruption on sun-exposed areas of the body) have revealed a defect in UVB-
induced immunosuppression . This appears to result from the ineffective migration of 
LCs from the epiderm is to the dra ining lymph nodes where antigen presentation 
normally takes place [372]. 
UVB-induced immunomodulatory mediators 
As well as local tolerance induction by LCs as part of the adaptive (antigen-specific) 
immune system, UVB irradiation of innate-system epidermal keratinocytes or dermal 
mast cells induces immunoregulatory cytok ines (see Figure 2.10), includ ing IL-10 , 
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TNF-a and IL-4 (IL-4 ultimately inducing IL-10). IL-10, in particular, is crucial to the 
induction of systemic immune suppression and tolerance (see Chapter 1, Section 1.3.1) 
by down-regulating IL-12 secretion (by lymphoid DCs) at a distance from the skin. The 
decrease in IL-12 in turn reduces both inflammatory effector T-cell immune reactions 
[362 , 371] and DNA repair [369]. 
IL-10 is also secreted in large amounts by infiltrating macrophages, particularly in 
humans [362, 368]. These non-LC macrophages have been shown to migrate to the 
epidermis 72 hours post-UV exposure and are involved in the activation of 
immunoregulatory (suppressor) T cells via IL-10. They also fail to secrete IL-12 upon 
activation, both these properties contributing to UV-induced immune suppression and 
tolerance induction [362, 368]. 
Additional innate-system mediators involved in UVB-induced immunosuppression 
include various neurogenic peptides and neuroendocrine hormones secreted by 
keratinocytes and by nerve cells on UV irradiation. Together with nitric oxide , these 
mediate suppression by down-regulating the antigen-presenting function of LCs and 
inducing I L-10 production [362]. 
UVB-induced regulatory T cells 
Kripke's pioneering work in 1974 with murine UV-induced skin cancers indicated that 
UV exposure at a subcarcinogenic level resulted in immunosuppression that allowed 
subsequent growth of UV-induced skin cancers. Most importantly, this UV-induced 
immunosuppression could be transferred to normal , unirradiated mice using T cells 
from the spleen (this was called 'infectious tolerance'), confirming the existence of 
specific 'suppressor' cells of the T-cell type [362 , 366 , 371 ]. After a recent resurgence 
of interest in these 'suppressor' cells (now termed 'regulatory T cells ', see Chapter 1, 
Section 1.3.1 ), there is now evidence from both murine and human stud ies that more 
than one type of these regulatory T cells with a role in tolerance induction can be 
induced by UVB irradiation . These include: 
• Tr1-Jike CD4+ CD25+ regulatory T cells, wh ich appear to be a un ique and 
specialised subset of skin-specific Tr1-type regulatory cells (secreting high 
levels of IL-10) [370] but also displaying the class ic nTreg (and iTreg ) ce ll 
markers CD4+ CD25+ (see Chapter 1, Section 1.3.1 ) [362 , 369, 370] . 
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• NKT cells (see Chapter 1, Section 1.3.1 ), which rapidly produce high quantities 
of IL-10 and IL-4 [362, 368-371] and have been shown to mediate particularly 
systemic UVB-induced immunosuppression. Importantly, these were the cells 
responsible for (adoptive) transference of this immunosuppression to 
unirradiated recipient (murine) hosts [98]. 
The mechanisms of action of UVB-induced regulatory T cells have yet to be fully 
understood. Besides high levels of immunosuppressive IL-4 and IL-10 in the micro-
environment, the necessary 'natural death' process of apoptosis of UV-irradiated, DNA-
damaged (self) 'sunburn cells' [373] (that is, keratinocytes that could otherwise 
eventually progress to malignancy) and then engulfment of apoptotic bodies by LCs, 
seems to play an important role in tolerance induction and immunosuppression, as 
does subsequent apoptosis of DNA-damaged LCs themselves via decreased IL-12 
[370] (Figure 2.10). As indicated by Saas and colleagues, any disruption in the orderly 
disposal of autoantigen-containing apoptotic cells can result in autoimmunity [111] and 
so UV-induced suppressor cells or cytokines that inhibit IL-12 and promote apoptosis 
are tolerogenic. 
A summary of mechanisms of direct UV-induced immune suppression Is shown In 
Figure 2.10. 
UVA radiation 
As the other component of solar UV radiation reaching humans, UVA has been less 
studied. However, recent work has focused attention on this higher-energy portion of 
the solar spectrum and is showing that UVA, too, can induce systemic 
immunosuppression , in both humans and animals , by apparently similar immunological 
mechanisms to those seen for UVB [362 , 371 , 374]. 
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Figure 2.10: Mechanisms of UV-induced immunosuppression independent of 
vitamin D synthesis. (Adapted from Aubin, 2003 [368] and updated from Ullrich, 
2005 [362], Schwarz, 2008 [369] and Timares et al., 2008 [370].) 
1. Epidermal LCs are the main targets of UV, which, via damage to DNA 
(conversion of DNA to pyrimidine dimers), inhibits the antigen-presenting 
activity of LCs and their capacity to stimulate allogeneic effector T cells, such 
as Th1 (via IL-12). Functionally UV-impaired LCs either migrate to the draining 
lymph node (DLN), where they fail to mature and become tolerogenic, or, if 
DNA damage is too great, undergo apoptosis. In human skin, the immune 
regulatory cytokines IL-10 and IL-4 are mainly produced by dermis 
macrophages and neutrophils (M/N) that infiltrate the epidermis after UV 
irradiation; UVB-induced infiltrating macrophages also fail to secrete IL-12, 
thus contributing to UV-induced immune suppression (IS) and tolerance 
induction, and to lack of DNA repair. 
2. Keratinocytes (K) are also a target of UV light and they produce and release 
numerous soluble and immunosuppressive mediators, such as platelet-
activating factor (PAF) and IL-12 inhibitory prostaglandin-E2 (PGE2). Mast 
cells (MST) are activated by PAF and directly by cis-urocanic acid (CUA, 
formed by UVB irradiation of epidermal trans-urocanic acid, a chromophore) , 
and secrete immune regulatory cytokines; histamine (HST) can up-regulate 
PGE2 and IL-10 and potently suppress IL-12. 
9 1 
3. Regulatory T cells are induced by tolerogenic DNA-damaged LCs and 
mediate IS by releasing immunosuppressive IL-4 and IL-1 O; regulatory T cells 
also induce further apoptosis of APCs (LC) in the absence of IL-12. 
UVR in photomedicine-human autoimmune disease and UVR 
Interestingly, several of the most significant findings about UV immunosuppressive 
mechanisms in the human field have resulted from a relatively recent subspecialty of 
medicine called 'photomedicine'. Beginning in the mid-1970s, this field uses different 
UV radiations therapeutically to treat cutaneous T-cell lymphoma, graft-versus-host 
disease and some autoimmune diseases. Phototherapy techniques employed include 
UVB irradiation, UVA irradiation, oral Psoralen+UVA irradiation (PUVA), photodynamic 
therapy and extracorporeal photopheresis (ECP) [373, 375]. ECP, or 
photochemotherapy, consists of exposing the patient's own (autologous) peripheral 
blood mononuclear cells, collected by apheresis, to 8-methoxypsoralen (8-MOP, a 
photosensitiser) photoactivated by UVA radiation, and then infusing these back into the 
patient. 
This process can be effective in treating autoimmune diseases such as SLE, systemic 
sclerosis and RA, as well as various dermatological diseases and allograft (transplant) 
rejections where a specific decreased immune response is required. The beneficial 
effects of phototherapy are thought to act by inducing antigen-specific rather than 
general immunosuppression ; UVB irradiation and ECP both can induce regulatory T 
cells as a possible main mechanism [369]. These two therapies also induce apoptosis 
of activated T cells , or of extracorporally treated mononuclear cells , respectively. It is 
thought that the processing and presentation of apoptotic T-cell antigens from clones of 
pathogenic T cells by macrophages and DCs might induce the generation of clone-
specific regulatory T cells , and thus explain the resulting systemic, and specific , cell-
mediated immunosuppression [370 , 375] . 
Summary 
In summary, there appear to be a number of different immunoregulatory mechan isms 
in humans and other mammals, for UVR at moderate, subcarcinogenic levels to effect, 
directly, significant systemic immunosuppression. As indicated by people with the 
uncommon disorder of polymorphic light eruption , this suppression appears to be a 
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natural protective mechanism to prevent autoimmunity to UV-induced auto-antigens 
from normal sun exposure. The evolutionary explanation of such UV-induced 
immunosuppression may be to prevent the UV-altered , DNA-damaged 'sunburn-cell ' 
molecules being recognised as 'non-self' neo-antigens and then being over-reacted to 
during everyday exposure to solar radiation [362 , 368 , 370, 372] . That is , UVR can 
induce or re-establish immunological self-tolerance to skin-associated antigens and 
these mechanisms exist to protect the skin barrier and prevent or ameliorate 
autoimmune disease. 
Thus, UVR in sunlight, even independent of vitamin D, is a contender, mechanistically, 
as an environmental factor possibly influencing the aetiology of MS and other such 
autoimmune diseases in a directly protective , beneficial way. Lack of UVR at critical 
stages in the life course may allow, or contribute to , the breakdown of immune self-
tolerance and so may increase propensity towards autoimmune disease. Such UVR-
induced immunosuppression may act through its direct immunoregulatory effects as 
discussed or, alternatively, indirectly through the production of vitamin D, considered 
next. 
2.4.2 Vitamin D from sunlight-additional mechanisms of 
. . 1mmunosuppress1on 
There is increasing evidence that some of the beneficial effects of sunl ight for the 
prevention of autoimmune disease are med iated through vitamin D. 
Vitamin D terminology 
'Vitamin D' is used here as a generic term , but the biologically act ive , hormona l form of 
vitamin D and its metabol ism now need to be defined . As suggested by Vieth (2004) 
[376] , the many terms and formulae conventions for the compounds in the vitam in D 
family are confusing and often misused . Following these recommendations , the terms 
'active ' and 'hormone' will be used only for the biolog ica lly active fo rm, 1 alpha , 25-
dihydroxyvitamin 03 (1 ,25(0H )2O3, or calcitriol ), which is formed from the 'pre-hormone' 
form , 25-hydroxyvitamin 03 (25(0H )D3, or calcidiol ). The term 'vitam in 03' refers to the 
cholecalciferol molecule formed in the skin by the action of UVB on the precursor 7-
dehyd rocholesterol . 
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Vitamin D sources and production 
Vitamin 03 (cholecalciferol), formed in the skin via UVB irradiation , is bioactivated in 
two enzyme-controlled steps: the first in the liver (and brain) to form the pre-hormone 
25(OH)03 and the second in the kidney (and neural tissue and macrophages) to form 
the active-vitamin 03 hormone 1,25(OH)203 (here termed 'active-vitamin 0'). 
While vitamin 03 can also be obtained from dietary sources, more than 90% is 
produced endogenously by conversion from 7-dehydrocholesterol in the skin, catalysed 
by the UVB received from sunlight [242]. Most importantly, vitamin 03 derived from 
sunlight exposure predominantly contributes to vitamin 03 stores (mainly in muscle and 
adipose tissue) and thus supplies vitamin 03 for future use; dietary sources (03 and 
less active, plant-derived 02) provide a meagre, inconstant supply that is less likely to 
be stored [377]. These UVB-produced stores help determine the level of circulating 
25(OH)03 available at any time (and place) in the body, from which the active hormone 
is then derived. 
New roles for vitamin D-effects beyond bone 
Until just over two decades ago, the human vitamin 0 endocrine system was 
recognised only for its homeostatic regulation of calcium and phosphorus metabolism 
for bone formation and maintenance. From this classical viewpoint, a vitamin 0 deficit, 
through sunlight deprivation , was synonymous with the childhood condition of 
nutritional rickets that was endemic in the 19th and early 20th centuries in Europe and 
North America [378] , this condition coinciding with the move from rural living to indoor 
work during the Western world 'industrial revolution ' [379] . 
New molecular evidence in the 1980s then identified the nuclear vitam in 0 receptor 
(V0R) which was found to be present in most immune system cells , suggesting 
additional immunological functions for the light-sensitive vitam in 0 system . Molecular 
genetic techniques have now helped reveal that the biologically active (h ormonal ) form 
of vitamin 0 has widespread effects on cel lular differentiation and proliferation , and can 
modulate not only immune responsiveness but also CNS development and function 
[380] . V0Rs have now been found in many different organs and tissues in the body, 
including the brain and the beta-(islet) cells of the pancreas [381] and in rheumatoid 
tissues [382] , suggesting vitamin 0-related function in many areas of the body. The 
94 
main non-classical effects of vitamin D now appear to be anti-inflammatory, anti-
infectious, immunomodulatory, anti-proliferative and as a neurotransmitter [379]. 
Importantly, the bioactivation of the hormonal form of vitamin D, which previously was 
thought to occur only in the kidney, is now known to occur in the brain and CNS [383], 
as well as within activated macrophages at inflammation sites [377] and possibly in 
several other organs [384]. Indeed, many human tissues are now known to possess 
the hydroxylase enzyme needed for the essential last step of bioactivation of the 
hormonal form of vitamin D. This extra-renal , paracrine production of vitamin D is 
particularly rapid and highly effective in controlling cell proliferation locally [384 , 385] , 
suggesting that the active form of vitamin D ('active-vitamin D') is important for rapid 
response in many different parts of the body. 
Vitamin D as potent immunomodulator 
Vitamin D is now being increasingly recognised as a potent immunomodulator based 
on seminal experimental work of research groups, such as that of Lemire and 
colleagues [386-394], as well as more recent work on human autoimmune disease 
reviewed by Arnson et al. (2007) [395] , Smolders et al. (2008) [396] and Hewison 
(2010) [397]. 
Many different immunologically relevant cells have now been found to express the VDR, 
including monocytes and DCs, activated B and T lymphocytes, activated CD4+ (helper) 
and CDS+ (cytotoxic) T cells (see Chapter 1, Section 1.2.1 ), and T cells in RA, 
suggesting a number of important roles for vitamin D in the immune system. How might 
vitamin D, particularly the active hormonal form , 'active-vitamin D' (1 ,25(OH )2 0 3) , act to 
suppress or regulate autoimmune processes? 
lmmunomodulatory effects of vitamin D 
Effects on APCs and T cells 
As discussed in Chapter 1 (see Section 1.2.2) , DCs are highly specialised APCs critical 
for the initiation of CD4+ (helper) T-cell responses and are present, in different stages 
of maturation , in the circulation , in lymphoid organs and (as LCs) in non-lymphoid 
organs such as the skin (see Section 2.4.1 ). Human and mouse DCs, and myeloid DCs 
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in particular (see Chapter 1, Section 1.2.2, footnote), appear to be key targets of 
hormonally active 1,25(OH)2D3, both in vitro and in vivo [53 , 398, 399]. 
Earlier research suggested that active-vitamin D (1,25(OH)2D3) targeted DCs by 
inhibiting the production of IL-12, the DC-derived cytokine critical for Th1 cell 
development [393]. More recent work has shown that active-vitamin D inhibits the 
differentiation and maturation of DCs [399], leading to decreased production of both IL-
12 (for Th1) and IL-23 (for Th17) [400,401], and enhanced IL-10 production. These 
cytokine changes characterise the induction of tolerogenic DCs (see Chapter 1, 
Section 1.2.2), which in turn results in decreased effector T-cell activation , or T-cell 
anergy (hyporesponsiveness) [52, 53, 402]. Active-vitamin D (1,25(OH)2D3) also 
promotes myeloid DC apoptosis and thus affects all major stages of the DC life cycle: 
differentiation, maturation, activation and survival [399]. 
T lymphocytes have also been shown to be direct targets for the action of active-
vitamin D (1,25(OH)2D3), which can inhibit, for example , the Th1-type cytokines such 
as IL-2 and IFN-y [402] and IL-17 (Th17) (see Chapter 1 ), as well as affect 
development of Th2 cells [52]. In addition, VDR agonists (including active-vitamin D) 
profoundly affect the migration of effector T cells to the target organ, such as to the 
pancreatic islets in the type 1 diabetes mouse model. Further, in both humans and 
mice, active-vitamin D (together with dexamethasone) can act directly on na"fve CD4+ 
T cells to induce differentiation in vitro into IL-10-producing regulatory T cells 
(discussed next), even in the absence of DCs [52]. 
Vitamin D-induced regulatory T cells 
Foxp3+ (CD4+ CD25+) regulatory T cells: By acting on myeloid DCs and rendering 
them tolerogenic, active-vitamin D (1 ,25(OH)2D3) also indirectly promotes the 
differentiation of Foxp3+ (CD4+ CD25+) regulatory T cells (nTreg and iTreg , Chapter 1, 
Section 1.3.1) [52 , 53]. Functionally, these vitamin D-induced regulatory T cells with 
suppressive properties can adoptively transfer tolerance to other na·fve animals [403], 
as well as arrest the development of autoimmune disease in vivo [52]. In recent MS 
patient studies, the function of Foxp3+ (CD4+ CD25+) regulatory T cells in suppressing 
T-cell proliferation correlates with serum levels of 25(OH)D3 [401 ]; these regulatory T 
cells are also directly increased in numbers in MS patients by active-vitamin D [400]. 
Active-vitamin D can also enhance the recruitment of Foxp3+ (CD4+ CD25+) 
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regulatory T cells at inflammatory sites, by inducing the expression of homing receptors 
in these cells to aid their localisation in, for example, the epidermis [73]. 
Tr1-like regulatory T cells: As noted above, by direct effects on na·i"ve T cells, Tr1-like 
regulatory T cells secreting anti-inflammatory IL-10 (similar, though not identical , to the 
Tr1 [see Chapter 1, Section 1.3.1] general type [52]) are able to be induced by active-
vitamin D without APCs present, by using IL-10 as a positive autocrine factor. Upon in 
vivo transfer, these cells also protected against the development of EAE [105]. Thus, 
both direct and indirect (via DCs) actions of vitamin D result in the inhibition of the pro-
inflammatory immune state, leading to an anti-inflammatory cytokine profile and 
tolerogenesis [396]. 
In summary, the main mechanisms by which active-vitamin D (1,25(0H)2O3) induces 
tolerance appear to be associated with profoundly reduced IL-12 production by myeloid 
DCs and by their consequent inability to induce full activation of CD4+ effector T cells, 
such as Th 1 and Th 17 ( see Chapter 1 ), as well as by the ability of tolerogenic DCs to 
enhance and promote Foxp3+ regulatory T cells and Th2 cells under certain conditions 
[52]. As described in Chapter 1 (see Section 1.3.1 ), these nTreg and iTreg have a 
unique ability to suppress neighbouring T cells by direct cell contact, and amplify 
tolerance by inducing these same T cells to produce the immunosuppressive cytokines 
IL-10 and TGF-~. Similarly to UVB, active-vitamin D (1,25(OH)2O3 ) also promotes 
apoptotic activity, both of T lymphocytes which could otherwise be potentially 
dangerous autoimmune effector cells, and of DCs [399] (Figure 2.11 ). 
In addition to being the major vitamin D targets , DCs themselves are able to synthesise 
1,25(OH)2O3 in vitro , as are macrophages and T cells; therefore , local production of 
1,25(OH)2O3 may contribute to regulatory T-cell induction or enhancement [52 , 398] . 
Overall, vitamin D is able to alter the T-cell compartment into a more anti-inflammatory 
and regulated state , with the inhibition of Th 1 and Th 17 cells and promotion of 
regulatory T cells in particular. To summarise, the main mechanisms of vitamin D-
induced immunosuppression are illustrated in Figure 2.11 , in a similar way, for 
comparison to that for direct, non-vitamin D mediated , UV-induced mechanisms in 
Figure 2.10, Section 2.4.1. For this diagram, I have used information from Penna and 
Adorini (2000) [399], Correale et al. (2009) [400] , Penna et al. (2007) [53] , Smolders et 
al. (2008; 2009) [396, 401] and Adorini and Penna (2009) [52] ; the initial production of 
active-vitamin D from the action of UVB from sunlight is also included in this diagram . 
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Figure 2.11: Production of active-vitamin D (1,25(OH)2D3) by UVB irradiation of 
the skin and mechanisms of vitamin D-induced . . ImmunosuppressIon. 
(Mechanisms summarised from Penna and Adorini, 2000 [399], Correale et al., 
2009 [400], Penna et al., 2007 [53], Smolders et al., 2008; 2009 [396, 401] and 
Adorini and Penna, 2009 [52].) 
1. UVB from sunlight catalyses vitamin D3 (cholecalciferol) production from 
the precursor 7-dehydrocholesterol in the skin. Vitamin D3 bioactivation 
then occurs first in the liver (and brain) to form the pre-hormone 25(OH)D3, 
and second in the kidney (and other tissues) to form active-vitamin D, 
1,25(OH)203. 
2. Antigen-presenting myeloid DCs in the circulation, lymphoid organs and 
skin (LC) are key targets of active-vitamin D, which inhibits differentiation 
and maturation of DCs leading to decreased IL-12 and IL-23, and 
enhanced IL-10 production. The tolerogenic DCs thus induced result in 
decreased T-cell activation and immunosuppression (IS); active-vitamin D 
also promotes DC apoptosis. Active-vitamin D further directly inhibits Th1 
and Th17-type cytokines (IL-2 and IFN-y, and IL-17), and may also affect 
development of Th2 cells. 
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3. Tolerogenic DCs also promote Foxp3+ (CD4+ CD25+) regulatory T cells, 
which suppress both by cell-to-cell contact and secretion of 
immunosuppressive IL-10 and TGF-beta, thus amplifying tolerance. Tr1-
like regulatory cells secreting anti-inflammatory IL-10 are also directly 
induced by active-vitamin D from na"i"ve T cells and further contribute to IS. 
Vitamin D status and autoimmune disease 
Goldberg postulated in 197 4 that insufficient UV light to support adequate vitamin 0 
biosynthesis might be the environmental factor contributing to development of MS [356]. 
He also estimated that the daily amount of vitamin O that would be required to prevent 
MS, based on amounts of sunshine in low-prevalence areas and on the rate of 
formation in the skin, was 10-fold higher than the then-accepted anti-rachitic dose for 
dietary vitamin 03 [357]. 
Because highly localised production of 1,25(0H)2O3 now appears to be required for 
immunological functions, the UV-produced vitamin 03 stores may be critical to vitamin 
0 status [377]. The solar radiation intensity, varying with both latitude and season , 
determines the vitamin 03 synthesis rate. In Boston, US (latitude 42.2°N) , there was 
found to be insufficient UVB photon energy in sunlight to initiate cutaneous production 
of vitamin 03, when human skin was exposed to the sun , during a four-month winter 
period from November to February. Further north, in Edmonton , Canada (latitude 52°N), 
the ineffective 'vitamin O winter' extended for six months from October to March [404, 
405], and up to eight months of the year at even higher northern latitudes [406]. Recent 
data on the biologically effective UVB received at ground level at four widely-differing 
sites in the US (latitude range 18.3 to 63. 7°N) support these findings and show that the 
relative production of vitamin Oat higher latitudes in winter is markedly decreased. This 
is due to increased scattering and ozone absorption of the shorter UVB wavelengths 
that are the most effective in producing vitamin O [407]. 
Vitamin O deficiency or insufficiency, as measured by serum levels of the pre-hormone 
25(0H)O3 , has been documented in several organ-specific autoimmune disorders , 
including MS [122 , 408, 409], type 1 diabetes [41 O] and RA [411 , 412] . The fact that 
low vitamin O status is implicated in such disparate organ-specific autoimmune 
diseases suggests an effect of vitamin O on the common underlying autoimmune 
process itself, such as control of tolerance of self-antigens (see Chapter 1) [413] . 
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For MS, for example , a recent genetic study has identified a vitamin D response 
element (a specific sequence of DNA in the promoter region of target genes, regulated 
by vitamin D) in the HLA-DRB1 (MHC class II) locus; this implies direct functional 
interaction between HLA-DRB1 , the main susceptibility locus for MS, and vitamin D, 
which is thus a strong candidate for mediating the environmental effect [188]. While the 
exact role of this gene-environment interaction in MS disease aetiology is yet to be 
revealed , it is plausible that a lack of vitamin D in early childhood might reduce the 
expression of HLA-DRB1 in the thymus, resulting in loss of central tolerance (see 
Chapter 1) and perhaps increasing risk of autoimmune disease in later life [197, 214 ]. 
Thus, this interaction provides new insight into how vitamin D status may contribute to 
MS pathogenesis and pinpoints the MHC as the likely site of gene-environment 
interaction in this disorder [214]. 
In addition to vitamin D status data , genetic variations expressed in the vitamin D 
regulatory genes in these diseases add further weight to a role for vitamin D [214]-
polymorphisms in the VDR genes have been correlated with increased susceptibility of 
MS, type 1 diabetes and RA in certain populations [413]. For example , variation in the 
VDR gene appears to be associated particularly with progressive forms of MS in an 
Australian population [414]. In type 1 diabetes, VDR gene variants linked to aetiology of 
disease may be influenced also by environmental UVR [415]. 
Another vitamin 0-influencing gene is the 1 a-hydroxylase enzyme gene controll ing the 
rate-limiting step in making vitamin D active [214] ; mutations in this gene cause a rare 
vitamin D-dependent type of rickets and this may be a risk factor also for MS [416]. In 
addition , a large Australian study reports an association between polymorph isms 
proximal to the 1 a-hydroxylase gene and MS [187] . For type 1 diabetes, 
polymorphisms in the hydroxylase enzyme gene are associated with disease risk [417], 
all these studies suggesting that common inherited variation in vitam in D metabolism 
may affect susceptibility to type 1 diabetes and MS. 
Vitamin D supplementation and autoimmune disease animal models 
The disease systems in munne models of MS, type 1 diabetes and RA are all 
suppressed by 1,25(OH )2 0 3 treatment in vivo. Both EAE and co llagen-induced arthritis 
(CIA) development can be prevented by 1,25(OH )2 0 3 supplementation [418-420] , and 
injected 1,25(OH)203 has been shown to slow the development of murine autoimmune 
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diabetes [421]. In these diabetic mice also, other autoimmune diseases such as EAE 
and CIA can be prevented by 1,25(OH)203 [422]. 
Synopsis 
Summing up, from these experimental and ecological studies and from the 
immunological mechanisms reviewed in Sections 2.4.1 to 2.4.2 , UVR, both directly and 
indirectly through vitamin D, is a plausible candidate as a component determinant of 
autoimmune disease. The next section will consider analytical epidemiological 
evidence for possible protective effects of both UVR/sunlight and vitamin D on MS, 
type 1 diabetes and RA. 
2.5 Analytical UVR studies and Vitamin D trials in human organ-
specific autoimmune disorders 
From the ecological studies reviewed , UVR directly, or mediated by vitamin D, could be 
important for the prevention of autoimmune disorders such as MS or type 1 diabetes at 
the population level. However, analytical studies at the individual level provide better 
epidemiological evidence for possible identification of the causal determinants of 
disease. 
Multiple sclerosis 
Table 2.3 summarises recent analytical studies of the effects of UVR/sunlight exposure , 
or trials of the effects or vitamin D supplementation , on the risk of MS; these are now 
discussed in turn. 
UVR /sunlight exposure 
Although perhaps better described as an ecolog ical s udy, a 'case-contro l' study by 
Freedman and colleagues on the effects of residential and occupational solar radiat ion 
on MS mortality in the US, based on death certificates, showed that both res idential 
and occupational sunlight exposure were inversely associated with MS mortality [423] 
(Table 2.3). The combined-effect odds ratio (OR) for outdoors- versus indoors-
occupation for the high-sunlight res idence group was 0.24 (95% Cl 0.1 5, 0.38 ). A more 
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recent Swedish cohort study also found reduced risk of MS-related death with 
increasing occupational exposure to UV light, particularly in the highest exposure group 
(adjusted relative risk (RR) 0.48; 95% Cl 0.28, 0.80) [424]. These results were 
consistent with those predicted by McMichael and Hall (1997) from their hypothesis 
that sunlight, and particularly UVR, were protective for MS [5]; these studies further 
suggest that MS risk may be affected by UVR exposure later than adolescence. 
Another individual-level study of the inverse links between skin cancer and MS in the 
UK showed that skin cancer (both melanoma and non-melanoma), here being used as 
a proxy for sunlight exposure, was significantly less common in people with MS (rate 
ratio 0.49; 95% Cl 0.24, 0.91 ). This adds to the prior analytical and ecological evidence 
that solar radiation may have a protective influence on the development of MS [425]. 
A further case-control study in TAS, Australia, linking the degree of expo--ure to 
sunlight with MS, is summarised in Table 2.3. This study by van der Mei and 
colleagues is the only such study on MS to date in Australia and in the southern 
hemisphere. The study found that higher exposure to sunlight during childhood and 
adolescence-that is, between the ages of six and 15 years-especially in winter, was 
associated with a decreased risk of MS, a dose-response relationship being evident. 
These authors also reported an independent dose-response relation between actinic 
skin damage (a measure of lifetime sun exposure not subject to recall bias) and MS 
[426]. 
A more recent North American case-control study of childhood sun exposure and MS 
using monozygotic twin pairs showed results consistent with these Australian data. 
Each of nine sun exposure-related activities conveyed protection against MS within the 
twin pairs, ORs ranging from 0.25 to 0.57 depending on the activity. For example , the 
risk of MS was substantially lower (OR 0.40; 95% Cl 0.19, 0.83) for the twin who spent 
more time suntanning in comparison with the co-twin [427] (Table 2.3). Authors Islam 
and colleagues concluded that early sun avoidance seemed to precede the diagnosis 
of MS, and that this protective effect was independent of genetic susceptibility. 
Kampman and co-workers further showed in a case-control study of Norwegians living 
above the Arctic Circle (where all winter, but not summer, vitamin D is provided by diet) 
that increased outdoor activity in summer in early life (particularly ages 16 to 20 years) 
reduced the odds of subsequent MS (OR 0.55; 95% Cl 0.39, 0.78) . This was also 
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achieved by cod-liver oil supplementation (in the low-activity group) and increased 
consumption of fish [428] (Table 2.3). 
All these studies suggest that insufficient UVR, perhaps both early and later in life, may 
influence the development of MS. The latter study further suggests that dietary intake 
or supplementation of vitamin D-related foods may have similar effects and may be 
compensatory when sun exposure is less. A subsequent review by Kampman and 
Brustad (2008) suggests that latitudinal UVR and diet may interact to influence MS risk 
at a population level, vitamin D being the common mediator [429]. 
Vitamin D intake/supplementation 
A large prospective cohort study of vitamin D intake has been completed by Munger 
and colleagues in the US, with more than 187,000 women being studied for either 10 
years (Nurses' Health Study; 92,253 participants) or 20 years (Nurses' Health Study II; 
95,310 participants) [430] (Table 2.3). Vitamin D intake at the study baseline was 
shown to be inversely correlated with subsequent MS incidence. The overall risk of MS 
(cohorts pooled) was 40% lower in women having taken vitamin D supplements of at 
least 400 I U/day in the form of multivitamins, compared with those not using 
supplements; sunlight was not accounted for. Dietary vitamin D levels were not 
associated with MS incidence. This study showed for the first time, prospectively, that 
sufficiently high levels of vitamin D can reduce the risk of developing MS, regardless of 
sunlight exposure. Interestingly, this study also suggested that high vitamin D intake 
was effective in lowering MS risk well into adult life. 
However, because intake of vitamin D in Munger et al. 's (2004) study was largely from 
multivitamins, the possibility that the observed association was due to other 
micronutrients in the multivitamin could not be excluded [238] . An alternative approach 
was to use biomarkers of vitamin D status , specifically serum levels of 25(OH)D in 
many thousands of healthy young adults , made available from the (US military) 
Department of Defense Serum Repository, and determine how many people developed 
MS subsequent to the collection of the two serum samples . This nested case-control 
design enabled essentially a fully prospective study of adolescent vitamin D status prior 
to MS onset [238]. The results of this study (Munger et al. , 2006; Table 2.3) supported 
the hypothesis of a protective effect of serum 25(OH)D for MS, at least in the majority 
white subpopulation. That is, among whites , MS risk declined with increasing levels of 
serum 25(OH)D-risk was 41 % lower for every 50 nmol/L increase in serum 25(OH)D 
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(Table 2.3). Further, the reduction in risk of developing MS among individuals with high 
serum 25(OH)D levels was considerably stronger before the age of 20 years than at 
older ages [431]9 . While such 'prospective ' analytical trials are not clinical trials , they do 
support the notion of the beneficial effects of sunlight for MS prevention . More definitive 
RCTs are thus needed , even though long follow-up periods would be required. 
Vitamin D interventions have also been used for MS patients but few formal 
randomised trials of vitamin D supplementation on MS progression have yet been 
published . In one early patient study, 77% of MS patients exhibited vitamin D 
insufficiency (defined as serum 25(OH)D <50nmol/l) [408]. A small double-blind 
placebo-controlled intervention using 800mg calcium + 1000 I U vitamin D daily 
supplementation for six months showed that vitamin D supplements increased serum 
levels of the anti-inflammatory cytokine TGF-~ in MS patients [122] . An earlier patient 
study using calcium , magnesium and vitamin D as cod-liver oil (5000 IU/day) for one 
year showed vitamin D to more than halve the frequency of MS-related exacerbations, 
compared with that expected from the patients ' case histories as controls [432]. 
Another small uncontrolled patient study suggested that vitamin O-containing fish oil 
together with other vitamin supplements and dietary/lifestyle advice reduced clinical 
severity of MS in 11 of 16 patients [433]. However, a recent randomised double-blind 
placebo-controlled trial in 23 MS patients in Australia failed to show any therapeutic 
benefit in terms of reduced MRI lesions of high-dose vitamin D supplementation (6 ,000 
IU vitamin O2/day) compared with low-dose vitamin D (1 ,000 IU/day) [434]. Some eight 
to 10 such RCTs to determine efficacy and safety of vitamin D supplementation for MS 
treatment are now underway worldwide , some of these trials testing vitamin D by itself 
and others using vitamin D together with current IFN-~ treatment for MS (see 
http: //www.clinicaltrials .gov) . 
9 Since this thesis was submitted, a nested case-control study in Sweden by Salzer et al. ( eurology 2012; 
79: 2 140-5) has been published showing that levels of 25(OH)D 2 7 5 nmo l/L in prospectively collected 
blood samples were associated with a decreased risk of MS (OR 0.39 ; 95% CI 0.16, 0.98) , supporting the 
protective effect of high 25(OH)D levels during the adult years preceding MS onset. 
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Table 2.3: Analytic observational studies on the association between UVR and/or vitamin D and MS. (Table adapted and extended 
from Ponsonby et al., 2005 [237] using additional data from Islam et al., 2007 [427], Kampman et al., 2007 [428] and Munger et al., 
2006 [431]) 
Author, 
year Location Design 
UVR /Sunlight exposure 
Freedman us Death 
et al. , (24 certificate 
2000 states) case-control 
[423] 
Population 
Deaths 1984-
1995 with 
same 
residence at 
birth & death 
Control or Case Exposure 
cohort n n assessment 
Controls 4282 
n=115 ,195 
1. Residential 
sunlight 
a) Low 
b) Med 
c) High 
2. Occupational 
sunlight 
a) Indoor worker 
b) Outdoor worker 
Outcome Adjusted 
assessment covariates 
Cause of Age, sex, race , 
death MS v. SES 
other 
OR/RR 
1.a) 1.00 
b) 0.89 
c) 0.53 
2.a) 1.00 
b) 0.75 
95% Cl 
(referent) 
0.55 , 0.63 
0.48, 0.57 
(referent) 
0.61 , 0.80 
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Author, 
year 
van der 
Mei et al., 
2003 
[426] 
Location Design 
TAS, Age- & sex-
Australia matched 
case-control 
Population 
T AS residents 
with 
grandparent, 
both in TAS 
Control or 
cohort n 
Controls 
n=272 
Case Exposure 
n assessment 
136 1. Higher sun 
exposures at ages 
6-15 (average ~2-
3hrs/day, summer 
weekends & 
holidays) 
2. Higher actinic 
damage on the 
dorsum of left hand 
(grades 4-6 v. 3) 
Outcome Adjusted 
assessment covariates 
MS 1. Melanin 
density, smoking 
history 
2. Melanin 
density, smoking 
history, 
sun exposure 
after diagnosis 
OR/RR 95% Cl 
1. 0.31 0.16, 0.59 
2. 0.32 0.11 , 0.88 
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Author, 
year 
Islam et 
al. , 2007 
[427] 
Location Design 
North Monozygotic 
America twin-paired 
case-control 
Population 
Disease- and 
exposure-
discordant 
monozygotic 
twin pairs in 
North 
American twin 
registry 
Control or 
cohort n 
Controls 
n=79 
Case Exposure 
n assessment 
79 1. Outdoor 
activities in 
childhood : 9 sun 
exposures : 
a) 4 seasons 
b) day temper-
ature (hot /cold) 
c) activity e.g . 
beach , suntanning , 
team sports 
2. Overall sun 
exposure index 
Outcome Adjusted 
assessment covariates 
MS 1. Childhood 
infection , 
infectious 
mononucleosis , 
OR/RR 
smoking , diet, a) 0.25 
age at menarche (spring) 
2. Sex, birth 
location , ancestry, 
age at diagnosis 
(i .e. stratification 
factors) 
b) 0.40 (hot 
day) 
c) 0.40 
(suntanning) 
2. 0.75 
( all pairs) 
0.69 
(females) 
95% Cl 
0.07 , 0.89 
0.18, 0.91 
0.19 , 0.83 
0.62 , 0.90 
0.53 , 0.86 
107 
Author, 
year 
Kampman 
et al. , 
2007 
[428] 
Location Design 
Norway Age- , sex- and 
place of birth-
matched 
case-control 
Population 
Norwegians 
born and living 
at latitudes 
66-71 °N (i .e. 
above Arctic 
Circle) 
Control or 
cohort n 
Controls 
n=402 
Case Exposure 
n assessment 
152 1. Increased 
outdoor activities in 
summer in early life 
v. low activity 
2. Cod-liver oil 
supplementation 
3. Consumption of 
fish ~3times/week 
Outcome Adjusted 
assessment covariates 
MS 1. Fish & cod-
liver oil intake 
2. Fish 
consumption ; 
Summer activity 
high v. low 
3. Cod-liver oil 
intake 
OR/RR 95% Cl 
1. 0.55 0.39 , 0.78 
(particularly 
ages 16-20 
yr) 
2. 0.57 0.31 , 1.05 
(in low-
activity 
subgroup) 
3. 0.55 0.33 , 0.93 
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Author, 
year Location Design 
Vitamin D intake /supplementation 
Munger et US 
al. , 2004 
[430] 
Prospective 
cohort 
Population 
Nurses' Health 
Study I and 11 
Control or Case Exposure 
cohort n n assessment 
I) 
n=92 ,253 
(followed 
1980-
2000) 
II) 
n=95 ,310 
( 1991 -
2001) 
173 Total vitamin D 
intake at baseline 
a) Highest v. 
lowest quintile 
b) Vitamin D 
supplement use 
~400 IU/d v. nil 
Outcome Adjusted 
assessment covariates 
Incident MS Age , smoker, 
latitude at birth 
OR/RR 
a) 0.67 
b) 0.59 
95% Cl 
0.40, 1.12 
(p*=0 .03) 
0.38 , 0.91 
(p*=0 .006) 
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Author, 
year Location Design 
Munger et us Prospective 
al., 2006 age- sex-
' ' 
[431] race- & date of 
blood 
collection-
matched 
nested case-
control 
p*=p for trend 
Population 
US Military, 
Dept of 
Defense 
Serum 
Repository 
Control or Case Exposure 
cohort n n assessment 
Controls 257 
n=514 
(from 
cohort 
followed 
1992-
2004) 
Vitamin D status 
from two serum 
samples prior to 
first symptoms; 
25(OH)D levels, 
within each 
racial/ethnic group: 
a) highest (>99 .1 
nmol/L) v. lowest 
( <63.3 nmol/L) 
quintile 
b) continuous, for 
50 nmol/L increase 
in 25(OH)D 
Outcome Adjusted 
assessment covariates 
MS Latitude of 
residence at 
military entry 
OR/RR 95% Cl 
a) 0.38 0.19, 0.75 
(whites only, (p*=0 .02) 
n=148) 
b) 0.59 
(whites) 
(partic. 
serum 
<20 yrs) 
age 
0.36 , 0.97 
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Other autoimmune disorders-type 1 diabetes and RA 
Tables 2.4 and 2.5 summarise recent analytical trials of the effects of vitamin D 
supplementation on risk of type 1 diabetes and RA, respectively. 
Type 1 diabetes 
Vitamin D has also been shown to be associated with a reduced risk of development of 
type 1 diabetes. A prospective birth cohort study of 10,366 children in Finland by 
Hypponen and colleagues, using vitamin D supplementation (2000 IU/day) during 
infancy, significantly reduced the development of type 1 diabetes evaluated 31 years 
later [435] (Table 2.4). Those children receiving regular doses of at least 2,000 IU/day 
during their first year of life had an adjusted RR of 0.22 (95% Cl 0.05, 0.89) compared 
with those receiving less than this amount. Further, a subset of these children 
suspected of having rickets, and thus vitamin D deficiency, during the first year of life 
showed a three-fold risk (RR 3.0; 95% Cl 1.0, 9.0) of developing type 1 diabetes 
compared with the remainder of children [435]. 
Two earlier case-control studies , again both in the northern hemisphere, show 
supporting results (Table 2.4 ). The EURODIAB substudy 2 was a large multicentre trial 
covering seven countries in Europe; the pooled estimate of diabetes risk over these 
countries gave an adjusted OR of 0.65 (95% Cl 0.52 , 0.83) for those children receiving 
vitamin D prophylaxis in early infancy compared with those not [436]. Interestingly, 
infants who received vitamin D supplements for one year or less showed a similar 
decrease in risk to those receiving vitamin D for more than one year, suggesting the 
early period after birth to be an important time for influencing diabetes risk . 
The second case-control study, by Stene and co-workers in a county of Norway, 
surveying vitamin 0-rich cod-liver oil , vitamin D supplements or multivitamins taken 
either during pregnancy or during the early infancy period , showed a reduced risk of 
type 1 diabetes in offspring when mothers took cod-liver oil during pregnancy (adjusted 
OR 0.36; 95% Cl 0.14 , 0.90) . This suggests the importance of environmental risk 
factors in utero [437]. While cod-liver oil or vitamin D supplements during the first year 
of life were not found to be associated with diabetes risk, and nor were multivitam in 
supplements that were taken during pregnancy (Table 2.4 ), these unrecorded doses of 
1 1 1 
vitamin D may have been too low in comparison with those used in the Finnish cohort 
study [237]. 
A subsequent nationwide and much larger Norwegian case-control study by Stene and 
Joner [438] again investigated the effects of cod-liver oil and other vitamin D 
supplements both during pregnancy and during the first year of life. In this study, 
however, the beneficial effect of cod-liver oil taken at least five times per week during 
the first year of life was the main finding (adjusted OR for supplementation > five times 
per week 0. 7 4; 95% Cl 0.56, 0.99), the effects during pregnancy, both for cod-liver oil 
and other vitamin D supplements, being non-significant (Table 2.4 ). 
A prospective birth cohort study by Fronczak and co-workers in Colorado, US, following 
233 children identified as at risk for type 1 diabetes based on their heredity and tissue-
typing screening at birth (Diabetes Autoimmunity Study in the Young [DAISY]), 
investigated the appearance of pancreatic islet autoimmunity as a pre-clinical type 1 
diabetes outcome. This study compared maternal intake of vitamin D via food and 
vitamin D supplements, as well as fatty acid intake as exposure variables , all during the 
third trimester of pregnancy; the food frequency questionnaires were completed by the 
mothers shortly after delivery and prior to development of offspring disease. The study 
found that maternal intake of vitamin D via food during late pregnancy was significantly 
associated with a decreased risk of islet autoimmunity in offspring , independent of HLA 
genotype, family history of type 1 diabetes, presence of gestational diabetes mellitus 
and ethnicity (adjusted hazard ratio 0.37; 95% Cl 0.17 , 0.78). Conversely, vitamin D 
intake via supplements and fatty acid intake during pregnancy were not associated with 
the appearance of islet autoimmunity in offspring [439] (Table 2.4) . 
However, a recent Finnish prospective birth cohort study (Diabetes Prediction and 
Prevention Study [DIPP]) of children also at increased genetic (HLA genotype) risk of 
type 1 diabetes showed no association between maternal intake of vitamin D, either 
from food or from supplements, during pregnancy and the risk of advanced beta-cell 
autoimmunity or type 1 diabetes in the offspring , when adjusted for genetic risk and 
familial type 1 diabetes [440] . The maternal intake of vitamin D in th is study was 
relatively low (44% receiving <Sµg/day) and it is possible that only a few mothers 
received a potentially effective dose [440]. In contrast , an extensive Swedish birth 
cohort study (All Babies in southeast Sweden [ABIS]) reported that the maternal intake 
of vitamin D at a dose of at least 5µg/day from supplements during pregnancy 
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protected the infant from autoimmunity at one year of age but not at later ages [441]. 
The Swedish cohort was also derived from the general population rather than from at-
risk children , raising the possibility that the effect of vitamin D may vary by HLA-related 
factors . 
A further case-control study of type 1 diabetes by Tenconi and colleagues in North Italy 
(Table 2.4 ), investigating the 'administration of vitamin D' during lactation (but no doses 
given) , found an inverse association with type 1 diabetes in the zero to 14 year age 
group (OR 0.31 ; 95% Cl 0.11 , 0.86). This similarly suggests the beneficial effects of 
vitamin D in early life [442]. In contrast, in a recent extension of the DAISY study of 
genetically at-risk children born in Colorado, US, there was no association of vitamin D 
intake during childhood (between two and 12 years of age) and subsequent islet 
autoimmunity or type 1 diabetes [443] , suggesting a relatively early time 'window' for 
efficacy. 
From a meta-analysis of the four case-control studies of type 1 diabetes discussed and 
summarised in Table 2.4 (i.e. not including the cohort studies of pre-clinical islet 
autoimmunity) , Zipitis and Akobeng (2008) [444] concluded that children supplemented 
with vitamin D in infancy had a 29% reduction in the risk of developing type 1 diabetes 
compared with those not being supplemented. Further, although recall bias , subjective 
and non-quantitative measurement of vitamin D and confounding were still likely 
weaknesses in these case-control studies , this reduction in risk was also demonstrated 
in the stronger cohort study of Hypponen et al. (2001 ) (Table 2.4 ). The cohort study 
and one of the case-control studies [438] also showed evidence of a dose-response 
effect for oral vitam in D supplementation [444]. 
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Table 2.4: Analytic observational studies on the association between vitamin D and/or related foods and type 1 diabetes. (Table 
adapted and extended from Ponsonby et al., 2005a [237] using additional data from Stene and Joner, 2003 [438], Fronczak et al., 2003 
[439] and Tenconi et al., 2007 [442]) 
Author, 
year 
EURODIAB 
1999 
[436] 
Location 
Seven 
European 
countries 
(Austria , 
Bulgaria , 
Latvia , 
Lithuania , 
Luxembourg , 
Romania , 
N. Ireland) 
Design Population 
Mu lt icentre Registry 
case- cases & 
control population-
based 
controls . 
Note control 
selection 
varied 
across 
centres , 
most 
commonly 
schools 
Control or Case Exposure 
cohort n n assessment 
Outcome Adjusted 
assessment covariates OR/RR 95% Cl 
n=2 ,335 820 Report of Type 1 Age , sex, 0.65 0.52 , 0.83 
vitamin D diabetes by breastfeeding 
supplementation age 15 using duration , 
in infancy with validated maternal age , 
partial record registries birth weight, 
validation study centre 
1 l 4 
Author, 
year 
Stene 
et al. , 
2000 
[437] 
Location Design 
Vest-Agder Population-
county, based 
Norway case-
control 
Population 
Birth cohort 
of 1982-98, 
resident in 
county 
during 1998 
Control or Case Exposure 
cohort n n assessment 
Controls n=85 
n=1 ,071 
a) Maternal report , 
re cod-liver oil 
during 
pregnancy 
b) Maternal report 
re multivitamin 
use during 
pregnancy 
c) Maternal report 
re cod-liver oil 
during first year 
of life 
d) Maternal report 
re vitamin D 
during first year 
of life 
Outcome Adjusted 
assessment covariates OR/RR 95% Cl 
Type 1 Age , sex, a) 0.36 0.14, 0.90 
diabetes breastfeeding 
before age duration, 
15, on maternal 
national education , 
register other b)1.11 0.69 , 1.77 
supplements 
c)0 .82 0.47 , 1.42 
d)1 .27 0.70 , 2.31 
1 15 
Author, 
year Location 
Hyponnen Northern 
et al., 2001 Finland 
[435] 
Design 
Birth cohort 
Population 
Live births 
due 1966 
Control or 
cohort n 
n=10 ,366 
(91 % of 
live births 
to one 
year, 86% 
to 1997) 
Case Exposure 
n assessment 
81 Parental interview 
data at infant age 
1 yr 
1. Vitamin D 
supplementation 
dose 
a )Recommended 
(2000 IU) v. low 
(<2000 IU) 
b)High (>2000 IU) 
v. low ( <2000 
IU) 
2. Vitamin D 
supplementation 
frequency 
a) Irregular v. 
none 
b) Regular v. 
none 
Outcome 
assessment 
Type 1 
diabetes by 
end of 1997 
by registry, 
(type 2 
diabetes 
checked for & 
excluded if 
age 20 or 
more at 
diagnosis) 
Adjusted 
covariates 
Sex, 
gestational & 
maternal age , 
parity, 
maternal 
education, 
social status , 
standardised 
birth weight, 
infant growth 
rate 
OR/RR 95% Cl 
1 a) 0.22 0.05 , 0.89 
b)0.14 0.02 , 1.01 
2a)0.16 0.04 , 0.74 
b) 0.12 0.03 , 0.51 
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Author, 
year 
Stene & 
Joner, 
2003 
[438] 
Location 
Norway 
Design Population 
Population- Birth cohort 
based of 1985- 99 , 
case- from 
control national 
population 
register 
Control or Case Exposure 
cohort n n assessment 
Controls 545 a) Maternal 
n=1 ,668 report , re cod-
liver oil during 
pregnancy 
b) Maternal report 
re multivitamin 
use during 
pregnancy 
c) Maternal report 
re cod-liver oil 
during first year of 
life 
d) Maternal report 
re vitamin D 
during first year of 
life 
Outcome Adjusted 
assessment covariates OR/RR 95% Cl 
Type 1 Age , sex, a) 1.00 0.74 , 1.55 
diabetes duration of (> 5 times 
before age breastfeeding , per week) 
15, on age of solid 
national food 
register, introduction , b) 0.98 0.73 , 1.31 
diagnosed maternal (> 5 times 
between education , per week) 
1997 & 2000 maternal age 
and born at delivery, 
between Jan . family history c) 0.74 0.56 , 0.99 
1985 & Dec. of diabetes, (> 5 times 
1999; maternal 
per week) 
excluding smoking , 
those in pilot number of 
study siblings 
d) 0.97 0.73 , 1.29 
(Stene et al. , (> 5 times 
2000 [437]) 
per week) 
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Author, 
year 
Fronczak 
et al. , 2003 
[439] 
Location Design 
Denver, US Prospective 
cohort 
Population 
Birth cohort 
recruited 
from Denver 
metropolitan 
area in 
DAISY from 
Jan . 1996 
Control or Case Exposure 
cohort n n assessment 
n=233 16 Maternal report of 
children 'at vitamin D and 
risk ' for polyunsaturated 
type 1 fatty acid intake 
diabetes via food and 
on HLA nutritional 
screening supplements 
at birth during 3rd 
and/or trimester, by food 
having frequency 
first- questionnaire 
degree (FFQ) 
type 1 1 . Vit. D via food 
relatives , 2. Vit. D 
whose supplements 
mothers (above or below 
completed 400 IU/day) 
FFQ within 3. Fatty acid 
3 months intake e.g. EPA & 
of delivery DHA from fish 
Outcome Adjusted 
assessment covariates OR/RR 95% Cl 
Islet HLA genotype, 
autoimmunity family history 
in offspring of type 1 
serum (=pre- diabetes, 
clinical stage presence of 
of type 1 gestational 
diabetes) diabetes 
within mellitus , 
average of 4- ethnicity 
year (range 
0.8-7 .3 years) HR (Hazard 
follow-up ratio) : 
1. 0.37 0.17, 0.78 
2. 3.09 0.88 , 10.83 
(>400 IU) 
3. 0.64 0.24, 1.71 
(EPA & 
DHA) 
l I 8 
Author, 
year 
Tenconi 
et al., 2007 
[442] 
Location 
Pavia, North 
Italy 
Vit. D, Vitamin D; 
Design Population 
Age- & sex- Population 
matched recorded 
case- from 1988 to 
control 2000 in 
registry of 
Pavia 
province 
EPA, Eicosapentaenoic acid 
Control or Case Exposure Outcome Adjusted 
cohort n n assessment assessment covariates 
Controls 
(hospital) 
n=318 
159 Maternal report of Type 1 
vitamin D diabetes (0-
administration 29 years of 
during lactation age) on 
Residency, 
family history 
of type 1 
diabetes, 
validated drugs taken 
registry during 
between pregnancy, 
1988 & 2000 type of 
delivery, bottle 
feeding, 
neonatal and 
common 
childhood viral 
diseases, 
genital surgical 
operations, 
scarlet fever, 
severe 
infections 
DHA, Docosahexaenoic acid 
OR/RR 
0.31 
(0-14 yr 
age group) 
95% Cl 
0.11 , 0.86 
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Table 2.5: Analytic observational studies on the association between vitamin D and RA. (Table adapted from Ponsonby et al., 2005 
[237]) 
Author, 
year 
Merlino 
et al. , 
2004 
[445] 
Location Design 
Iowa, US Prospective 
cohort 
Population 
Women aged 
55- 69 yrs who 
did not have RA 
in 1986, followed 
up in 1992 or 
1997 surveys 
Control 
or cohort 
n 
At-risk 
cohort 
n=29,368 
(follow-
up=11 
years 
(314 ,181 
person-
years) 
p*=p for trend FFQ, food frequency questionna ire 
Case Exposure 
n assessment 
152 1. Baseline 
dietary vitamin 
Dover past 
year by FFQ 
a)<169 IU/day 
b)169-289.9 
IU/day 
c) > 290 IU/day 
2. Baseline 
vitamin D 
supplements 
(questionnaire) 
a )Non-users 
b )<400 I U/day 
c) > 400 IU/day 
Outcome 
assessment 
Incident RA 
(validated) 
Adjusted 
covariates 
Age , calorie intake, 
smoking , hormone 
replacement 
therapy, 
decaffeinated 
coffee intake, r3-
crypto-xanthin 
intake 
OR/RR 
1a)1 .00 
b) 0.87 
c) 0.72 
(p*=0 .16) 
2a) 1.00 
b) 0.65 
c) 0.66 
(p*=0 .03) 
95% Cl 
(referent) 
0.58 , 1.29 
0.46 , 1.14 
(referent) 
0.36 , 1 .15 
0.43 , 1.00 
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RA 
A prospective cohort study by Merlino and colleagues of 29,000 older women over a 
follow-up period of 11 years in Iowa, US, has shown that total vitamin D intake at 
baseline (sunlight not accounted for) was inversely associated with the risk of 
developing RA (adjusted RR 0.66; 95% Cl 0.43, 1.00; for those women using vitamin D 
supplements of at least 400 IU/day compared with those using none) [445]. Vitamin D 
intake from diet alone showed no association with RA; however, these dosages were 
lower than in the supplements (Table 2.5). Interestingly, the beneficial effect of vitamin 
D supplementation appeared to be evident even in middle or older age, the cohort 
being made up of women aged 55 years and older at cohort entry [237]. 
An inverse association between serum 25(OH)D levels and disease activity was shown 
in RA patients compared with normal controls in Europe [446], and an inverse 
relationship between serum 25(OH)D levels and disease activity at baseline was seen 
in patients with early inflammatory polyarthritis (includes RA) in a cross-sectional UK 
study [447]. Both studies suggest an immunomodulatory role of vitamin D in RA. In an 
intervention study in RA patients, supplementation with a synthetic precursor to 
1,25(OH)203 decreased the severity of RA symptoms in a small case-control study 
[448]. Other patient intervention studies with variable results are reviewed by 
Zittermann (2003) [385] and, again , dosage of vitamin D appears to be important. 
Summary 
The large prospective cohort studies , in particular, summarised in Tables 2.3 to 2.5, 
support the hypothesis that high vitamin D intakes can reduce the risk of developing 
any of the three autoimmune diseases, MS, type 1 diabetes or RA [413]. These vitam in 
D studies in humans, together with the case-control studies of sun exposure and MS in 
Table 2.3, also now support mounting evidence from many animal-model studies (see 
Section 2.4) for UVR and vitamin D being protective for these disorders. 
Additionally, it is now evident that both UVR and vitam in D are linked mechan istica ll y 
with immunological self-tolerance, maintenance of which has been shown to be key to 
preventing autoimmune disease development. Both UVR and vitam in D are potent 
immunomodulators, acting to suppress inappropriate immunolog ical responses against 
self-antigens. Both UVB and active-vitam in D (1 ,25(OH )2 0 3) down-regulate the action 
of APCs, and particularly DCs, preventing presentation of (self-)antigen to effector T 
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cells in both skin and lymph nodes, via cytokine mediators such as IL-10 (and reduced 
IL-12 and IL-23), thereby decreasing inflammatory autoimmune processes (see 
Sections 2.4.1 and 2.4.2). Both UVB and active-vitamin D also promote tolerogenic 
DCs, which then enhance the production of tolerance-crucial regulatory T cells. All of 
the main types of regulatory T cells shown to be involved in self-tolerance in Chapter 1 
(see Section 1.3.1) are induced or enhanced by either UVR (UVB) or vitamin D. That is , 
UVB induces Tr1-like (CD4+ CD25+) regulatory T cells and NKT cells (producing 
immunosuppressive IL-10 and IL-4), both of which may up-regulate apoptosis 
necessary for normal disposal of auto-reactive cells (see Section 2.4.1 ). 
lmmunosuppressive Foxp3+ (CD4+ CD25+) T cells and Tr1-like regulatory T cells 
(producing IL-10 and TGF-~) are induced by active-vitamin D, and again enhanced 
apoptosis appears to be an important vitamin D-induced regulatory mechanism, 
together with further potentiation of the highly anergic and immunosuppressive Foxp3+ 
(CD4+ CD25+) nTreg and iTreg cells (see Section 2.4.2). 
Thus , UVR in sunlight, either directly or acting through vitamin D, appears to be a 
prime candidate as an extrinsic environmental factor possibly influencing the 
development of organ-specific autoimmune diseases such as MS. Interestingly, 
although vitamin D is increasingly considered to be the key environmental factor rather 
than UVR itself, recent work by Becklund and co-workers using the EAE murine model 
[449] showed that vitamin D dietary supplementation was not sufficient to clinically 
suppress this disorder, whereas continuous daily UVR could suppress EAE far more 
effectively. This suggests that UVR can suppress independently of vitamin D. This 
notion is also supported by the recent results for humans from the Australian MS 
'Ausimmune' study, wherein both past sun exposure and vitamin D status were shown 
to be independently associated with a reduced risk of FOE of MS [361 ]. 
2.6 Timing of action of UVR/vitamin D 
Several of the analytical trials summarised in Tables 2.3 to 2.5 have suggested the 
importance of either UVR or vitamin D acting early in life , or even in utero. For example , 
sun exposure (UVR) in ch ildhood was associated with reduced MS ri sk in TAS , 
Australia [426], and in North America [427] , but also in adolescence (16 to 20 years of 
age) in Norway, above the Arctic Circle [428] (Table 2.3). Serum vitamin D status prior 
to MS was similarly shown to be inversely associated with the risk of MS particularly in 
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adolescence (up to 20 years of age) but also , less strongly, after 20 years of age in US 
white people [431] 10 . Age-related migration studies (see Section 2.3.2) further suggest 
major effects of environmental UVR acting prior to adulthood. 
For type 1 diabetes, an autoimmune disorder with earlier onset (generally <30 years 
and often by 15 years of age) than MS, the beneficial effects of vitamin D intake as 
food , cod-liver oil or other supplementation appear to act at an early stage; that is, in 
infancy or the first year of life [435, 436, 438 , 442] (Table 2.4) or during pregnancy [437, 
439, 441 ]. While these individual type 1 diabetes studies varied slightly, some showing 
food or cod-liver oil intake to be superior to other vitamin D supplements, particularly in 
pregnancy [437 , 439] (Table 2.4 ), the overall conclusion for both type 1 diabetes and 
MS is that UVR and/or vitamin D appear to be protective for these disorders when 
received , or are sufficient, relatively early in life. 
These observations are consistent with increasing information on the effects of vitamin 
D deficiency, or insufficiency, as risk factor(s) for a variety of chronic diseases [450] , 
early life effects in particular being important, as reviewed by Lucas and colleagues 
[451 ]. Ponsonby et al. (2010) further review this topic, concentrating on the prenatal 
period as possibly the most critical time for subsequent effects of low vitamin D status 
[452]. For example , maternal diabetes and obesity in pregnancy, known to contribute to 
vitamin D deficiency [214], are possibly associated with higher offspring MS risk [453] . 
A low vitamin D status is common in many pregnant women , even in sunny Australia , 
particularly in non-Caucasian populations and those not receiving supplementation 
(studies summarised in Table 2.6) . Vitamin D deficiency during pregnancy has been 
similarly noted by other studies (for example , Datta et al. , 2002 [454]) and in recent 
reviews (for example , Hollis and Wagner, 2006 [455]). In Australia , further , there is little 
fortification of food with vitamin D [456 , 457] and several studies have recorded the 
high prevalence of low vitamin D status in both pregnant women and other Austra lian 
populations [457-461] , even in subtropical regions [462]. Moreover, even in pregnant 
women previously considered to be 'not at risk ' in Australia or NZ (i. e. Caucas ians , not 
veiled or dark-skinned and in abundant sunshine areas), low vitamin D status has been 
recently found to be widely prevalent [463-465]. 
10 Supporting the early-life findings, a longitudinal study by Mirzaei et al. (2011) showed that gestational 
vitamin D, as measured by maternal milk intake. maternal dietary vitamin D intake and predicted 
maternal serum 25(0H)D in mother of nurses in the US urses· Health Study II, \Yas in\·ersely 
associated with subsequent MS risk in their nur e-daughter offspring [675]. 
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Table 2.6: Prevalence of low vitamin D status in pregnancy. (Table adapted and extended from Ponsonby et al., 2010 [452] using 
additional data from Maghbooli et al., 2007 [469]) 
Year Country 
1997 Iran 
1997- us 
2001 
1999 Northern 
Ireland 
Population (all pregnant women) Stage of 
pregnancy 
25(0H)D 
definition 
Iranians (age 16-40 yr) attending largest Tehran Delivery at term <25 nmol/L 
hospital 
Pittsburgh (40°N) residents (>90% on prenatal 4-21 weeks <37.5 nmol/L 
vitamins)- African-American gestation 
37-42 weeks 
4-21 weeks <37 .5 nmol/L 
- White gestation 
37-42 weeks 
Caucasians attending Belfast hospital 12 weeks <25 nmol/L 
(54-55°N)- no supplements gestation 
20 weeks 
35 weeks 
12 weeks <25 nmol/L 
- on supplements gestation 
20 weeks 
35 weeks 
Prevalence 
% (n/N) 
80 .0% (40/50) 
44 .9% (89/194) 
29 .2% (54/185) 
2.0% (4/199) 
5.0% (10/199) 
44.2% (34/77) 
50.6% (39/77) 
20.8% ( 16/77) 
4.5% (1/22) 
22 .7% (2/22) 
0% (0/22) 
Reference 
Bassir et al. , 2001 
[470] 
Bodnar et al. , 2007 
[471] 
Holmes et al. , 2009 
[472] 
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Year 
1999-
2000 
1999-
2000 
2002 
2002 
2002-
2004 
2005-
2006 
Country 
Australia 
UAE 
Iran 
India (North) 
The 
Netherlands 
India (North) 
Population (all pregnant women) Stage of 
pregnancy 
Veiled and/or dark-skinned attending antenatal First antenatal 
clinic , Melbourne visit 
Attending two hospitals in Kuwait Delivery 
Attending Tehran university hospitals Delivery 
Attending Lucknow (26.8°N) hospital Delivery 
The Hague residents- Turkish 12 weeks 
(midwife clinic) - Moroccan gestation 
- other non-Western 
- Western 
Barabanki district residents (26 .8°N) Second 
trimester 
25(0H)D 
definition 
<22 .5 nmol/L 
<25 nmol/L 
<35 nmol/L 
<22 .5 nmol/L 
<25 nmol/L 
<50 nmol/L 
Prevalence 
% (n/N) 
Reference 
80.5% (66/82) Grover & Morley, 
2001 [459] 
40.0% (86/214) Molla et al. , 2005 
[473] 
66.8% Maghbooli et al. , 
(380/552) 2007 [469] 
84.0% Sachan et al. , 2005 
(174/207) [474] 
83.5% (66/79) van der Meer et al. , 
81 .2% (56/69) 2006 [475] 
59 .0% (62/105) 
8.0% (8/105) 
74.1%(103/139) Sahu et al. , 2009 
[476] 
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As discussed in Section 2.2, foetal life experience may well influence the onset of 
chronic disease in later life (i.e. Barker's 'foetal origins hypothesis'). Low vitamin D 
status during the prenatal period may thus be a major 'imprinting' influence, as 
hypothesised by McGrath in 2001 [221]. The mechanisms through which vitamin D 
might act include modulation of the immune system early in life. For example , in a 
German study of winter-born newborns, low vitamin D status was associated with low 
cord blood levels of the immunosuppressive cytokine IL-10 important in regulating 
immunological tolerance (see Sections 2.4.1 and 2.4.2) and preventing allergy [466] . 
In another study, vitamin D acted to inhibit further differentiation of na·fve cord blood T 
cells into either Th1- or Th2-type effector T cells [467], underlining the regulatory 
importance of vitamin D in the early developing immune system. The importance of 
vitamin D availability in utero is further suggested by the recently shown epigenetic 
control of a 24-hydroxylase enzyme regulating vitamin D availability and activity 
specifically in the placenta [468] . 
Other plausible mechanisms of early life vitamin D action , particularly for MS and other 
CNS disorders, include neurotrophic and neuroprotective effects on CNS development 
[4 77], because this period coincides with the rapid development of the nervous system 
[214]. For example, vitamin D has been shown to have a potent effect on the induction 
of human nerve growth factor synthesis [4 78 , 4 79]. 
The incidence of the human CNS disorder, schizophrenia , may also be influenced 
protectively by early life vitamin D. In a notable Finnish birth cohort study by McGrath 
and colleagues, regular vitamin D supplementation during the first year of life 
(assessed for offspring by maternal self-report) was associated with a reduced risk of 
schizophrenia , particularly in males (RR 0.12, 95% Cl 0.02 , 0.90 ) [480]. Many anima l 
studies by McGrath and other collaborators further link vitamin D and the develop ing 
brain and spinal cord [481-484]; for example , maternal vitam in D depletion alters 
neurogenesis in the developing rat brain [485] . The specific VDR is also found 
throughout the CNS of the foetal rat [486] , all suggesting an early role for vitamin D in 
the development of the mammal ian CNS . 
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2.7 Conclusion 
Ecological studies in terms of 'person ', 'place' and 'time', the immunological 
mechanisms involved , and the analytical epidemiological studies reviewed herein all 
point to a role for sunlight as a possible environmental determinant of MS, and of other 
autoimmune disorders such as type 1 diabetes and RA. Sunlight exposure, acting 
through UVR directly and/or enhanced by vitamin D generation early in life, may thus 
be one component cause that, together with genetics , can (inversely) affect the risk of 
developing such organ-specific autoimmune disorders later in life. 
The next chapter, Chapter 3, will consider other possible environmental factors that 
may additionally, or alternatively, be involved as possible determinants of autoimmune 
disorders , and at what stages in the life course these may act. 
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CHAPTER 3 
INFECTIOUS AND OTHER ENVIRONMENTAL DETERMINANTS AND THEIR 
TIMING IN MS AND OTHER ORGAN-SPECIFIC AUTOIMMUNE DISORDERS 
This chapter forms a continuation of the review of possible 'causes that can explain 
patterns of disease occurrence ' [1] (see Chapter 2) and now focuses on environmental 
factors other than sunlight for autoimmune disease. As in Chapter 2, discussion will be 
restricted mainly to MS, with type 1 diabetes and RA considered where appropriate for 
comparison. This chapter will consider possible infectious and other contributory 
causes of these autoimmune disorders, with a special focus on the putative timing of 
environmental factors during the period before disease onset. 
3.1 Infections as autoimmune disease determinants-causal 
and/or protective? 
3.1.1 Possible infectious causes of autoimmune disorders 
As discussed in Chapter 2, the 'person ', 'place' and 'time' characteristics of 
autoimmune disease epidemiology suggest the action of factors such as infectious 
agents-among other environmental factors such as sunlight-as possible 
determinants of such disease. In particular, the geographical grad ient of increasing 
prevalence (or incidence) with increasing latitude north and south of the equator, 
together with corresponding differences in populations migrating from high- to low-
prevalence regions (or vice versa) (i.e. variation in 'place') seen in both MS and type 1 
diabetes, suggest environmental factors similarly varying with distance from the 
equator. These factors include infections-perhaps dependent on climatic factors such 
as temperature-and 'person ' or cultural/agricultural factors such as diet. The 
infectious hypothesis is also strongly supported by the different temporal patterns of the 
disease (variation in 'time') in different geographic areas; incidence rates have changed 
over time in many regions but have remained stable in other areas [487]. In addition , a 
seasonal cycle in disease onset or other disease parameters further suggests an 
environmental factor, such as infections , that typically cycles from cold to warmer parts 
of the year, particularly in temperate regions. 
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The notion that autoimmune disease might be infection-determined is not new. For 
example, apart from the geographic and temporal patterns discussed , MS in the North 
Atlantic (Danish) Faroe Islands appeared to be an infectious, point-source epidemic 
occurring in a previously-unexposed population after occupation by British troops there 
in 1940 [488]. Kurtzke postulated a widespread transmissible agent that causes an 
asymptomatic, persistent, primary infection. That is, the 'prevalence hypothesis ', 
wherein the disease is most common where the causal agent is most widespread [489]; 
then , years after the primary infection and only rarely , this agent could cause 
neurological symptoms of MS [8]. 
With regard to possible mechanisms overall, there have been two parallel hypotheses 
for the pathogenesis of organ-specific autoimmune disorders such as MS: 
1. autoimmune, with immune injury to an essentially normal target organ (the CNS 
in the case of MS) 
2. infectious, with chronic or re-activated latent infection provoking immune injury. 
More recently, these hypotheses have fused into a third: 
3. a common pathogen drives or initiates autoimmunity, whether or not the 
pathogen resides in the target organ [490]. 
Infectious agents-mechanisms of breaking self-tolerance 
Section 1.3.2 in Chapter 1 introduced the concept of temporarily 'breaking ' tolerance of 
self-antigens in order to satisfactorily respond to infection , as , for example , when 
infectious microbes such as viruses are held within host (self) cells. Indeed , the 
immune system has evolved primarily to protect ourselves from invasion by foreign 
organisms. So, we might ask, what could make the immune system turn on itself? 
What makes it break self-tolerance to the extent that self-tissues are attacked and 
destroyed? A popular answer, as noted by Benoist and Mathis (2001 ), is that 
autoimmune disease is a by-product of the immune response to microbial infection 
[ 491]. 
In support of this view, several associations between infectious agents and 
autoimmune disorders have been observed ; for example , between ~-haemolytic 
streptococci and rheumatic fever; B3 Coxsackie viruses and myocarditis; herpesviruses 
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and MS; enteroviruses or rubella and type 1 diabetes; the spirochaete Borellia and 
Lyme arthritis , to name a few [491 ]. 
How might such microbial agents incite autoimmune disease? As discussed in Chapter 
1, a necessary feature of the immune system is that all individuals have potentially self-
reacting T-cell lymphocytes, but that these cells remain innocuous unless activated. 
Multiple mechanisms to explain how viruses may trigger autoimmune disease have 
been investigated, including non-specific virus-induced general activation of the 
immune system, as well as antigen-specific immune responses to viral antigens that 
cross-react with self-antigens and ultimately cause auto-reactive immuno-pathologies 
[492, 493]. 
The initial innate immune system response to invading microbes, involving (microbe)-
pattern recognition by the host's cells (see Chapter 1 ), triggers signalling pathways 
leading to cellular activation, expression of co-stimulatory molecules on APCs, 
activation of APC antigen-presenting capacity and their production of type 1 interferons, 
pro-inflammatory cytokines and chemokines, which initiate and direct the immune 
response against the pathogen. Thus, pathogens act as adjuvants for the immune 
response, while also providing the antigen source for adaptive T-cell and B-cell 
activation and effector function (Chapter 1 ). It is then relatively easy to imagine how 
auto-reactive cells normally present might trigger an aberrant destructive immune 
response in this highly inflammatory environment [492] . 
Molecular mimicry 
Figure 3.1 indicates possible mechanisms of infection-induced autoimmune disease. 
Most evidence in animal disease models supports the concept that such disease is 
caused by adaptive, cross-reactive immune responses due to similarities between 
microbial and self-antigens , known as molecular mimicry [492 , 494] (Figure 3.1 a). 
Molecular (or epitope) mimicry is a mechanism by which infectious agents (or other 
exogenous substances) may trigger an immune response against auto-antigens 
because their antigens are immunologically similar to the host antigens but differ 
sufficiently to induce an immune response when presented to T cells . Such mimicry is 
thought to result from the necessary flexibility of the TCR recognition system , wherein 
T cells can be activated by the majority of different peptides likely to be encountered 
from pathogens, these peptides being bound to one or more MHC (i .e. self) molecules. 
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That is , a side effect of this 'degeneracy' of the immune recognition system is the 
potential induction of reaction-to-self by the immune response to microbial antigens 
[492]. This 'breakdown of tolerance ' to self-antigens means that the pathogen-specific 
immune response generated then cross-reacts with host structures to cause tissue 
damage and disease [493 , 494] . 
For example , MS may be initiated by an infection by a virus sharing antigenic 
structures with human CNS tissue. The self-antigens involved , such as MBP or PLP, 
cross-react with the host's anti-viral immune response, leading to demyelination. 
Subsequent viral infections may then cause exacerbations , or relapses , of the disease 
by reactivating the immune response against viral antigens and auto-antigens. In type 
1 diabetes, as another example , mimicry may be based on sequence homology 
between glutamate decarboxylase, an enzyme concentrated in pancreatic beta-cells , 
and an enzyme involved in replication of the enterovirus Coxsackie virus B [494]. 
As evidence for the possibility of such a mechanism in humans, molecular mimicry has 
been shown to trigger autoimmune disease in several experimental animal models. 
These include Theiler's murine encephalomyelitis virus (TMEV) , engineered to express 
mimics of encephalitogenic myelin epitopes, a model of human MS; autoimmune 
demyelinating disease associated with Semliki Forest virus (SFV) ; and various models 
of type 1 diabetes (reviewed by Ercolini and Miller, 2008 [495] , Munz et al. , 2009 [493] 
and Getts and Miller, 2010 [492]) (Table 3.1 ). 
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Figure 3.1: Possible mechanisms of infection-induced autoimmune disease. 
(a) Auto-reactive T cells can be activated via molecular mimicry by cross-reactive 
recognition of a viral antigen that has similarity to self-antigen. 
(b)(i) Microbial infection stimulates TLRs and other pattern-recognition receptors 
on APCs, leading to the production of pro-inflammatory mediators, which can 
lead in turn to tissue damage. 
(ii) Self-antigen that is released from damaged tissue can be taken up by 
activated APCs, processed and presented to auto-reactive T cells (concomitant 
with presentation of virus antigen to virus-specific T cells) in a process known as 
bystander activation. Alternatively, an infection can lead to microbial 
superantigen-induced activation of a subset of T cells, some of which could be 
specific for self-antigen. 
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(iii) Further tissue destruction by activated T cells and inflammatory mediators 
causes the release of more self-antigen from tissues. 
(iv) The response can then spread to involve T cells (or antibodies) specific for 
other self-antigens in a process known as epitope spreading. (Figure adapted 
from Getts and Miller, 2010 [492].) 
Table 3.1: Selected murine models of infection-induced autoimmune diseases. 
(Table adapted from Getts and Miller, 2010 [492]) 
Disease Infectious agent Mechanism(s) of disease 
modelled initiation/exacerbation* 
MS TMEV Bystander activation and 
epitope spreading 
TMEV expressing PLP139 Molecular identity 
TMEV expressing PLP 139 Molecular mimicry 
mImIcs 
Lymphocytic choriomeningitis Molecular identity 
virus (LCMV) (in mice expressing 
LCMV protein in CNS) 
SFV Molecular mimicry 
EAE + bacterial superantigen Superantigen* 
staphylococcal enterotoxin B* 
Type 1 diabetes Coxsackie B4 Bystander activation 
LCMV (in mice expressing LCMV Molecular identity 
protein in pancreas) 
Pichinde virus (in mice expressing Molecular mimicry* 
LCMV protein in pancreas)* 
RA CIA+ murine arthritogenic Superantigen* 
mycoplasma superantigen* 
*In these examples , the indicated infectious agent does not cause disease but results in exacerbation of 
disease established by other means. 
In addition, there are many experimental models of molecular identity (rather than 
mimicry) (Table 3.1 ), in which an exact microbial protein or epitope is expressed 
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transgenically in a particular tissue. Under these conditions, animals develop 
autoimmune disease in that tissue after infection with the protein-expressing microbe, 
rather than spontaneously. These approaches, although artificial and not proving 
causation, do indicate that T cells specific for a 'self-antigen can become activated by 
infection with a microorganism containing an identical antigen, resulting in autoimmune 
disease [492]. 
There are further indications of possible mImIcry cross-reactions in humans with 
autoimmune disorders such as MS, RA and SLE, whose self-reactive T and B cells 
have been shown to be at higher frequencies and activation states, these evident 
clonal expansions being also persistent and long term. For example, patients with MS 
have predominant clonal expansions of CD4+ T cells specific for the EBV nuclear 
antigen 1 (EBNA 1 ), and EBNA 1-specific T cells recognise myelin antigens more 
frequently than other auto-antigens that are not associated with MS [492, 496]. (MS 
and EBV are further discussed in detail in Section 3.1.3.) 
Bystander activation and epitope spreading 
As shown in Figure 3.1 b, APCs activated during the inflammatory response to 
microbes can also stimulate the activation and proliferation of self-reactive T or B cells 
by 'bystander activation ' (Figure 3.1 b, i to ii); in this case, self-antigen , perhaps 
exposed by the initial immune response, is presented subsequent to tissue destruction. 
Further tissue destruction (Figure 3.1 b, iii) can then compound this , and may lead to an 
immune response by a broader set of T cells to other epitopes of the same self-protein 
or even to other self-proteins, a phenomenon known as 'epitope spreading ' (Figure 
3.1 b, iv). Epitope spreading has been shown in EAE ('mouse MS'), as well as in TMEV-
induced demyelinating disease in mice (Table 3.1 ), and in the spontaneously arising 
NOD mouse model of type 1 diabetes [492]. By such antigen-non-specific mechanisms 
for initiating autoimmune disease , no particular microbe is implicated ; however, a 
combination of antigen-specific (i.e . mimicry) and non-specific mechanisms can also 
occur, resulting in overall activation of auto-reactive T cells that expand , differentiate 
and ultimately become pathogenic. 
Other mechanisms of breaking self-tolerance 
Recent reviews have suggested that viral infection can also cause changes in normal 
immunoregulatory mechanisms, such as those involving regulatory T cells [497]. For 
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example, susceptibility to TMEV-induced demyelinating disease in mice is mediated (in 
a particular susceptible strain) by virus-induced activation of regulatory T cells , which 
interfere with virus clearance leading to persistent CNS infection and later initiation of 
autoimmune disease via epitope spreading. Conversely, in a mouse strain that Is 
disease resistant, infection fails to activate these regulatory T cells and the virus Is 
rapidly cleared [492]. 
Table 3.2 summarises specific viral pathogens that have been implicated in selected 
human autoimmune disorders and evidence for, and/or proposed mechanisms (in 
italics) for, their action. (MS and type 1 diabetes will be also discussed more fully in 
subsequent Sections 3.1.3 and 3.1.4.) 
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Table 3.2: Viral pathogens implicated in selected human autoimmune disorders. 
(Table adapted from Munz et al., 2009 [493]) 
Virus 
EBV 
EBV 
HHV6 
(Human 
herpes 
virus 6) 
Measles 
virus 
Autoimmune 
disorder 
MS 
RA 
MS 
MS 
Evidence/ proposed mechanism( s) 
• Increased risk to develop MS 
after primary symptomatic 
infection 
• Increased antibody responses in 
healthy individuals who will 
develop MS 
• Increased seroprevalence 
• Altered T-cell and humoral 
immune responses 
• Localisation in diseased tissue 
• Molecular mimicry/bystander 
activation 
• Higher viral loads in circulating 
blood cells 
• Altered immune responses 
• Localisation in diseased tissue 
• Localisation in diseased tissue 
• Clonally expanded CSF-
infiltrating T cells recognise virus-
encoded antigen 
• Infection can result in 
demyelination 
• Higher titres of virus-specific lgG 
and increased frequencies of 
virus-specific T cells in CSF 
Selected 
references 
[498] 
[499] 
[500] 
[501] 
[502] 
[503] 
[504] 
[496] 
[505] 
[506] [510] 
[507] [511] 
[508] 
[509] 
[512] 
[513] 
[514] 
[515] 
[516] 
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Virus 
Coxsackie 
virus 
Autoimmune 
disorder 
Type 1 
diabetes 
Rubella Type 1 
virus diabetes 
Parvovirus RA 
B19 
Evidence/proposed mechanism(s) 
• Altered immune responses 
• Experimental infection causes 
type 1 diabetes 
• Enterovirus positive beta-cells 
detected in pancreata from type 1 
diabetes subjects 
• Bystander activation, molecular 
m,m,cry 
Selected 
references 
[517] 
[137] 
[518] 
[519] 
• Tropism for pancreatic beta-cells [520] 
• Molecular mimicry [521] 
• Detection of viral DNA in synovial [522] 
tissue [523] 
• Phenotype of acute infection can 
mimic early RA 
3.1.2 Infections as protection from autoimmune disease, and their 
timing 
As well as possibly being causal determ inants of autoimmune disease , infections may 
also be protective and thus prevent development of these , and various allerg ic, 
disorders [524] . For example , Le ibowitz and colleagues suggested as early as 1966 
that the risk of MS was increased among persons who spent the ir ch ildhood in a home 
with a high level of sanitation [525] . This concept, based on what is now known as the 
'hygiene hypothesis ', seeks to explain some of the more obvious epidemiolog ica l 
observations of autoimmune (and allergic) disorders , particu larly their rising incidence 
over the last few decades (i.e. variation in 'time'). 
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Hygiene hypothesis-evidence and mechanisms 
The 'hygiene hypothesis' was proposed originally for allergic disorders by Strachan in 
1989, who observed an inverse correlation between hay fever and the number of 
siblings, particularly older siblings, in the family when following a cohort of more than 
17,000 British children for 23 years from their birth in 1958 [526]. Strachan reasoned 
that birth order and the size of the family reflected the degree of exposure to common 
infections within households in early childhood, and that these infections have a role in 
preventing allergic disease [3]. The resulting hypothesis was then extended to include 
autoimmune disorders such as type 1 diabetes and MS in 2002 by Bach, who 
proposed that the rise in allergic and autoimmune diseases in developed countries was 
related to the decrease in infectious diseases over the same period as a result of 
increased sanitation and better socio-economic conditions (Figure 3.2) [3]. 
Figure 3.2 illustrates this inverse relation at the population level between the incidence 
of various prototypical infectious diseases (panel A) and the incidence of immune 
disorders (panel B) over the 50-year period from 1950 to 2000. While some of the 
immune disorder increase may be attributable to better diagnosis or improved access 
to medical facilities in economically developed countries, the increase in those 
countries over a short period of time is less easily dismissed for readily diagnosed 
autoimmune diseases such as type 1 diabetes, and perhaps also for MS that can be 
definitively, if not easily, diagnosed [527]. 
The concomitant decline in infectious diseases over the same period is particularly 
clear for hepatitis A , childhood diarrhoea and especially parasitic infections such as 
helminthiasis , all of which are chronic disorders in countries with substandard health 
systems. In Western countries , conversely, the spread of infections was limited after 
the industrial revolution by public health measures such as decontamination of water, 
pasteurisation of milk, antibiotics and vaccination against common childhood infections 
[3 , 527]. Thus , the hygiene hypothesis accounts for differences between developing 
and developed countries , where both intestinal and paras itic infections in particular 
have decreased , particularly among children [3]. 
The timing of infections and of disease onset is of fundamental importance to this 
hypothesis (timing discussed in more detail subsequently) ; for example , intestinal 
colonisation with gram-negative bacteria occurs later in developed , compared with 
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developing, countries [3], and type 1 diabetes now occurs earlier in life than in the past 
[527]. Indeed, type 1 diabetes has now become a serious public health problem in 
some European countries such as Finland , and in central and eastern Europe, where 
an increasing number of cases in the zero to four year age group has been reported 
[275 , 280]. 
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Figure 3.2: Inverse relationship between the incidence of prototypical infectious 
diseases (panel A) and the incidence of immune disorders (panel B) from 1950 to 
2000. (Figure from Bach , 2002 [3]; data sources given in Bach, 2002 [3].) 
Which epidemiological features of autoimmune disease can the hygiene 
hypothesis explain? 
As well as variation in 'time', the global distribution (variation in 'place') of autoimmune 
diseases appears to mirror that of various infectious diseases, includ ing hepatitis A, 
gastrointestinal infections and parasitic infections. As discussed in Chapter 2 (see 
Section 2.3.2) , there is an overall north-south latitude grad ient for autoimmune 
disorders in the northern hemisphere, and a south-north gradient in the southern 
hemisphere. There is also a west-east grad ient in autoimmune disease in Eu rope- the 
incidence of type 1 diabetes in Bulgaria or Roman ia being lower compared with 
western Europe but also rapidly increasing [291 ]-and a west-east grad ient is also 
evident in the US for MS [189] . Genetic differences, and/or differences in sun exposure, 
do not fully explain such gradients; for example, in Europe the incidence of type 1 
diabetes is six-fold higher in Finland compared with the adjacent Karelian republic of 
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Russia , even though the genetic background is the same [528] and sun exposure also 
similar [527]. Sanitary conditions, and related infections, may be the discriminating 
factor here. 
Migration studies (see Chapter 2, Section 2.3.2) have shown that offspring of 
immigrants acquire the same risk as the host country by the first generation for MS 
[304, 529] and type 1 diabetes [530]. Asian immigrants to the US show increasing risk 
of MS when migrating from their low-incidence countries [531 ], and immigrant families 
from Pakistan to the UK similarly show increasing frequency of type 1 diabetes [532]. 
Several factors may explain these differences in 'place', including confounding by SES. 
As discussed in Chapter 2, there is a positive correlation between gross national 
product and the incidence of asthma, MS and type 1 diabetes in Europe [3]. This is 
also found in smaller, within-country regions such as Northern Ireland, where the low 
incidence of type 1 diabetes is correlated with low average SES [533]. In Australia, 
frequency of MS was significantly higher in those who left school at an older age and 
who achieved a higher educational level [534]. However, SES itself may not be the 
factor directly responsible but may be a marker for sanitary conditions linked to early 
life infections. Several epidemiological studies have indicated a positive correlation 
between sanitary conditions and MS [525] or type 1 diabetes [533] , suggesting a 
possible beneficial role of infections consistent with the hygiene hypothesis. 
Protective infections in animal models 
The most direct evidence of the protective influence of infections on autoimmune 
diseases comes from animal models, such as the NOD mouse model that typically 
develops spontaneous type 1 diabetes. These mice develop this autoimmune disorder 
spontaneously only if bred under sanitary, pathogen-free conditions ; in 'conventional ' 
facilities, the incidence of type 1 diabetes is very low to zero. Conversely , sterile-bred 
mice can be completely protected from developing type 1 diabetes by infecting them 
with a variety of bacteria , viruses and parasites [3]. Similarly , admin istration of 
mycobacteria (as complete Freund 's adjuvant) can prevent murine EAE [535]; even 
bacterial or parasitic extracts , rather than living microbes or parasites, are sufficient to 
achieve such protection for type 1 diabetes [536, 537] . 
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Human patient studies 
A small recent MS patient cohort study in Argentina showed an inverse association 
between intestinal helminth parasitic infection and the rates of MS progression [538], 
indicating the beneficial effect of parasitic infection on this autoimmune disorder, 
consistent with the hygiene hypothesis. To further test this effect, RCTs of helminth 
immunomodulation on the clinical course of MS are now in progress or imminent, 
including one using a low dose of live hookworm larvae applied to the skin as 
'controlled parasite exposure' and measuring immunoregulation as increase in various 
types of regulatory T cells (see www.clinicaltrials.gov). Similar studies on other 
autoimmune disorders such as Crohn's disease or ulcerative colitis have achieved 
encouraging results; for example, patient symptoms were markedly improved in both 
these conditions by deliberate administration of ova from the swine parasite Trichuris 
suis [527], supporting the hygiene hypothesis as a mechanistic concept. 
Mechanisms of protection by infections 
A number of possible mechanisms by which infectious agents might result in a 
protective effect against autoimmune disease have been proposed. Antigenic 
competition has been known for some time, whereby two immune responses elicited by 
distinct antigens at the same time tend to inhibit each other; for example , strong 
immune responses against antigens from infectious agents may inhibit responses to 
weaker antigens such as auto-antigens [539]. Recent attention has been given to 
competition by lymphocytes for cytokines, growth factors and for recognition for 
MHC/self-peptide complexes-all of which are necessary for the proliferation and 
differentiation of T and B lymphocytes and for the maintenance of lymphocyte 
homeostasis-to explain such antigenic competition [527]. 
Regulatory T cells, shown in Chapters 1 and 2 to be critically involved in many different 
areas and functions of the immune system , form another likely mechanism of 
maintaining immune homeostasis by means of bystander suppression [539 , 540] . That 
is, immunosuppression can occur against antigens other than the specific antigen of 
the infectious agent and thus result in a lack of response by effector T cells to 
otherwise-antigenic self-tissues. Indeed , there are several known instances of 
infectious agents, such as gut-associated parasites , 'hijacking ' the regulatory T-cell 
machinery of the human immune system and effecting general immunosuppression , 
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precisely in order to prevent efficient clearance of the pathogen to allow their long-term 
persistence in the host [541 ]. 
Which regulatory T cells might be involved in dampening the inflammatory reactions 
characteristic of autoimmune disease? Transfer experiments in a murine parasite 
model suggest the role of Foxp3+ (CD4+ CD25+) regulatory T cells [542]. Consistent 
with this, parasite-infected MS patients followed prospectively in an extension to the 
aforementioned Argentinian study [538] appeared to develop three different regulatory 
T-cell populations-Foxp3+ (CD4+ CD25+) regulatory T cells , IL-10 -secreting cells 
(Tr1) and TGF-~ -secreting cells (Th3) (see Chapter 1 )-as shown by decreases in 
these cell types three months after anti-parasite treatment [543]. 
Non-antigen-specific mechanisms may also be important, though they are as yet ill-
defined [539]. For example, although TLRs of the innate immune system can trigger or 
exacerbate inflammatory autoimmune responses (as a by-product of pathogen 
recognition) (see Section 3.1.1 ), surprisingly, it has been observed that TLR stimulation 
can also prevent the onset of spontaneous autoimmune diseases such as type 1 
diabetes in NOD mice [527, 544]. That is, in the gut, for example , the TLR system is 
required for recognition not only for pro-inflammatory effector T-cell responses against 
pathogens, but also for tolerance of commensal microbes leading to necessary anti-
inflammatory or dampening action by regulatory T cells. In addition , TLR signalling is 
required for induction of oral tolerance to dietary antigens encountered in the gut. Thus , 
TLRs and regulatory T cells together result in normal intestinal homeostasis and also 
mucosal immunity, and these, both , in turn can affect long-term systemic responses 
including autoimmunity [540 , 541]. 
That is, pathogens may have evolved to exploit, and even imitate, our symbiotic 
relationship with commensal gut flora , which we 'tolerate ' by means of 
immunosuppressive regulatory T cells that generally prevent over-exuberant immune 
responses. Probiotic microorganisms, found to be beneficial in the treatment of 
inflammatory bowel diseases, similarly induce regulatory T-cell populations , and it now 
appears that parasitic helminths can also act this way. Thus , the presence of symbiotic 
and pathogenic microbes in the gut or other peripheral tissues could result in a supply 
of activated regulatory T cells (both natural and inducible , see Chapter 1) that would 
maintain host immune homeostasis over time , perhaps at a relatively unresponsive 
(towards the chronic pathogen) level. The microbes or helminths would thereby 
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decrease the chance of aberrant immune responses to self-antigens such as are 
otherwise seen in autoimmune (or allergic) disorders [541 ]. 
In summary, although underlying mechanisms of the hygiene hypothesis are, as yet, 
not fully understood, the key concept is that infectious agents interact with the innate 
and adaptive arms of the immune system as it develops and while it is susceptible to 
modulation , thus helping to shape the type and degree of immune responses through 
later life. 
The importance of timing of infections 
J.F. Bach noted in 2002 that when infections are associated inversely (i.e. protectively) 
with disease, they often occur early in childhood [3]. This concept was also noted by 
Poskanzer some 40 years earlier for poliomyelitis paralysis , wherein infection with the 
poliomyelitis virus at a late age was believed to be responsible for the development of 
paralysis. The 'polio ' or 'late-exposure' hypothesis for MS, for example , thus proposed 
that MS could be caused by an infectious agent that is harmless and confers protective 
immunity when acquired in early childhood , but pathogenic when acquired later in life 
[545]. An example of this hypothesis applied to MS was the attention paid to measles 
virus for nearly two decades [189], for which it was observed , in case-control studies, 
that age at onset of measles was later in MS patients than in controls. 
The 'polio/late-exposure' hypothesis evolved into the more general hygiene hypotheses 
of Leibowitz (1966) [525] , Strachan (1989) [526] and Bach (2002) [3], where exposure 
to infections early in life was protective , as in the poliomyelitis model. However, there 
was no specific microbe identified-rather, an autoimmune (or allergic) reaction could 
be triggered by multiple microbes in genetically susceptible people , and risk of cl inical 
disease increased with age at infection [490 , 546]. Consistent with this notion , children 
who experience more infections in the first year of life have a reduced risk of type 1 
diabetes [145] . 
A proxy measure that has been used for early exposure to ch ildhood infections is the 
degree of social mixing early in life. For example , a case-control study in Yorksh ire , UK, 
showed a correlation between frequency of day-care centre attendance during the first 
six months of life and type 1 diabetes [54 7] . 
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Another proxy measure of early exposure to childhood infections, as noted by Strachan 
(1989) [526], is given by the number of siblings, and particularly older siblings , in the 
family, these siblings being postulated to bring common childhood infections into the 
home. That is, the birth-order, and number of older siblings, of the child may influence 
their time and degree of exposure to such infections (i.e. more older siblings-later 
birth order-would result in higher exposure at an earlier age, and greater beneficial 
stimulation of the immune system). 
For example, higher (later) birth order (comparing third or later born with first born) was 
associated with a significant decrease in the risk of type 1 diabetes in a large cohort 
study in Northern Ireland, UK (adjusted RR 0. 75; 95% Cl 0.62, 0.90) [548]. 
Correspondingly, the frequency of type 1 diabetes was found to be higher in first-born 
children and decreased progressively (15% risk reduction per child born) with 
increasing birth order in a prospective family study in the UK; this could be explained 
by a lower exposure of first barns than siblings to infections [549]. In another 
population-based cohort study in Austria, there was borderline significance for lower 
risks of type 1 diabetes in second and later-born siblings [550]. However, in a further 
Northern Ireland, UK, case-control study, there was significant reduction in type 1 
diabetes risk in children having three or more siblings at home per se (rather than older 
siblings in particular) (OR 0.58; 95% Cl 0.39, 0.85) [551 ]. A recent meta-analysis of six 
cohort and 25 case-control studies found some overall evidence of a lower risk of type 
1 diabetes with increasing birth order (second or later born compared with first born) , 
but particularly in the subgroup of children aged under five years (adjusted OR 0.84; 95% 
Cl 0.75, 0.93; n=25 studies) [552]. 
Variable results have also been seen for MS (discussed in more detail in Chapter 8). In 
an Australian case-control study in TAS , exposure to younger infant siblings during the 
first six years of life , independent of birth order, was found to be associated with 
reduced MS risk ; nevertheless , this marker may still be indicative of early exposure to 
common childhood infections [553]. For MS in Canada, no general pattern was found 
over all family sizes in a large population-based cohort, although higher (i. e. later) birth 
order was associated with greater MS risk in larger famil ies [554 ]. However, a large 
Swedish case-control study found both older and younger siblings to be protective 
against MS [555], while a nationwide cohort study in Denmark failed to find any 
association between any sibship characteristics and MS risk [556] . 
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More work is needed on sibship structure and its relation to the hygiene hypothesis for 
MS. Birth order, sibling number and the hygiene/late-exposure hypothesis will be 
explored for MS in Australia in Chapter 8 of this thesis , where analysis of national MS 
survey data at the individual level will be presented. 
In summary, infections as determinants of autoimmune disease can be either causal or 
protective [524], and in many cases the timing of these infections (late versus early 
exposure) may determine the particular outcome. Moreover, the hygiene hypothesis is 
not necessarily in conflict with directly causal mechanisms, because infectious or other 
microbial exposure during the critical stage of development of the immune system can 
provide non-specific protection that does not preclude specific viruses, or other 
infectious agents, acting to precipitate the immune-mediated destruction of the 
particular target organ (e.g. brain and spinal cord myelin for MS, or pancreatic islet 
cells for type 1 diabetes) [539]. 
Evidence for specific infectious agents and their associated mechanisms will now be 
considered in more detail for MS, before other autoimmune disorders are considered 
briefly in Section 3.1.4. 
3.1.3 MS and infections 
As discussed in Chapter 1, MS is characterised by a loss of the myelin sheath 
surrounding axons in the CNS. Demyelination is associated with elevated levels of 
CD4+ T cells specific for major myelin proteins , and the disease is generally thought to 
be autoimmune (see Chapter 1, Section 1.5) . Although it is not known what initiates, or 
eventually triggers , the development of MS, it is well established that relapses or 
disease flares in RRMS patients are often associated with exogenous infections, 
particularly upper respiratory infections [495] . For example , in TAS , Austral ia, a 
population-based cohort of MS patients followed prospectively for two to three years 
showed a seasonal cycle in relapse rates that was positively correlated with upper 
respiratory tract infections (r=0.39 , p=0.014) [327]. 
Active MS plaques are characterised by inflammatory cell infiltrates that have features 
consistent with an active infection: T and B lymphocytes, plasma cells and 
macrophages or microglia [557] . Further evidence supporting infection as a cause of 
MS is that the brain and CSF of more than 90% of MS patients have high 
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concentrations of lgG antibody, seen as oligoclonal bands. This is also evident in other 
CNS diseases including subacute sclerosing panencephalitis (SSPE) caused by 
measles virus, chronic progressive rubella panencephalitis caused by rubella virus, 
mumps virus meningitis and cryptococcal meningitis caused by fungal Cryptococcus. 
However, while the causative organisms that the lgG antibodies are directed against 
are known in these latter CNS diseases, the specific organism in MS has been difficult 
to identify [557], although more recent work suggests that these antibodies may be 
directed against nuclear antigens of EBV (discussed in more detail subsequently). 
Indeed, although more than 24 viral infectious agents have been linked to MS, and 
several experimental rodent infectious models of demyelination exist that closely 
resemble different aspects of clinical MS (animal demyelination models reviewed in 
detail by Ercolini and Miller, 2008 [495]), no single infectious organism has been 
consistently found in this complex autoimmune disorder in humans. Some studies have 
found evidence of specific pathogens in MS plaques or CSF; for example, MS plaques 
were found to contain HHV6 antigens that were not found in tissues from other 
neurological disorders [512] (see Table 3.2), and CSF from MS patients was shown to 
have higher levels of (bacterial) Chlamydia pneumoniae DNA and antibody compared 
with that from patients with other neurological diseases [558]. Evidence of EBV 
infection has been found in brain-infiltrating B cells and plasma cells in MS cases and 
not in other inflammatory neurological diseases [504], although this finding has not 
been confirmed in subsequent studies. These three main infectious organisms linked 
with MS will now be discussed with regard to MS epidemiology. 
Chlamydia pneumoniae 
C. pneumoniae is an obligate intracellular parasite of macrophages that establishes a 
banal respiratory infection in a large number of normal individuals ; 70 to 80% of healthy 
individuals are seropositive by the seventh decade, and 10% of community-acquired 
pneumonia is caused by this species [559]. Although evidence of this pathogen was 
originally found in CSF of MS patients [558] and in brain tissue [560] , other studies 
have been inconsistent or have been unable to relate the finding to any cl inical disease 
parameter (such as course, duration , MRI activity, disability) [8 , 490 , 557]. However, a 
nested case-control study within the American Nurses' Health Study found an 
association between C. pneumoniae infection , as measured by C. pneumoniae-specific 
lgG antibodies, and an increased risk of development of MS (OR 1. 7; 95% Cl 1.1 , 2. 7). 
There was a stronger association between seropositivity and progressive disease (OR 
146 
7.3; 95% Cl 1.4, 37.2), perhaps suggesting a co-factor role for this infection in disease 
progression [561 ]. Thus, the role of C. pneumoniae in MS is unclear. 
HHV6 
This ubiquitous neurotropic and lymphotropic herpesvirus causes a common childhood 
febrile illness, infantile exanthema subitum (roseola), and rarely a mononucleosis 
syndrome [490]. Viral antigens occur in the brain tissue of MS patients [512], and lgM 
(but not lgG) antibody titres are elevated in serum [513] (see Table 3.2). However, 
these findings have not been confirmed by other research groups, and more recent 
studies with mixed findings mean that a causal association with MS has not been 
substantiated [490, 557], even though the evidence for HHV6 appears stronger than for 
C. pneumoniae. As HHV6 is a virus known to be latent in T cells , the detection of DNA 
and antibody of HHV6 in brain in MS, as well as in other neurological diseases, might 
reflect reactivation of the virus from latency in blood T cells trafficking through the 
brains of patients with inflammatory CNS disease [557]. That is, the observed changes 
may be a consequence of such disease, rather than its cause [8]. 
Moreover, HHV6 contributes little to explain aspects of MS epidemiology, particularly 
the age-at-migration data (see Chapter 2, Section 2.3.2) [8]. As HHV6 infects virtually 
all children by the age of two years , it is not only difficult to compare MS risk for 
infected versus non-infected individuals, but this early age of seroconversion does not 
explain why the critical age for migration differences , particularly from high- to low-
incidence regions , is generally agreed to be up to the age of 15 years [306 , 312] . 
Epstein-Barr virus 
EBV is a ubiquitous lymphotropic herpesvirus that maintains a nonlytic , latent infection 
of lymphoid B cells , and causes infectious mononucleosis (IM) [490], particularly when 
infection occurs in adolescence or adulthood [8]. EBV has been a leading candidate 
trigger for several autoimmune diseases since the initial finding of raised EBV-specific 
antibody titres in SLE patients in 1971 [562] (Table 3.2 ). Like HHV6, EBV fulfils the 
prediction that agents inducing or exacerbating autoimmune disease are most likely to 
be ubiquitous pathogens of high prevalence in the population [21 , 199]. EBV is further 
biologically plausible because it establishes a lifelong dormant infection (with 
continuous virus production due to reactivation) and , importantly, modulates the 
immune system (by rescuing infected B cells via latent antigen expression and 
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assisting their differentiation into memory B cells in which the virus persists). In addition , 
EBV continuously stimulates strong T-cell responses via chronic antigen presence (this 
immune control being crucial to prevent EBV-associated malignancies, such as 
Burkitt's lymphoma and naso-pharyngeal carcinoma) [562]. 
EBV sero-epidemiology 
In developing countries, almost all children are infected with EBV in the first years of 
life, and prevalence of seropositivity is typically higher than 90% at the age of four 
years. In most developed countries, EBV infection is delayed in many children until 
adolescence, when the infection is more likely to result in IM; prevalence of EBV 
seropositivity here also follows a latitude gradient parallel to that of MS [238]. 
Large prospective sero-epidemiological studies consistently showed that MS patients 
were almost universally seropositive for EBV compared with healthy age-matched 
controls [499, 500, 563], suggesting that infection with EBV is required for the 
development of MS. Such longitudinal studies of serum samples collected before the 
onset of disease in healthy adult populations further showed that MS risk increased 
significantly with elevated EBV-antibody titres more than 10 years before the onset of 
symptoms [500 , 563, 564], particularly for EBNA1 11 -specific lgG, which also exhibits a 
dose-dependent relationship with MS risk. Moreover, these EBNA 1-specific antibodies 
have been found to interact with the major MS-susceptibility gene locus HLA-DRB 1 *15 
(see Chapter 2) in determining MS risk [565]. 
Importantly, a recent study by Levin and colleagues prospectively followed a 
subsample (10 cases) of individuals who were initially seronegative for EBV (i.e. 
uninfected) and who later became infected with EBV (i.e. seropositive) and still later 
developed MS. These cases were selected from more than eight million military 
personnel whose serum had been stored in the US Department of Defense Serum 
Repository, a total of 305 of whom developed MS, including some individuals who were 
seropositive at the outset. All of the 10 EBV-negative MS cases became EBV-positive 
before MS onset, whereas none of those individuals among the matched controls who 
remained seronegative throughout the study developed MS; in addition , only 35.7% of 
the controls seroconverted (p=0.0008 for difference in seroconversion rates between 
11 EBNA 1 is the dominant latency-associated antigen of EBV that is consistently expressed in healthy virus 
carriers and is crucial for viral persistence. It represents a key target antigen for CD4+ T-cell mediated 
immune control mechanisms of EBV infection in healthy individuals [562] . 
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cases and controls) [566] . The mean time interval between primary EBV infection and 
MS onset was estimated to be 5.6 years (range 2.3 to 9.4 years). This study shows that 
MS risk is extremely low among individuals not infected with EBV, but that it increases 
markedly in the same individuals following EBV infection-that is, to a similar rate as 
that manifested by individuals who were already EBV-positive at the study baseline 
[566]. Thus, primary infection with EBV was proposed to significantly increase MS risk. 
IM 
Recent epidemiological studies have shown an even stronger positive association 
between a history of IM and occurrence of MS, further suggesting a causal link with 
EBV. For example, a large Scandinavian cohort study of IM patients followed for 
occurrence of MS showed a more than two-fold risk of developing MS compared to 
subjects who acquired the virus asymptomatically (standardised incidence ratio 2.27; 
95% Cl 1.87 , 2.75); this increased risk also persisted for at least 30 years after the 
infection [503]. A similar increase in MS risk in those with an IM history was shown in a 
case-control study in TAS , Australia (RR 2.01 ; 95% Cl 1.11 , 3.62) [553] , and in a meta-
analysis of 14 cohort and case-control studies , including the latter Australian study and 
others from Europe and the US (RR 2.3; 95% Cl 1.7-3.0; p<10-8) [501] . Remarkably 
consistent with these findings , the most recent meta-analysis of 18 individual-level 
case-control and cohort studies (including a recent large Canadian MS cohort with an 
OR of 2.06 [95% Cl 1.71 , 2.48] for history of IM [567]) showed an overall RR of MS of 
2.17 (95% Cl 1.97, 2.39) , firmly establish ing that IM is a significant risk factor for MS 
[568]. 
IM may also modify the MS risk associated with the MS-susceptibility gene locus HLA-
DRB1 *15, a 2.4-fo ld (95% Cl 2.0, 3.0) increased MS risk associated with this gene 
locus in IM-negative individuals becom ing a seven-fold (95% Cl 3.3, 15.4) increased 
risk in IM-positive people [569] . 
Possible mechanisms for EBV infection in MS pathogenesis 
Figure 3.3 illustrates some potential mechan isms that may underlie the association of 
EBV infection with MS, none of which depend on direct infection of the CNS. The first 
hypothesis is that the immune response to EBV infection in genetica ll y suscepti ble 
individuals cross-reacts with myelin antigens, and this response cou ld be by T ce lls 
and/or antibodies [8 , 562]. That is , there is some evidence that EBV cou ld break 
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immune tolerance to myelin antigens through molecular mimicry [570] (Figure 3.3 (1 )). 
For example , CD4+ T cells specific to EBNA 1 are increased in frequency and 
recognise a broader range of epitopes in individuals with MS than in healthy controls ; 
two EBV peptides, one of which was from EBNA 1, have also been recognised as 
targets of the immune response in the CSF of MS patients. Further, EBNA 1-specific 
cell lines cross-reacting with myelin antigens have been isolated from MS patients [238 , 
571 ]. 
Alternatively, EBV infection may assist in the maintenance and increased survival of 
auto-reactive B cells (which would otherwise be neutralised or controlled during 
establishment of peripheral tolerance, see Chapter 1, Section 1.2) as shown in Figure 
3.3 (2) . Otherwise, EBV may transactivate the expression of human endogenous 
retroviruses (HERV), which are cytotoxic for oligodendrocytes (cells responsible for 
myelinating the CNS) , as in Figure 3.3 (3). Another possibility is that the altered 
immune responses to EBV, seen as a persistently dysregulated EBV infection [570], 
are an 'epiphenomenon' resulting from host factors that predispose for autoimmune 
disease but are not directly involved in MS pathogenesis [562], as in Figure 3.3 (4 ). 
EBV infected 
Bcell_,...__...... © 2. 
Lytic EBV 
Infection 
Figure 3.3: Potential mechanisms responsible for the association of EBV 
infection with MS. 
(1) EBV-specific T cells or antibodies could cross-react with auto-antigens 
expressed in the CNS and attack the myelin sheath of axons. 
(2) Latent EBV antigens could sustain the survival of auto-reactive B cells. 
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(3) EBV infection transactivates retroviral elements such as HERV, which in turn 
mediate cell death of oligodendrocytes. 
(4) Auto-reactive 8-cell activation could initiate EBV replication and in turn 
augment EBV-specific T- and 8-cell responses. (Figure from Lunemann et al., 
2007 [562].) 
Other proposed mechanisms for which there is some evidence include the activation of 
superantigens (see Section 3.1.1 ), or an increased expression of alpha-B-crystallin 
heat-shock protein in lymphoid cells post-infection [8] that provokes a CD4+ T-cell 
response attacking alpha-B-crystallin in oligodendrocytes in a 'mistaken self' scenario 
resulting in demyelination [572]. The predominant mechanisms may even vary across 
different patients, and may reflect the observed heterogeneity of MS disease in the 
affected population (see Chapter 1, Section 1.5). 
In synopsis, although many associations between EBV infection and MS have been 
observed (level of evidence reviewed and summarised by Lucas et al. , 2011 [572]) and 
possible mechanisms for these associations elucidated , a direct causal role of EBV in 
the pathogenesis of MS is still debated [8 , 562]. However, EBV may act as a 'primer' or 
initiator of the pathological process (i.e. necessary but not sufficient, see Chapter 2, 
Section 2.2), and the observation that MS tends to occur several years after IM [573] or 
primary EBV infection [566] suggests that other factors may be needed to eventually 
trigger clinical disease [8]. Further, as will now be discussed in the next subsection , the 
timing of primary EBV infection may be the most important key to action of this 
infectious agent for this complex autoimmune disorder, MS. 
EBV, timing and the hygiene hypothesis 
As discussed earlier in this section , the hygiene/late-exposure hypothesis posits that 
MS, as with other autoimmune disorders , is an autoimmune reaction that can be 
triggered by multiple microorganisms in genetically susceptible individuals, and risk of 
clinical disease increases with age at infection. As reviewed by Ascherio and Munger 
(2010) , the hypothesis in this general form could explain several features of MS 
epidemiology (see Chapter 2, Section 2.3) , including: 
• the latitude gradient 
• the protection from MS of individuals migrating from low-risk to high-risk areas 
• the higher MS rates among individuals of higher SES 
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• (possibly) the attenuation of the latitude gradient within the US, if this can be 
explained by improved conditions in hygiene in the south and thus a lower 
incidence of childhood infections [571 ]. 
Also supporting this hypothesis is: 
• a trend towards later age at infection with childhood viruses in MS cases 
compared with controls [57 4] 
• lower MS risk among individuals exposed to older and/or younger siblings in 
early childhood [553, 555]. 
However, if EBV is the causative infectious organism for MS, the hygiene hypothesis is 
limited, in this general form, in explaining the substantial differences in MS risk 
between EBV-negative individuals, EBV-seropositive (but asymptomatic) individuals, 
and those who become EBV-positive via clinical IM. 
As discussed earlier in this section, one of the most striking and consistent 
observations is that MS is extremely rare among EBV-negative individuals, and this 
finding is confirmed and emphasised in recent studies of paediatric MS [575 , 576]. 
However, if EBV infection occurs early in childhood, as happens in most populations 
but particularly in developing countries , the risk of MS is about 10-fold higher compared 
with EBV-negative individuals [238]. Yet, if EBV infection is delayed (hypothetically by 
higher levels of hygiene in early childhood) and infection then occurs during 
adolescence and young adulthood , the infection is more likely to manifest as IM. The 
risk of subsequent MS is then at least 20-fold higher than for EBV-negative individuals 
(who ostensibly share the same high-hygiene early life environment and should have 
high , rather than negligible, MS risk). That is, there is a two- to three-fold difference in 
MS risk between the two classes of EBV-positive individuals (compared with EBV-
negative people) depending on whether EBV infection occurs early in childhood 
(generally asymptomatically) or later in adolescence or adulthood as clinical IM [571] 
(Figure 3.4). 
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Figure 3.4: The relative risk of developing MS according to EBV infection and 
history of IM. Bars represent the 95% confidence intervals of the RR estimates. 
(Figure adapted from Ascherio and Munger, 2010 [571].) 
According to the hygiene hypothesis in its strictest sense, individuals not infected with 
EBV should have high MS risk, because EBV infection in early childhood is strongly 
associated with non-hygienic conditions. That is, most children in developing countries 
are EBV-seropositive at four to six years of age, whereas in most developed countries 
more than half may be still uninfected at these ages [577]. Thus, if EBV is to be a 
determining infectious agent of MS, the timing of primary EBV infection appears to be 
key to the MS-risk patterns in Figure 3.4 and needs to be incorporated into any model 
of the hygiene hypothesis for MS [307]. 
Which features of MS epidemiology are consistent with the 'EBV variant of the 
hygiene hypothesis' [BJ? 
As reviewers Ascherio and Munger indicate, a role of EBV in MS causation could 
explain the following remarkable similarities between the epidemiology of MS and IM: 
• age of peak incidence 
• latitude gradient 
• rarity in populations in which EBV infections occur early in life (i nclud ing Japan 
and most of Asia) 
• earlier age at peak onset in women than men 
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• lower incidence in blacks, Asians and Eskimos than in whites , and positive 
correlation with SES [8 , 571 ]. 
In addition : 
• early age at EBV infection could explain the retention of low MS risk among 
people migrating from areas of low MS prevalence to areas of high prevalence 
(see Chapter 2, Section 2.3.2). 
However, migration in the reverse direction-from high to low MS prevalence areas-
and the associated reduction in risk , cannot be similarly explained by EBV infection ; 
nor can the possible occurrence of an MS 'epidemic' in the Faroe Islands [238]. Other 
factors may therefore be involved , including latitude-related factors such as vitamin D 
(see Chapter 2), or infection with other microbes, such as other herpesviruses, that 
may modify the effect of EBV infection . Or, there may be different EBV strains involved 
in different regions , some more likely to increase MS risk than others [571]. 
Summing up, there is some supportive , but not conclusive, evidence for the role of a 
generally hygienic environment (i.e. no particular infectious agents) in early life and the 
development of MS [307]. There is also compelling evidence for EBV infection being a 
strong risk factor for MS [238]. Although the mechanisms by which EBV infection 
increases MS risk are still unclear, some combination of the hygiene hypothesis and an 
adverse EBV infection may be important, wherein insufficient early life infections are 
associated with an adverse characteristic of EBV infection , such as later age of 
infection , which may lead to a dysregulated host immune response to EBV [307] . 
Therefore, more work on the effect of early childhood infections on MS is needed-
particularly in the southern hemisphere where such work is sparse-to gain further 
evidence of the possible protective role of these infections in development of MS. 
Birth order and sibsh ip structure of MS cases at the ind ividual level in Austra lia will be 
considered in detail in Chapter 8. 
Other MS determinants 
To complete this review of the pathogenesis of MS, the influence of other candidate 
environmental factors , and their poss ible interactive role with factors already deta iled , 
will be briefly considered here. 
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Smoking 
There is strong and growing evidence that cigarette smoking is an important risk factor 
for MS [236, 238, 578-580], even though the smoking-MS link is independent of latitude 
and ancestry and does not contribute directly to explaining the geographical variation in 
MS incidence [189]. A recent meta-analysis of 14 studies shows that smokers have 
about a 50% higher risk of developing MS than non-smokers (RR 1.5; 95% Cl 1.3, 1.7) 
[581 ], and evidence suggests that smoking may adversely affect MS disease 
progression particularly [238, 582, 583]. 
Several mechanisms have been proposed for these effects, including a systemic 
effect-indicated by an increased risk for smokers also for other autoimmune diseases 
such as RA, SLE and Grave's disease-and direct effects on the BBB and the CNS, 
perhaps by nitric oxide. Among the plethora of possible mechanisms (reviewed in detail 
by Shirani and Tremlett, 2010 [580]), the established fact that smoking also increases 
the frequency and persistence of respiratory infections is notable because of the link 
between such infections and the increased frequency and damaging effects of MS 
relapses [580]. Further evidence of possible interaction between MS-linked infectious 
agents and smoking includes higher levels of specific antibodies to Chlamydia 
pneumoniae [584] and EBV [503] in smokers than in non-smokers. 
Interestingly, with regard to the timing of action of this factor, passive smoking was 
shown to be associated with a significantly higher risk of childhood MS [585], but 
maternal smoking during pregnancy did not appear to be associated with higher MS 
risk in the offspring [586]. 
In summary, the main candidate determinants of MS-UVR/vitamin D, EBV infection 
and smoking-are listed in Table 3.3 with other currently considered candidate factors , 
together with their summarised epidemiological evidence and putative mechanisms 
[289]. 
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Table 3.3: Summary of potential environmental risk factors for MS. (Table 
adapted from Handel et al., 2010 [289]) 
Environmental 
factor 
UVR/Vitamin D 
Infection : EBV 
Smoking 
Sex hormones 
and/or oral 
contraceptive pill 
Stressful life 
events* 
Respiratory tract 
infections 
Organic solvents 
Diet 
Source of evidence+ Putative mechanism+ 
Epidemiological case- Levels of vitamin D experienced in 
control/cohort studies assessing utero can have long-lasting effects on 
the association of MS risk with the development of numerous organ 
disease geography, sun systems , including the CNS; during 
exposure, outdoor occupation or life , vitamin D has clear 
vitamin D levels (Chapter 2, immunomodulatory functions (Chapter 
Table 2.3) 2) 
Epidemiological case-control 
studies assessing the 
Clonal expansion of B lymphocytes in 
the CNS or EBV infection triggers 
association of MS risk with IM or autoimmunity via molecular mimicry 
antibody titres (Chapter 3) 
(Chapter 3) 
Cohort and case-control studies 
(Chapter 3) 
Cohort and case-control studies 
Cohort and case-control studies 
Epidemiological studies 
Epidemiological studies 
Epidemiological studies 
Nitric oxide-mediated demyelination , 
axonal loss and epigenetic effects 
(Chapter 3) 
Altered antigen reactivity, tolerance 
and epigenetic effects 
Dysregulation of the hypothalamic-
pituitary-adrenal axis 
Immunological trigger for inflammatory 
demyelination 
Damage to BBB 
Vitamin D supplementation from oily 
fish 
* The evidence is conflicting . 
+ References for factors additional to UVR/vitamin D, EBV and smoking are given in Handel et al . (2010) [289]. 
3.1.4 Other organ-specific autoimmune disorders-evidence for 
infections and other factors 
Type 1 diabetes 
Type 1 (insulin-dependent) diabetes mellitus is considered to be an autoimmune 
disease in which T lymphocytes infiltrate the pancreatic islets and destroy the insulin-
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producing beta-cell population (see Chapter 1 ). As markers of the autoimmune process , 
auto-antibodies to insulin, glutamate decarboxylase and tyrosine phosphatase appear 
successively often years before clinical symptoms of type 1 diabetes, but auto-
antibodies alone do not cause the disease, which is hypothesised to be largely T-cell 
mediated [198, 587]. 
Apart from dietary vitamin D ( considered in Chapter 2), two types of environmental 
factors have particularly been associated with type 1 diabetes in epidemiological and 
immunological studies-exposure to enteroviral infections and other dietary factors 
such as cow's milk proteins early in childhood-both of which appear to act by affecting 
the immune system in the gut [587, 588]. 
Viral infections 
While congenital rubella [520], mumps, measles, cytomegalovirus and retroviruses 
[589], as well as rotaviruses [590], have all been linked with type 1 diabetes, the 
current main candidates as initial determinants of type 1 diabetes are enteroviruses, 
and particularly the Coxsackie virus group [136] (see Table 3.2). Some four decades 
ago, antibodies against Coxsackievirus B serotypes were found to be more frequent in 
patients with newly diagnosed diabetes than in control subjects [591] and this has since 
been confirmed using more recent techniques [587, 592]. 
Enteroviruses are frequent among children and adolescents but usually are subclinical 
or manifest with mild respiratory symptoms; the group includes the well-known 
polioviruses. The primary replication of the virus occurs in the lymphoid tissues of the 
pharynx and small intestine, and can then spread to various organs including the 
pancreas. Enterovirus has been isolated from the pancreas of patients newly 
diagnosed with type 1 diabetes (Table 3.2); enterovirus RNA has also been detected in 
the blood of significant numbers of similarly newly diagnosed patients [198] . 
The first epidemiological reports linking enterovirus infections to type 1 diabetes were 
also more than 40 years ago; for example , the seasonal variation of the onset of 
diabetes was observed to parallel that of enterovirus infections [593] (Table 3.4 ). This 
has since been confirmed by other, prospective studies following the first appearance 
of diabetes-associated auto-antibodies (reviewed by Akerblom et al. , 2002 [587] and 
Knip et al., 2005 [198]). Prospective studies (included in Table 3.4) have been 
particularly informative in determining not only the higher frequency of enteroviral 
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infections in those who progressed to clinical diabetes, but also the temporal 
relationship between enteroviral infections and the appearance of auto-antibodies , 
these considered to reflect the initiation of ~-cell damage. Several of these studies 
have been conducted in Finland , where the incidence of type 1 diabetes is particularly 
high. 
Table 3.4: Evidence supporting a causal relationship between enterovirus 
infections and type 1 diabetes. (Table adapted from Akerblom et al., 2002 [587] 
and Knip et al., 2005 [198]) 
Seasonal variation in the appearance of auto-antibodies and the incidence of 
diabetes resembles that of enterovirus infections 
Epidemiological association observed in several studies in different countries using 
various methods (virus antibodies , viral RNA, cellular immunity) 
Association observed in prospective studies (DiMe, DIPP)* in addition to age, sex 
and HLA-matched case-control studies 
Clustering of enterovirus infections in prospective studies to period immediately 
preceding appearance of auto-antibodies (DiMe, DIPP)* 
Association specific for enteroviruses and not observed in other virus infections 
Inverse correlation between frequency of enterovirus infections and risk of type 1 
diabetes in different populations and periods in ecological studies (analogy with 
poliomyelitis) 
No evidence of abnormal regulation of enterovirus-specific immune responses after 
standardised enterovirus exposure (e.g. poliovirus vaccinations) 
~-cell damage in patients with severe enterovirus infections (consistency with an imal 
and in vitro studies showing that enteroviruses can infect and damage ~-cells) 
*DiMe, Ch ildhood Diabetes in Finland study (non -diabetic sibli ngs of type 1 diabetes pati ents foll owed) 
[594-596] . DIPP, Finn ish Diabetes Pred ict ion and Prevention trial (i nfants with diabetes -associated HLA-
DQ alle les followed from birth ) [597 , 598] . 
However, it should be noted that other prospective studies in Germany and the US 
failed to find such associations between enterovirus infections and ~-cell auto immunity 
[599 , 600], possibly because of limited statistical power, limited sampling times and 
virus detection strategies [198]. The role of enterovirus infections is thus still debated , 
although recent studies have again strengthened the view that enteroviruses contribute 
significantly to the pathogenesis of type 1 diabetes [601 ]. Current large international 
prospective trials such as The Environmental Determinants of Diabetes in the Young 
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(TEDDY) should help establish the role of this and other putative environmental factors 
more clearly [588] . 
Interestingly, ecological studies have suggested that the frequency of enterovirus 
infections is actually very low in Finland, even though the incidence of type 1 diabetes 
is the highest in the world [602]. In addition, the frequency of enterovirus infections 
decreased rapidly during the three-decade period before 2000, while the incidence of 
type 1 diabetes increased over the same period [603], as seen also for other infections 
in Europe as a whole (see Section 3.1.2 , hygiene hypothesis [3]). Paralytic poliomyelitis , 
a well-known enterovirus disease, has also followed the same epidemiological pattern 
and, as discussed in Section 3.1.3 for MS, was found to depend on the age at 
exposure to the virus (i.e. the late-exposure, or 'polio ', version of the hygiene 
hypothesis). It is possible that, analogous with paralytic polio , type 1 diabetes may be 
similarly caused by late exposure to an enterovirus , consistent with the observation of 
higher disease incidence where the frequency of enterovirus infections is low [587] 
(Table 3.4 ). This means that enteroviruses such as Coxsackievirus B may indeed have 
an ambiguous (i.e. causal or possibly protective depending on conditions) role in the 
context of autoimmune type 1 diabetes [497 , 592]. 
Possible ways by which enterovirus could cause ~-cell damage include two main 
mechanisms: infection and direct destruction of the ~-cells (Table 3.4) and induction of 
an autoimmune response against ~-cells. Evidence of both types exists from animal 
models (reviewed by Akerblom et al. , 2002 [587]) , the latter type including molecular 
mimicry and bystander activation of auto-reactive clones (see Section 3.1 .1 ), together 
with epitope spreading [198] . Recent studies suggest that certain diabetogenic 
enterovirus variants establish persistent infection by induction of IL-10 [497], particularly 
in the intestinal mucosa and the pancreatic islets where local inflammation then leads to 
breakdown of tolerance in young , genetically susceptible individuals [592 , 601 ]. 
Importantly, with regard to timing , several analytical studies suggest that the 
autoimmune process could be initiated before birth by maternal enterovirus infections, 
indicating the possible role of in utero exposures [595 , 604]. Certainly, the appearance 
of auto-antibodies as early as three to six months after birth [605] suggests early 
exposure to causal factors. For example , gestationa l infection could induce 
immunological tolerance to the virus , and this recognition as 'self' by the offspring 
immune system could have consequences for viral persistence (i. e. latency) and later 
re-infection [588]. 
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Other factors-dietary 
Early exposure to dietary cow's milk in infancy may be another important environmental 
factor affecting risk of subsequent type 1 diabetes, the primary antigen involved 
possibly being bovine insulin [198]. While the vast majority of infants are exposed to 
cow's milk proteins in the first months of life without any harmful effects, it seems that 
some with a genetic risk for diabetes are vulnerable to the diabetogenic effect of such 
proteins. That is, the intestinal immune system is thought to play a key role as a 
modulator of (non-self, bovine) insulin-specific immunity and in establishing , and 
preventing the breakdown of, immunological tolerance (see Chapter 1) to these and 
other dietary antigens. The pathogenic mechanisms involved in type 1 diabetes, by 
which self-insulin proteins become antigenic and induce (human-) insulin-specific auto-
antibodies, may thus be related to the aberrant regulation of oral tolerance (to bovine 
insulin) in the gut [198]. However, most of the supporting evidence for cow's milk as a 
determinant factor comes from the Finnish population and its role is still debated [592] . 
Alternatively, the increased immunity to cow's milk proteins , and to other proteins such 
as wheat proteins in dietary cereals (seen in both type 1 diabetes and coeliac disease), 
may instead reflect a general impairment in mucosal immunity in the intestine [606]. To 
answer the question of whether cow's milk is a possible determinant, the current 
Finnish prospective Trial to Reduce IDDM in the Genetically at Risk (TRIGR) will 
attempt to prevent type 1 diabetes by eliminating cow's milk in infant nutrition before 
the onset of islet autoimmunity (see www.clinicaltrials.gov) . 
In addition , other environmental factors , such as gastrointestinal infections, including 
bacterial infections, may interact with the dietary antigen-induced disease process by 
modifying the normal gut flora or causing changes in the intestinal cytokine 
environment [587, 592] . Still other candidate environmental determinants of type 1 
diabetes are reviewed fully by Akerblom et al. (2002) [587] and van Belle et al. (2011) 
[592]. Some of these are considered to belong to the group of likely initiators of ~-cell 
damage, such as enteroviral infections, dietary proteins and antenatal and perinatal 
factors , while others , such as high growth rate and stressful life events, may belong to 
the promoters or precipitators of the disease process [240] . The large prospective 
cohort TEDDY trial being conducted over six centres in the US and Europe will 
investigate several different infectious, dietary, psychosocial and other environmental 
and genetic factors proposed to initiate or protect against type 1 diabetes [588]. As in 
other organ-specific autoimmune disorders such as MS, it is likely that different 
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combinations of genetic and non-genetic risk factors act together, or in sequence [198], 
to produce disease in different individuals [240] . 
Rheumatoid arthritis 
RA is a chronic inflammatory joint disease resulting in bone and joint destruction [194, 
292]. The disease is characterised by persistent synovitis, systemic inflammation and 
auto-antibodies (particularly to rheumatoid factor and citrullinated peptide). RA affects 
0.5 to 1.0% of adults in industrialised countries and is most typical in women after age 
50 [607, 608]. 
Like MS and type 1 diabetes, RA appears to be a multifactorial disease resulting from 
interactions between genetic (mainly HLA-DRB1 and, in European populations, the 
tyrosine-phosphatase gene on chromosome 1) and environmental factors, all of which 
may act many years before disease onset. Among environmental factors implicated in 
the development of RA, smoking shows the strongest association with susceptibility 
and is also linked to worse clinical outcomes [292] . Other candidates include hormonal 
factors , adverse pregnancies, obesity and diet, as well as infections [194, 607]; vitamin 
D intake (see Chapter 2, Table 2.5) and dietary omega-3 fatty acids appear protective 
[292]. 
Infections 
There has long been a belief that RA is caused by an infection, although no single 
organism has been identified. However, RA has been observed to begin within a few 
weeks of an infection in a substantial proportion of cases, and vaccination can trigger 
RA in some people [194]. Moreover, an infectious aetiology is strongly suggested by 
examples of infection-induced , chronic erosive arthritis in humans, and the known 
ability of infectious agents , especially viruses , to induce immuno-inflammatory 
dysregulation [609] . 
Infections linked with RA include mainly EBV and human parvovirus B19 (see Table 
3.2), as well as bacteria such as Proteus, and mycoplasma [292 , 607]. For example , 
sera from RA patients show high titres of EBV antigens and of antibodies to latent and 
replicative EBV antigens; in addition , EBV RNA has been identified in B cells in 
synovial tissue from RA patients [61 OJ . Evidence supporting a role for human 
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parvovirus B19 includes the presence of viral DNA in the synovial fluid , synovial cells 
and/or tissue of RA patients [609 , 611 ]. 
As found for both MS and type 1 diabetes, environmental factors acting early in life 
may be particularly important in determining subsequent RA. For example , high birth 
weight was found to be associated with increased RA risk in the American Nurses' 
Health Study [612]. Early life studies also suggest that a history of infections in infancy 
may protect against RA in adulthood [292], suggesting a hygiene hypothesis 
mechanistic effect for this disorder in company with other autoimmune conditions. 
Summary 
Summing up, the evidence for the effects of environmental factors on pathogenesis of 
the three organ-specific autoimmune disorders-MS, type 1 diabetes and RA-shows 
similarity in overall principles and underlying mechanisms, even though some specific 
factors may vary. Lack of UVR and/or vitamin D appears to be a plausible candidate 
determinant common to all three disorders (see Chapter 2), while infections appear to be 
causal and/or protective for the same disorders, depending on conditions and specific 
timing (see Section 3.1 ). To tease out the evident importance of timing in such disorders, 
and to construct a framework for the subsequent analyses in this thesis , the final section 
of this review will focus particularly on MS and will consider the overall timing and 
integration of the major environmental factors considered in Chapters 2 and 3. 
3.2 Overall timing and integration of environmental factors for 
MS 
Chapters 2 and 3 have reviewed the accumulating evidence for the major candidate 
environmental factors implicated in MS, type 1 diabetes and RA. Sunlight as 
UVR/vitamin D and infections-particularly EBV for MS (and possibly RA) and 
enteroviruses for type 1 diabetes-have been shown to be important environmental 
determinants based on current epidemiological and immunological evidence for these 
autoimmune disorders. Smoking has also been shown to be important for MS and RA. 
The different life periods to which the evidence pertains for the major environmental 
factors for MS-UVR/vitamin D, EBV infection and smoking-will now be considered , 
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before integrating these together In a possible causal-pathway model in the final 
subsection of this chapter. 
Prenatal and perinatal exposure 
From northern hemisphere studies, the period around the time of birth, including before 
birth and shortly after, appears to be important for its subsequent influence on MS risk. 
As discussed in Chapter 2, a seasonal pattern in month of birth found in Canadian MS 
cases [324] implicates causal factors acting in early development; the observation that 
these factors seem to be latitude related adds further weight to this finding [189]. In 
addition, maternal parent-of-origin effects , and higher MS concordance rates among 
dizygotic (non-identical) twins than among siblings of the same family [202, 214] (see 
Chapter 2) , further support a critical role for the prenatal environment in determining 
subsequent MS risk. 
Either sunlight/vitamin D or EBV could play a role in determining future MS risk in this 
important period (maternal smoking appears unrelated). However, while maternal 
transmission of EBV during pregnancy has been observed [613] , there is little further 
evidence that viral infection in utero or as a neonate determines the subsequent risk of 
MS [289]. Conversely, there is substantial and accumulating evidence for action of 
UVR or vitamin D in early life , including in utero, where vitamin D appears to have 
significant effects (see Chapter 2, Section 2.6). This factor remains potentially the most 
important modulator of subsequent MS risk acting during this early period. 
Childhood and adolescence 
Studies of migration with respect to age implicate childhood and early adolescence as 
a risk period for the subsequent development of MS, even though these studies are 
often small and prone to error [189 , 307]. Overall , these studies suggest that people 
younger than 15 years at the time of migration tend to adopt the MS risk of the host 
country, whereas those older than 15 years have a risk of MS similar to their home 
country [306, 312] (see Chapter 2). Consistent with this , ch ildhood sun exposure Is 
associated with decreased risk of MS in Australia , as well as in the northern 
hemisphere, and greatest reduction of MS risk with vitamin D supplementation was 
seen in individuals less than 20 years old in the US (see Chapter 2, Table 2.3). 
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A role for the environment in modifying MS risk during childhood and adolescence is 
further suggested by space-time cluster analysis ; a Sardinian study found MS patients 
were more likely to live near each other than expected between age one to three years 
[614], and an earlier Norwegian study found such clustering between 13 and 20 years 
[615]. These studies together suggest that environmental factors that are active during 
adolescence or early adulthood alter MS risk [289]. 
EBV infection, in particular, is linked primarily with the childhood and adolescent period. 
Importantly, people who develop adult-onset MS have significantly elevated EBV-
antibody levels early in adult life [500, 564], suggesting that there is a period in 
adolescence and early adulthood during which EBV infection predisposes to 
subsequent development of MS [289]. Related to this , the risk of MS is particularly high 
in people who, because of a hygienic childhood environment, fail to become infected 
with EBV in early childhood and instead contract EBV-induced IM later in childhood or 
adolescence (see Section 3.1 .3) , particularly if this occurs after the age of 15 years 
[616] . 
Also related to this period , and the hygiene hypothesis, it appears likely that infection 
with other microbes, or helminths, during this time may influence subsequent risk of 
developing MS by protective modulation of the immune system (see Section 3.1 .2). 
Adulthood 
The age at MS onset is variable , implying that environmental factors might continue to 
alter MS susceptibility even in adulthood. In addition , in the most common form of MS, 
RRMS , relapse rates appear linked to seasonal changes (see Chapter 2) , suggesting a 
role for environmental factors also as pre-onset 'triggers ' .12 
Outdoor occupation and/or higher vitam in D levels in adulthood may reduce MS risk 
(see Chapter 2, Table 2.3) ; however, fully prospective trials of vitam in D 
supplementation in adulthood still need to be carried out, and the main effects of 
UVR/vitamin D with respect to MS seem to be prior to adu lthood . EBV, also , appears to 
have its major effects prior to adulthood , most of the adult population be ing already 
seropositive (see Section 3.1.3). Other viruses could act during adulthood as a final 
'trigger' for demyelination ; for example , viral respiratory tract infections are associated 
12 The term 'trigger' has been used variously in the literature, to mean either an 'initiator' of autoimmune 
disease, or a (later) 'promoter' or 'precipitator' of such disease . The latter meaning is used here. 
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with new-onset MS during adulthood [617] and , as discussed earlier, these infections 
may also be linked to relapses. 
Smoking, in particular, later in life seems to be related to MS susceptibility (Section 
3.1.3) and may also affect the clinical course of disease. Patients with RRMS have an 
increased risk of developing secondary progressive MS if they have ever smoked, and 
the risk of presenting initially with primary progressive MS is significantly higher in 
smokers than in non-smokers [582]. 
Summing up the epidemiological and other evidence, and assuming a multifactorial 
causation sequence for clinical MS (see Chapter 1 ), the most influential environmental 
risk factor appears to act early in life and determine geographical prevalence gradients 
in ethnically homogeneous populations. As latitude is the most strongly associated 
environmental factor, an obvious candidate factor in this period is sunlighUvitan1in D 
exposure, with other factors such as diet possibly accounting for geographical 
exceptions. The next factor in the life course also seems to be geographically 
distributed and may be infections; these may be further influenced, or primed , by early 
or late exposure, as in EBV-induced IM [6, 189]. 
Integration of main potential factors in possible causal model 
Goodin (2009) has postulated a possible life-course mathematical model for the timing 
and the role of environmental factors in the aetiology of MS. The model comprises a 
'causal cascade' of a series of factors , these acting sequentially and at 'appropriately 
timed ' periods before disease onset [229]. This idea was also proposed earlier by 
McMichael and Hall (2001) for the sequence of UVR, infections and other possible 
factors for MS [6] and , further, is similar to the 'two-hit hypothesis' for schizophrenia 
described by Torrey and colleagues (1997) [642]. 
In Goodin 's model for MS, the two most influential periods for exposure to such factors 
are postulated to be near birth and during childhood or adolescence , with a third period 
in adulthood closer to onset [229]. While the two leading environmental candidate 
factors are proposed by Goodin (and several other reviewers , based on current 
evidence, Table 3.3) to be vitamin D deficiency and EBV infection , the mathematical 
model also allows for the eventuality that these factors are replaced by other factors , 
should future evidence indicate this [229]. The model further proposes a third factor 
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acting long after the first two, the identity of this factor, or factors, being presently 
unknown (Figure 3.5). 
Possible Causal Cascade to MS Pathogenesis 
Conception Birth Childhood/adolescence ?Adulthood 20- 40yr 
Genetic 
~ 
Vitamin D 
~ 
Infections 
..... 
?Other 
..... 
MS 
factors r deficiency? ~ e.g. EBV? ~ factors ~ 
Figure 3.5: 'Most probable' causal pathway leading to MS, showing timing of 
environmental factors. (Figure based on possible pathways according to 'causal 
cascade' model of Goodin, 200913 [229].) 
Goodin proposes a possible causal pathway for MS, with the first environmental factor 
being 'necessary but not sufficient' but, importantly, acting near the time of birth . The 
second factor is again 'necessary but not sufficient', and is further postulated to be 
acting in childhood or adolescence. Together with the third, still necessary, factor 
acting post-childhood/adolescence (Figure 3.5) , this causal-pathway model is 
essentially based on the 'life-course component cause model' of disease causation [1] 
pictured in Chapter 2 (Figure 2.3) and repeated here as Figure 3.6, but with the timing 
for each factor now specified in the causal hypothesis. 
Birth 
'Component causes do not need to act at the same time, and may interact and accumulate over the life 
course to result in sufficient cause. ' 
Figure 3.6: Life-course disease causation model for a multifactorial disorder with 
genetic (G) and environmental (E1 to E3) component causes. 
13 It should be noted that Goodin 's causal pathway does not specifically include the possibility of protective 
infections in childhood that may act to modify later causal effects of infections such as EBV in adolescence 
(see Section 3.1.3). 
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Importantly, Goodin's life-course model gives a basis on which to frame the research 
questions for MS for this thesis. That is, if the timing of effects of environmental factors 
can be determined for MS, it may then become possible to discern the likely nature of 
the environmental factors involved. For example, if a month-of-birth pattern is found to 
be evident in MS cases (but not the general population) in Australia , an environmental 
factor acting around the time of birth (the first of Goodin's 'critical ' periods) , would be 
indicated. Additionally, an association with latitude or with seasonal perinatal UVR 
might further increase knowledge of the factor's nature (see Chapters 5 to 7). Similarly, 
an investigation of Goodin's second 'critical' period, childhood , by means of a hygiene-
hypothesis proxy marker for childhood infections-birth order-may give information on 
both the importance of this period and the possible nature of the factor(s) acting in this 
period (see Chapter 8). 
Thus, this thesis will approach candidate environmental determinants of MS, by means 
of the first two possibly critical life-course periods indicated in Goodin's (2009) model 
[229]. That is, the period around the time of birth and the childhood period will be 
investigated separately using individual-level data from the 1981 Australian MS Survey 
(see Chapters 5 to 8), in order to attempt to determine the nature of the possible 
determinant factors acting in each of these periods. 
3.3 Conclusion 
Epidemiological evidence in terms of 'person ', 'place' and 'time' and the immunological 
mechanisms reviewed herein point to a role for infections as a possible environmental 
determinant of MS and other autoimmune disorders such as type 1 diabetes and RA. 
Such infections, acting early in life , may be a component cause that, together with 
genetics and other interacting factors such as UVR/vitamin D (see Chapter 2) , may 
affect the risk of developing such organ-specific autoimmune disorders later in life. 
3.4 Postscript 
This chapter has reviewed the evidence for infections as a possible determinant 
environmental factor for MS and other organ-specific autoimmune disorders-type 1 
diabetes and RA-and considered how the major factors identified in Chapters 2 and 3 
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for MS may be related to each other according to an overall timing-based life-course 
model. 
Using such a model as a conceptual framework , the main analysis chapters of this 
thesis will investigate whether there is, first , a timing-of-birth pattern for MS cases in 
Australia-that might indicate particular determinants acting near birth-and whether 
such a pattern is related to southern latitude and/or perinatal UVR ( see Chapters 5 to 
7) . Second , Chapter 8 will investigate a further life-course stage-childhood-and 
attempt to discern the nature of environmental factors acting then , both studies using 
available individual-level data from a national MS survey. 
Prior to this , in addition to the main MS 'timing ' analyses in Chapters 5 to 8, available 
population-level data for type 1 diabetes, RA and other immune disorders will be 
explored for possible southern hemisphere associations with latitude and UVR in 
Chapter 4, as corroborative evidence for corresponding ecological associations 
between latitude/UVR and MS in Australia that were already known [9 , 301 ]. These 
disorders other than MS had not previously been investigated in this way in Australia , 
even at the ecological level , prior to commencement of this thesis. 
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CHAPTER 4 
DISTRIBUTION OF AUTOIMMUNE DISEASE IN AUSTRALIA: ECOLOGICAL 
ANALYSIS OF LATITUDE, REGIONAL UVR AND IMMUNE-RELATED DISEASE 
PREVALENCE 
4.1 Introduction 
As reviewed in Chapter 1, autoimmune diseases such as MS, type 1 diabetes mellitus 
and RA are organ-specific immune system disorders that share common features of 
self-reactive T cells and the presence of auto-antibodies. As a group, these disorders 
affect some 5% of the global population, particularly in Western countries [2]; at least 
0.1 % of children and adolescents (up to 20 years of age) are affected by type 1 
diabetes [26, 28] and incidence worldwide is rapidly increasing , particularly in younger 
age groups (see Chapter 2). At least two-thirds of MS and RA patients are female, but 
a relatively equal risk between males and females is evident in childhood onset type 1 
(insulin-dependent) diabetes. 
While their precise aetiologies are unknown, these autoimmune disorders are generally 
agreed to reflect interactions of polygenic traits with various ill-defined environmental 
factors (see Chapters 2 and 3) that result in altered homeostatic balance between self-
reactive and regulatory T cells to cause ongoing disease (see Chapter 1 ). Ecological 
study at the population level may help elucidate the role of environmental factors in the 
aetiology of the organ-specific autoimmune diseases MS, type 1 diabetes and RA, as 
well as other immune-related disturbances such as asthma and eczema/dermatitis. 
MS, type 1 diabetes and , to a lesser extent , RA display a latitudinal gradient in disease 
frequency in the northern hemisphere, particularly in Western Europe and North 
America , with the prevalence of these disorders increasing at higher latitudes (see 
Chapter 2). MS exhibits a similar prevalence gradient in the southern hemisphere, in 
Australia and NZ [302 , 304]. In Australia , however, where the opportunity exists to 
study gradients in prevalence rates across a large-area population (Figure 4.1) that is 
less ethnically and genetically diverse than across Europe, analyses for other immune-
related disorders had not been conducted prior to this thesis study. 
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Figure 4.1: World map showing position and latitude range of Australia compared with other continents and particularly those in the 
northern hemisphere. (Figure from GraphicMaps.com; accessed at http://www.worldatlas.com/aatlas/printpage/latlog.htm.) 
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28 October 2004 
' 
"In the area of the ozone hole, UV irradiance 
increases dueto the reduced ozone column 
andresults in UV Index values never 
observed at such latitudes." 
"The Global Solar UV Index (UV/) is a simple 
measurement of the UV radiation level at the Earth's 
surface. It has been designed to indicate the 
potential for adverse health effects and to 
encourage people to protect themselves. The higher 
the Index value, the greater the potential for damage 
to the skin and eye, and the less time it takes for 
harm to occur. 
In countries close to the equator, the UV/ can be as 
much as 20. Summertime values in northern 
latitudes rarely exceed 8." 
Daily maximum of the UV index by clear sky 
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Source: GMES, 2006; INTERSUN, 2007. 
INTERSUN, the Global UV project, is a collaborative project 
between WHO, UNEP, WMO, the International Agency on 
Cancer Research (IARC) and the International Commission 
on Non-Ionizing Radiation Protection (ICNIRP). 
Figure 4.2: World map showing variation in solar UVR reaching the Earth's surface with latitude. (Figure from 
http://maps.grida.no/go/graphic/the-global-solar-uv-index). 
171 
UVR reaching the Earth's surface varies inversely with latitude (Figure 4.2) ; UVR is 
thus a prominent latitude-related environmental factor (see Chapter 2). Recent photo-
immunological work shows that UVR suppresses cellular immunity, attenuating T-
helper (Th)-cell-mediated immune responses [362 , 363]. The mechanisms by which 
this is achieved have been described in Chapter 2 and include tolerogenic effects on 
APCs and induction of regulatory T cells. Vitamin D may also be a major mediator of 
UVR (see Chapter 2). Breakdown of these mechanisms of immune self-tolerance is 
thought to be significantly involved in the development of autoimmune disorders such 
as MS, type 1 diabetes and RA (see Chapter 1 ). UVR might therefore be expected to 
be beneficial for the prevention of these disorders by preventing tolerance breakdown. 
However, few organ-specific autoimmune diseases or other immune-related disorders 
had been assessed ecologically with respect to UVR prior to this thesis. An exception 
for the southern hemisphere was an analysis of MS in Australia, where the regional 
variation in MS prevalence was shown to be strongly inversely associated with ambient 
UVR levels (r=-0.91; p=0.01) [9]. This finding supported the possibility of UVR being a 
protective modulator of immune and autoimmune processes involved in the aetiology of 
such immune disorders [5 , 6]. Therefore, type 1 diabetes and RA were chosen for 
similar ecological analysis , to determine whether these organ-specific autoimmune 
disorders also showed environmental gradients as observed for MS in Australia. 
Another immune-related disorder of interest is atopic eczema. There is some evidence 
that this disorder shows a latitude-prevalence gradient in the northern hemisphere 
(Europe) similar to that of type 1 diabetes (A.J. McMichael , unpublished data , pers. 
commn) [618]. An ecological analysis of worldwide International Study of Asthma and 
Allergies in Childhood (ISAAC) data from 146 centres further showed that symptoms of 
eczema in six- to seven-year-old children correlated positively with increasing latitude 
[619]. An RCT in the UK on adult atopic eczema has shown UVR, particularly narrow-
band UVB, to have a beneficial effect on this immune-related disorder [620]. Moreover, 
UV therapy (see Chapter 2) is also a recognised treatment for atopic dermatitis . 
The possible effect of latitude and UVR on asthma is of further interest. UVR has been 
thought to effect a shift from Th 1- to Th2-mediated processes by down-regulating Th 1-
mediated immunity [363] . Th2 cells are responsible for immediate-type hypersensitivity 
to allergens such as dust mites; thus , UVR may have the potential to exacerbate 
allergic disease [621]. However, recent work has cast doubt on the mutual antagonism 
of Th1 and Th2 cytokine expression , particularly in humans [2 , 26, 622 , 623] and 
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understanding of immune disorders is now considerably more complex, involving 
several types of regulatory T cells (see Chapter 1 ). For example , UVB can directly 
inhibit both Th1- and Th17-type immune responses , particularly through IL-10 (see 
Chapter 1 ), but also suppress Th2 and allergic responses [114] . Conversely, vitamin D 
inhibits both Th1 and Th17 cells while inducing Foxp3+ regulatory T cells (Chapter 1) 
and , under certain conditions , also Th2 cells [52] (see Chapter 2, Figure 2.11 ). 
Importantly, asthma can coexist with disorders such as type 1 diabetes, RA and coeliac 
disease in children , suggesting a common environmental influence [624] . Therefore, 
eczema/dermatitis and asthma were chosen to be similarly analysed for regional 
prevalence gradients, to compare with any associations evident for type 1 diabetes and 
RA. 
This chapter examines the possible association between latitude and prevalence of the 
immune-related disorders, type 1 diabetes mellitis, RA, eczema/dermatitis and asthma 
in Australia , a country with a relatively genetically homogeneous population 14. Regional 
differences in ambient UVR were further considered in order to examine possible 
associations between regional and seasonal UVR levels and the prevalence of these 
four immune disorders in Australia. 
4.2 Methods 
4.2.1 Outcome measures 
Prevalence data source-1995 NHS 
The Australian NHS is a nationwide cross-sectional survey carried out every three to 
five years by the ABS , responsible also for the five-yearly Austra lian Census of 
Population and Housing. The 1995 NHS was conducted during the 12-month period 
from January 1995 to January 1996, but on a quarterl y basis to take account of 
possible seasonal effects. Approximately 54 ,000 people from all states and territories 
of Australia and across all age groups provided information about the ir own hea lth 
status in response to a series of questionnaires. Res idents of a stratif ied , mu lti-stage 
14 T he Australi an population is largely of European origin, the indigenous population comprising just 
1.5% of the total population in 1986 and 2 .0% in 1996 (ABS publication 4 705 .0 : Population Distribution, 
Indigenous Australians, 1996; accessed at 
http: //www.abs.gov.au/ AUSST A TS/abs@nsf/DetailsPage/4 705 .0 l 996?OpenDocument) 
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area, random sample of 23,800 private households (houses, apartments) and 
households in non-private dwellings (such as hotels, hostels and caravan parks) were 
included ; the base sample size corresponded to approximately one-third of 1 % of the 
Australian population. Residents of hospitals and other institutions (such as nursing 
homes, prisons and military institutions) were excluded, and the Northern Territory (NT) 
sample was also predominantly urban (because of vast, sparsely populated areas in 
that territory) [ 13]. 
Residents of the selected households were interviewed in person by trained ABS 
interviewers, and all persons within each state/territory had a known, and in the main, 
equal, chance of selection. Responses were received from 91.5% of sampled 
households (i.e. total unweighted response rate) and 97% of people from these 
households completed the questionnaires fully. Independent quarterly population 
estimates were used by ABS for population standardisation, and prevalence rate 
estimates were adjusted for household size. The estimation procedure used 
information on the patterns of response to counter known biases in target variables 
resulting from partial response [13]. 
The 'Personal Interview Questionnaire' used to obtain health information was designed 
by the ABS to be administered using standard ABS procedures for conducting 
population interview surveys, and was fully field tested to ensure particular aims of the 
survey were addressed. The survey interviewers recorded information on recent illness 
and long-term conditions, as reported by respondents. Specific questioning about 
conditions , including diabetes, arthritis and asthma , was followed by 'actions-based ' 
questions on recent visits to hospitals , clinics etc. or health professionals , and about 
days away from work or school. Information on medications usage, including insulin 
and specific medications for asthma, arthritis and allergies , was further elicited [13 , 
625]. Disease conditions were classified by categories of the International 
Classification of Diseases, 9th Revision. However, information recorded in the survey 
was self-reported and not medically verified . 
Prevalence estimates-summary data 
For this thesis study, summary-data prevalence estimates from the published survey 
results [626] for four different immune-related disorders were used. The age- and sex-
standardised prevalence rates, per 1000 population, of type 1 diabetes, RA, 
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eczema/dermatitis and asthma were compared over the eight major state and territory 
regions of Australia, as listed in Table 4.1. 
4.2.2 Exposure measures 
Latitude 
The latitude of the capital city of each state or territory (Figure 4.3), expressed In 
decimal degrees south, was used for each region (Table 4.1 ) . 
I Australia I 
SOUTH 
AUST~ 
.. .. 
' -: 
Brisb 
NE\I 
SOUTH 
WALES 
10 °S 
. 27°S 
44°s 
Figure 4.3: Australian states and territories and their capital cities, shown 
together with the overall latitude range. (Figure from 
http://www.cse.unsw.edu.au.) 
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Table 4.1: Australian state and territory regions and approximate latitude ranges; regional capitals and their latitudes+ (decimal 
degrees south) shown together with midsummer (January) and midwinter (June) solar-noon UVR# (mW/m 2) for each regional capital 
State/Territory region 
NT Northern Territory 
QLD Queensland 
WA Western Australia 
NSW New South Wales 
SA South Australia 
ACT Australian Capital Territory 
VIC Victoria 
TAS Tasmania 
Latitude range 
for region {0 S) 
11-26 
10-29 
14-35 
28-37 
26-38 
35-35.5 
34-39 
41-43.5 
Regional 
capital 
Darwin 
Brisbane 
Perth 
Sydney 
Adelaide 
Canberra 
Melbourne 
Hobart 
Latitude 
of capital 
12.4 
27.5 
31.9 
33.9 
34.9 
35.3 
37.8 
42.9 
Midsummer UVR 
(mW/m 2) 
339.5 
332.4 
326.1 
306.1 
303.4 
302.7 
287.6 
256.7 
Midwinter UVR 
(mW/m 2) 
205.9 
103.9 
82.9 
66.5 
60.7 
55.7 
48.6 
31.4 
+ Latitude values obtained from Geoscience Australia mapping agency (http ://www.ga.gov.au). 
# UVR data are monthly averages from daily (at local solar noon) erythemally-weighted clear-sky UV Index values derived from satellite ozone data over the period 1979 
to1993 (supplied by Dr Lilia Lemus-Deschamps, BMRC , Australia) and expressed as mW/m2 . 
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Figure 4.4: Average annual UV Index values for Australia, 1979 to 2007 (Figure from Bureau of Meteorology, 
http://www.bom.gov.au/isp/ncc/climate averages/uv-index/index.jsp.) 
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UV radiation 
Three ambient UVR measures were examined , each relating to the WHO's Global 
Solar Ultraviolet Index (UVI) measuring UVR intensity (see Figure 4.2), and expressed 
in milliWatts per square metre (mW/m2) (where 1 UVI unit=25mW/m2). The UVI is a 
daily (at local solar noon) erythemally-weighted clear-sky UV-intensity value derived 
from total ozone mapping spectrometer (TOMS) satellite data and in Australia ranges 
from one to about 14 (equivalent to 25 to 350 mW/m2) [627, 628] (Figure 4.4). For this 
study, the first UVR measure for each regional capital was an arithmetic mean of 12 
monthly UVI averages supplied by the Australian Bureau of Meteorology Research 
Centre (BMRC Australia), each monthly average having been calculated from daily UVI 
values derived over the period 1979 to 1993 (L. Lemus-Deschamps, BMRC Australia , 
pers. commn). In addition, a midwinter (minimum , June) UVI value and a midsummer 
(maximum, January) UVI value for each regional capital (Table 4.1) were investigated. 
These additional measures were included for comparison with the average monthly 
UVI values because over the Australian latitude range from north to south , UVR varies 
over a wider range (approximately two-fold) in midwinter than in midsummer (Table 
4.1 ). This means that the independent variable in linear regression , UVR, may have 
greater discriminatory power in midwinter than in midsummer. 
4.2.3 Statistical analysis 
Standard error of prevalence estimates 
To account for the NHS sampling variability between regions , approximate standard 
errors for each regional prevalence estimate were calculated , as recommended by the 
ABS and outlined in Appendix H and the 'Technical Note: Sampl ing Variability ' in the 
respective ABS publications [13 , 626]. The approximate standard errors were 
calculated from standard errors for the corresponding numerator estimates shown in 
Table 4.2 , as listed by the ABS for each region [13 , 626] . Age-standardisation factors 
for the different regions were also applied , as recommended in the same Technical 
Note, and the final standard errors for the prevalence rates calculated (Table 4.2) . 
Table 4.2: Regional prevalence rates+ of type 1 diabetes, RA, eczema/dermatitis 
and asthma (in bold with SE# in parentheses) together with numerator data on 
which SE estimates were based 
State/ 
Territory 
Type 1 
diabetes 
RA 
NT No. cases 200 1,500 
Prevalence 2.9 (1.80) 18.2 (5.56) 
OLD No. cases 10,500 82 ,100 
Prevalence 3.2 (0.62) 25.7 (1.34) 
WA No. cases 6,900 49 ,000 
Prevalence 4.2 (0.79) 29.8 (1.66) 
NSW No. cases 
Prevalence 
26,300 170,700 
4.2 (0.56) 27.3 (1.24) 
SA No. cases 8,300 41 ,900 
Prevalence 5.4 (0.63) 26.8 (1.15) 
ACT No. cases 1,100 5,600 
Prevalence 4.6 (0.99) 21.4 (1.65) 
VIC No. cases 23 ,800 106,400 
Prevalence 5.2 (0.50) 23 .2 (0.88) 
T AS No. cases 2, 1 00 19, 1 00 
Prevalence 4.5 (1.14) 39 .5 (2.38) 
Eczema/ 
dermatitis 
2,900 
19.2 (4.43) 
96,900 
29.5 (1.40) 
82,400 
47.1 (1 .90) 
181 ,900 
29.8 (1.30) 
73,000 
50.3 (1.55) 
14,400 
45.5 (3.98) 
171 ,500 
38.2 (1 .07) 
20,700 
44.0 (2.53) 
Asthma Regional 
population 
17,200 145,300 
127.2 (13.11) 
438,000 3,277,800 
132.6 (2.51) 
201 ,500 1,732 ,400 
115.2 (2. 76) 
633,700 6,120,500 
103.9 (2.10) 
163,500 1,474,800 
112.4 (2.16) 
35,500 304 ,900 
111.9 (2.65) 
501 ,500 4,503 ,100 
111.8 (1.63) 
48 ,800 473,600 
102.1 (3.48) 
+ Rate per 1000 , age- and sex-standardised to the 1995/96 Australian population (data from ABS [626]). 
# Approximate SE ca lcu lated from ABS-provided SE fo r numerator [1 3, 626]. 
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Weighting of prevalence estimates 
The reciprocal of the variance of each prevalence rate was then used to weight the 
estimates to take account of differing sample sizes in the regions. For example, the 
region with the lowest population, NT, and the largest SE (and variance) (Table 4.2) , 
contributed less weight to the overall regression analysis of the eight regions. 
Linear regression 
Associations between each of the environmental variables and the immune disorder 
prevalence rates were examined by variance-weighted least squares regression, using 
the statistical software program Stata 7.0 (Stata Corporation, College Station, Texas). 
The eight regional prevalence rate estimates were regressed , first, versus the latitude 
values of the regional capital cities and, second, versus each of the three UVR 
measures for the regional capitals. The magnitude of change in disease prevalence 
rates over the north-south range was compared by substituting latitude values for 
northernmost Darwin and southernmost Hobart into the regression equations. 
Sensitivity analysis to check use of capital-city latitudes 
Since the use of capital-city latitudes was convenient but may not have been 
representative of the regional population distribution, particularly for larger regions with 
the capital at either a northern or southern extreme of the region rather than medially 
placed (e.g. QLD and NT), a sensitivity analysis was carried out. This tested the effect 
of using an alternative latitude value midway between the two main population centres 
in these regions. Results using the substitute latitude values were then compared with 
those obtained from the regional capitals. 
4.3 Results 
4.3.1 Latitude and immune disorders 
The relationships between latitude of the regional capitals and immune disorder 
prevalence are shown in Figure 4.5 as regression lines fitted to the eight regional 
prevalence estimates for each immune disorder; 95% confidence intervals are also 
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shown and the width of these indicate, reciprocally , the relative weighting applied to 
each estimate in the regression analysis. 
Prevalence of type 1 diabetes was positively correlated with latitude (Pearson r=O. 77 ; 
p=0.026) , the prevalence increasing 2.97-fold over the north-south latitude gradient. 
Conversely, asthma prevalence was inversely correlated with latitude (Pearson r=-0. 72 ; 
p=0.046) , the prevalence rate decreasing 0. ?-fold-that is , by approximately one-
third-over the same latitude range. Although both eczema/dermatitis and , to a much 
lesser extent, RA showed trends of increasing prevalence with increasing latitude, 
these were not statistically significant (Figure 4.5). 
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Figure 4.5: Associations between latitude and prevalence per 1000 of type 1 diabetes, asthma, eczema/dermatitis and RA. (95% 
confidence intervals of prevalence estimates shown as error bars; solid lines denote statistically significant association, p <0.05; 
dotted lines denote non-significant trend.) 
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Sensitivity analysis 
Since the aim of this study was to relate regional disease prevalence to the latitude 
where most of the population resided within each region , the proportion of the 
population living in the regional capitals was checked using both the 1991 and 1996 
Australian censuses. In four of the eight regions, WA, SA, VIC and the ACT, at least 70% 
of the state or territory populations resided in the capital metropolitan area (ABS 
Census data for 1991 /96, not shown). Among the remaining regions, where the 
population was more dispersed outside of the capital, only the NT and QLD covered a 
wide latitudinal range and had their capital cities located non-centrally in terms of the 
regional latitude range, thus potentially biasing the associations. 
Alternative latitude values for both the NT and QLD were therefore investigated in this 
sensitivity analysis: For the NT, a latitude value of 18.1 degrees south , midway 
between the two main population centres , Darwin and Alice Springs, was substituted. 
For QLD, a latitude value of 23.4 degrees south, midway between Brisbane and 
Townsville , was used. However, the effect on the initial associations of using these 
alternative latitudes was to strengthen the statistical significance of the associations for 
type 1 diabetes, asthma and eczema/dermatitis when one or both midway latitudes 
were substituted. For example, for type 1 diabetes and asthma, the maximum increase 
in statistical significance of the associations (from p=0.026 to p=0.010 for diabetes 
(r=0.77 to 0.84) , and from p=0.046 to p=0.013 (r=-0.72 to -0.82) for asthma) resulted 
when midway latitudes were used for both regions. Less deviation resulted when only 
one latitude value was substituted , but this was still in the more significant direction , 
that is , away from the 'null ', or no-association , situation. 
Both approaches unavoidably entail some exposure misclassification for dispersed 
regional populations . Whereas the latter (midway-latitude) approach may lead to better 
estimation of the prevalence-latitude correlation , by using the capital latitude values for 
type 1 diabetes and asthma as first conducted (see Table 4.1 ), the estimates were 
somewhat biased towards the null hypothesis of 'no association ' and thus towards 
under-estimation of the Pearson correlation coefficient, 'r'. Similarly for 
eczema/dermatitis the maximum rise in statistical significance (from p=0 .206 to 
p=0.174 [r=0.50 to 0.54]) was obtained when the QLD latitude, only, was altered but 
this was still non-significant at the 5% level. For RA, conversely, using both midway 
latitudes gave maximal change but the statistical significance of the observed trend 
was lowered (from p=0. 727 to p=0. 795 [r=0 .15 to 0.11 ]). 
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In summary, the use of the regional-capital latitude values, rather than latitude values 
of the midway points, was more conservative and did not alter the overall conclusions 
of whether or not the observed associations were statistically significant at the 5% level. 
4.3.2 Regional UVR and immune disorders 
Because the use of the regional capital-city latitudes was able to be justified by the 
sensitivity analysis, capital-city solar-noon UVR values were also used. Midday, or 
noon-time, exposure to the maximal UVR level in sunlight has been shown to suppress 
the systemic immune response in humans in Australia [629]. The amount of skin-
damaging UV radiation expected to reach the Earth's surface when the sun is highest 
in the sky (i.e. UVI) is thus an appropriate UVR measure and is now an internationally 
recognised standard for expressing solar UV radiation levels [359] . Type 1 diabetes 
prevalence was inversely correlated with regional average monthly (solar-noon) UVR 
(Pearson r=-0.80; p=0.018), whereas asthma prevalence was positively correlated with 
the same UVR measure (Pearson r=0.73; p=0.040) (Figure 4.6). Eczema/dermatitis 
and RA prevalences showed inverse trends with all of the measures of UVR (average 
monthly, midwinter [June] and midsummer [January]) , but none of these was significant 
(Table 4.3). 
Comparing the three different ambient UVR measures, the prevalence of asthma was 
positively correlated with either average monthly or midwinter UVR, but not midsummer 
UVR (at the 5% level). While type 1 diabetes prevalence was inversely correlated with 
all three ambient UVR measures, it was more closely correlated with average monthly 
or midwinter UVR than with midsummer UVR (Table 4.3) . 
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Table 4.3: Correlations between immune disorder prevalence in the 1995 NHS 
and regional solar-noon UVR levels for 1979 to 1993. (Pearson correlation 
coefficients+ [p-values# in parentheses]) 
Immune 
disorder 
Type 1 diabetes 
Eczema/dermatitis 
RA 
Asthma 
Average UVR 
-0.80 (0.018)* 
-0.47 (0.243) 
-0.08 (0.845) 
0.73 (0.040)* 
Midwinter UVR Midsummer UVR 
-0. 77 (0.024 )* -0.72 (0 .045)* 
-0.49 (0.215) -0.34 (0.412) 
-0.06 (0.880) -0.12 (0. 77 4) 
0.72 (0.044 )* 0.68 (0 .060) 
+Pearson correlation coefficients (correlations based on the eight Austral ian state/territory regions ) 
between immune disorder prevalence and solar-noon UVR, for each type of immune disorder and three 
different measures of UVR-monthly average over year, midwinter (minimum) and midsummer (maximum ). 
#Strength of association examined by variance-weighted least squares regression . 
*Statistically sign ificant association , p <0 .05 . 
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Figure 4.6: Associations between average monthly ambient UVR and prevalence 
per 1000 of type 1 diabetes and asthma. (95% confidence intervals of prevalence 
estimates shown as error bars.) 
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4.4 Discussion 
Findings 
Using summary age- and sex-standardised data on self-reported prevalence of 
immune disorders from the ABS 1995 NHS, strong gradients in type 1 diabetes 
prevalence with latitude and , inversely, with all UVR measures were found . The 
magnitude of change for type 1 diabetes in Australia was an approximately three-fold 
increase in prevalence from the lower-latitude northernmost region , the NT, to the 
higher-latitude southernmost region , TAS. These ecological data provide support for a 
previously proposed beneficial effect of UVR on autoimmune disorders such as type 1 
diabetes [5]. In contrast to type 1 diabetes, asthma correlated negatively with latitude 
and positively with regional annual or midwinter UVR, but the magnitude of change for 
asthma prevalence from the north to south of Australia was only 0. 7-fold. For both RA 
and eczema/dermatitis there were possible trends but no statistically significant 
associations between latitude or UVR and disease prevalence. 
Strengths of study 
A strength of this ecological analysis derives from the relative genetic homogeneity of 
the Australian population and relative uniformity also in the standard of national health 
care [301 ]. A further advantage is the wide latitude range and the resulting wide range 
of ambient UVR levels over the Australian continent. A high total response rate to the 
survey was achieved by the ABS over all regions. 
Sources of error 
Outcome classification: One potential source of (probably random ) error lies in the 
self-reported , non-verified nature of the data , which could have resulted in some 
misclassification of disease conditions. Th is is particularly so for eczema/dermatitis, the 
classification of which appears from the questionnaire to have been based largely on 
medications usage; there were no direct disease-specific questions on eczema [625] . 
The classification 'eczema' is often used as an 'umbrella ' term , encompassing various 
dry, itchy skin conditions [630] ; 'dermatitis ' similarly can include contact dermatitis. The 
'eczema/dermatitis ' category in the NHS further included heat eczema and sunburn 
[13] , and may have led to possible regional differences in prevalence. 
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RA, also, is difficult to differentiate from unspecified polyarthritis [292]. Therefore, 
misclassification between rheumatoid, osteoarthritis and general arthritic or 
'rheumatism' conditions could have occurred even though 'arthritis ' was allocated four 
specific questions. Likewise, outcome misclassification of self-reported 'asthma' may 
have occurred, this condition being sometimes difficult to differentiate from general 
'wheezing' disorders, in spite of specific questions on medications usage [625]. 
Type 1 diabetes, conversely, was classified on the basis of 24 direct questions for 
diabetes and insulin usage, including duration of use, both past and future expected 
use and age at first use [625]. Therefore, the relative validity of classification of type 1 
diabetes, a serious disease requiring specific treatment, was probably more regionally 
consistent. 
Exposure classification: Some exposure misclassification at the ecological (i.e. state 
or territory) level compared to the individual level could have occurred because actual 
personal UVR exposure depends on behaviour in relation to the sun (i.e. whether sun-
avoidant or taking sun protection measures) as well as on regional ambient UVR. For 
example, regional UVR would not have been a good measure of personal sun 
exposure among sun-avoidant people, and if the proportion of such people in each 
local population varied markedly, then population-level exposure assessment would be 
biased. In fact , the recorded proportion of 'sun-avoidant' people was small and did not 
vary substantially by region. That is, the percentage of people who reported in the 
survey 'don't go out in sun ' was 3.4% for the NT, 2.0% for QLD and 2.3% for TAS [626], 
which is perhaps surprising given that the outside temperatures in northern Australia 
are much higher than in southern Australia in summer or winter. Further, for most 
individuals , personal UVR exposure varies only between 5 and 15% of daily total 
ambient UVR [631]. Thus, ambient UVR levels may provide a reasonable measure of 
average personal sun exposure at the population level. 
Another possible source of measurement error-using capital-city latitudes and UVR 
values as representative of each region-was shown by sensitivity analysis to be not 
significantly biasing the results , even for the two regions having greater non-
metropolitan distribution together with the most non-central capitals and the widest 
latitude ranges, namely, QLD and the NT. Further, mean state latitude calculated from 
population distribution, as used in Chapter 5, is subsequently shown to be minorly 
different from the capital-city latitudes used here (see Chapter 5, Section 5.1 , Figure 
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5.2). However, only current residence was considered in this study and the contribution 
of prior residence areas could not be taken into account, nor the timing of the critical 
UVR exposure, which may have occurred earlier in life, nor even possible migration 
after disease initiation, because prevalence rather than incidence data were used. It 
was also not possible to control for latitude when examining the relationships between 
the immune disorders and UVR, because of the high degree of collinearity between 
UVR and latitude. 
Possible confounders 
Potential ecological confounders include other possible causal factors for immune-
related disorders that vary with latitude or UVR; for example, regional infection patterns 
that may be associated with climatic differences. Infectious agents have been linked to 
the aetiology of immune disorders, including type 1 diabetes [136, 198, 240, 601, 632], 
RA [194, 292, 494, 607, 633] (see Chapter 3) and asthma [307, 634] . As discussed in 
Chapter 3 (see Section 3.1.2), a lack of infections in early life may also adversely affect 
immune development-that is, the 'hygiene hypothesis' [3]. Infectious agents may be 
either causal or even protective for such immune disorders [292, 497, 587, 592], 
depending on conditions and particularly their timing of action in the life course 
(Chapter 3). 
Other confounding factors could include environmental temperature and dietary 
differences [198 , 240, 592] (Chapter 3). These potential confounders warrant more 
detailed consideration in future research. There may also be interaction between some 
of these environmental exposures; for example, infection and nutritional factors [241]. 
However, as indicated by Ponsonby and colleagues, it is not possible to determine 
such interactions in ecological analyses , since there is a lack of data on joint 
environmental exposures at the individual level [358] . 
In this study, UVR has been shown to have either an inverse, or no, association with 
the immune-related disorders analysed , except for asthma, which showed a positive 
association between UVR and prevalence. The significance of this finding for asthma is 
uncertain , particularly as the prevalence increase over the UVR range was only low. 
UVR-induced Th2 up-regulation mediated by vitamin D [52] would expla in this result, 
even though other workers have noted suppression rather than stimulation of Th2 by 
UVR [365], particularly through IL-10 [114]. However, much asthma at the population 
level may even be non-allergic [635] with Th2 mechanisms not involved. In addition , 
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the contribution of regional allergen levels to asthma prevalence could be important. 
For example, an 11-fold higher level of mean house dust mite allergen concentration in 
homes in Sydney, NSW (low latitude, warm and more humid), compared to TAS 
(higher latitude, cool and dry) [636] may explain the inverse latitude gradient for asthma. 
An inverse latitude gradient for asthma was also found in a subsequent Australian 
study but this association was accounted for by regional (average daily) temperature 
[637]. This reinforces the likelihood that the findings here for asthma may be explained 
by factors related to regional temperature, such as house dust mite levels, an 
examination beyond the scope of this investigation. 
Latitude, UVR and type 1 diabetes 
The association found between latitude and type 1 diabetes prevalence in Austra ia is 
consistent with similar incidence gradients found in Western Europe and North America 
[30, 313, 314] and within China [315], and has now been shown for the first time in the 
southern hemisphere. The corresponding inverse association between regional 
ambient UVR levels in Australia and type 1 diabetes prevalence extends this latitude-
gradient finding for type 1 diabetes and is also now consistent with the strong inverse 
UVR association found for MS in another Australian ecological study [9]. Subsequent to 
this chapter's findings (published 2003, see Appendix I), ecological analyses of both 
MS and type 1 diabetes largely in the northern hemisphere have further confirmed 
inverse associations between UVR levels and disease prevalence or incidence rates. 
For example, northern hemisphere findings for MS confirm a strong ecological 
association between UVR and MS prevalence in North America by geospatial analysis 
[359], and in an ethnically homogeneous farming population in France [189 , 289]. For 
type 1 diabetes, worldwide incidence rates for 1990 to 1994 (WHO multinational 
'DiaMond' project) [316] have been subsequently analysed versus regional UVB 
radiation levels taking per capita health expenditure into account, an inverse 
relationship between UVR and risk of type 1 diabetes being reported over 51 regions 
[317]. In Australia , however, a recent study of regional residential UVR and type 1 
diabetes incidence (also subsequent to this thesis study) was able to support the 
present findings for type 1 diabetes only in low-density (i.e. rural) populations , the 
association being reversed in high-density (urban) populations [351 ]. 
The findings in this chapter for type 1 diabetes are also consistent with photo-
immunological work showing that UVB irradiation has systemic as well as local 
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immunosuppressive effects in humans and animals [362-365, 368 , 371 ], as does UVA 
irradiation [362 , 371 , 374] (see Chapter 2). UVR exposure may be protective against 
disorders such as type 1 diabetes, by down-regulating effector T-cell (Th 1 /Th 17) 
autoimmune responses by several different immunoregulatory mechanisms, including 
direct effects on antigen presentation , and promotion and induction of regulatory T cells 
[362 , 368-371, 373] (see Chapter 2). 
As discussed in Chapter 2 (Section 2.4.2) , another of these possible mechanisms for 
immunosuppression involves UVR-induced vitamin 0 , which , like direct UVR, can 
inhibit Th1 and Th17 cell responses (via effects on OCs) and promote and induce 
regulatory T cells , but also enhance Th2 cells [52]. That is, the proposed protective role 
of UVR for both MS and type 1 diabetes may be mediated at least in part through its 
important role in vitamin O synthesis in the skin. For example , a recent multicentre 
incidence study of FOE, a common precursor to MS, in Australia showed that a four-
fold increase in FOE incidence from Brisbane, QLO, to TAS regions [305] was partly 
accounted for by both past sun exposure and vitamin O status [361 ]. Some 90% of 
plasma vitamin O in humans is produced endogenously via skin exposure to UVR in 
sunshine [242], and particularly so in Australia where foods are not generally fortified 
with vitamin O [456 , 457, 638]. There are also recent reports of vitamin O deficiency in 
some Australian populations [458 , 459, 461], particularly in winter [457 , 462]. 
For type 1 diabetes, this possible vitamin O mechanism is consistent with reports of 
decreased risk of this disorder in offspring of mothers supplemented with cod-liver oil or 
other vitamin O foods in pregnancy [437 , 439], and decreased incidence of type 1 
diabetes in children supplemented with vitamin O in infancy [435 , 436 , 438 , 442] (see 
Chapter 2, Section 2.5). The Finnish birth cohort study, for example , reported an 
incidence rate ratio (IRR) of 0.12 (95% Cl 0.03, 0.51) for diagnosis of type 1 diabetes 
by the age of one year, comparing regular versus no vitamin O supplementation in the 
first year of life [435] . A recent meta-analysis of four case-control studies further 
concluded that children supplemented with vitam in O in infancy had a 29% lower risk of 
developing type 1 diabetes than those not supplemented [444] (see Chapter 2). These 
studies suggest that vitamin O supplementation may prevent initiation of type 1 
diabetes, and thus accord with the vitamin O-protective hypothesis proposed for th is 
and other organ-specific autoimmune disorders, such as MS [25, 357] . 
This finding for ambient UVR and type 1 diabetes in Austra lia supports the specif ic 
prediction that autoimmune diseases other than MS, such as type 1 diabetes , shou ld 
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show latitude and/or UVR gradients analogous to those seen for MS if these immune 
disorders are similarly influenced by UVR exposure [5]. 
Type 1 diabetes and MS-underlying similarities and common mechanisms? 
Although type 1 diabetes and MS are organ-specific autoimmune disorders with 
disparate target organs and clinical manifestations, there is evidence of underlying 
similarities in epidemiology, as well as genetics and pathogenesis, and possibly similar 
causal influences for these two autoimmune conditions in particular. As reviewed by 
Handel and colleagues, type 1 diabetes and MS may be more similar than any other 
pair of autoimmune conditions. Importantly, most of this similarity appears to be 
attributable to environmental rather than genetic factors, and study of one of these 
autoimmune disorders may therefore illuminate pathogenesis and possible prevention 
of either [211]. 
The present UVR-associated ecological findings for type 1 diabetes that are consistent 
with those for MS in Australia , and with findings for both disorders in the northern 
hemisphere, support the notion of possibly similar aetiological mechanisms for these 
two autoimmune disorders. Individual-level study of such disorders is now required and , 
in particular, the timing of putative environmental exposures, such as UVR, in the life 
course before disease onset [6]. Investigation of possible seasonal and other early life 
influences (seasonal variation being a property of UVR and a feature also of other 
candidate factors such as infections) is now needed , particularly for these disorders in 
the southern hemisphere; therefore , the remainder of this thesis will focus on MS and 
utilise an existing Australian MS dataset for these purposes. 
4.5 Conclusion 
In conclusion , ecological analysis of existing prevalence data from the 1995 NHS has 
demonstrated a regional gradient of type 1 diabetes prevalence within Australia that is 
inversely associated with regional ambient UVR levels . The inverse association with 
UVR is consistent with type 1 diabetes latitudinal grad ients seen in the northern 
hemisphere, and consistent with that found for another organ-specific autoimmune 
disease, MS, in Australia and North America. The finding is cons istent also with photo-
immunological evidence of UVR-induced immunosuppression and suggests a 
beneficial effect of UVR in preventing both these immune-related conditions. Analytical 
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epidemiology studies, investigating risks of type 1 diabetes and MS in relation to other 
facets of UVR exposure in humans, such as seasonal (monthly) variation and critical 
timing of exposure, are now required-these will be explored for MS in the following 
chapters of this thesis. 
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CHAPTER 5 
TIMING OF BIRTH AND MS RISK IN AUSTRALIA: THE 1981 AUSTRALIAN MS 
SURVEY-VERIFICATION OF NUMERATORS FOR TIMING-OF-BIRTH ANALYSES 
5.0 Preface 
The ecological study in Chapter 4 adds to previous findings and suggests that at the 
population level, a gradient of increasing latitude and decreasing UVR is associated 
with an increase in prevalence of organ-specific autoimmune disorders such as MS 
and type 1 diabetes. UVR varies seasonally as well as latitudinally and it would now be 
informative to investigate this latitude-UVR-disease relationship in more detail using 
data at the individual level. 
Additionally, the timing of action of putative environmental determinants, such as UVR, 
on such organ-specific disorders may indicate the nature of these factors (see Chapter 
2). For example, a causal ( or protective) factor that varies seasonally and operates 
around the time of birth may contribute to a seasonal or other temporal birth 'pattern ' 
among these immune disease patients that is not seen in the general population. That 
is, such patients may be born in higher (or lower) frequencies in some months relative 
to others, if the environmental factor is indeed causal or protective and if the critical 
period for action of this factor is close to the time of birth. Such a 'peak', or excess , in 
births of people that subsequently develop the autoimmune disease may be a result of 
seasonally varying environmental factors acting around the time of birth , including UVR, 
temperature and infections. That is, the risk of developing an organ-specific 
autoimmune disease, such as MS or type 1 diabetes, at some time after birth may be 
influenced by the time of the year in which gestation and birth occurs. 
Disease registers of incident cases have frequently been used to examine seasonal 
birth patterns-for example , in psychotic disorders such as sch izophrenia in several 
northern and southern hemisphere countries [639-642]. Neurological autoimmune 
disorders such as MS have also been studied thus , but to a lesser extent than 
schizophrenia and largely in the northern hemisphere [7 , 324 , 643]. 
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In these case-register studies, consecutive patients are typically assessed and 
diagnosed at a disease clinic over a specified period of time (i.e. longitudinal data). An 
example for both schizophrenia and MS is the Danish study by Templer and co-
workers (1992) where 'all schizophrenia patients with onset between 1970 and 1987 
( ~9000 cases) ' and 'all MS patients with onset between 1950 and 1984 ( ~6000 cases) ' 
were registered. They were then compared with the general population born between 
1901 and 1960 ( ~4.5M persons) [321 ]-that is, those born around the same time as 
the cases taking into account time to disease onset (an historical or retrospective 
cohort study). Timing of birth of the disease cases relative to the population controls 
can then be examined and any periodicity existing across the years determined [642]. 
Type 1 diabetes has been similarly studied for temporal birth patterns using incident 
case registers , but nearly all of these studies have been based in the northern 
hemisphere (see Chapter 2). A recent exception is the study by Elliott and colleagues 
on timing of both birth and disease onset in Australia using a national type 1 diabetes 
register, which found no season-of-birth effect [351 ]. 
In the case of MS, a large population-based longitudinal study by Willer and colleagues 
has been completed in the northern hemisphere, where a timing-of-birth pattern has 
been shown using register data from 19 MS clinics in major cities across Canada [324]. 
These 19 registers formed the CCPGSMS, totalling 17,874 Canadian patients, and 
were studied together with additional incident case data from a population study in 
Scotland plus cases derived from death records from the UK (another 11 ,502 British 
patients). Pooled with further Scandinavian data , this large register study showed a 
deficit in MS births in November together with an increase in MS births in May [324] . 
Another register study in British Columbia , Canada confirmed the same May to 
November peak-and-trough pattern in MS-case births there [644]. Willer and 
colleagues (2005) further reported a greater timing-of-birth effect size in the country 
with highest MS prevalence in their study, namely Scotland [324] . 
In Australia , such national registers for MS are not available . However, a 
comprehensive epidemiological survey of known MS cases in Australia was conducted 
by Professor J. McLeod, University of Sydney, NSW, on 30 June 1981 , th is date 
chosen to coincide with a national census. These data provided much deta iled 
epidemiological and clinical information for MS in Austral ia and the southern 
hemisphere, and resulted in several key publications (Table 5.1) that put antipodean 
MS 'on the map'. Although not designed for the present purpose, this national MS 
196 
survey dataset provides an opportunity to examine the timing-of-birth hypothesis for 
MS in the southern hemisphere. Thus, MS has been chosen for detailed individual 
study for the remainder of this thesis. 
How do we best use an existing cross-sectional dataset to analyse timing of birth 
in MS? 
In order to examine a timing-of-birth effect on MS risk, a dataset of MS incidence rates 
by birth month and by birth year is needed, to allow a longitudinal type of study to be 
conducted. It is possible to create such a dataset from McLeod's 1981 MS prevalence 
survey, by linking with available reference-population data, including the Australian 
1981 Census of Population and Housing. That is, the McLeod dataset provides the MS 
cases by birth month and year (the numerators), and the Australian census and other 
available register data will provide the number of births by month and by year for the 
reference population (the denominators), as shown diagrammatically in Figure 5.1. 
The present chapter describes the available unit-record, cases-only, cross-sectional 
1981 MS Survey dataset, focusing on the numerators required for analysis of seasonal 
or other timing-of-birth patterns. For initial exploratory and data-checking purposes , the 
1981 Australian census data from the same day in 1981 will also be used to compare 
MS prevalence rates by survey area, sex and age with those described in the relevant 
McLeod research-group publications given in Table 5.1. Early-, mid- and late-born 
cohorts will be further investigated with the aim of determining the optimal sample for 
timing-of-birth analysis. 
The next chapter, Chapter 6, will then focus on determining appropriate reference-
population denominators for the surveyed MS cases , specifically for timing-of-birth 
analysis. The 1981 Australian Census of Population and Housing will be used , together 
with other Australian births-registration data necessary to supplement the available 
census data (Figure 5.1 ). 
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MS Cases-surveyed by state 30 June 1981 (1981 Australian MS Survey) 
Data available: 
(Chapter 5) 
Date (month and calendar year) of birth (1920 to 1950) 
Place of birth (state) in Australia 
Sex 
Sources of Data for Timing of Birth 
Analysis 
□ Census pop'n 
■ MS cases 
Reference (census) population-census date 30 June 1981 
Data available: 
Unavailable: 
Age in completed years on 30.06.81 
(➔ census year of birth) 
Country of birth 
Sex 
Month and place of birth (state) 
( ➔ to be estimated using supplementary 
Australian births registrations (by state) 
covering same years of birth 
(Chapter 6) 
Figure 5.1: Sources of data for analysis of timing of birth in MS cases. 
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5.1 Introduction-the 1981 Australian MS Survey 
The nationwide MS survey, coordinated by Professor J. McLeod , Discipline of Medicine, 
University of Sydney, was conducted in 1981 throughout Australia , with the prevalence 
day being taken as 30 June 1981, the same day as a national census conducted by the 
ABS. Ascertained MS cases were confirmed by the study neurologists in each survey 
area, and standardisation of procedures was ensured by regular meetings of survey 
coordinators from each area [299 , 645]. 
A primary aim of this original 1981 survey was to determine the relationship between 
MS frequency and latitude within Australia [301 ]. Such a relationship between southern 
latitude and MS prevalence had been suggested by earlier, separate, regional and 
metropolitan surveys in 1961 and was confirmed by the 1981 survey in the McLeod 
group's separate-area publications [301, 645-647] (Table 5.1 ). 
The Australian MS survey further aimed to compare MS prevalence in 1981 with that 
recorded 20 years earlier in 1961 [301, 646-648] (Table 5.1 ). Additional clinical findings 
resulted , this survey being the largest population-based clinical study of MS then 
undertaken [649, 650]. For example, clinical prognoses and survival estimates 
confirmed those found in the northern hemisphere [177] ; for example, a worse 
prognosis for later age of onset [650]. 
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Table 5.1: Selected analyses and findings based on the 1981 MS Survey and 
published by the McLeod research group, 1987 to 2011 
Survey area analysed 
OLD (tropical/subtropical zones) 
Perth SD (WA), Newcastle SDist 
(NSW), Hobart SD (TAS) 
OLD, Perth SD (WA), Newcastle 
SDist (NSW), Hobart SD (TAS) 
WA 
OLD, WA, SA, Newcastle SDist 
(NSW) , Hobart SD (TAS) 
OLD (tropical/subtropical) , WA, 
Perth SD (WA) , SA, Adelaide 
SD (SA) , Newcastle SDist 
(NSW), Hobart SD (TAS) 
Nine regions , Australia & NZ 
NSW (whole state) , SA 
OLD, WA, NSW, SA, Hobart SD 
(TAS) 
Main subject/findings 
1981/1961 prevalence; 1981 
prevalence versus latitude 
difference within OLD 
1981/1961 prevalence and 
incidence; 1981 /1961 
prevalence versus latitude 
relationship 
Clinical differences between 
medium- (OLD) and high-
frequency (3 cities) prevalence 
zones 
1981/1961 prevalence 
Mortality-prevalence-latitude 
relationship (mortality-all 
states and UK) 
1981 prevalence versus latitude 
gradient 
Prevalence-latitude gradient -
tropical OLD/southern NZ 
1981 /1961 prevalence ; 1981 
prevalence versus latitude 
relationship (including all states 
and survey areas in Hammond 
etal. , 1989b) 
Socio-economic factors 
Publication 
reference 
Hammond et al., 
1987 [646] 
Hammond et al. , 
1988a [647] 
Hammond et al. , 
1988b [649] 
Hammond et al. , 
1988c [648] 
Hammond et al. , 
1989a [299] 
Hammond et al. , 
1989b [645] 
Miller et al. , 1990 
[302] 
McLeod et al. , 
1994 [301] 
Hammond et al. , 
1996 [534] 
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Survey area analysed Main subject/findings 
QLD, WA, NSW, SA, Hobart SD Migration study: risk with 
(TAS) respect to age of UK/Ireland 
migrants to Australia (latitude-
gradient differences, 
prevalence , age range) 
QLD, NSW, WA, SA, Hobart SD 1981 Clinical prognostic factors 
(TAS), VIC for disability 
Newcastle SDist (NSW) 1996/1981/1961 prevalence 
and incidence 
Newcastle SDist (NSW) Long-term prognostic survival 
and disability 
* Data in Hammond et al. (2000a) [304) re-analysed in McLeod et al. (2011) [312) . 
SD, statistica l division ; SDist , statistica l district. 
Publication 
reference 
Hammond et al. , 
2000a [304] ; 
McLeod et al. , 
2011 [312]* 
Hammond et al. , 
2000b [650] 
Barnett et al. , 
2003 [246] 
McLeod et al. , 
2007 [177] 
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Survey case ascertainment and diagnostic classification 
All MS cases were recorded and verified by the McLeod research group for the states 
of QLD [646]; WA [648]; NSW (including ACT) and SA [301]; and the Hobart (TAS state 
capital) statistical division (SD) [647] on 30 June 1981. These states and areas are 
shown together with their mean south latitude values (mean latitude based on the 
census-population distribution in 1981 ), and their capital-city latitude values, in Figure 
5.2. The NT and the TAS rural region outside of Hobart were not able to be surveyed, 
because of a lack of neurologists in those regions (J. McLeod, pers. commn). Case 
ascertainment from the state of VIC unfortunately was also incomplete (J. McLeod, 
pers. commn) [534] and so VIC MS cases in the supplied dataset could not be included 
in this analysis. The required adjustments to the dataset to overcome these data 
limitations will be discussed further in Chapter 6. 
10° 
27° 
44° . 
•· 
Indian 
Ocean 
Indian Ocean 
600 
_________ 600 
Latitude {0 S) of survey 
areas 
Mean Capital 
QLD; 25.1 
Brisbane 27.5 
WA; Perth 31.3 31.9 
NSW; Sydney 33.4 33.9 
SA; Adelaide 
SD; Hobart 
(TAS) 
34.9 34.9 
42.8 42.9 
Figure 5.2: Australian states and territories and their capital cities, shown 
together with mean south latitude and capital-city latitude of 1981-surveyed 
areas (mean south latitude as given by Hammond et al., 2000a [304] and based 
on 1981-census state population distribution; NSW includes ACT). (Figure from 
GraphicMaps.com, accessed 23/03/10 WorldAtlas.com.) 
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In this 1981 Australian survey, the MS cases were sourced from the following: 
• Diagnostic indices of major hospitals. 
• Practising doctors: a circular letter was sent to all neurologists, internal medicine 
specialists, neurosurgeons and general practitioners requesting the name, most 
recent address, approximate date of diagnosis and hospital where notes might be 
found, of any patient known to them, either currently or in the past, in whom the 
likely diagnosis was MS. Follow-up procedures included a second mailing of this 
letter if no reply was received to the first, and personal telephone calls in some 
instances. 
• MS Society (state/territory). 
• Department of Veterans' Affairs (State) Diagnostic Index. 
• Chronic care hospitals. 
• Commonwealth statistician: a request was made to notify the survey of any deaths 
from MS subsequent to prevalence day (30 June 1981) [301, 646-648]. 
Details of doctors' records and hospital admission notes were transferred by the survey 
team to a standard protocol form suitable for subsequent entry of its information into a 
computerised data base. Permission for the main surveyors (neurologists) to contact all 
notified patients was obtained and subsequently these patients were all interviewed 
personally and examined in all states except NSW [301 , 646-648]. In NSW, where the 
highest number of patients was notified, it was only possible for the surveyors to 
interview and personally examine 57% of the total. However, almost all of the 
remaining 43% had been examined by another neurologist [301 ]. 
All patients in whom the diagnosis of MS was considered to be correct were then 
classified according to the clinical criteria of Rose et al. (1976) [159] into clinically 
definite, probable or possible groups. Hammond et al. (1987) [646] and the subsequent 
McLeod group's publications stress that no laboratory results (e.g. CSF analysis , 
evoked-potential studies or brain scans) were considered in the allocation of individual 
patients to particular diagnostic categories. The disability status of the patients on 
prevalence day was assessed according to the Kurtzke disability status scale (DSS) 
[651]. 
For case validation , a 10% sample of the protocol forms was selected on an 
alphabetical basis and submitted to an independent neurologist arbiter for assessment 
of the correctness of the diagnosis and of the diagnostic classification into which each 
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patient had been placed [301, 646-648]. In NSW, this 10% sample was taken from the 
57% in whom a personal interview and examination had been possible [301 ]. In all 
cases, the veracity of diagnosis of MS was not disputed but the category of the disease 
was reclassified in 6 to 30% of cases [301 ]. 
Survey data variables 
The resulting unit-record 1981 MS-case dataset (as received for this thesis by this 
candidate) comprised the following survey information: 
• Survey ID number (five-digit number, the first digit indicating the survey area, for 
example, 20,001 ... =NSW; 40,001 ... =OLD). 
• Name; place of residence (Australian postcode or overseas code); day, month and 
year of birth; place of birth (postcode or overseas code); sex; age left school; 
highest level of education. 
• Residence history from birth to MS onset. 
• Family history: parental birthplaces; race; whether twin; total number siblings and 
place in family; parental ages at (case's) birth; whether cat or dog in house. 
• Onset of illness: month and year of onset (first symptoms); residence at onset; 
whether first symptoms multiple or single (and which first symptom). 
• Source of case information. 
• Postcode on each of two intended prevalence dates, P 1 ( 1976) and P2 ( 1981) 
[301 ]. 
• Status and diagnosis on P1 and P2: Two sets of clinical variables for the two 
intended prevalence dates were included in the dataset. Variables included : 
diagnostic category; clinical course (e.g. relapsing-remitting and secondary 
progressive v. primary progressive) ; clinical type (further clinical subcategories, 
seven types); grade of stair disability (zero to four); symptoms (Kurtzke grade zero 
to five or six) for each of pyramidal , cerebellar , brain stem , sensory, bowel and 
bladder, visual , mental or other disability; Kurtzke DSS (zero to nine). 
• Date and postcode of death (if patient had died prior to P1 or P2) . 
Table 5.2 lists the variable names in the dataset as received , and distinguishes those 
variables that were primary (i.e. from the original patient interview) and those that had 
been derived by subsequent McLeod group investigators for various other analyses . 
204 
Table 5.2: 1981 MS Survey dataset: original and derived variables and their 
description (variables used in this thesis, for either case verification or analysis, 
shown in bold) 
Data category Variable names 
ORIGINAL (primary) data: 
ID survey no. 
Name, 
residence 
svn1 
surname1, surname2, 
frstnam 1, pc 
Date & place of dd, mm, yy, pcbirth, 
birth, sex sex 
Education agelsch, hied 
Residence pcres 1- pcres 15 
history ( <onset) 
Parents' mpc, fpc 
birthplace 
Race race 
Family twin, sibs, fampl , 
information matage, patage 
Pets 
Onset details 
First symptoms 
Information 
source 
catdog , cat, dog 
mmonset, yyonset, 
pconset 
fstsymm , fstsyms 
srcIn 
Prevalence day pcp1; symp1 
P1 (1976) 
P1 diagnosis diagctp1, clintyp1, 
clincrp1 
Variable description 
Survey (case) number identifier 
Surname name, first name; postcode of 
residence (in Australia) 
Day, month and year of birth; postcode of 
birth; sex 
Age left school; highest education 
Postcode of residence 1-15 years prior 
to onset 
Postcode of birth of mother, father 
Race (Aboriginal or not) 
Whether twin; total number of siblings ; 
place in family ; age of mother, father, 
when born 
Whether cat and/or dog in household 
Month , year and postcode of residence 
at onset 
Whether multiple first symptoms; which 
single first symptom 
Source of information 
Postcode on prevalence day P1 ; whether 
symptoms on prevalence day P1 
Diagnostic category, clinical type and 
clinical course on P1 
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Data category 
P1 clinical info. 
P1 death info. 
Variable names 
stdisp1 , pyram1 , 
cerbp1 , bstemp1 , 
sensp1 , bowelp1 , visp1 , 
mentp 1, otherp 1; ku rp 1 
ddiep1, mdiep1, 
pcdiep1 
Prevalence day pcp2; marp2 
P2 (1981) 
P2 diagnosis 
P2 clinical info. 
P2 death info. 
diagctp2, clintyp2, 
clincrp2 
stdisp2 , pyram2 , 
cerbp2 , bstemp2 , 
sensp2 , bowelp2 , visp2 , 
mentp2, otherp2 ; kurp2 
ddiep2, mdiep2, 
pcdiep2 
DERIVED (by subsequent investigators) data: 
Residence yrrs 1- yrrs 15 
history ( <onset) 
Age on P1 , P2 age 76 , age81 
dates 
MS on P1 , P2 ms81 , ms76 
dates 
Age of onset ageonset 
Duration of MS dur76 , dur81 
Residence on statep 1, statep2 
P1 , P2 dates 
Ascertainment instap1 , instap2 
information 
New ID newid 
Variable description 
Symptoms on P1 (and Kurtzke grades): 
stair disability, pyramidal , cerebellar, 
brainstem, sensory, bowel and bladder, 
visual , mental , other; Kurtzke DSS on P1 
Day, month and postcode of death (if 
dead on P1) 
Postcode on prevalence day P2 ; marital 
status on prevalence day P2 
Diagnostic category, clin ical type and 
clinical course on P2 
Symptoms on P2 (and Kurtzke grades): 
stair disability, pyramidal , cerebellar, 
brainstem, sensory, bowel and bladder, 
visual , mental , other; Kurtzke DSS on P2 
Day, month and postcode of death (if 
dead on P2) 
Residence history pre-onset in number of 
years 
Age (years) in 1976 and 1981 
Whether MS had been diag nosed by 
1981 and/or 1976 
Age at onset 
Duration of MS in 1976 and/or 1981 
State/territory of res idence on P1 and P2 
Whether in state of ascerta inment on P1 
and P2 
New? ID number 
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Data category Variable names 
Birth in Australia ausborn 
Residence 
P2 
on placep2 
5.2 Methods 
Variable description 
Whether born in Australia 
Place of residence in 1981, P2 
5.2.1 Initial treatment of national case data 
The 1981 MS dataset, as received, comprised identified case data (n=3,277) from the 
states of OLD, WA, NSW (including ACT), SA and VIC, and the Hobart SD in the state 
of TAS. Data records were first de-identified by removing names, and the unique 
survey ID numbers used for individual identification thereafter. 
Identification of dead-in-1981 cases 
Because the dataset was found to contain some records of deaths prior to the 1981 
prevalence day (such cases having been part of the dataset for earlier prevalence-
survey dates, Table 5.2), these cases needed to be identified and excluded from the 
current analyses. 15 The 143 cases dead in 1976 and a further 27 cases dead by 1981 
were identified and a new data variable 'alive81' generated for the cases who were 
alive on 30 June 1981 (n=3, 107) (Table 5.3). 
15 Prevalence in 1981 is defined as the ratio of persons with an acceptable diagnosis of MS that are living 
in the defined area on 30 June 1981 to the total number of persons in the population of the same area on 
the same day [646-648]. Therefore , inclusion of previously surveyed and now dead (in 1981) MS cases 
would have over-estimated the 1981 prevalence. 
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Table 5.3: 1981 MS Survey dataset. Further variables (and their coding) derived 
specifically for the purposes of this thesis 
Variable description 
Confirmation of alive in 1981 
Confirmation of MS diagnosis in 1981 
Residence in 1981 (state) 
Birthplace in Australia (state) 
New generated variables (coding) 
alive81 (1,0) 
diagMS81 (1,0) 
state81 (2-7)* 
statborn (2-7, 9l 
* 'state81 ' coded as 2, 3, 4, 5, 6 or 7, these codes being the first digit of the 4-digit state postcodes and 
thus denoting the states of NSW/ACT, VIC , OLD, SA, WA and the area of Hobart SD in the state of TAS , 
respectively . 
# 'statborn ' coded as for 'state81 ', with the additional '9' denoting NT born . 
Verification of 1981 MS diagnosis 
The diagnostic category variable 'diagctp2' (Table 5.2) comprised five main categories 
( coded one to five), of which only the first three-namely 'definite ', 'probable' and 
'possible'-were considered by Hammond, McLeod and colleagues to constitute 
'diagnosed MS' [301 , 646-649]. A new variable 'diagMS81' was generated (Table 5.3) , 
comprising just the diagnostic categories one to three, the first two of these categories 
('definite' and 'probable') constituting 88% of the diagnosed cases in the final dataset 
used. The few cases with missing 'diagctp2 ' data were considered individually (one 
case from SA and three cases from VIC) and were retained only if all three other main 
clinical variables (namely, clinical course, clinical type and Kurtzke DSS) were recorded 
for 1981 . At the same time , it was also ensured that the final total sample numbers by 
survey area agreed with those published by the McLeod group [301 , 646-648]. A total 
of 2,912 living cases in the supplied dataset were thus verified as having been 
diagnosed with MS in 1981. 
Survey area-verification of place in 1981 
Although this thesis study will be primarily concerned with place of birth of each MS 
case rather than place of ascertainment (in order to examine any latitudinal effect on 
timing of birth of MS-discussed further in Chapters 6 and 7) , it was necessary to 
examine also where each MS case was residing and thus surveyed in 1981 , because 
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some of the states or areas were insufficiently ascertained or not surveyed at all (i.e. 
VIC, NT and non-Hobart TAS) and adjustments would be required to allow for this. A 
'state81 ' variable was generated (Table 5.3) to describe the place (i.e. survey area, 
usually state) in Australia where each MS case was resident in 1981 , using data from 
the relevant residence postcodes together with the survey ID number (whose first digit 
indicated original survey area). Where there were inconsistent or missing residence 
data, the McLeod group's published total sample numbers by survey area were used 
as the definitive guide [301, 646-648]. 
Exclusion of VIC cases 
As outlined in Section 5.1, cases surveyed in the state of VIC (i.e. 'state81 '=3) were 
then necessarily removed from the dataset. 
Adjustment for incomplete ascertainment of VIC, NT and non-Hobart TAS 
Because VIC, NT and non-Hobart TAS were not able to be surveyed in 1981 (J. 
McLeod, pers. commn), adjustments to the dataset were required to overcome this 
data limitation for timing-of-birth analysis. This was achieved by adjusting the 
reference-population denominators in particular and is described fully in Chapter 6 (see 
Section 6.2.3). 
Region of birth (state) 
A 'statborn' (denoting state born) data variable was generated (Table 5.3) from the 
original 'postcode of birth ' variable to enable examination of the effect of region of birth 
(and its mean latitude) on the timing of birth of Australia-born cases (these cases 
denoted 'ausborn ' in the dataset). 
The 'ausborn ' variable in the dataset, which had been generated by previous 
investigators to denote whether cases were born in Australia or elsewhere (see Table 
5.2), was also used to help determine inconsistencies in coding of the 'postcode of birth ' 
variable. For example , this variable indicated that double-digit postcodes, as opposed 
to the usual Australian four-digit postcodes, denoted an overseas country of birth. Also , 
single-digit postcodes one to six occasionally apparent in the dataset, but only in 
Australia-born cases were determined as being state codes based on an early ABS 
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system of denoting the states NSW to TAS one to six in order of their population sizes 
(J. Wall, ABS, pers. commn). 
5.2.2 Completion of NSW data-addition of missing records 
When the supplied dataset was found to contain only the 57% of the NSW sample that 
had been followed up and fully verified by the survey neurologists [301], the remaining 
43% of NSW data needed to be separately obtained after assurance by the surveyors 
that all of these remaining cases had indeed been diagnosed with MS in 1981 (J. 
McLeod, pers. commn). Many (but not all) of the more recent McLeod group 's 
publications-for example McLeod et al. (1994) [301] and Hammond et al. (2000a, b) 
[304, 650] (Table 5.1 )-had examined and described the complete NSW sample, 
including this 'missing ' 43%. 
However, unlike the rest of the supplied dataset, the supplementary (43%) NSW 
sample lacked some data variables required, particularly for the timing-of-birth 
analyses; for example, month of birth and place of birth. To gain these data, the original , 
hard-copy patient files of the 43% NSW sample (831 cases, including 11 from ACT) 
were accessed by this candidate at the University of Sydney's Discipline of Medicine 
department; these clinical case notes then provided the required information for the 
majority ( ~ 75%) of the supplementary cases. For the remainder for which birth-date 
and/or birthplace details were missing in the clinical notes (~25%), a request was then 
made to the NSW Registry of Births, Deaths and Marriages for this information , using 
full names and sex as the main search parameters . 
The NSW/ACT supplementary data in Microsoft Excel 2000 (n=831 cases) were then 
incorporated into the overall numerator dataset in the statistical analysis program Stata 
8.0 (release 8.0 , 2003; Statacorp , College Station , Texas) . To aid later identification , 
these records were also given a unique prefix to their (new) ID survey numbers. 
5.2.3 Prevalence comparisons with previous 1981 MS survey 
publications 
After cleaning and completing the unit-record case dataset, the data were summarised 
using available 1981 census totals in order to obtain basic prevalence estimates by 
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survey area , sex, age group and year-of-birth cohort. Where applicable , these 
prevalence estimates were then compared with those published by the McLeod 
research group, these previous results generally being for just a few, or even a single, 
survey area per publication (Table 5.1 ). All MS cases surveyed , whether Australia- or 
overseas-born , were thus included in these earlier, and the present, estimates. 
5.2.4 Consideration of dataset numerators for main analysis 
Because the 1981 MS dataset was originally cross-sectional , having been sampled at 
just one point in time, both numerator case data and the (reference) census-population 
data were finally considered in detail by decade of birth , in order to investigate any 
inherent biases and any possible need for restriction of the data for timing-of-birth 
analysis . 
5.3 Results 
5.3.1 Numerator dataset cleaning-summary 
Including the 831 supplementary NSW/ACT cases , all of whom were confirmed as alive 
in 1981 and diagnosed with MS (J. McLeod , pers . commn), 3,938 of the total 4,086 
cases of the dataset were verified as alive on the prevalence day 30 June 1981 and 
coded as 'alive81 '=1. Living cases numbering 3,743 were then confirmed as having 
been diagnosed with MS in 1981 ('diagMS81 '=1 ). After exclusion of seven cases 
because their place of residence in 1981 ('state81 ') could not be confirmed , a total of 
3,736 MS cases remained (Table 5.4). 
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Table 5.4: Number of MS cases in the initial (cleaned) 1981 MS Survey dataset by 
survey area. (Corresponding sample numbers used by the Mcleod research 
group, and their relevant publications, given in parentheses) 
Survey area 
QLD 
WA 
NSW/ACT 
SA 
VIC 
Hobart SD, T AS 
Total 
TOTAL excluding VIC 
1 Hammond et al. (1987) [646) . 
2 Hammond et al. (1988c) [648) . 
3 McLeod et al . (1994) [301 ]. 
4 Hammond et al. (1988a) [647) . 
Number of MS cases 
420 ( 420) 1 
318 (318 )2 
1907 (1907)3 
378 (378)3 
588 
125 (125)4 
3736 
3148 
An initial numerator dataset of 3,148 MS cases resulted after exclusion of the 588 
cases identified as from the VIC survey area in 1981 ('state81 '=3). The dataset 
comprised the same sample numbers as given by the McLeod group for the total MS 
cases in the separate survey areas [301 , 646-648] (Table 5.4) and at this stage 
included MS cases born in Australia and elsewhere. 
5.3.2 Basic statistics of MS cases 
Total number of cases and prevalence by sex 
The total 3,148 MS cases comprised 2,208 females and 940 males (70.14 and 29.86%, 
respectively) (Table 5.5) , giving a female to male case ratio of 2.35. Crude prevalence , 
defined as the ratio of persons with an acceptable diagnosis of MS living in the defined 
area on 30 June 1981 to the total number of persons in the population of the same 
area on the same day [646-648] , was calculated by sex using survey area popu lation 
numbers from the 1981 Australian Census (Table 5.5) . 
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Table 5.5: Total survey population and 1981 MS prevalence by sex 
Sex 
Males 
Females 
Total 
Number MS cases 
940 
2208 
3148 
Survey population# Prevalence (per 
(1981 Census) 100,000) 
5,174,328 18.2 
5,195,641 42.5 
10,369,969 30.4 (30.4 *) 
* Adjusted for sex using 1981 Australian census population . 
# Note: Survey population totals are for the surveyed areas, QLD, WA, NSW/ACT, SA and Hobart SD 
(TAS), only. 
Year of birth and age range 
Year of birth ranged over seven decades, from 1901 to 1968 for males (Figure 5.3) and 
1897 to 1969 for females (Figure 5.4 ). Equivalent age in June 1981 , expressed in 
completed years on the census date, ranged from 11 to 84 years for females and 12 to 
80 years for males. 
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Figure 5.3: Year-of-birth distribution for males in 1981 MS Survey (n=940 cases). 
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Figure 5.4: Year-of-birth distribution for females in 1981 MS Survey (n=2,208 
cases). 
MS prevalence by survey area 
Prevalence (both crude and age-standardised to the 1981 Australian population) is 
shown by survey area , together with corresponding prevalence estimates given by the 
relevant McLeod group's publications , in Table 5.6. 
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Table 5.6: MS prevalence (age-standardised to 1981 Australian population, In 
parentheses) by survey area 
Survey Mean+ Number Survey Prevalence Prevalence 
area latitude MS population per 100,000 per 100,000 by 
05 cases (1981 McLeod group 
Census) 
OLD 25.1 420 2,295,123 18.3 (18.6) 18.3 (18.6) 1 
WA 31.3 318 1,273,624 25.0 (25.9) 25.0 (25.9)2 
NSW/ACT 33.4 1907 5,347,826 35. 7 (35.2) 37.2 (36.6)3 # 
SA 34.9 378 1,285,033 29.4 (28.8) 29.4 (28.8)3 
Hobart SD 42.8 125 168,363 7 4.2 (75.6) 74.2 (75.6)4 
(TAS) 
TOTAL 3148 10,369,969* 30.4 (30.3) 
+Mean latitude of survey area in decimal degrees as given by Hammond et al. (2000a) [304], calculated 
from the population distribution by SD in the 1981 Census. 
1 Hammond et al. (1987) [646] . 
2 Hammond et al. (1988c) [648] . 
3 McLeod et al. (1994) [301] . 
4 Hammond et al. (1988a) [647] . 
# NSW/ACT prevalence (both crude and age-standardised) given by McLeod et al. (1994) [301] for 'NSW' 
is consistent with the ACT population total not having been included in the denominator. 
* 'Total ' survey population is total of areas surveyed . 
Age-standardised MS prevalence increased with increasing mean south latitude from 
survey areas OLD to Hobart SD (TAS) (Figure 5.5). This trend in prevalence from the 
north to the south of Australia, here estimated over all four states , OLD, WA, NSW/ACT, 
SA and the fifth state city SD, Hobart (TAS), is consistent with similar trends shown 
separately by Hammond , McLeod and colleagues for: (i) within the state of OLD [646], 
(ii) between three Australian state cities , Perth (WA), Newcastle (NSW) and Hobart 
(TAS) [647] and (iii) overall among three states (OLD, WA and SA) and two other state 
cities (Newcastle and Hobart) [299 , 645]. McLeod et al. (1994) later reported MS 
prevalence for all of the survey areas , including NSW, and reported age-standardised 
prevalence for the southernmost Hobart SD (TAS) survey area (75.6/100,000) as four 
times higher than that of the northernmost state surveyed , OLD (18.6/100,000) [301 ]. 
Consistent with this , Hammond et al. (2000a) reported a prevalence ratio of 3.84 (95% 
Cl 3.05, 4.83) for TAS-resident compared with OLD-resident persons for just the 
Australia-born portion of the MS survey population [304]. 
215 
......... 
0 
ro 
00 
O<D 
0 
0 
0 
,.-
L. 
Q) 
Q. 
..__.. 
Q) 0 
uV 
C: 
Q) 
ro 
> Q) 
L. 
Cl. 
(J) 0 
2N 
0 
• 
25 
OLD 
30 
• 
• 
35 
Latitude ( degrees s) 
WA NSW SA 
/ACT 
40 
• 
45 
Hobart SD 
(TAS) 
Figure 5.5: Mean latitude of survey area and age-standardised prevalence of MS 
(p=0.029 for linear regression; n=3, 148 cases). 
Prevalence by survey area and sex 
MS prevalence by both survey area and sex is shown in Table 5.7, and Figure 5.6. 
Table 5.7: MS prevalence (age-standardised to 1981 Austral ian population, In 
parentheses) by survey area and sex 
Survey area* MS prevalence (per 100,000) 
Males (n=940 cases) Females (n=2,208) 
OLD 11 .3 (11.6) 25.4 (25.8) 
WA 12.0 (12 .5) 38.2 (39.5) 
NSW/ACT 21 .6 (21 .3) 49.6 (48.9) 
SA 18.1 (17.7) 40.5 (39.6) 
Hobart SD (TAS) 53.2 (54.5) 94.6 (95.8) 
*Survey areas listed in order of increasing mean south lati tude (see Table 5.6) 
Figure 5. 7 indicates a linear relationship between mean south latitude-and age-
standardised MS prevalence in both sexes. 
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Figure 5.6: Age-standardised MS prevalence by survey area and sex (n=3, 148 
cases). 
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Figure 5. 7: Age-standardised MS prevalence by mean latitude of survey area and 
sex (p=0.024 and 0.043 for linear regressions for females [n=2,205] and males 
[n=940], respectively). 
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Age-specific prevalence-MS case data by (10-year) age group 
Age-specific prevalence of MS for the total survey area is given in Table 5.8, using ten-
year age groups as used by the McLeod research group for the survey areas 
separately [301 , 646-648]. However, for consistency with subsequent analyses in this 
thesis, corresponding years of birth for each age group have been calculated and are 
here expressed in 'census years ' as defined in the table footnote. The number of MS 
cases has been apportioned to these years of birth (and thus to the corresponding age 
groups) using individual data on their month of birth-that is, whether born in the 
January to June or July to December half-year periods. Age-standardised prevalence 
for the overall survey population, adjusted to the age structure of the total Australian 
census population in 1981, is also shown . 
Table 5.8: Age-specific MS prevalence in 1981 (n=3, 148) 
Age Year-of-birth group# Number Survey 
group of MS population 
(years+) cases (data from 
1981 Censust) 
0-9 Ju I y 1 9 71-J u n e 1 9 81 0 1,680,309 
10-19 July 1961-June 1971 29 1,798 ,196 
20-29 July 1951-June 1961 346 1,728 ,980 
30-39 July 1941-June 1951 740 1,545 ,420 
40-49 July 1931-June 1941 752 1,097 ,364 
50-59 J u I y 1 9 21-J u n e 1 9 31 742 1,057,326 
60-69 July 1911-June 1921 435 816 ,029 
70+ Before July 1911 104 646,345 
Total 3148 10,369,969 
Prevalence 
(per 100,000) 
0 
1.6 
20.0 
47.9 
68.5 
70.2 
53.3 
16.1 
30.4 
(30.3*) 
+ Age in completed years on census date 30 June 1981 . 
#year of birth calculated in 'census years ' spann ing 1 July to 30 June , because the Australian census 
records only 'age in completed years on 30 June 1981 ' rather than actual year of birth . For example, 'age 
10 (completed) years ' on 30 June 1981 equates to a date of birth between July 1970 and June 1971 
(inclusive) census year. Similarly, 'age 19' on 30 June equates to a date of birth between July 1961 and 
June 1962 census year. Therefore , the years of birth for the 10 to 19 years age group span the 10 census-
year period July 1961 to June 1971 (inclusive). (Similarly, the years of birth for the age 20 to 29 years age 
~roup span the 10 census-year period July 1951 to June 1961 [inclusive], and so on .) 
Census total for Hobart SD as given by Hammond et al. (1 988a) [647] . 
*Prevalence age-standardised to the 1981 Austra lian census population . 
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For the total survey area, highest MS prevalence was seen in the 40 to 49 and 50 to 59 
age groups, consistent with the McLeod group's results for the survey areas separately 
[301 , 646-648]. The overall age-standardised prevalence was 30.3/100,000. 
Age-specific prevalence by sex 
Age-specific prevalence for MS cases is shown by sex in Table 5.9, together with 
overall prevalence, both crude and adjusted for age structure of the 1981 total 
Australian population. Figure 5.8 illustrates this generally found clear difference in 
prevalence by sex, particularly in the mid-age groups [301 , 646-648, 652]. 
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Figure 5.8: Age-specific MS prevalence by sex (data from Table 5.9; n=2,205 and 
940 for females and males, respectively). 
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Table 5.9: Age-specific MS prevalence by sex 
Age 
group 
(years+) 
0-9 
10-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70+ 
Total 
Year-of-birth group 
MS 
cases 
July 1971-June 1981 0 
July 1961 - June 1971 8 
July 1951-June 1961 72 
July 1941 - June 1951 214 
July 1931-June 1941 246 
July 1921-June 1931 238 
July 1911 - June 1921 130 
Before July 1911 32 
940 
+ Age in completed years on census date 30 June 1981 . 
# Census years , as defined in Table 5.8. 
Males 
Survey Prevalence 
population ( /100,000) 
860,560 0 
919,983 0.9 
869,880 8.3 
784,161 27.3 
562,508 43.7 
533,913 44.6 
386,024 33.7 
257,299 12.4 
5,174,328 18.2 (18.1*) 
*Prevalence age-standardised to 1981 Australian census population . 
MS 
cases 
0 
21 
274 
526 
506 
504 
305 
72 
2208 
Females 
Survey Prevalence 
population ( /100,000) 
819,749 0 
878,213 2.4 
859,100 31.9 
761,259 69.1 
534,856 94.6 
523,413 96.3 
430,005 70.9 
389,046 18.5 
5,195,641 42.5 (42.4 *) 
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Prevalence by survey area and birth cohort 
To consider the effects of both survey area and age structure together, the age range 
of MS cases (on 30 June 1981) was considered as three cohorts , namely early-born 
(age 60+ completed years [on census date] , i.e. born before July 1921 ), mid-born (age 
30-59 completed years , i.e. born between July 1921 and June 1951 [inclusive]) and 
/ate-born (age up to 29 completed years , i.e. born after June 1951 ). Crude and age-
standardised MS prevalence by both survey area and birth cohort are given in Table 
5.10. 
Table 5.10: MS prevalence (age-standardised to 1981 Australian population, In 
parentheses) by survey area and birth cohort (n=3, 148) 
Survey area* MS prevalence (per 100,000) 
Early-born cohort Mid-born cohort Late-born cohort 
(born <July 1921) (born July 1921- (born > June 1951) 
June 1951) 
QLD 21.2 (21.1) 38 .6 (38. 7) 3.7 (3.7) 
WA 34.8 (35 .0) 52 .9 (53.4) 3.9 (3 .9) 
NSW/ACT 41.4 ( 41 .1) 68 .7 (68.6) 9.9 (9.8) 
SA 39.7 (39.8) 59.0 (58 .4) 4.9 (4.8) 
Hobart SD (TAS) 105.4 (105.7) 148.4 (148.2) 16.2 (15.9) 
*Survey areas li sted in order of increasing mean south latitude (see Tab le 5.6). 
MS prevalence in general was highest in the mid-born cohort in all survey areas 
(Figure 5.9). As shown in Figure 5.10, age-standardised MS prevalence increased 
linearly with increasing mean south latitude of the survey areas in both early- and mid-
born cohorts (p=0.024, 0.029 , respectively , for linear regress ion ). Although the late-
born cohort shows a slight increase in prevalence with mean south latitude in Figure 
5.10 , th is was not statistical ly sign ificant (p=0.072). 
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5.3.3 Numerators for timing-of-birth analysis 
To assess the suitability of this dataset for timing-of-birth analysis, the numbers of both 
the MS cases and the total survey population at risk were considered separately, by 
decade of birth , as illustrated in Figure 5.11. 
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Figure 5.11: Distributions of MS cases and total survey (census) population by 
decade of birth . (*Decades of birth each span July to June in accordance with 
census years, for example, July 1910 to June 1920 but, for convenience for 
subsequent analysis, now differ by a shift of one year from the year-of-birth 
periods in Tables 5.8, 5.9 and 5.1 0; decades thus correspond with age [in 1981] 
of one to 10, 11 to 20, 21 to 30 ... 61 to 70 and 71 + completed years.) 
While the total survey (census) population distribution follows what might be expected 
as a typical 'survival curve', the MS cases in Figure 5.11 suggest a decrease in surviva l 
of MS cases compared with the total at-risk survey population in the early birth 
decades (in the left-hand part of the figure) , particularly in those born prior to mid-1910 
(71 + age group). That is , wh ile the MS cases to the left of the figure can be assumed to 
have all reached MS onset if that was going to occur, there appears to be a slight 
survival difference in these earliest birth decades (i. e. possible survival bias). 
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However, in the right-hand part of the figure the large differences between the 
distributions of the MS cases and the total survey population are likely to be related 
more to disease onset than to survival , given that onset of MS can occur up until the 
mid-years of life (age of onset ranges from eight to 60 years of age in this current 
dataset) and that MS overall does not appear to cause substantial mortality [177 , 178, 
653] . That is, there is a very clear difference in frequency of MS cases compared with 
the total survey population in the later birth decades in Figure 5.11-that is , fewer MS 
cases than expected-particularly in those born after mid-June 1950 (i.e. those who 
are one to 30 completed years of age in 1981 ). Some at-risk survey-population persons 
born in these decades are thus likely to be 'future ' MS cases that have not yet been 
diagnosed by the date of the survey (i.e. diagnosis bias). 
Therefore, it was decided to exclude both early- and late-born MS cases from the 
subsequent timing of birth analyses (in Chapter 7) and include only the three central 
birth decades in Figure 5.11 , so that these possible 'diagnosis' and 'survival ' biases 
could be minimised . The aim was to compensate to some extent for the inherent 
limitations of the available cross-sectional dataset, while still retaining sufficient case 
numbers for analysis. 
Restriction to years of birth 1920 to 1950 and to Australia born 
Restriction to years of birth 1920 to 1950 
For the purpose of timing-of-birth analysis in Chapter 7, MS cases born in the three 
central birth decades in Figure 5.11 (from July 1920 to June 1950 census years ) were 
retained , together with the remaining half census year at each end of th is period in 
order to maximise the available sample. That is , the MS-case sample used comprised 
those born during the complete calendar years 1920 to 1950. Thus , exclud ing ea rl y-
born (before January 1920) and late-born (after December 1950) MS cases , the 
number of MS cases with their year of birth with in the restri cted 1920 to 1950 pe riod 
was 2,322 (73.8 % of the available total sample of 3,148). 
Restriction to Australia born 
For subsequent analysis , and particularly for the effect of birthplace on timing of birth , 
only the MS cases born in Australia were able to have relevant population month-of-
birth denominators derived (see Chapter 6) for the purpose of answering the specific 
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research questions posed for this thesis (see Chapter 7). MS cases not born in 
Australia (n=680 [29.3% of those born 1920 to 1950]) or of unknown birthplace (n=10 
[0.43%]) were therefore omitted from the cleaned and year-of-birth-restricted 1981 
dataset, reducing the number of MS cases for timing-of-birth analysis to 1,632. The 
resulting number of Australia-born MS cases with their year of birth within the restricted 
1920 to 1950 period is shown by sex and survey area in Table 5.11. 
Table 5.11: Number of MS cases born in Australia between January 1920 and 
December 1950 (inclusive), by sex and survey area 
Survey area Number of MS cases born 1920 to 1950 in Australia 
Males Females Total 
QLD 80 161 241 
WA 28 110 138 
NSW/ACT 292 686 978 
SA 61 147 208 
Hobart SD (T AS) 26 41 67 
Total 487 1145 1632* 
*Month of birth was missing for one MS case from 1920 to 1950 Australia-born cohort , leaving 1,631 MS 
cases available for timing-of-birth analysis . 
Summing up, the January 1920 to December 1950 year-of-birth period , including ages 
30 to 61 completed years in 1981 (and approximating-to within one year-the 'mid-
born' cohort of total MS cases shown in Table 5.10), has been chosen for analysis , to 
maximise the Australia-born sample while minimising probable diagnosis and survival 
biases evident in Figures 5.11 (for total sample) and 5.12 (for Australia-born cases) . 
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Figure 5.12: Year-of-birth distribution of Australia-born MS cases in the 1981 
dataset (n=2,214), indicating final sample of 1920- to 1950-born cases used in 
timing-of-birth analysis (shown bounded by dashed lines; n=1,632). 
The resulting 1920- to 1950-born cohort with known month of birth (n=1,631 ), required 
for timing-of-birth analysis, comprised 73. 7% of the total 2,214 Australia-born cases in 
the cleaned numerator dataset (Figure 5.12). The mean age of onset of MS, calculated 
from year-of-birth and year-of-onset data for this 1920- to 1950-born cohort (aged 30 to 
61 completed years in June 1981 ), was 32.9 + 9.0 (s.d.) years. Of these MS cases , 85% 
were classified as relapsing-remitting (RRMS) from onset (i.e. 15% were primary 
progressive). 
5.4 Discussion 
The 1981 MS Survey by the McLeod group of researchers contributed much 
epidemiological and clinical information to the study of MS both in Austral ia and 
internationally (Table 5.1 ). As summarised by McLeod et al. (1994 ), MS in Australia is 
clinically remarkably similar to MS in predominantly white populations in the northern 
hemisphere [301 ]. Females are affected about twice as often as males and the age of 
onset is mostly between 20 and 50 years. About 80% of patients have an exacerbating-
(i.e. relapsing-)remitting clinical cou rse in the early stage of their disease, the remaining 
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20% having a progressive course from onset [301, 649]. The mean duration of disease 
from onset to death is more than 25 years, about 45% of patients having only mild to 
moderate disability after a period of 15 years. The clinical profile appears to be very 
similar throughout Australia, although male patients in the hotter climate of OLD show a 
greater tendency to develop progressive disease, and hence more disability, than 
those in more southern states such as TAS [649]. 
By using and extending (in Chapters 6 and 7) this existing, well-coordinated Australian 
survey, more information on possible environmental factors causing MS is now 
possible. However, the survey dataset in its original form required initial checking and 
verification of the numerator data (described in this chapter) as well as subsequent 
derivation of suitable denominators (described in Chapter 6) to maximise the 
usefulness of the dataset for this current thesis study. The main purpose of this chapter 
was to describe how a comprehensive national survey of MS patients in 1981 was 
prepared in order to construct (in Chapter 6) a longitudinal dataset suitable for analysis 
(see Chapter 7) of timing of birth in these MS cases. 
The verification and organisation of the MS cases in the unit-record dataset, as 
received, has been detailed in Sections 5.2.1 and 5.2.2 of this chapter. Cases present 
on the earlier prevalence day, P1 , in 1976 and who had died by P2 , 1981 , were 
removed. Diagnostic categories as defined by the McLeod research group were 
retained and those cases in other categories were removed from the dataset. Where 
some diagnostic data were missing , it was possible to make a judgement about 
inclusion or exclusion of these few cases by using other clinical data variables. In 
addition , several NSW cases found to be missing from the dataset (831 cases , 43% of 
the total NSW/ACT sample) were fortunately able to be accessed as original , hand-
written clinical files at the University of Sydney. Where this supplementary information 
required for analysis of timing of birth was still incomplete, particularly for month and 
place of birth (approximately 25% of the 831 cases) , the missing parameters were 
obtained from the NSW Registry of Births , Deaths and Marriages. The final case 
numbers were then consistent with those reported for each survey area by the McLeod 
group in their relevant publications (Table 5.6). 
The summary prevalence data in this chapter have been given for comparison with 
previous McLeod group findings for individual survey areas , and 1981 census totals 
have been used as denominators here. It should be noted that these prevalence data 
include all persons in Australia on the census date, whether born in Australia or 
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overseas, as given in most of the McLeod group publications listed in Table 5.1. The 
new estimates by survey area given in this thesis (Table 5.6) , for example, are thus 
comparable to those in the publications for the survey areas separately; however, the 
discrepancy for prevalence in the NSW/ACT survey area appears to be a result of the 
ACT population not having been included in the denominator by McLeod et al. ( 1994) 
[301 ]. Most importantly, this chapter reinforces the existence of an overall association 
between latitude of residence and prevalence of MS in Australia reported in the 
McLeod group's summary publications [299, 304], and corroborates the statement 
made by McLeod and colleagues (1994) that MS prevalence in residents of Hobart SD, 
TAS is four times higher than that in OLD residents [301 ]. Consistent with this, a four-
fold difference in incidence of FOE (a precursor to MS) from Brisbane (OLD) to TAS 
has been found in the 'Ausimmune' study in Australia [305]. 
The remaining results on age-specific MS prevalence for the overall Australian 
population have also been included for comparison with previous McLeod group 
findings for separate areas; similar 10-year age groups have been used. In the present 
study, 'census age' (i.e. age in completed years on the census -date) has been used to 
derive 'census years' of birth, as these will be required in the subsequent analyses for 
timing of birth in Chapter 7. Therefore, while the distribution of MS prevalence by 'age' 
for the total survey population was slightly different from any of those given by McLeod 
and colleagues for the separate survey areas , the overall prevalence age-standardised 
to the 1981 Australian population (30.3 per 100,000), was found to be the same as 
calculated for the McLeod group's survey areas when considered together as a single 
sample (data not shown). The highest prevalence rates in the 40 to 49 and 50 to 59 
year age groups, and the differing age-specific prevalence rates for males and females , 
were also consistent with previously reported findings [301 , 646-648]. 
Bringing the results for 'latitude' and 'age ' together, the prevalence rates by survey 
area and birth cohort showed highest overall prevalence in the mid-born cohort (Table 
5.1 O); a linear latitude-prevalence relationship was also evident for both early- and mid-
born cohorts , but not for the later-born cohort (Figure 5.10). This information , together 
with the separate decade-of-birth distributions for MS cases and the total (census) 
survey population (Figure 5.11 ), suggested possible biases present in both the early-
born and late-born cohorts , and particularly in the later born due to under-
representation of (not yet) diagnosed cases. This conclusion underpinned the decision 
to restrict the final sample of MS cases for timing-of-birth analysis to essentially the 
'mid-born' cohort only, in order to limit any effects of either late onset of MS or survival 
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differences between cases and controls. The restricted sample was chosen , for 
convenience, to be those MS cases born between calendar years January 1920 and 
December 1950, inclusive; this sample should therefore avoid major error resulting 
from use of an initially cross-sectional dataset, while maximising sample size as much 
as possible. 
With regard to regional latitude as an exposure factor for MS acting together with timing 
of birth (both to be discussed further in Chapter 7), the latitude of birthplace is arguably 
considerably more relevant than the latitude of later-life residence, if the time around 
birth is critical to the initiation of MS. That is, potentially causal ('causal' including either 
detrimental or beneficial here) environmental factors acting around the time of birth 
may be linked to place of birth, or to its (southern) latitude; if so, testing for such causal 
factors for MS should be more sensitive if place of birth rather than later place of 
residence, or survey area, is used. Hence, the following chapters (Chapters 6 and 7) 
will investigate time and place of birth within Australia, as factors potentially affecting 
MS outcome, rather than using the survey area as an exposure factor, as discussed so 
far. Accordingly, only those MS cases born in Australia will now be relevant to the 
present thesis study (see research questions in Chapter 7). 
A case sample of 1,631 Australia-born MS cases with known month of birth results . 
The focus on individual birthplace rather than place of residence within Australia in the 
present study further ensures that the timing-of-birth data will not be diluted by 
inclusion of overseas-born migrant cases, particularly any northern hemisphere-born 
who may show a reciprocal seasonal birth timing. In the 1981 survey, the number of 
overseas-born cases represented 29% of the total 1920- to 1950-born persons, the 
Australian migrants in 1981 originating mainly from the UK and Ireland [304 , 64 7]. In 
comparison with the present thesis strategy of restriction to Australia-born persons on ly, 
register timing-of-birth studies , such as that of Willer et al. (2005) [324] in the northern 
hemisphere, have generally included all cases ascertained in a particular area , 
regardless of where born and regardless of when any overseas-born persons migrated 
to the area. 
Chapter 6 will detail the construction of a longitudinal type of dataset from the basic 
cross-sectional , cases-only 1981 MS Survey described here. Numerator data (cases) 
and suitable denominator data (population controls) will be combined into the same 
dataset, month-by-month and year-by-year, to give a series of 'MS rates ' relative to the 
1981 Australian reference population , by birth month and year, and by place of birth. 
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CHAPTER 6 
TIMING OF BIRTH AND MS: DERIVATION OF DENOMINATORS FOR TIMING-OF-
BIRTH ANALYSES 
6.0 Preface 
How do we provide suitable population controls for the MS cases in the existing 
MS survey dataset? 
To answer this question, this chapter will focus on determining appropriate population 
denominators for MS rates for the 1981 surveyed cases and detail the construction of a 
longitudinal by-year and by-month MS-rates dataset from the cross-sectional 1981 MS 
Survey discussed in Chapter 5. Suitable denominators will be calculated for the 
available MS-case numerators, taking into account region of birth within Australia and 
sex. The Australian census, taken on the same day as the survey in 1981 , will be used 
together with other necessary Australian births-registration data. The denominators will 
also be adjusted to account for the non-surveyed state of VIC and the NT, in particular. 
This will enable timing-of-birth analysis for MS cases in Chapter 7; that is , MS risk 
expressed as MS-births incidence rate by month and place of birth . 
As outlined in the previous chapter, only Australia-born persons will be included in the 
final dataset, and only those Australians born between January 1920 and December 
1950 will now be considered. 
6.1 Introduction 
As discussed in Chapter 5, the original MS dataset was a cross-sectional prevalence 
survey. For timing of birth (by month), year of birth will also be taken into account rather 
than simply combining all years of birth together for analysis , enabling MS incidence 
rates to be obtained. Reconstruction of such a longitudinal dataset from the original 
point-prevalence cross-sectional survey, and incorporation of the appropriate 
reference-population denominators, will be detailed in Sections 6.2.1 to 6.2 .4. 
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Comparison with register studies 
As outlined in Chapter 5 (see Section 5.0) , most longitudinal timing-of-birth stud ies use 
registers of incident cases, wherein disease cases are registered over a period of time 
as they are diagnosed or otherwise notified. Registration may cover, for example , a 
period of 20 years, say 1960 to 1980, and these cases may be found to have been 
born between 1920 and 1950, depending on the average age of onset of disease. For 
such a disease register, the same range of year of birth from a total-population births 
register-that is , 1920 to 1950-would generally be used to obtain month-of-birth 
denominators for the reference population , enabling a (retrospective) case-cohort study. 
These reference-population births would ideally be from the same ascertainment area 
as the disease cases, for example , Australia (as in Table 6.1 , left-hand column). 
In the present study, an existing survey dataset is the available data source , and MS 
cases have been ascertained at one point in time (30 June 1981 ). The most 
appropriate reference population here is the total population surveyed at the same 
point in time, namely the 30 June 1981 census population (Table 6.1, right-hand 
column). The main difference compared with the register study is that both cases and 
the reference population are survivors of the original birth cohorts in the register 
population at the time of survey/census. That is , both cases and the reference 
population were alive and in Australia on the survey/census date. Further, in the 
present study, both the cases and the reference population may have been born 
overseas or in Australia (however, this study will choose to restrict to just Australia born 
for both cases and the reference population for timing-of-birth analysis) , whereas the 
total-population births registrations , at least, will represent those who have been born 
only in the relevant registration area. Table 6.1 summarises these main differences 
(balded italics) between the available data for the present thesis study and usua l 
register studies. 
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Table 6.1: Similarities (italics) and differences (balded italics) in numerator (MS 
cases) and denominator (reference) populations between an example register 
study and the present thesis study 
Example Register Study (longitudinal) Thesis Study ( cross-sectional ➔ 
longitudinal) 
MS cases registered in ascertainment MS cases surveyed in 1981, therefore 
area (e.g. Australia) between e.g. 1960 - alive and in Australia when surveyed, 
1980, and born (in Australia or overseas) and born (in Australia or overseas) 
between e.g. 1920 to 1950 between 1920 to 1950 ➔ Australia born 
only 
Reference population (denominators): Reference population (denominators): 
Total population registered as born in Total population alive and in Australia 
ascertainment /register area (e.g. 
Australia) between 1920 to 1950 (i.e. 
Australia-born register) 
Place (region) of birth 
on census date in 1981 (i.e. census 
population), and born (in Australia or 
overseas) between 1920 to 1950 ➔ 
Australia born only 
As discussed in Chapter 5 (see Section 5.4 ), the present study will also investigate 
timing of birth by place of birth rather than by place of ascertainment. Birthplace-that 
is , where a person is at this early stage in the life course of this disorder-is likely to be 
more relevant and have more effect on subsequent environmentally initiated disease 
than residence in 1981, particularly if the influential environmental factor is , as 
hypothesised, acting early in life . In comparison with register studies using place of 
ascertainment, which may also include immigrants to the ascertainment area (for 
example, Willer and colleagues' Canadian MS study [324]) , the present study should 
have fewer dilution effects . As indicated by Torrey and colleagues for timing-of-birth 
studies in disorders such as schizophrenia, failure to account for individuals born 
elsewhere and later immigrating to the study area may influence results for countries 
such as Canada and Australia with high immigration rates [642]. 
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However, while birthplace (i.e. state) data are readily available for the MS cases (i.e. 
the numerators) in the 1981 survey, such data are more difficult to obtain for the 
denominators when a register is not the starting point. That is, the 1981 census did not 
record region of birth (state) within Australia for the reference population , nor did it 
record month of birth ; only age in completed years on the census date was available , 
from which year of birth in 'census years ' could be derived , as summarised in Table 6.2. 
This table again gives comparison with a register type of study, and indicates how 
additional national births-registration data could be used to gain the required 
denominator data for analysis. That is , the shaded box in the lower right-hand column 
of Table 6.2 shows the required reference-population data that were absent from the 
1981 census; namely, month of birth and birthplace (state) within Australia. These 
parameters could be derived from available Australian births-registration data (Table 
6.2, shaded box in lower left-hand column) to address this issue; these derivations are 
detailed subsequently in Section 6.2.2. 
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Table 6.2: Availability of data for timing-of-birth analysis, in an example register 
study and the present thesis study, for both cases and the reference populations. 
(Directly available data are shown bolded; data not directly available are shown 
in italics; shaded boxes and arrow emphasise the main areas of difference and 
indicate which data had to be sourced for this thesis study and where it could be 
sourced from) 
Example Register Study (longitudinal) Thesis Study ( cross-sectional ➔ 
longitudinal) 
Cases: Cases: 
(Disease Register) • Register area (1981 Survey) • Birthplace 
area 
(Not necessarily (All alive and in (Australia or not) 
. . 
survIvIng or In • Year of birth Australia when • Year of birth 
ascertainment • Month of birth surveyed 30 June • Month of birth 
/register area [e.g. 
• Birthplace 1981) • Birthplace 
Australia] post- (state) within (state) within 
registration) register area? Australia 
Reference Reference 
Population: • Birthplace Population: • Birthplace 
(Births Register) area (1981 Census) area 
(=register area , (Australia or notf 
(Similarly to cases, e.g.Australia) (Similarly to cases, 
not necessarily 
• Year of birth all alive and in • Year of birth 
. . 
Australia on census (in census years t surviving or in 
ascertainment 
• Month of birth date 30 June 1981) • Month of birth** 
/register area [e .g. 
• Birthplace • Birthplace** 
Australia] post- {state) within I > (state) within registration) 
register area Australia 
(e.g. Australia) 
+ Derived from proportion Austra lia born by age in 1981 ( census table). 
# From age in completed years on census date 1981 . 
** To be derived from supplementary Austral ian births -reg istration tables (l eft-hand column ) fo r 1920 to 
1950 born . 
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Adjustment for migration between time of birth and 1981 
Finally, because the Australian MS survey was not able to ascertain cases in the areas 
encompassing the state of VIC , the NT and the area of the state of TAS outside of the 
Hobart SD (see Chapter 5), further adjustment to the dataset to compensate for this 
lack of ascertainment in 1981 was required before analysis. As birthplace was the 
required exposure factor rather than place of residence or ascertainment, an estimate 
of net migration between the time of birth and time of survey/census was necessary in 
order to adjust the data. Adjustments were made either to the numerators (for the 
unsurveyed state/territory areas of VIC and NT) or to the denominators (for all of the 
other surveyed state/territory areas) , as detailed in Section 6.2.3. Although relatively 
small , these adjustments were considered necessary to account for ascertainment 
losses, which would have occurred by cases migrating to (or from) the unsurveyed 
areas during the period from their birth to 1981. 
The main purpose of this chapter is to derive the appropriate at-birth denominators for 
the MS cases (i.e. by month and place of birth) using 1981 census and other available 
supplementary data (as shown in Table 6.2) , and then to adjust either the numerators 
or these denominators to take account of net migration to or from the unsurveyed areas. 
The aim of this chapter is to describe the construction of an MS-rates dataset, using 
the MS-case numerators and the derived denominator estimates in a longitudinal 
format, and to examine necessary assumptions and limitations of these data. 
6.2 Methods 
6.2.1 Required MS-rates dataset 
Format of dataset 
The format of the required longitudinal dataset is shown in Table 6.3. The six main 
variables describing birth ( columns 2 to 7) are year, month, place and sex, as we ll as 
the number of MS births ( often zero) and the number of reference-population births. 
Also shown is census year (column 1 ), necessary when deriving the reference-
population births and defined in Chapter 5 (see Section 5.3.2 , Table 5.8). The 
relationship between census years (July to June) and calendar years (January to 
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December) is indicated at the right-hand side of Table 6.3 . Thus, the dataset will 
include the case dataset of MS cases , expressed in frequency form by year and month 
of birth , together with the corresponding population denominators also by (same) year 
and month of birth. Likewise, to examine a regional (latitude) effect on MS (and 
henceforth , latitude of birth rather than ascertainment area) these data will be 
separated by place of birth (i.e. state) for both numerators and denominators (column 5, 
Table 6.3). 
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Table 6.3: Format of MS-rates dataset: MS and reference-population births by 
month (January to December denoted as 1 to 12) for the first three calendar 
years, January 1920 to December 1922, for males (sex=1) born in NSW/ACT 
(place=2). (Calendar years and census years indicated to right of table. July 
1920/June 1921 census-year example given in text is shown in bold) 
1 2 3 4 5 6 7 1919/20 census-year 
I 
T 
Gens Year* Year# Month Sex Place MS births Pop. births 
---------------------------------------------------------------------
1. 20 20 1 1 2 0 1426.993 1920 calendar year 
2. 20 20 2 1 2 2 1317.430 Jan . - Dec. 
3. 20 20 3 1 2 1 1408.955 I 
--------------------------------------------------------------------- T 
4. 20 20 4 1 2 0 1372.212 
5. 20 20 5 1 2 1 1457.056 
6. 20 20 6 1 2 0 1672.174 
7. 21 20 7 1 2 2 1828.180 1920/21 census-year 
8. 21 20 8 1 2 0 1761.388 Jul. - Jun . I 
-------------------------------------------------------------------- T 
9. 21 20 9 1 2 1 1669.807 
10. 21 20 10 1 2 0 1640.198 
11 . 21 20 11 1 2 0 1601.637 
12. 21 20 12 1 2 0 1651.215 
13. 21 21 1 1 2 2 1602.326 1921 calendar year 
--------------------------------------------------------------------- I 14. 21 21 2 1 2 0 1476.316 T 
15. 21 21 3 1 2 0 1528.648 
16. 21 21 4 1 2 1 1572.717 
17. 21 21 5 1 2 0 1577.537 
18. 21 21 6 1 2 0 1582.357 
---------------------------------------------------------------------
19. 22 21 7 1 2 0 1622.595 1921 /22 census-year 
20 . 22 21 8 1 2 2 1695.139 I 21 . 22 21 9 1 2 0 1588.652 T 
22 . 22 21 10 1 2 0 1568.686 
23 . 22 21 1 1 1 2 0 1572.013 
---------------------------------------------------------------------
24. 22 21 12 1 2 1 1574.010 
25. 22 22 1 1 2 1 1617.936 1922 ca lendar year 
26. 22 22 2 1 2 1 1365.695 I 27. 22 22 3 1 2 1 1647.220 T 
28 . 22 22 4 1 2 0 1455.543 
---------------------------------------------------------------------
29 . 22 22 5 1 2 0 1589.983 
30. 22 22 6 1 2 2 1508.787 
31 . 23 22 7 1 2 0 1694.207 1922/23 census-year 
32 . 23 22 8 1 2 1 1739.096 I 33 . 23 22 9 1 2 0 1596.948 T 
---------------------------------------------------------------------
34. 23 22 10 1 2 0 1656.120 
35. 23 22 1 1 1 2 1 1639.116 
36 . 23 22 12 1 2 0 1491 .528 
*CensYear '21 ' denotes 1920/1921 census year, i.e. July 1920 to June 1921 . 
#Year '20 ' denotes 1920 calendar year, i.e. January to December 1920. 
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For timing-of-birth analysis, the required outcome measure describing MS risk is MS-
births rate, where 'rate ' is the number of MS births each month relative to the number 
of births in the reference Australian population: 
MS-births rate (by month and year) - No. MS births per month per year 
No. reference-population births per (same) 
month per (same) year 
This MS-births rate is required also by place of birth (in Australia) and sex. 
The 1981 (McLeod) MS Survey can be used to create such an 'MS-rates ' dataset 
based on comparative birth rates, thus providing an opportunity to examine timing-of-
birth effects on MS risk while also taking place of birth into account. The structure of 
this MS-rates dataset would be: 
• Number of records=5,208 (=31 years x 12 months x 7 states/territories x 2 
sexes): 
o birth year: 1920 to 1950 ( n=31) 
o (birth) month: January to December (n=12) 
o (birth) place (state/territory): NT to TAS (n=7) 
o sex (n=2) . 
• For each record: 
o the 1981 MS Survey, described in Chapter 5, gives the number of MS 
cases born (per month , year, place and sex) 
o the 1981 census data, together with other Australian births-registration 
data (Table 6.2) , will be used to derive the reference-population births 
denominators. 
Thus, this MS-rates dataset comprises six variables pertaining to births-the four 
variables, year, month , place and sex (columns 1 to 5 in Table 6.3 )-as well as : 
• The total number of births in the Australian reference population in each 
month and year, separately for each birthplace and each sex, of persons who 
were still alive and in Australia on 30 June 1981 (column 7, Table 6.3) , this 
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denominator to be derived using data from the 1981 census and national 
registration data covering births over the relevant period . 
• The number of these births of persons who, by 30 June 1981 , had been 
diagnosed as an MS case and who were still alive and in Australia on 
that date (column 6, Table 6.3) (case ascerta inment using data from the 
1981 MS Survey in Chapter 5) . 
Numerator data 
For column 6 in Table 6.3, the numbers of MS births per month for every year over the 
31-year period from 1920 to 1950, by birthplace and sex, were directly obtained by 
contracting unit-record data in the 1981 MS Survey dataset to frequencies of MS births 
per month per year, using Stata 8.0 software (release 8.0 , 2003; Statacorp, College 
Station , Texas) . 
An example of these contracted frequency data for just the 1920/1921 census year (i.e. 
July 1920 to June 1921) is given in tabular form for males in Table 6.4, and for females 
in Table 6.5. For example, from Table 6.4, the MS survey dataset comprised two males 
born in NSW/ACT in July 1920; this is then seen in Tab le 6.3 in column 6 as the 
seventh record . 
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Table 6.4: Number (frequency) of Australian male MS cases born July 1920 to 
June 1921, by birth month and birth state (data contracted from unit records in 
1981 MS Survey) 
Year/month Birth place ( state/territory)* 
NSW/ VIC OLD SA WA TAS NT Not Total 
ACT known 
1920 July 2 1 0 0 0 0 0 0 0 
Aug . 0 0 0 0 0 0 0 0 
Sept. 1 0 0 0 0 0 0 0 
Oct. 0 0 0 2 0 0 0 1 
Nov. 0 0 0 0 0 1 0 0 
Dec. 0 0 0 0 0 0 0 0 
1921 Jan . 2 0 0 0 0 0 0 0 
Feb. 0 0 2 0 0 0 0 0 
Mar. 0 0 0 0 0 0 0 0 
Apr. 1 0 0 0 0 0 0 0 
May 0 0 0 0 0 0 0 0 
June 0 0 1 0 0 0 0 0 
Total 6 0 3 2 0 1 0 1 
* Birthplace states or territories listed in order of decreasing population size . 
Table 6.5: Number (frequency) of Australian female MS cases born July 1920 to 
June 1921, by birth month and birth state (data contracted from unit records in 
1981 MS Survey) 
Year/month Birth place ( state/territory)* 
2 
0 
1 
3 
1 
0 
2 
2 
0 
1 
0 
1 
13 
NSW/ VIC OLD SA WA TAS NT Not Total 
ACT known 
1920 July 1 0 1 1 3 0 0 0 6 
Aug . 2 0 0 0 0 1 0 0 3 
Sept. 1 2 0 1 0 0 0 0 4 
Oct. 2 0 0 1 0 0 0 0 3 
Nov. 1 0 1 1 1 0 0 0 4 
Dec. 1 0 0 0 0 1 0 0 2 
1921 Jan. 1 0 0 0 1 0 0 0 2 
Feb. 1 0 0 1 1 0 0 0 3 
Mar. 0 0 0 0 0 0 0 0 0 
Apr. 6 1 0 0 0 0 0 0 7 
May 2 0 0 1 0 0 0 0 3 
June 4 0 0 0 0 0 0 0 4 
Total 22 3 2 6 6 2 G 0 41 
* Birthplace states or territories listed in order of decreasing popu lation size . 
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In order to calculate the MS risk for males born in NSW/ACT in July 1920, for example , 
the total number of males born in NSW/ACT in July 1920 (i.e. the denominator) also 
needs to be ascertained. Further, as shown in Tables 6.1 and 6.2 , because the 
numerator data in Table 6.4 represent surviving males in 1981 , the corresponding 
denominator must also take this survival to 1981 into account. 
6.2.2 Derivation of population denominators for MS rates 
This section describes how the values for column 7 in Table 6.1 were derived ; that is, 
the number of the reference Australian population born by month , year, birthplace and 
sex in Australia over the 1920 to 1950 period that were still alive on 30 June 1981 (and 
still in Australia). 
To derive the reference-population denominators, the 1981 Australian census taken on 
the same day as the MS survey provides a suitable starting point, being a similarly 
cross-sectional sample and including only those persons alive on 30 June 1981 and 
those residing in Australia on that date (Tables 6.1 and 6.2). However, the 1981 census 
did not contain the month-of-birth and place-of-birth information required for timing-of-
birth analysis (Table 6.2). Fortunately, summary births-registration data provided by the 
ABS recorded the number of Australian births registered by sex and state (and by 
SD-the latter required for TAS because Hobart SD was surveyed rather than the 
whole state) for each month and year. It was therefore possible to estimate the number 
of persons born in each month and year from 1920 to 1950 and still alive on 30 June 
1981 , in each state/area and for each sex, by combining the ABS births-registrations 
data with the 1981 census data, as indicated in Table 6.2 and described in the 
following subsections. 
Census data 
Census year of birth 
The 1981 census totals for each sex were given by 'census age'; that is, 'age in 
completed years on the census date, 30 June 1981 ', rather than directly by year of birth . 
For the purpose of denominator derivation , this 1981 'census age' could be equated to 
year of birth expressed in 'census years '; that is, in years spanning July of one year to 
June of the following year, as defined in Chapter 5 (footnote to Table 5.8) . 'Census 
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year', as defined, was shifted six months from the calendar years , as illustrated in 
Table 6.3. (Later, once the denominators per month were derived and the MS-rates 
dataset reconstructed, timing of birth could be analysed simply by calendar year.) 
Thus, the 30 June 1981 Census gave the numbers of males and females by census 
age, from which the numbers born in a given census year and surviving to 1981 could 
be deduced. 
Restriction to Australia born: estimated numbers of Australia-born males and 
females for each census year of birth 
The 1981 census totals by year included all those in Australia on census day, 30 June 
1981 , whereas only Australia-born persons were required for timing-of-birth analysis. 
For example , from the census, 68 ,328 men and 73,560 women born during the July 
1920 to June 1921 census year were alive and in Australia on 30 June 1981 , but these 
were not necessarily born in Australia. An additional 1981 census table provided the 
proportion of Australia born by census age group and sex, these age groups covering 
periods of five or 10 years and being for the whole region of Australia (Table 6.6) . 
Assuming that the proportion Australia born did not differ markedly within these age 
groups, nor between regions within Australia , an estimate of the number of Australia 
born per census year of birth could be obtained for each sex. 
Table 6.6: Proportion of persons Australia born, by age- and year-of-birth group 
and sex (data from the 1981 Census) 
Year-of-birth group 
July 1916-June 1921 
July 1921-June 1926 
July 1926-June 1936 
July 1936-June 1946 
July 1946-June 1956 
Age group 
(years*) 
60-64 
55-59 
45-54 
35-44 
25-34 
*Census age in completed years on census date 30 June 198 1. 
Proportion Australia born 
Males Females 
0.71841 0.75844 
0.67489 0.72443 
0.64837 0.70598 
0.64400 0.68079 
0.72455 0.73184 
For example, of the total 68 ,328 males born during the 1920/1921 census year and 
alive on 30 June 1981, the proportion of these that were Australia born was 0. 71841 
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(Table 6.6) , giving an estimate of 49 ,087.5 for the number of males born in Australia 
between July 1920 and June 1921 and still alive in 1981 (Table 6.7 , column 4). The 
resulting Australia-born estimates for both males and females for each year of birth 
over the 1920 to 1950 ( calendar year) study period are shown in Table 6. 7 in columns 
4 and 6, respectively. 
The Austral ia-born estimated totals ( columns 4 and 6 of Table 6. 7) for each census 
year of birth were then ready to be apportioned into month-of-birth and place-of-birth 
subtotals using the supplementary Australian births-registration data, these subtotals 
being the basis for the eventual denominators for analysis of timing of birth. 
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Table 6.7: Number of Australia-born persons in 1981 by sex and census year of 
birth over the 1920 to 1950 calendar-year period (columns 4 and 6). This is 
calculated from the total numbers of males and females (columns 3 and 5) and 
the proportions of Australia-born persons by census-age group and sex (Table 
6.6). (All data from the 1981 Census; numeric example given in text shown in 
bold) 
Year of birth 
(census year 
July-June#) 
1919 /1920 
1920 /1921 
1921 /1922 
1922 /1923 
1923 /1924 
1924 /1925 
1925 /1926 
1926 /1927 
1927 /1928 
1928 /1929 
1929 /1930 
1930 /1931 
1931 /1932 
1932 /1933 
1933 /1934 
1934 /1935 
1935 /1936 
1936 /1937 
1937 /1938 
1938 /1939 
1939 /1940 
1940 /1941 
1941 /1942 
1942 /1943 
1943 /1944 
1944 /1945 
1945 /1946 
1946 /1947 
1947/1948 
Census 
age 
(years) 
61 
60 
59 
58 
57 
56 
55 
54 
53 
52 
51 
50 
49 
48 
47 
46 
45 
44 
43 
42 
41 
40 
39 
38 
37 
36 
35 
34 
33 
Total in 
1981 
60596 
68328 
69569 
70852 
72164 
74607 
76150 
75548 
78316 
78142 
75594 
79569 
73866 
72876 
72603 
73546 
78115 
78370 
81044 
85337 
85072 
91776 
92782 
91988 
100513 
105153 
107240 
126914 
119398 
Males 
Australia born 
1981 
43532.77 
49087.50 
46951.42 
47817.31 
48702.76 
50351 .52 
51392.87 
48983 .06 
50777 .74 
50664 .93 
49012.88 
51590.15 
47892.50 
47250 .61 
47073 .61 
47685 .02 
50647.42 
50470 .28 
52192 .34 
54957.03 
54786.37 
59103 .74 
59751 .61 
59240.27 
64 730.37 
67718 .53 
69062 .56 
91955 .54 
86509 .82 
Females 
Total in Australia born 
1981 1981 
63505 48164.73 
73560 55790.85 
71346 51685 .18 
71748 51976.40 
71339 51680 .11 
74285 53814.28 
74425 53915.71 
73116 51618.43 
74288 52445 .84 
74198 52382.30 
71410 50414 .03 
77363 54616.73 
69325 48942 .06 
69242 48883.47 
68311 48226 .20 
70541 49800 .53 
74714 52746 .59 
74408 50656.22 
77471 52741.48 
81868 55734.92 
79652 54226 .28 
87703 59707 .32 
88440 60209 .07 
88435 60205 .66 
96998 66035 .27 
102351 69679 .54 
103333 70348 .07 
123426 90328 .08 
116407 85191 .30 
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Year of birth 
(census year 
July-June#) 
1948 /1949 
1949 /1950 
1950 /1951 
Census 
age 
(years) 
32 
31 
30 
Males 
Total in Australia born 
1981 1981 
116254 
117525 
120578 
84231 .84 
85152.74 
87364 .79 
Females 
Total in Australia born 
1981 1981 
116035 
115322 
120373 
84919 .05 
84397 .25 
88093 .78 
# Census year as defined in Chapter 5, Table 5.8, e.g. 1919/1920 census year is July 1919 to June 1920. 
Supplementary births-registration data 
Summary births-registration data (provided by J. Wall , ABS , pers . commn) were utilised 
to overcome the main limitation of the census data , namely the absent month-of-birth 
and place-of-birth data (see Table 6.2). Using these data , estimated numbers born by 
month , year, state/division and sex in Australia were able to be derived to fill column 7 
in Table 6.3. That is , population births in Australia recorded by state (and SD) from 
1860 to 1969 and available also by sex and month over most of the years required 
were able to be used to derive the required births estimates by direct proportion from 
the census by-year and by-sex totals , as detailed in the following subsection . 
Month and place of birth estimates for males and females for each census year 
of birth 
From the ABS Australian births-registration summary tables , the numbers of births 
registered by month and state (and SD for Hobart, TAS) were tabulated for each 
census year and sex separately , over the period 1920 to 1950, as shown in the 
example for male births during the 1920/1921 census year (Table 6.8). The tota l 
number of reg istered births over all states and months for that census year was then 
calculated for each sex. 
For example , in Table 6.8 for the 1920/1921 census year, 2,655 ma le births were 
reg istered in July 1920 in NSW (includ ing ACT) and the tota l ma le births ove r the Ju ly 
1920 to June 1921 year in Austral ia was 71 ,290 . The correspond ing Australia-born 
census total estimated for th is (census) year of birth for males was 49 ,087.5 (Tab le 6.7) 
and this number represents the male survivors (to 1981 ) of that initial 1920/1 92 1 birth 
cohort of 71 ,290. 
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The proportion of these surviving male ( or female) persons born that year in Australia 
(and in Australia in 1981) relative to the total initial number of male (or female) births in 
Australia that year (i.e. 49,087.5 / 71,290 for males) was then applied to each by-month 
and by-state (or division) births number in example Table 6.8, resulting in the new by-
month and by-state/area estimates in example Table 6.9 . 
For example, in Table 6.8, 2,655 initial male births in NSW/ACT in July 1920 were 
estimated to become 1,828.13 still alive in 1981 (and still residing in Australia) male 
births in Table 6.9. That is, each initial births-registration value has now been adjusted 
(downwards) to take account of both the survival of each birth cohort to 30 June 1981 
and their residence still in Australia: 
1981 male resident survivors of Australian 1920/1921 birth cohort X 2,655 
Total Australian male births 1920/1921 
1.8. 49,087.5 
71,290 
X 2,655 1,828.13 
Thus, each monthly regional (initial) birth rate has been multiplied by a proportion 
expressing the survival of that age group or census year group to 1981 and their 
continued residence in Australia. 
In other words , the 1981 census total of Australian residents (for each census year and 
sex) has been subdivided into by-month and by-state/area values , as required for 
analysis ; these values are now in the same by-month and by-state/area proportions as 
existed in the corresponding initial birth cohorts. This can be seen by re-arranging the 
above equation for the same example NSW/ACT July 1920 male births. That is, 
1,828.13 = 2,655 
71 ,290 
Or, 
NSW July 1920 male births 
(New estimate) 
= 2,655 
Total male 
1920/1921 births 
(both numerator 
and denominator 
X 
from births register) 
X 49,087.5 
Resident males born 1920/1 921 and 
surviving to 1981 (from 1981 Census) 
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The 'add-up-check total' shown in parentheses in the last column of Table 6.9 ; that is, 
49 ,088.19, is within just 0.001 % 'rounding error' of the original census total , 49 ,087.5 , 
showing that the new month of birth and place of birth estimates correctly add up to the 
original totals for each census year. 
As depicted diagrammatically in Figure 6.1, the 1981 yearly census totals have now 
been apportioned into by-month and by-state/area births estimates using the same by-
month and by-state/area proportions that existed in their initial Australian birth cohorts , 
solving the problem of the absence of these data in the 1981 Australian census. 
To derive month of birth and place of birth as described , it was necessary to assume 
that survival from birth to 1981 of this 1920- to 1950-born restricted group (i.e. 30 to 61 
year olds in 1981 ), and their continued residence in Australia until 1981, were not 
dependent on either month or place of birth (state) within Australia. These and other 
necessary assumptions made will be discussed further in Section 6.4. 
These month- and place-of-birth estimated values for each sex and year would then 
become the required population denominators (of MS rates) for column 7 in Table 6.3 , 
after further slight adjustment to account for the effects of incomplete case 
ascertainment in the MS survey-this final adjustment is discussed in the following 
section (Section 6.2.3). 
Estimates from 1928 onwards 
Since the ABS summarised registered births separately by sex only up until 1928, the 
remaining 1929 to 1950 period required an additional estimation step. For this period , 
only totals (males and females combined) were available by month , but male and 
female data were given by state/division. Therefore, after first establishing for the 
earlier period for which full data were available (i.e. up to 1928) that male to female 
ratios at birth did not vary significantly by month (within state/division and year) , annual 
sex ratios were applied , within each state/division and year, to divide the monthly tota ls 
into male and female subtotals to give the required denominators by sex. 
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Table 6.8: ABS births-registration data (from summary tables for 1920 and 1921) for males born in Australia, by state/territory and by 
month from July 1920 to June 1921 (census year 1920/1921 only). (TAS births shown separately for Hobart SD and remaining non-
Hobart area of state, because Hobart SD denominator is required for TAS sample; specific numeric example given in text shown in 
bold) 
Year/month Registered births of Australian males born 1920/1921 census year 
NSW/ACT VIC* QLD SA WA TAS NT* Total 
Hobart SO Non-Hobart* 
1920 July 2655 1737 977 504 378 63 170 2 6486 
Aug . 2558 1610 1006 577 394 68 185 0 6398 
Sept. 2425 1679 837 568 351 87 212 1 6160 
Oct. 2382 1581 866 500 326 82 187 2 5926 
Nov. 2326 1576 829 523 343 78 189 0 5864 
Dec. 2398 1534 910 508 333 69 164 1 5917 
1921 Jan. 2326 1464 906 489 279 63 174 4 5706 
Feb. 2144 1422 858 526 355 61 159 6 5531 
Mar. 2220 1482 955 535 340 67 178 2 5779 
Apr. 2284 1599 881 505 390 64 179 3 5905 
May 2291 1502 861 522 336 65 191 0 5768 
June 2298 1591 880 497 337 73 165 9 5850 
Total 28308 18777 10766 6254 4162 840 2153 30 71290 
* VIC , NT and non-Hobart TAS necessarily included for apportioning at-birth denominators but not included in final dataset (see Section 6.2.3). 
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Table 6.9: Reference-population denominators given by estimated births of 1981 survivors from 1920/1921 Australian birth cohort, by 
month and birthplace. (TAS births shown separately for Hobart SD and non-Hobart areas, because Hobart SD denominator is 
required for TAS sample; specific numeric example given in text shown in bold) 
Year/month Estimated births of 1920/1921-born Australian males still alive 30 June 1981 in Australia 
NSW/ACT VIC* OLD SA WA TAS NT* (Check 
Hobart SD Non-Hobart* Total) 
1920 July 1828.13 1196.03 672 .72 347.03 260.28 43.38 117.06 1.38 (4466.01) 
Aug. 1761.34 1108.58 692.69 397.30 271.29 46.82 127.38 0.00 (4405.41) 
Sept. 1669.76 1156.09 576.33 391.10 241.68 59.90 145.97 0.69 (4241.53) 
Oct. 1640.15 1088.61 596.29 344.28 224.47 56.46 128.76 1.38 (4080.41) 
Nov. 1601 .59 1085.17 570.82 360.12 236.18 53.71 130.14 0.69 (4038.41) 
Dec. 1651.17 1056.25 626.59 349.79 229.29 47.51 112.92 0.69 (4074.21) 
1921 Jan. 1602.28 1008.05 623.84 336.71 192.11 43.38 119.81 2.75 (3928.93) 
Feb. 1476.27 979.13 590.79 362.18 244.44 42.00 109.48 4.13 (3808.43) 
Mar. 1528.60 1020.45 657.58 368.38 234.11 46.13 122.56 1.38 (3979.19) 
Apr. 1572.67 1101.01 606.62 347.72 268.54 44.07 123.25 2.07 (4065.95) 
May 1577.49 1034.22 592.85 359.43 231.36 44.76 131.52 0.00 (3971.62) 
June 1582.31 1095.50 605.93 342.21 232.04 50.26 113.61 6.20 (4028.08) 
Total 19491.78 12929.10 7413.05 4306.26 2865.79 578.39 1482.47 21.35 (49088.19) 
* VIC , NT and non-Hobart TAS necessarily included for apportioning at-birth denominators but not included in final dataset (see Section 6.2.3) . 
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Figure 6.1: Diagram showing apportioning of 1981 census totals (top of diagram), for each census year of birth and sex, into 
birthplace and birth-month subtotals for required denominators, using births proportions from ABS registration summary tables. 
Boxed areas shown for birthplaces across centre of diagram indicate their approximate population sizes. Twelve by-month 
denominators result for each birthplace but for clarity are shown for NSW/ACT and VIC only. (Shaded cells indicate birthplace 
denominators not used in final MS-rates dataset [i.e. VIC, NT and non-Hobart TAS, see Section 6.2.3], but necessarily included for 
apportioning.) 
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Figure 6.2 summarises the process of derivation of MS-rates denominators described 
so far. That is, the 1981 Census (indicated by blue areas of pie-chart and text boxes) 
provides the total surviving Australia-born numbers by year of birth and by sex, and the 
ABS births-registration information (light blue/green text box) provides the 
supplementary data required to derive the denominator estimates by month and place 
of birth from these census totals. 
6.2.3 Birthplace and place in 1981-further adjustment for 1981 case 
ascertainment losses 
This section will describe how and why the required dataset will be adjusted to 
overcome the effects of the incomplete ascertainment of cases in the 1981 MS Survey. 
The 1981 MS Survey did not satisfactorily survey the following areas of Australia: the 
state of VIC, which has the second highest population in Australia ; the lowest-
populated state/territory area , the NT; and the area of TAS outside Hobart SD ( denoted 
as 'non-Hobart TAS') (J. McLeod, pers. commn). This has potential consequences for 
the required dataset, particularly for highly populated VIC , because some MS cases 
may have migrated from their original birthplace state to another Australian state during 
the period between birth and when both the MS survey and the census were taken in 
1981. Depending on whether their 'new' state was surveyed sufficiently or not, these 
cases migrating interstate may or may not have been ascertained (Table 6.10). 
Table 6.10 shows birthplace and place in 1981 (i .e. survey area) data (taken from the 
1981 Australian MS Survey) for the surveyed MS cases born between 1920 and 1950, 
and summarises the net interstate post-birth migration for the MS cases. It can be seen 
for the surveyed states that a high proportion of cases ascertained in each state or 
survey area were , in fact , born in that state (last column of Table 6.10). At the same 
time , lower numbers born in other states or territories have also migrated to each 
surveyed state by 1981 . 
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Figure 6.2: Initial sources and treatment of data for analysis of timing of birth. 
253 
Table 6.10: 1981 survey area and birthplace of MS cases born 1920 to 1950 (data 
from 1981 Australian MS Survey) 
1981 MS Birthplace (state) in Australia* % 
Survey born NSW VIC OLD SA WA TAS NT Unknown Total 
area* /ACT In 
/residence survey 
state 
NSW/ACT 875 50 28 10 5 3 1 6 978 89.5 
VIC 0 
QLD 32 16 183 1 3 6 0 0 241 75.9 
SA 1 1 1 1 1 181 3 1 0 0 208 87.0 
WA 7 10 3 4 112 2 0 0 138 81.2 
non-H TAS 0 
Hobart SD 3 13 1 1 0 49 0 0 67 73.1 
NT 0 
Total 928 100 216 197 123 61 1 6 1632 
*State/territory areas shown in order of decreasing population size . 
The two main scenarios that need to be considered are: 
1. MS cases born in the unsurveyed areas of VIC , NT and non-Hobart TAS will 
have either stayed in their 'home' area since birth and not have been ascertained , 
or will have migrated to one of the surveyed state/territory areas and have been 
ascertained there in 1981 . 
2. MS cases born in the surveyed areas will have either stayed in their 'home' area 
(or other surveyed area) and have been ascertained , or will have migrated to one 
of the unsurveyed areas by 1981 and then not have been ascertained. 
In this section , only the migrating cases need be considered for adjustment, as those 
not migrating will have been ascertained (scenario 2) , or not (scenario 1 ), correctly. 
Those migrating cases in the first scenario , for VIC and NT born at least, wil l be 
considered directly as numerators and eventually excluded , for reasons given 
subsequently. TAS-born MS cases will necessarily be considered a special case. The 
migrating cases in the second scenario will be estimated as a proportion and used to 
adjust the denominators , rather than the numerators , for the five surveyed birth states. 
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MS cases born in unsurveyed areas VIC, NT and non-Hobart TAS 
From Table 6.10, because VIC and NT (and non-Hobart TAS) were not surveyed in 
1981, there are likely to be considerable proportions of VIC-born and NT-born (and 
possibly non-Hobart-T AS-born) MS cases residing in these survey areas that have not 
been ascertained (see scenario 1, above). The few VIC-born and NT-born cases that 
have migrated to other, surveyed areas (and, therefore, have been inadvertently 
ascertained in the survey), are likely to be unrepresentative of the total born in that 
state or territory; therefore, these VIC-born (n=100 cases) and NT-born (n=1 case) 
migrants to other surveyed areas should, and will, be excluded. 
By the same reasoning, non-Hobart-born cases should also be excluded; however, 
these are not identifiable in the dataset from those born in Hobart SD-only 'TAS-born' 
cases are identifiable. Therefore, T AS has to be considered a special case. All 'T AS-
born' MS cases were considered to be Hobart SD-born and included in timing-of-birth 
analysis using a reference-population 'Hobart SD' birthplace denominator. Indeed, TAS 
is such a small state that most TAS MS cases in 1981 would have been born in the 
major medical facilities in the Hobart capital (A-L. Ponsonby, pers. commn). Given 
TAS's high latitude (and low UVR, see Chapter 4) and the possible importance of this 
to the analysis, this strategy was considered preferable to the alternative strategy of 
considering all 'TAS born' as non-Hobart born and then excluding all TAS-born cases 
from the analysis. The potential effects of this strategy will be further discussed and 
justified in Section 6.4. 
MS cases born in surveyed areas and migrated to unsurveyed areas 
The effects of net post-birth migration from the surveyed states (i.e . see scenario 2, 
above) to VIC and NT (but not non-Hobart TAS) could be taken into account by utilising 
another census dataset to estimate these likely sampling losses and then adjusting the 
appropriate denominators. 
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Calculation for adjustment of denominators 
To determine the amount by which the denominator data should be adjusted , by 
census year of birth , a single census-year birth cohort-for example , NSW/ACT-born in 
census year July 1920 to June 1921-can be considered. 
For this cohort , there are five possibilities with respect to surveying both the whole 
population cohort and MS ascertainment of the cohort in 1981 (i .e. to gain the MS rate 
in th is cohort) , these categories including 'death before 1981 ' and 'migration out of 
Australia '. Since the Australian census counts only those persons alive and in Austral ia 
on census day, and since the MS survey was conducted similarly, only the remaining 
three possibilities need be considered. That is , the survey possibilities for those 
persons al ive in Australia on census and prevalence day (30 June 1981) are as shown 
(with theoretical percentages and proportions) in Table 6.11 . 
Table 6.11: Theoretical ascertainment and proportions indicating post-birth 
migration of both MS cases ('M', 1981 MS Survey) and the reference population 
('C', 1981 Census), for a single census year, 1920/1921, and a single birthplace, 
NSW/ACT 
Place in 1981 (%) 1981 MS Survey* 1981 Census** 
1. Still in NSW/ACT 85% Ascertained 0.85M Counted 0.85C 
2. Migrated interstate to 10% Ascertained 0.10M Counted 0.10C 
surveyed states OLD, 
SA, WA, or Hobart SO 
(TAS) 
3. Migrated interstate to 5% Not 0.0SM Counted 0.05C 
VIC or NT (not surveyed ) ascertained 
( or non-Hobart T AS) 
Total 100% M C 
*Persons with MS and born in NSW/ACT in 1920/1921 census year. 
**Persons born in NSW/ACT-estim ated from 1981 census and Ju ly 1920 to June 1921 births-reg istration 
tab le (ABS): the census counts only th ose persons in categories 1, 2 and 3 for all of Australia, and the 
births-reg istration table is used to determ ine the number estimated to have been born in NSW/ACT by 
month (see Section 6.2.2). 
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The MS rate in this 1920/1921-born cohort is given by M/C. If VIC , NT and non-Hobart 
TAS MS cases were fully ascertained, then the (true) MS rate is easily estimated using 
the counts in 1, 2 and 3: 
0.85M + 0.10M + 
0.85C + 0.1 oc + 
0.05M 
0.05C 
1.00M 
1.00C 
M 
C 
However, in the MS survey the '0.05M' category (shown in bold in Table 6.11 ), 
comprising those persons who migrated to the unsurveyed states or areas has not 
been ascertained. That is, a proportion of the MS cases (here, theoretically 0.05) has 
been 'lost to survey'. 
Therefore, either: 
a. the numerator, M, should be increased by 0.05M, or 
b. the denominator, C, should be decreased by 0.05C. 
However, in practice only the denominator-that is, the estimated denominator for each 
month and place of birth (Table 6.9)-can actually be adjusted; it would not be possible 
to increase the numerators when month(s) of birth cannot be allocated to these 
'generated' MS cases. Therefore, in the above example, the denominator, C, should be 
multiplied by 0.95, this factor given by 1 - 0.05. Or, in general terms for each surveyed 
birthplace state: 
Each by-month , by-sex and by-year denominator, C (as given in Table 6.9) , will be 
multiplied by (1-x) , where x is defined as the proportion of the total number of those 
persons born in that state each year that are later resident in VIC or NT in 1981. 
Thus, for the surveyed birthplace states, NSW/ACT, OLD, SA and WA, and TAS 
(=Hobart SD birthplace, by definition) , the above (1-x) adjustment factor was used to 
account for case ascertainment losses to the unsurveyed state/territory areas of VIC 
and NT, as shown in Table 6.12 , but not for potential case losses to non-Hobart TAS . 
Using census-population residence-by-birthplace data, these potential losses to non-
Hobart TAS are discussed further at the end of this section (Section 6.2.3) and shown 
to be relatively small. 
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Use of 1976 census-population migration data to adjust for 1981 case losses to 
VIC and NT 
Available residence-by-birthplace data from the 1976 Census (these data were not 
available in the 1981 Census but were for the previous Australian census in 1976) were 
used to determine the actual proportions (x) by which each denominator needed to be 
adjusted in order to account for sampling losses to the main unsurveyed areas of VIC 
and NT. These data (provided by the Australian Social Science Data Archive [ASSOA]) 
comparing birthplace (state/territory) and residence (state/territory) of the Australia-
born 1976 census population , quantified net interstate movement within Australia 
between the time of birth and 1976 for the Australia-born census population by census 
age. A necessary assumption for this adjustment was that there was little change in net 
migration in the Australian population between the two censuses in 1976 and 1981. 
Table 6.12 shows how 'x' was derived for each birthplace state/territory and each 
census year of birth between 1920 and 1950, using the single census year, 1920/1921 , 
as an example. The lower part of Table 6.12 indicates the proportions , for each 
birthplace , of the example Australian 1920/1921-born population that were resident in 
VIC and NT in 1976-that is , had migrated to areas that were not surveyed in 1981. 
Although quite small for the surveyed states , these are the proportions that were taken 
into account for deriving the denominator estimates for these states. For example , 3.88% 
of the total number (36 ,470) of NSW/ACT-born persons in 1920/1921 who were still 
alive and in Australia in 1976, would not have been included in any survey that 
excluded these two areas , VIC and NT, because of net interstate migration between 
the birth year and the survey year. 
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Table 6.12: Area of residence in 1976 and birthplace of Australians born in example 1920/1921 census year (ASSDA 1976 census 
data). Lower part of table shows number, and proportion (x)* (balded for surveyed states), residing in VIC or NT, of total for each 
birthplace state/territory 
1976 area 
of 
residence 
NSW/ACT 
VIC 
QLD 
SA 
WA 
TAS 
NT 
Total 
VIC+ NT 
Proportion* 
VIC+NT (x) 
NSW/ACT 
31970 
1351 
2161 
493 
314 
116 
65 
36470 
1416 
0.038826 
VIC QLD 
1985 1344 
20395 353 
1060 11878 
551 77 
397 74 
182 31 
52 56 
24622 13813 
20447 409 
0.830436 0.029610 
Birthplace (state/territory) in Australia 
SA WA TAS NT Unknown Total 
521 295 272 10 4008 40405 
582 252 635 4 2681 26253 
191 108 150 9 1578 17135 
7265 137 67 14 686 9290 
219 4531 50 4 673 6262 
35 14 2857 0 184 3419 
66 29 7 153 89 517 
8879 5366 4038 194 9899 103281 
648 281 642 157 
0.072981 0.052367 0.158990 0.809278 
* Proportion resident in VIC or NT indicates proportion (x) of each birthplace population that would have beeri 'lost to survey' were VIC and NT not sampled at all (as in 1981 
MS Survey) . 
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Assuming that net interstate migration among the MS cases and among either of the 
reference Australian populations in 1976 and 1981 were similar, this proportion of 
otherwise-excluded persons (x) from the 1976 population was used to adjust the 
corresponding 1981 population denominators (by 1-x). This was to account for the 
losses of cases to the unsurveyed states, VIC and NT, in the 1981 MS Survey. 
For each birthplace state, It was necessary to use the same (1-x) factor for the 
denominators for each month within each census year, and for each sex, because the 
1976 migration data was available only by census age (and therefore census year) and 
for the total number of persons. The required additional assumption , therefore , was that 
net interstate migration did not depend on month of birth within each census year, or on 
sex. 
For the example 1920/1921 census year for males, the estimated births shown in Table 
6.9 have now become the final migration-adjusted values shown in Table 6.13, for the 
surveyed birth states NSW/ACT, OLD, SA, WA and TAS (=Hobart SD by definition) . 
For example , for NSW/ACT males born in July 1920, the previous example estimate of 
1828.180 births in Table 6.9 has now decreased (by 3.9%) to an estimated 1757.199 
births in Table 6.13. The values in Table 6.13 are now the reference-population 
denominators required for the final MS-rates dataset for just the 1920/1921 birth cohort , 
after accounting for migration of that birth cohort to the unsurveyed areas , VIC and NT, 
by 1976/1981 . 
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Table 6.13: Migration-adjusted population denominators for 1920/1921 census-
year-born males, given by estimated male births of 1981 survivors from 
1920/1921 Australian birth cohort adjusted for migration 'losses' to unsurveyed 
states VIC and NT in 1981, by month and birthplace. (Specific example given in 
text shown in bold) 
Year/month Birthplace (state/area)11 
NSW/ACT OLD SA WA Hobart SD* 
1920 July 1757.199 652.823 321.717 246.653 36.483 
Aug. 1693.000 672.201 368.315 257.093 39.379 
Sept. 1604.974 559.276 362 .570 229.035 50.382 
Oct. 1576.515 578.654 319.163 212.722 47.486 
Nov. 1539.452 553.931 333.845 223.815 45.170 
Dec. 1587.104 608.054 324.270 217.290 39.958 
1921 Jan. 1540.113 605.381 312.142 182.053 36.483 
Feb. 1418.996 573.308 335.760 231.645 35.325 
Mar. 1469.296 638.123 341.505 221.857 38.800 
Apr. 1511.654 588.677 322.355 254 .483 37.063 
May 1516.287 575.313 333.207 219.247 37.642 
June 1520.920 588.008 317.248 219.900 42.275 
#Surveyed birthplace states/areas only shown (cases and denominators from unsurveyed VIC and NT 
birthp laces not included in final MS-rates dataset). 
*Assum ing TAS-born cases to be (all ) Hobart born , the denominator requ ired is that of Hobart SD, 
adjusted for migration losses to VIC and NT (assuming same relative proportion lost for Hobart SD born as 
for TAS born ). 
As an illustration of the data adjustments described in this subsection , the data in Table 
6.12, for the Australian population born 1920/1921 , can be further summarised by 
comparing the relative proportions residing in the total 'surveyed ' area (as defined in 
the 1981 MS Survey) and the main 'unsurveyed ' area, VIC plus NT, for each birthplace. 
That is , the 'surveyed proportion for each birthplace will include those persons 
remaining in their birthplace state or territory, for the 1981-surveyed states/territories 
only. However, for the 1981-unsurveyed VIC and NT, the relat ively high proportion 
remaining 'home' will necessarily now be included in the 'unsurveyed proportion 
(Figure 6.3). 
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Figure 6.3: Relative proportions of 1920/1921-born Australian population residing 
(in 1976) in total 'surveyed' and 'unsurveyed' states/territories as defined in 1981 
MS Survey, by birthplace. (Data from 1976 Census for 1920/1921-born persons 
[ASSDA]; *Unsurveyed states/territories [1981 MS Surv_ey]=VIC, NT; surveyed 
states/territories [1981 MS Survey]=NSW/ACT, QLD, SA, WA, TAS [Hobart SD].) 
Figure 6.3 shows the proportions of the state-born populations (and, by assumption , of 
their MS cases) that potentially would have been 'lost to survey' because of migration 
to the unsurveyed areas, VIC and NT, but which have now been accounted for. This 
figure further emphasises the relatively large proportions of VIC-born and NT-born 
'losses' from the population (if sampled as in the 1981 MS Survey) and , by inference, 
from the MS survey itself, when these two areas were not sampled , because in these 
states/territories the high proportion remaining 'home' since birth have not been 
ascertained. As previously stated with regard to Table 6.10, because the relatively few 
VIC-born and NT-born migrants to other, surveyed states are probably not 
representative of this much larger, unsurveyed group remaining 'home' (>80% of total) , 
Figure 6.3 shows why the migrating VIC-born and NT-born MS cases cannot be 
included in the final MS-rates dataset. TAS-born losses to VIC and NT, on the other 
hand , while greater than from other surveyed states, are still less than 20%, and these 
have now been accounted for in the final Hobart SD denominator estimate (by 
assuming the same relative proportion lost for Hobart SD born as for TAS born). 
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In conclusion , a similar table to Table 6.13 , of migration-adjusted denominators by birth 
month and by birthplace , was constructed (in Microsoft Excel 2000) for each of the 31 
census years of birth over the 1920 to 1950-born study period , for each sex. These 
tables of adjusted denominators were then ready for conversion to Stata 8.0 format for 
the purpose of merging with the numerator data for timing-of-birth analysis. 
Potential sampling losses to non-Hobart TAS not accounted for 
Using the 1976 population migration data, Table 6.14 summarises, for the example 
1920/1921 birth year, the relative sampling losses to VIC and NT from each birthplace 
(=proportions from Table 6.12, shown in bold , these losses now having been taken into 
account). The table also summarises potential losses to non-Hobart TAS that have not 
been accounted for, as calculated from the ASSDA residence-by-birthplace population 
data from the 1976 Census. This table , expressed as both proportions and 
percentages of each birthplace total , shows that the potential unaccounted-for case 
losses to non-Hobart TAS from each of the other surveyed birthplace states were much 
smaller (~0 .1 to 0.2%) than the proportions 'lost' to VIC and NT (2 .96 to 15.9%) that 
have now been accounted for. 
Table 6.14: Potential case ascertainment losses (as proportion and % of 
birthplace population) from each of the 1981-surveyed birthplace states because 
of migration from birthplaces to unsurveyed (1981) areas VIC and NT, and non-
Hobart TAS, estimated from residence-by-birthplace data in 1976 Census for 
1920/1921-born Australians 
Unsurveyed 
areas (1981) NSW/ACT 
VIC + NT 0.03882 
(%)# (3.88%) 
Non-Hobart 0.00161 
TAS (%)* (0 .16%) 
# Losses now accounted fo r. 
* Loss unaccounted for. 
1981-surveyed birthplace states 
QLD SA WA 
0.02961 
(2 .96%) 
0.00130 
(0.13%) 
0.07298 
(7.30%) 
0.00224 
(0.22%) 
0.05236 
(5.24%) 
0.00 186 
(0.1 8%) 
TAS 
0.15899 
(15.90%) 
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Potential case losses due to net migration from Hobart SD to non-Hobart TAS were not 
quantifiable at all, because specific birthplace within this smallest Australian state (TAS) 
could not be obtained, but these losses were assumed to have also been small. As 
previously stated, most Tasmanians surveyed in 1981 would likely have been born in 
the Hobart capital. 
6.2.4 Merging numerators and denominators for longitudinal MS-
rates dataset 
Numerator and denominator data derived as described were combined into a single 
year-by-year and month-by-month series in count (frequency) form, as shown in Table 
6.18 (see Results, Section 6.3.3). The adjusted denominator tables in frequency format 
in Microsoft Excel 2000 for each census year were converted from MS Excel 2000 to 
Stata 8.0 using the software conversion program Stat Transfer v7.0 . These were then 
merged with the numerator data (also in frequency format, see Section 6.2.1) in Stata 
8.0, using a unique identifier for each of the now 3,720 database categories (31 years x 
12 months x 2 sexes x 5 birthplace states/areas, NSW/ACT, OLD, SA, WA, Hobart SD 
[TAS]). 
This merged MS-rates dataset with adjusted denominator estimates by birthplace and 
month of birth (and by year of birth and sex) will now make it possible (in Chapter 7) to 
derive estimates of MS rates by sex, month of birth and year of birth for timing-of-birth 
analysis, and by birthplace rather than by 1981 survey area as in Chapter 5. 
6.3 Results 
6.3.1 Final MS-case numbers (numerators) 
The final MS-case sample numbers available for subsequent timing-of-birth analyses 
(in Chapter 7) are summarised by birthplace state and sex in Table 6.15. A total of 
1,524 MS cases (i .e. 1,631 [Chapter 5] with known month of birth , less VIC born 
[n=100] and NT born [n=1] as well as unknown birthplace [n=6] [Table 6.1 O]) resulted. 
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Table 6.15: Final sample numbers for MS cases for MS-rates dataset. Number of 
MS cases (1920 to 1950 born) by Australian birthplace (state) and sex 
Birthplace in Number of MS cases (1920 to 1950 born) 
Australia (state) Males Females 
NSW/ACT 279 649 
QLD 76 140 
SA 54 143 
WA 26 97 
TAS (Hobart SD) 21 39 
Total 456 1068 
6.3.2 Final population denominators and preliminary prevalence 
estimates 
Total 
928 
216 
197 
123 
60 
1524 
The final migration-adjusted denominator estimates are summarised in the next two 
tables and are shown together with the final MS-case numbers. The total reference-
population denominator represented 2,468,779 persons born in Australia between 
1920 and 1950 (i .e. aged 30 to 61 completed years in June 1981 ). Preliminary crude 
prevalence estimates have also been calculated and are shown by birthplace state and 
sex in Table 6.16 (all years of birth and months of birth combined , and states now 
shown in order of increasing south latitude) , and by month of birth and sex (years of 
birth and birthplace states combined) in Table 6.17. The purpose of the summary crude 
prevalence estimates in these tables is to check the adjusted denominator estimates 
calculated in this chapter for obvious errors and to provide an indication of the possible 
relationships of interest to the analyses in the next chapter. In addition , the 
assumptions made particularly for TAS can also be checked (discussed in Section 6.4 ). 
Crude prevalence by birthplace and sex 
Consistent with total age-specific prevalence calculated in Chapter 5 for 30 to 59 year 
olds (then using the 1981 census denominators : prevalence 62 .2/100,000, see Section 
5.3.2 , Table 5.8) , Table 6.16 shows an overall MS prevalence of 61.7 per 100,000 for 
the approximately similarly-aged 1920 to 1950 Austral ia-born cohort using the now 
birthplace-apportioned and migration-adjusted denominators. A female to male overall 
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prevalence ratio of 2.27 (Table 6.16) is also comparable with the previous ratio of 2.33 
evident in Table 5.5, giving confidence in the final denominators derived in this chapter. 
Table 6.16 also indicates an association with increasing south latitude of birthplace for 
the total Australia-born sample with all years and months of birth combined ; that is , a 
4.6-fold increase in prevalence from QLD born (low mean latitude, 16 25.1 °S) to TAS 
born (high mean latitude, 42.8°S) is suggested. This result is consistent with the 
McLeod group's findings of an overall four-fold increase in prevalence from QLD to 
TAS for survey area within Australia rather than birthplace (see Section 5.3.2), but now 
indicates a similarly strong relationship between latitude of birthplace and MS 
prevalence. Moreover, there appear to be no sex differences in this latitude-of-
birthplace association with MS prevalence, both males and females indicating a 4.6-
fold (or 3.6%) increase in prevalence from QLD to TAS birthplaces. 
Crude prevalence by month of birth and sex 
Importantly, for the total Australia-born sample with all years of birth and birthplaces 
combined, Table 6.17 indicates a possible timing-of-birth 'pattern ', with lowest 
prevalence of MS births in May and highest in December. Whether such a pattern is 
real and statistically significant will be considered in the next chapter, where the now 
longitudinal data will be analysed in detail taking year of birth into account. As a 
secondary inquiry, whether this timing-of-birth pattern changes significantly with region 
of birth , or by sex, will also be investigated (see research question 2, Chapter 7). 
16 Mean latitude based on state population distribution in 1981 , as given by Hammond et al. (2000a ) [304) . 
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Table 6.16: MS cases, final reference-population denominators and crude prevalence estimates for males, females and total persons 
by birthplace (1920 to 1950 Australia born) 
Birthplace Males Females 
(state/area)# MS Reference Prevalence MS Reference Prevalence 
cases population /100,000 cases population /100,000 
OLD 76 266 ,364.0 28.5 140 273,396.8 51.2 
WA 26 117,804.8 22.1 97 121,480.0 79.8 
NSW/ACT 279 676 ,636.4 41.2 649 697 ,006.1 93.1 
SA 54 139,817.3 38.6 143 143,437.3 99.7 
TAS+/Hobart++ 21 + 16, 177.3++ 129.8 39+ 16,659.0++ 234.1 
Total 456 1,216,799.8 37.5 1,068 1,251 ,979.2 85.3 
TAS to OLD* Ratio 4.6 4.6 
(%) (3.6) (3.6) 
#Birthplace states listed in order of increasing mean (based on state population distribution in 1981) south latitude. 
+TAS-born MS cases (assumed to be Hobart SD born) ascertained in Hobart SD or other surveyed areas in 1981 . 
++ Hobart SD-birthplace denominators . 
*Prevalence ratio of TAS compared with OLD shown also as % increase OLD to TAS (in parentheses) . 
Total 
MS Reference Prevalence 
cases population /100,000 
216 539,760.8 40.0 
123 239,284.8 51.4 
928 1,373,642.5 67.5 
197 283,254.6 69.5 
60+ 32,836.3++ 182.7 
1,524 2,468,779.0 61.7 
4.6 
(3.6) 
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Table 6.17: MS cases, final reference-population denominators and crude prevalence estimates for males, females and total persons 
by month of birth (year and region of birth not distinguished; 1920 to 1950 Australia born) 
Month of Males Females Total 
birth MS Reference Prevalence MS Reference Prevalence MS Reference Prevalence 
cases population /100 ,000 cases population /100,000 cases population /100,000 
January 40 102,025.3 39.2 91 105,105.7 86.6 131 207,131.0 63.2 
February 33 95 ,049.1 34.7 87 97 ,825.0 88.9 120 192,874.1 62 .2 
March 41 102,902.5 39.8 86 105,828.1 81.3 127 208 ,730.6 60.8 
April 45 97 ,470.2 46.2 83 100,338.4 82.7 128 197,808.6 64.7 
May 32 103,397.2 30.9 74 106,748.8 69.3 106 210,146.0 50 .4 
June 35 99 ,455.8 35.2 71 102,582.5 69.2 106 202,038.3 52.5 
July 30 105,415.7 28.5 101 108,406.3 93.2 131 213,822 .0 61 .3 
August 43 104,962 .1 41.0 95 107,929.2 88.0 138 212 ,891.3 64.8 
September 38 102,475.7 37.1 95 105,330.3 90.2 133 207,806.0 64.0 
October 34 106,142.4 32.0 98 108,933.4 90.0 132 215,075.8 61.4 
November 37 99 ,401.5 37.2 95 102,229.4 92.9 132 201,630.9 65.5 
December 48 98 ,102.4 48.9 92 100,722.0 91.3 140 198,824.4 70.4 
Total 456 1,216,799.9 37.5 1,068 1,251 ,979.1 85.3 1,524 2,468,779.0 61.7 
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6.3.3 Longitudinal dataset by year of birth, sex, birthplace and 
month of birth for timing-of-birth analyses 
The complete merged MS-rates dataset included the final case dataset of 1,524 MS 
cases expressed in frequency form by month (and year) of birth , together with the 
corresponding migration-adjusted reference-population denominators also by month 
(and year) of birth , as shown in Table 6.18. 
Table 6.18 also displays an additional data column compared with Table 6.3 , this 
column (column 8) comprising values for 'MS rate '; these values express the number of 
MS births by month (column 6) relative to the corresponding reference-popu lation 
denominator for that month (column 7) , as defined in Section 6.2 .1. However, this 
variable was not used directly for the regression analyses in Chapter 7, and is simply 
indicative of the relatively low MS disease rates overall ; that is , the column values are 
often zero , or otherwise very low values , for example , ~6 x 10-4, or ~6/10,000 (shown 
balded in Table 6.18) . Such a 'rare disease' may be suitable for regression analysis 
based on , for example , a 'Poisson ' distribution [654]. Regression analysis for timing of 
birth using Poisson and other related techniques will be detailed in the following 
chapter (see Chapter 7) . 
To sum up, Figure 6.4 , which extends the previous Figure 6.2, illustrates the complete 
process of deriving the reference-population denominators required for construction of 
the longitudinal MS-rates dataset, as has been detailed in th is chapter. 
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Table 6.18: Final MS-rates longitudinal dataset (portion only shown). MS-case 
and reference-population births, adjusted for sampling losses to unsurveyed 
areas, VIC and NT, by month for the first three calendar years, January 1920 to 
December 1922, for males (sex=1) born in NSW/ACT (place=2). (Reference-
population births adjusted using population migration data from 1976; July 
1920/June 1921 census-year example given in text indicated on right-hand side; 
MS rates other than zero are shown in bold) 
1 2 3 4 5 6 7 8 
Adjusted (MS rate) 
CensYear* Year# Month Sex Place MS births pop. births (E format) 
----------------------------------------------------
-----------------
1 . 20 20 1 1 2 0 1372.325 0.000e+00 
2. 20 20 2 1 2 2 1266.959 1.579e -03 
3. 20 20 3 1 2 1 1354.978 7.380e -04 
----------------------------------------------------
-----------------
4. 20 20 4 1 2 0 1319.642 0.000e+00 
5. 20 20 5 1 2 1 1401 .236 7.137e -04 
6. 20 20 6 1 2 0 1608.113 0.000e+00 
7. 21 20 7 1 2 2 1757.199 1.138e -03 1920/21 census yr 
8. 21 20 8 1 2 0 1693.000 0.000e+00 July to June I 
----------------------------------------------------
----------------
T 
9. 21 20 9 1 2 1 1604.974 6.231 e -04 
10. 21 20 10 1 2 0 1576.515 0.000e+00 
11 . 21 20 11 1 2 0 1539.452 0.000e+00 
12. 21 20 12 1 2 0 1587.104 0.000e+00 
13. 21 21 1 1 2 2 1540.113 1.299e -03 
----------------------------------------------------
-----------------
14. 21 21 2 1 2 0 1418.996 0.000e+00 
15. 21 21 3 1 2 0 1469.296 0.000e+00 
16. 21 21 4 1 2 1 1511 .654 6.615e -04 
17. 21 21 5 1 2 0 1516.287 0.000e+00 
18. 21 21 6 1 2 0 1520.920 0.000e+00 
----------------------------------------------------
-----------------
19. 22 21 7 1 2 0 1557.307 0.000e+00 
20. 22 21 8 1 2 2 1626.932 1.229e -03 
21 . 22 21 9 1 2 0 1524.729 0.000e+00 
22 . 22 21 10 1 2 0 1505.567 0.000e+00 
23 . 22 21 11 1 2 0 1508.760 0.000e+00 
----------------------------------------------------
-----------------
24 . 22 21 12 1 2 1 1510.677 6.620e -04 
25 . 22 22 1 1 2 1 1552.835 6.440e -04 
26. 22 22 2 1 2 1 1310.744 7.629e -04 
27 . 22 22 3 1 2 1 1580.941 6.325e -04 
28 . 22 22 4 1 2 0 1396.977 0.000e+00 
----------------------------------------------------
-----------------
29 . 22 22 5 1 2 0 1526.007 0.000e+00 
30. 22 22 6 1 2 2 1448.078 1.381e -03 
31 . 23 22 7 1 2 0 1623.763 0.000e+00 
32 . 23 22 8 1 2 1 1666.785 6.000e -04 
33. 23 22 9 1 2 0 1530.548 0.000e+00 
----------------------------------------------------
-----------------
34. 23 22 10 1 2 0 1587.259 0.000e+00 
35. 23 22 1 1 1 2 1 1570.963 6.366e -04 
36 . 23 22 12 1 2 0 1429.511 0.000e+00 
*CensYear '21 ' denotes 1920/1921 census year, i.e. Ju ly 1920 to June 1921 . 
#Year '20' denotes 1920 calendar year, i.e. January to December 1920. 
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Figure 6.4: Sources and treatment of data for analysis of timing of MS births In 
Australia. 
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6.4 Discussion 
This chapter has detailed the construction of a longitudinal dataset from the cross-
sectional 1981 MS-case survey, in order to analyse timing of birth of the surveyed MS 
cases relative to the 1981-census reference population. Individual-level numerator and 
birthplace-denominator data have been incorporated into the one dataset, month-by-
month and year-by-year for the 1920- to 1950-born age group, to give MS-births rates 
relative to the reference population by birth month (and year) and by birthplace. 
Compared with the original cases-only survey dataset, there is now an emphasis on 
Australia-born MS cases, and only the Australia-born reference population has now 
been included. Thus, data can be expressed as 'MS rates' for these surviving Australia 
born in 1981, using estimates of reference-population births by month and state ( or SD 
for Hobart) as denominators for these rates. The resulting dataset contains information 
on birthplace (state) within Australia by sex, for both the reference population and MS 
cases. Birthplace as the latitude-related exposure factor at the time of birth , instead of 
survey area at the later time of census, is now emphasised and this has not been 
investigated previously in relation to timing of birth in Australia, nor by notable northern 
hemisphere studies [324, 644] . Therefore, this thesis study will enable analysis at the 
individual level of MS risk in Australia by month of birth , taking into account year of birth , 
birthplace and sex (see Chapter 7). 
For analysis, the year-of-birth range from the 1981 survey has been restricted to the 
central three decades, 1920 to 1950, where MS prevalence was highest and relatively 
uniform. This restriction allowed exclusion of the more obvious sampling biases 
pertaining to the numerators , including 'survival ' bias among the older cases due to 
likely differential survival between cases and the general population , and the very 
obvious 'diagnosis' bias evident among the younger cases , where cases at this end of 
the year-of-birth distribution were under-represented (see Chapter 5, Section 5.3.3). 
Assumptions necessary for estimation of reference-population denominators 
As the original 1981 MS Survey was carried out on an Australian national census day, 
this allowed convenient use of the 1981 census data for derivation of the required 
reference-population denominators. While the 1981 Census was the appropriate 
starting point, representing survivors to 1981 like the surveyed MS cases , these census 
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data did not have all of the initial information required for the subsequent analyses , 
particularly month- and region-of-birth information for Australia-born persons. However, 
the availability of other Australian (ABS) births-registration data covering the same 
period enabled these shortfalls in the denominator census data to be overcome, but 
various assumptions were required in order to do this (Table 6.19). First, the proportion 
of Australia born was provided only for total Australia (and for five- to 10-year age 
groups) , requiring an assumption of no differences in this proportion , within each age 
group, between regions. This assumption for region is difficult to check , but the 
possible effects should be considered: if northern hemisphere migrants settled in 
Australia in greater proportions in any region, and survived (to 1981) similarly to (or 
longer than) Australia born, and if they showed an opposite 'northern hemisphere 
timing-of-birth ' pattern , this would have the effect of diluting any timing-of-birth effect for 
that region, even though only the denominators, and not the numerators , would be 
affected . 
Second , the census totals , now adjusted to represent only Australia born , were 
apportioned into subtotals by birthplace and by month of birth , using supplementary 
ABS births-registration data available by state/territory and by month and year. To 
apportion these census totals in the same proportions as existed in the original by-year 
birth cohorts (see Figure 6.1 ), it was necessary to assume that survival from birth to 
1981 (including continued residence in Australia until 1981) of the Australia-born 
reference population was not dependent on region of birth within Australia , nor on 
month of birth. In addition , the assumption that the ABS births registrations adequately 
reflected actual month of birth was basic here (Table 6.19). The next three subsections 
consider these three assumptions and possible sources of error separately. 
273 
Table 6.19: Summary of assumptions necessary for estimation and adjustment of 
reference-population denominators for MS-rates dataset 
Required estimate Assumptions 
Proportion Australia born (from 1981 Same proportion within five- to 10-year 
census totals) age groups, and among regions (states) 
Month-of-birth and place-of-birth Registrations reflect actual month (and 
proportions (from ABS 1920 to 1950 place) of birth 
births-registration tables and 1981 census 
totals) Survival from birth to 1981 (and lack of 
emigration from Australia) not dependent 
on place of birth or month of birth 
Net interstate migration to unsurveyed Net interstate migration similar among MS 
states/areas (VIC, NT and non-Hobart cases and reference population, and 
TAS) between birth and 1981 similar for both in 1976 and 1981 
Net interstate migration not dependent on 
month of birth within each birth year, or 
sex 
'TAS-born' cases are all Hobart SD born 
(and net migration loss for Hobart SD born 
similar to TAS born ; net migration loss 
from Hobart SD to non-Hobart TAS 
negligible) 
Interval between birth and registration of birth 
Measurement bias would be an important issue if, for example , month of birth was 
being measured differently for MS cases and the reference population. For the 
reference-population denominators , this thesis study was limited to using summary 
monthly births-registration data (ABS), rather than records of actual dates of birth as 
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were available for the MS cases. The delays before registration of births could be 
checked for some years-for example, 1920 and 1921-which were the earliest birth 
years represented in the reference population and which should indicate the maximum 
possible error in measurement of month of birth for the reference population (noting 
that time intervals between birth and registration generally decreased in the later years) . 
For both these years 1920 and 1921 , a median registration interval of 10 days was 
observed, with 90% of all births being registered within 31 days (one month); that is , 
the possible error in month of birth for most of the oldest members of the reference 
population was less than or equal to one month. Although only the denominators would 
be affected thus, and final MS rates should therefore be affected only minimally, this 
possible error could have a dilution effect on the month-of-birth variable. This provides 
further reason to restrict the dataset to 1920 to 1950 born to exclude earlier years when 
the interval between birth and registration would likely have been longer. 
Region of birth within Australia and survival to 1981 
Given Australia 's nationwide health system, major differences in survival by region of 
birth within Australia would not be expected , particularly for the restricted dataset of just 
30 to 61 year olds (in 1981 ). Nor would different rates of emigration overseas from the 
birth regions be expected . Nevertheless, the ASSDA residence-by-birthplace data in 
Table 6.12 for the oldest members of the reference population (1920/1921 census year 
of birth) can be used to indicate the likely maximum differences in regional birthplace 
proportions since the time of birth , at least for the 1976 census population for which 
these data were available. That is , the proportion from each birthplace state , of the total 
1920/1921-born persons with known birthplace states who were present in Australia in 
1976 (see Table 6.12) , can be compared with the original proportion known to have 
been born in each state that year (from the ABS births-registration data) . This indicates 
any major differences in survival (and emigration from Austra lia) between the states. 
Table 6.20 shows this comparison as regional percentages of total number of persons , 
for both the oldest reference-population members born in the 1920/1 921 census year 
(left-hand side of table) and the overall 1920- to 1950-born persons in the final dataset 
(right-hand side). 
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Table 6.20: Distribution of total number of persons by region of birth, comparing 
proportions (as percentages) at time of birth with those in the 1976 Census, for 
persons born in the 1920/1921 census year and for all persons born between 
1920 and 1950 
Birthplace Born in 1920/1921 census year Born between 1920 and 1950 
( state/territory) At birth (% )* In 1976 (%)** At birth (% )* In 1976 (%)** 
NSW/ACT 39.8 39.1 39.5 39.0 
VIC 26.3 26.4 25.8 25.7 
QLD 15.0 14.8 15.4 15.5 
SA 8.8 9.5 8.4 8.7 
WA 5.8 5.7 6.9 6.9 
TAS 4.2 4.3 3.9 4.0 
NT 0.1 0.2 0.1 0.2 
Total 100.0 100.0 100.0 100.0 
* Regional proportions from ABS births registrations . 
** Regional proportions from 1976 Census , representing the surviving and non-emigrating persons from 
the initial regional birth cohorts . 
Minimal differences between the regional percentages at birth and in 1976 (and 
presumably still in 1981) are indicated in both halves of this table , particularly for the 
1920 to 1950 born (right-hand half of table). That is , only minimal regional differences 
in survival (and emigration) for the whole 1920- to 1950-born reference population over 
the period from birth to 1976/1981 are apparent, giving confidence in the at-birth 
proportions used to allocate the 1981 census-total denominators. To confirm this , a 
sensitivity analysis using the 1976 birthplace proportions , rather than the 'at-birth ' 
calculated proportions, to derive the denominators for 1920 to 1950 born was also 
conducted (data not shown). This analysis showed that timing of birth (as MS risk by 
period of birth for the overall 1920 to 1950 born , see Chapter 7, Section 7.3) was 
unaffected (the MS risk IRRs for each two-month period , shown to two decimal places 
in Table 7.8 , Chapter 7, were unchanged) , confirming the validity of this assumption . 
Month of birth and survival to 1981 
The initial restriction of the dataset to just the 30 to 61 year-old age group (in 1981) will 
have limited any differences in survival with month of birth to a certain extent. However, 
any such differences could potentially affect a timing-of-birth pattern for MS, because 
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the surviving (and non-emigrating) persons to 1981 are being used as proxy for the 
original birth cohorts of the reference population, in order to apportion the denominator 
subtotals by month (and region) of birth . There is some evidence for season- or month-
of-birth effects on adult life expectancy past the age of 50 years for Australians born 
between the 1890s and 194 7, Doblhammer and Vaupel (2001) observing a decreased 
post-50 lifespan in spring and early summer born that they attributed to early infant 
health [655]. However, these authors acknowledge that this seasonal variation is 
relatively small compared with, for example, social factors and gender effects on 
longevity; they further show (using Danish data) that later-born cohorts within this time-
span exhibit many fewer longevity differences because of significantly improved 
maternal and infant health in more recent years [655]. The 1920- to 1950-born group 
used in this thesis study falls into the later-born category within this period, and the 
possible variation in survival between different birth months should be limited; in 
addition, any differences would again affect only the denominators and thereby limit 
changes in MS rates. Indeed, the preliminary prevalence estimates given in Table 6.17 
show the opposite pattern to that which would be expected if seasonal survival 
differences as seen by Doblhammer and Vaupel (2001) were contributing here (over-
estimated spring-summer denominators would reduce spring-summer MS rates), giving 
further confidence in the denominators as estimated assuming no survival differences 
by month of birth. 
Adjustment for migration of cases to unsurveyed states or areas 
Because of the lack of 1981 MS-case survey data for some regions , notably VIC and 
NT, MS cases born in either of these two areas and ascertained in other, surveyed 
areas were necessarily excluded from the final dataset (see Section 6.2.3) ; 
denominators were then not required for these two regions . Final adjustment of the 
remaining denominator estimates was required to compensate for the lack of survey 
data for the regions VIC and NT, because cases born in surveyed areas would have 
been 'lost to survey' if they had migrated interstate to either VIC or NT by 1981. 
Available residence-by-birthplace data from the 1976 census was used to gain these 
adjustment factors for each surveyed region and each year of birth , necessarily 
assuming that net migration between regions did not change significantly in the final 
five unrecorded years from 1976 to 1981 (see Table 6.19). This assumption appears 
reasonable given that the 1920- to 1950-born study cohort were 25 to 56 years old in 
1976 and only 30 to 61 years old five years later in 1981. As these interstate migration 
data were available only by (census) year of birth and for all persons born in Australia , 
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the additional assumption required was that net interstate migration did not depend on 
month of birth or sex; this additional assumption is not testable with available data but 
again appears reasonable. 
While lack of case survey data for VIC and NT and migration to these areas from 
surveyed regions could be satisfactorily adjusted for, the 1981 survey of Hobart SD 
rather than the whole of TAS was more problematic, because the 'T AS-born ' MS cases 
could not be differentiated into those born in Hobart SD and those born in non-Hobart 
TAS. Therefore, 'TAS-born' cases ascertained in any of the surveyed areas, including 
Hobart SD, were considered to have been all born in Hobart SD, in order to be able to 
include the 'TAS-born' cases in the analysis. Fortunately, the areas 'Hobart SD' and 
'TAS' as birthplace exposure factors are relatively similar in mean latitude and UVR 
received, and it was considered preferable to include, rather than exclude, the TAS 
cases given that high-latitude (and lower UVR) TAS was potentially able to have 
important effects on MS risk. (The alternative to this was to consider all 'TAS-born ' 
cases as 'non-Hobart-born' and then exclude all from analysis, as was done for VIC 
and NT.) The potential effect of the assumption that all 'TAS-born ' cases were 'Hobart 
SD-born ' is discussed further in the next subsection, where preliminary prevalence 
estimates are used to justify this strategy. 
The TAS-birthplace denominators, conversely, were able to be differentiated into 
'Hobart-born ' and 'non-Hobart-born ' (in the ABS register) , this allowing use of the more 
relevant 'Hobart SD' birthplace denominator, rather than one simply for 'TAS' (which 
would have underestimated the MS rate in the 'TAS-birthplace' area). Then , for 
migration adjustments, the Hobart SD-born denominator could be adjusted to account 
for potential (case) losses to VIC and NT survey areas , assuming the same relative 
proportion lost fo r 'Hobart SD-born ' cases as for 'TAS-born ' cases (see Table 6.19) 
(TAS-born case losses calculated from 1976 census data). 
However, 'losses to survey' by migration of cases from the other (surveyed) birthplace 
states to the u nsurveyed portion of T AS-that is , non-Hobart T AS-cou Id not be easi ly 
estimated , but these were shown (using 1976 census proportions) to be very small in 
comparison with the now accounted-for case-migration losses to VIC and NT (see 
Table 6.14 ). As well, potential losses of cases from the surveyed Hobart SD birthplace 
to unsurveyed non-Hobart TAS could not be estimated at all but were assumed to be 
negligible given the relatively small area and population size of TAS. 
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Summing up this subsection , all of the case ascertainment losses due to migration are , 
in reality, quite small and could be expected to have minimal effect on MS rates when 
only the denominators are involved. However, the majority of these potential errors 
have now been taken into account in estimating the final reference-population 
denominators to be used for detailed analysis of the MS-rates dataset. 
Prevalence by birthplace and month of birth-preliminary estimates 
Preliminary to Chapter 7, this chapter has included some simple exploratory analysis of 
crude prevalence rates to indicate some of the possible expected effects on MS risk , 
but also to allow a check of assumptions made for T AS-born cases. The increase in 
prevalence indicated in birthplace regions of higher latitude (see Table 6.16) recalls 
that seen with survey area (and its latitude) in Chapter 5. Perhaps this is not surprising 
given that both the MS cases and the Australia-born reference population appear to 
have not migrated from their birthplace states/territories to any great extent by 
1976/1981 (see Tables 6.10 and 6.12). Most importantly, the increase in prevalence for 
both sexes from QLD to TAS birthplaces of 4.6-fold seen here is only slightly greater 
than that seen for survey area in Chapter 5 (four-fold in TAS compared with OLD) . It 
appears that making the assumption for TAS-born cases (that these were all 'Hobart 
SD-born ' and then using the Hobart SD-born denominator) is not greatly overestimating 
the number of cases allocated to the Hobart SD birthplace, nor underestimating the 
true denominator (i .e. by using 'Hobart SD-born ' rather than the 'TAS-born ' 
denominator) , either of which would have increased the TAS-(/Hobart SD-)born 
prevalence more. Moreover, if latitude/UVR effects on the prevalence of MS are 
initiated early in life as postulated , then a latitude-prevalence association might be 
expected to be somewhat stronger at birth , compared with later in life when migration 
to other areas would dilute this association. Therefore , these preliminary results in 
Table 6.16 give additional confidence not only in the estimation techniques for the 
place-of-birth and month-of-birth denominators but also for the necessary assumption 
made for 'TAS born ' surveyed in 1981-that is , that all 'TAS-born ' cases were 
effectively Hobart SD born , justifying use of the Hobart SD denominator. 
With regard to the main research question for this thesis concern ing timing of birth in 
Chapter 7, Table 6.17 gives prelim inary estimates for prevalence rates by month of 
birth , but for all years of birth from 1920 to 1950 and all regions of birth combined . For 
total MS cases (males and females considered together) , these indicate possibly 
higher MS rates in December (early Australian summer) and lower rates in May and 
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possibly June (early winter) . Regression analys is techniques will be appl ied in Chapter 
7 to further define this suggested timing-of-birth pattern using the now longitud inal 
dataset. Thus , Chapter 7 will examine whether a timing-of-birth pattern exists in MS 
cases in Australia , using longitudinal case and reference-population data for the (birth-
year) cohorts born between 1920 and 1950. Effects of other factors , including 
birthplace and latitude of birthplace, on any timing-of-birth pattern , and on MS risk per 
se , will also be considered. 
In conclusion , the construction of a longitudinal dataset of MS frequency from the 
original cross-sectional data means that every month of every year over the study 
period can now be analysed for MS risk by regression modelling , rather than simply 
collapsing all the year-of-birth data and considering only a month-of-birth variable , as in 
the preliminary prevalence results indicated in this chapter (see Table 6.17). A 
complete timing-of-birth , gender and region-of-birth comparison between MS cases 
and the reference population in the 1920 to 1950 Australia-born cohort is now 
achievable from the original cross-sectional survey data, rather than simply a disease 
prevalence study. 
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CHAPTER 7 
TIMING OF BIRTH AND MS RISK IN AUSTRALIA: ANALYSIS OF TIMING OF 
BIRTH, BIRTHPLACE AND PRENATAL UVR PATTERNS IN MS CASES 
'Whoever wishes to pursue the science of medicine in a direct manner must first 
investigate the seasons of the year and what occurs in them' 
Hippocrates, 460 BC, in On Endemic Diseases: Airs, Waters and Places [656]. 
7.1 Introduction 
The investigation of seasonal birth patterns for specific diseases has been a classical 
approach in the epidemiological study of disease since the time of Hippocrates in 
460BC. In the 1900s, such studies began to become accepted as having serious 
importance, especially in the field of psychiatric disorders such as schizophrenia and 
bipolar disorder. In the late 1960s, schizophrenia was one of the first disorders, apart 
from infectious diseases, to be shown to have a distinct seasonal timing-of-birth cycle ; 
E. Hare in England and P. Dalen in Sweden were then regarded as the founders of 
modern psychiatric studies in this field , because they were able to use large sample 
numbers, adequate controls and more sophisticated statistical analyses to add 
credence to their findings [642]. Significantly, the presence of a seasonal birth pattern 
gives evidence of early life origins of disease that can provide important clues to 
disease aetiology [7]. 
As discussed in Chapters 1 to 3, the precise aetiology of MS is unknown . However, 
evidence has been accumulating for a number of years that causation of MS is 
multifactorial and most certainly involves a combination of genetic and environmental 
exposure factors . 
Rothman and Greenland (1998) use a 'component cause model ' to describe disease 
causation, wherein 'sufficient cause' for a disease to occur is defined as a 'set of 
minimal conditions and events that finally produce disease' (see Chapter 2). Each 
'sufficient cause' comprises a set, or series , of 'component causes ', the latter being 
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defined as 'an antecedent event, condition or characteristic that is necessary for the 
occurrence of disease, but which may not be sufficient by itself to produce disease' [1 ]. 
As discussed in Chapters 2 and 3 also, component causes acting in the same sufficient 
cause may be thought of as interacting biologically to produce disease. Further, this 
interaction or joint action need not be simultaneous: one component cause could act 
many years before the other, the condition being that the first component cause leaves 
some effect that interacts with the later component [1 ]. A similar concept of interaction 
of factors in a 'two-hit hypothesis' has been proposed for schizophrenia, in which this 
disorder 'might be predisposed by a seasonal factor occurring during the prenatal 
period and then precipitated by another factor, not necessarily seasonal , many years 
later' [642] . Such a causal scenario comprising a series of interacting components also 
appears likely for MS; this thesis study aims to investigate some of the possible 
environmental causal components of MS through their apparent timing (see Chapter 3, 
Section 3.2) . 
The present chapter will focus on timing of birth in MS cases , in order to examine the 
perinatal period for a possible component disease cause acting around the time of birth . 
That is , a seasonal or other temporal birth pattern for a specific disorder that differs 
significantly from the general birth pattern of the population would suggest a 
component causal factor operating very early in life; such a pattern may then provide 
information about the disorder's aetiology [7] . Particularly for a late-onset disorder such 
as MS, a difference in the timing of birth of cases compared with the general population 
could be a useful risk indicator, or 'proxy', for determining the nature of a causal 
component factor acting around the time of birth . Such specific early life environmental 
factors would otherwise be too difficult to recall when onset of a disorder such as MS 
typically occurs decades after birth . 
Only a few published studies have investigated timing-of-birth patterns in MS patients , 
and all of these have been located in the northern hemisphere. In Denmark , excess MS 
births (that is , births of people who later developed MS) were seen in the March to 
June period , particularly May and June, and deficits were evident in the other eight 
months [321 ]. Swedish data showed similar excesses in the same four months, 
particularly in May, and deficits in the remain ing eight months [322] . Data from British 
Columbia , Canada, revealed a similar peak in MS births in May, with excesses from 
April to July, and in January (Sadovnick and Yee , 1994 [657] , re- interpreted by James, 
1995 [320]). However, Salemi and co-workers (2000) showed a pattern of excess MS 
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births in the June to November period In Sicily, perhaps indicating some seasonal 
differences at lower latitudes [323] . 
More recently, northern hemisphere work on larger MS datasets from Canada and the 
UK by the Canadian Collaborative Study Group (CCSG) has shown a significant deficit 
of births in the month of November and an excess in May. These data pooled with 
Danish and Swedish data by CCSG showed an overall 13% increase (95% Cl 5% to 
22%) in MS risk in May-born compared with November-born persons [324]. Tremlett 
and Devonshire (2006) further confirmed this May/November peak-and-trough pattern 
in MS-case births in British Columbia , Canada [644]. Consistent with these studies, a 
November deficit in MS births was also seen in France [658], while a spring (March to 
May) excess and autumn (September to November) deficit occurred in Scotland [659]. 
Southern hemisphere analyses on month of birth of MS cases are now required. Of 
particular interest would be similar excesses and/or deficits in MS births , relative to that 
of the reference Australian population, in the corresponding seasons in the southern 
hemisphere. For example, excess MS births may be found to occur in or close to 
November in the southern hemisphere (or December, as suggested by the preliminary 
prevalence data in Chapter 6, Section 6.3.2 , Table 6.17) , in comparison with minimum 
MS births in or around May. Such a temporal MS-case birth pattern acting similarly in 
both parts of the world would suggest causal environmental factors that are 'time-
locked ' to the time of birth [229] . Seasonally fluctuating UVR levels , possibly mediated 
through vitamin D (see Chapter 2) , may be contributing to such a birth pattern in MS 
cases. Alternatively, or additionally, seasonal infection cycles also may contribute. 
As noted in Chapters 4 and 5, the continent of Australia covers a broad latitude range 
between approximately 10 and 44 degrees south (see Figures 4 .3 and 5.2) . The 
seasons in Australia vary from two main 'dry' and 'wet' seasons in the tropical far north 
(the NT and northern QLD) to a pattern of four seasons (based on temperature: 
summer in December to February, autumn in March to May, winter in June to August , 
spring in September to November) in the temperate mid- and southern regions (NSW, 
SA, VIC and TAS). (The State of WA covers the broadest latitude range (see Figure 
5.2) but most of its population is centred in the southern , temperate , half.) As noted in 
Chapter 2, MS exhibits a prevalence gradient of more than six-fold between low-
latitude northern QLD and high-latitude TAS, and an approximately four-fold gradient 
between subtropical southern QLD (Brisbane) and T AS [301] . 
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It is possible that the effect size of any timing-of-birth pattern found in Australia may 
also vary regionally with latitude, as suggested by recent northern hemisphere work . In 
particular, the CCSG MS study suggested a trend in effect size with prevalence , the 
magnitude of the May-born to November-born ORs for incident cases increasing from 
lower-prevalence, lower-latitude Canada to higher-latitude Scotland where prevalence 
was highest. This work suggested that the seasonal birth effect may be linked with 
environmental factors determining prevalence rates [324]. Such a finding in the 
southern hemisphere may further implicate fluctuating UVR and/or seasonal infections 
as component causal factors , given that both of these potential factors may cycle more 
strongly at higher latitudes. For example , in Australia , ambient winter effective UVR 
(UVRett) falls relatively lower, compared with summer UVR, in southernmost TAS than 
in the northern state of QLD. That is, the seasonal variation in UVR in Australia as 
given by the ratio of maximum (summer) to minimum (winter) UVRett is 3.5-fold higher 
in higher-latitude (and higher-prevalence) TAS than in lower-latitude Brisbane (QLD) 
(Table 7.1 ). 
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Table 7.1: Monthly averages of daily total UVRett (MED)+, 1996 to 2000, for 
Australian capital cities of states included in 1981 MS Survey. (Unpublished data 
for Brisbane, Perth, Sydney and Adelaide provided by P. Gies, Australian 
Radiation Protection and Nuclear Safety Agency [ARPANSA], pers. commn; 
latitude of capitals 17 in decimal degrees south shown in parentheses) 
January 
February 
March 
April 
May 
June 
July 
August 
September 
October 
November 
December 
Max : Min* 
Brisbane 
(QLD) 
(27.5 °S) 
24.7 
22.3 
19.0 
12.5 
8.6 
6.6 
7.5 
10.4 
14.6 
18.9 
22.7 
24.4 
3.7 
Perth 
(WA) 
(31.9 °S) 
30.4 
27.9 
18.9 
11.8 
7.1 
4.9 
5.4 
7.9 
12.1 
18.8 
23.8 
29.2 
6.2 
Sydney 
(NSW) 
(33.9 °S) 
22.2 
21.7 
16.2 
9.8 
5.6 
3.9 
4.1 
6.9 
10.4 
15.3 
19.1 
21.9 
5.7 
Adelaide 
(SA) 
(34.9 °S) 
28.1 
24.5 
13.7 
9.4 
5.2 
3.6 
3.7 
6.3 
10.0 
15.5 
21.5 
26.1 
7.8 
(TAS) 
(42.9 °S) 
20.4 
18.6 
12.4 
6.5 
3.7 
1.7 
1.6 
3.9 
7.0 
12.0 
15.7 
18.1 
12.8 
+ UVRett18 in units of minimum erythemal dose (M ED ), defined as the cumu lative UVR exposure required to 
induce erythema or sunburn in humans [660] . 
# Data for Hobart for 1991 from Gies et al . (1 994 ) [660] . 
* Seasona l variation as given by a ratio of summer maximum to winter minimum UVRett-
As discussed in Chapter 4, Australia also has the advantage of a relatively genetically 
homogeneous population distributed over the latitude range. Fortunately, most of this 
broad area has been included in the 1981 MS Survey dataset, giving an opportunity for 
this additional inquiry (see research question 2, this chapter) . 
17 Latitude values for the state capital cities used in this chapter were shown in Chapter 5 to be little 
different from mean state latitude values based on 1981 popu lation distribution (see Section 5.1, Figure 
5.2). 
18 UVR measurements are validated ground measurements supplied by the ARPANSA , rather than UV 
Index forecasts from satellite mon itoring as used in Chapter 4. 
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The main research questions for this chapter are: 
1. Is there a timing-of-birth pattern for Australia-born MS cases relative to 
the general Australian population? 
For example, is there an excess (or deficit) of MS cases born in any particular 
month, or months, of the year in Australia, relative to the reference Australia-born 
population? That is, is there an association between timing of birth and MS risk? 
Specifically, an excess of (i.e. relatively more) MS cases born in November 
compared with May is posited. 
2. Within Australia, does region of birth modify an association between 
timing of birth and MS risk? 
If a timing-of-birth pattern for MS cases relative to the reference population exists, 
does this pattern differ according to the birthplace (state) of MS cases in Australia? 
Specifically, MS births in November, for example, relative to those in May are 
posited to be greater at higher latitudes; that is, there would be a greater relative 
difference between early summer and early winter MS births (i .e. a higher early 
summer to early winter ratio) in TAS compared with QLD. 
Additionally, as shown in Table 7.1, there are monthly ambient UVR data available that 
have been reliably measured over a number of years for the regional state capitals of 
Australia by the ARPANSA (P. Gies, pers. commn) [660]. Such quantitative UVR data 
can be used directly as an additional exposure factor, and independently of timing of 
birth, the latter being proxy for a number of possible exposure factors that include UVR 
and/or vitamin D, but may also include such factors as temperature , diet/nutrition and 
infections. Further, the UVR data conveniently encompass both the regional ambient 
UVR variation and the monthly (seasonal) variation in a single variable . This wide 
variation in ambient UVR with latitude and between summer and winter (Table 7.1) 
may be useful to explore the effects of (maternal) ambient UVR levels during the 
perinatal period, including the prenatal period in particular. For example , Sayers and 
co-workers have shown that 'erythemal UV' during pregnancy can be used as an 
instrumental variable that is strongly linked to maternal serum vitamin D during 
pregnancy, and that such UV data can be used to investigate subsequent vitamin D-
dependent health outcomes in offspring [661 ]. Thus , research question 3 is: 
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3. Is prenatal UVR associated with MS risk? If so, can this account for a 
timing of birth risk pattern? 
The aims of this chapter are to investigate, using individual-level data, the timing of 
birth of MS cases relative to the reference 1981 Australian population (research 
question 1 ). The MS-rates dataset constructed for this purpose in Chapter 6 will be 
used. Other factors potentially affecting MS risk directly, such as sex and birthplace, 
will also be considered. As well, the possible modifying effects of factors such as 
birthplace on any temporal birth pattern found will be investigated (research question 2) . 
Finally, a possible link between maternal UVR exposure during the perinatal period and 
MS risk will be independently explored using available regional and seasonal UVR data 
(research question 3). 
7.2 Methods 
7.2.1 MS-rates dataset by month and year of birth 
As detailed in Chapters 5 and 6, a longitudinal dataset in frequency (or count) format 
spanning every (birth) month of every year over the chosen study period has been 
constructed from the original unit-record cross-sectional 1981 MS Survey data. This 
MS-rates dataset comprises numerator data taken directly from the 1981-surveyed MS 
cases (see Chapter 5) , together with reference-population denominators derived from 
both the 1981 Australian Census and supplementary Australian births-registration data 
covering the same birth years (see Chapter 6). Necessary assumptions for derivation 
of these denominator estimates have been examined , and final adjustment of 
denominators to account for the main case losses from surveyed to unsurveyed state 
regions between the time of birth and time of survey (1981) have also been made (see 
Chapter 6). 
For timing-of-birth analysis , a restricted dataset of those MS cases born in Austral ia 
between 1920 and 1950 (inclusive) has been chosen to minimise potential biases 
arising from the use of the whole year-of-birth range in the original cross-sect ional 
dataset (see Chapter 5, Section 5.3.3). The resulting MS-rates dataset comprises 
numerator and denominator data for a total of 1,524 MS cases born in any of the five 
surveyed states, QLD, WA, NSW/ACT, SA and TAS, during this 1920 to 1950 period 
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(see Chapter 6, Section 6.3.1, Tables 6.15 and 6.16). Female cases numbered 1,068 
(70%) and the mean age at onset was 32.9 years (s.d. 9.0). A relapsing course from 
onset (which included relapsing-remitting and those who had entered a secondary 
progressive phase) comprised 85%, and 15% had a primary progressive course from 
onset (see Chapter 5). 
7.2.2 Statistical analysis: MS incidence rate 
The main outcome measure is the number of MS births in each period (e.g. month) 
relative to births in the same period in the general population, expressed as an MS-
births incidence rate. Regression analysis was used to explore the possible association 
between the period as the independent variable , and the number, or frequency, of MS 
births as the dependent variable, taking into account the estimated population births 
(i.e. estimated denominator) as the offset, or statistical exposure , 19 variable. The 
constructed MS-rates dataset was different from the individual-level unit records in the 
original MS survey in that each record now represented a 'cell' or unique combination 
of factors comprising year of birth, month of birth , state and sex (see Chapter 6, Table 
6.3). The number (or frequency) of MS cases and the corresponding population 
denominator for each 'cell' record then pertained to that particular combination of 
factors. The population-denominator (i.e. offset) variable thus expressed the maximum 
number of times that the event (=birth of a person who would later become an MS case) 
could have occurred in the relevant population-that is , if there was 100% probability of 
the disease-by month and year, and by state and sex. 
Poisson and negative binomial regression models 
To explore MS risk, a Poisson regression model was first investigated, the Poisson 
distribution often being suitable to model discrete events , such as count data , that 
occur infrequently in time or space. Although the data arise from a binomial situation in 
which there are two distinct outcomes for every birth-disease or no disease-in cases 
such as this , where the population is large and the event is rare , it is appropriate to use 
a Poisson distribution , which is sometimes called the 'distribution of rare events ' [654]. 
19 The term 'exposure' is used here with its statistical mean ing , rather than an epidemiolog ical risk 
'exposure'. 
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The low probability of MS in the Australian population is indicated by the overall 
prevalence of around 30 per 100,000 (see Chapter 5, Section 5.3.2 , Table 5.5) and by 
the very low and sparse MS frequencies shown in Tables 6.4 and 6.5 (see Chapter 6, 
Section 6.2.1) and Table 6.18 (see Section 6.3.3). Given the underlying assumptions of 
the Poisson distribution (that is, if events occur independently and with constant 
probability), then the counts of events (such as MS outcome) over a given period of 
time are expressed by the incidence rate, rj [662]: 
r-J count of events (MS births) 
no. of times event could have occurred (population births) 
The denominator is the offset variable and is given by the number of reference-
population births for each period (i.e. each month of each year, in each state and for 
each sex, as described above). Under a Poisson regression model, the logarithm of the 
incidence rate is then modelled as a linear function of one or more predictor (x) 
variables, which represent the epidemiological exposure (or risk) factors of interest: 
Assuming that a Poisson distribution underlies the events of interest (MS births) , 
Poisson regression finds maximum-likelihood estimates of the ~ parameters . Estimates 
of relative incidence rates , or IRRs, rather than regression coefficients can also be 
gained (i.e. estimated coefficients transformed to IRRs defined as exp(~) rather than ~) 
[662] and will be used here. 
For example , to ask the question: 'Does MS-births incidence rate differ between the 
sexes?' (i .e. 'Does the incidence rate of MS births depend on the single predictor, sex? ' 
as in univariate model (2) , Section 7.2.3) , using the Stata 8.0 statistical analysis 
program (release 8.0 , 2003 ; Statacorp, College Station , Texas) and the MS-rates 
dataset constructed in Chapter 6, the following Stata command for the Poisson 
regression model is used : 
.poisson MSfreq sex, nolog exposure(Denom) irr 
where MSfreq is defined as the dependent variable (MS births, by month) , sex is the 
single independent variable (male or female) and Oenom is the Poisson exposure (or 
offset) variable (reference-population births, by month) ; 'nolog ' requests that iterations 
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for convergence of the model not be shown ; 'irr' requests IRRs to be calculated rather 
than regression coefficients. This gives the following Stata output: 
Poisson regression 
Log likelihood=-2627.3256 
MSfreq IRR Std. Err. 
sex 2.276294 .1273365 
Denom (exposure) 
z 
14.70 
Number of obs= 3720 
LR chi2(1 )= 235. 70 
Prob > chi2= 0.0000 
Pseudo R2= 0.0429 
P>lzl [95% Conf. Interval] 
0.000 2.039915 2.540065 
The interpretation of this regression analysis is that the MS-births rate for females (data 
coded female=2 , male=1) is 2.28 times (95% Cl 2.04, 2.54) higher than for males 
(significant p-value <0.001 ), though the fit of this Poisson model with only a single 
predictor, as shown by pseudo R2 , is poor. Additional predictor variables can then be 
added to such a model to examine their effects and improve model fit [662]. 
A characteristic of the Poisson distribution is that the mean of the distribution is equal 
to the variance , both being able to be represented by a single parameter [654] . 
However, as count data are commonly over-dispersed-that is , the variance of the 
count data is greater than the mean-a negative binomial regression model , which is a 
more general type of binomial regression but still of the Poisson structure , often fits 
these types of data better [663]. Summarising the MS-frequency data in Stata 8.0 
(i.e .. summ MSfreq, detail) showed that the variance (0.65) was , indeed , some 50% 
greater than the mean (0.41 ). 
Therefore , a negative binomial regression model was investigated as an alternative to 
the Poisson model , and in most instances the negative binomial model was more 
appropriate for analysing these MS data . This was shown by likelihood ratio tests for 
departure of this 'gamma' type of distribution from a Poisson model , these tests being 
automatically carried out by the statistical software package (Stata 8.0) used during 
negative binomial regression analysis. For example , for the same univariate model as 
previous-examining the effect of sex on MS-births incidence rate-the Stata 
command: 
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.nbreg MSfreq sex, nolog exposure(Denom) irr 
gives the following output: 
Negative binomial regression Number of obs=3, 720 
LR chi2(1 )= 208.89 
Prob> chi2= 0.0000 
Log likelihood=-2625.1494 Pseudo R2= 0.0383 
MSfreq IRR Std. Err. z P>lzl 95% Conf. Interval 
Sex 2.275949 .1309311 14.30 0.000 2.033267 2.547596 
Denom (exposure) 
/lnalpha -2 .452673 .5243685 -3.480416 -1.424929 
alpha .0860633 .0451289 .0307946 .2405255 
Likelihood ratio test of alpha=0: chibar2(01 )=4.35 Prob>=chibar2=0.018 
The negative binomial regression model adds a parameter, alpha, that reflects 
unobserved heterogeneity among the observations leading to the over-dispersion [663]. 
The likelihood ratio test shown in the last line of the output (for whether the over-
dispersion parameter alpha=0) is significant here (p=0.018) , providing evidence that 
the MS-frequency distribution was indeed different from the Poisson type. These tests 
within the negative binomial regression analyses generally confirmed the over-
dispersion of the MS frequencies , often at highly significant levels (p<0.0005) ; the 
negative binomial model is therefore preferable to the Poisson model for these data. 
7.2.3 MS risk by month of birth 
Negative binomial regression models were used to provide an estimate of the MS 
incidence rate for each period of birth , expressed as the IRR for each period relative to 
a single reference period. The independent month-of-birth variable was eventually 
chosen as six two-monthly categories ; that is , the year was considered as six two-
monthly periods: January to February, March to April , May to June, July to August, 
September to October, and November to December, with the May to June period then 
chosen as the reference period. 
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Initial analysis using single months of birth , with May as a reference , indicated that the 
sample size of MS cases available (n=1 ,524 cases) was inadequate for such analysis 
by monthly intervals-there were few IRRs significantly different from the reference 
level and most months showed marginal effects. Indeed , Hare (1975) emphasises that 
for a seasonal birth distribution to show a statistically significant 8% deviation (i .e. 
excess or deficit in births , albeit using different estimation techniques from those used 
here), 1,500 'subjects ' (presumably cases) would be needed for seasonal (four per 
year) periods and 4,500 for monthly intervals [664]. However, Torrey and colleagues 
indicate in their methodological review that quarterly periods (i .e. seasons) are 
unsatisfactory if a birth excess or deficit occurs in an individual month or in two 
contiguous months in different quarters , when statistical significance may not be 
reached and the birth excess/deficit missed [642]. Therefore , two-monthly periods (six 
per year) were chosen for analysis in order to increase the power to detect a significant 
excess or deficit , but still achieve sufficient discrimination with respect to the periods. 
May to June was chosen as the reference period because this two-monthly period 
showed the lowest UVR level in our region (Table 7.2). In addition , a 'trough ' in MS 
rates in May to June was suggested by preliminary prevalence estimates shown in 
Table 6.17 (see Chapter 6, Section 6.3.2). MS incidence rate , or MS risk , for each of 
the other five two-monthly periods of birth was then expressed as the IRR relative to 
the reference period , May to June, for which IRR=1 .0. 
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Table 7.2: Two-monthly averages of daily total UVRett (MEDf for Australian state 
capitals in 1981 MS Survey, 1996 to 2000 (two-monthly values obtained by 
averaging monthly values in Table 7.1). (Latitude of capitals in decimal degrees 
south in parentheses) 
Brisbane Perth Sydney Adelaide Hobart# 
(QLD) (WA) (NSW) (SA) (TAS) 
(27.5 °S) (31.9 °S) (33.9 °S) (34.9 °S) (42.9 °S) 
January to February 23.50 29.15 21.95 26.30 19.50 
March to April 15.75 15.35 13.00 11.55 9.45 
May to June 7.60 6.00 4.75 4.40 2.70 
July to August 8.95 6.65 5.50 5.00 2.75 
September to October 16.75 15.45 12.85 12.75 9.50 
November to December 23.55 26.50 20.50 23.80 16.90 
+ UVRett in MED units defined in Table 7.1. 
# Monthly data for Hobart for 1991 from Gies et al. (1994) [660] . 
Because the two-monthly periods were a set of indicator (or categorical, i.e. dummy) 
variables-the five test periods each being compared pair-wise with the sixth May to 
June (winter) reference period-any pattern could be considered. That is , any 
departure from a uniform MS incidence rate by month of birth compared to the 
reference period could be investigated. In particular, no pre-conceptions of any 
temporal pattern shape, such as sinusoidal , were imposed . 
Further, because MS is an irreversible disorder once onset occurs , the number of 
cases reflected the numerator of a cumulative incidence rate. Analysis using negative 
binomial (or Poisson) models provided an estimate of lifetime MS risk , in terms of the 
cumulative incidence of cases for each two-monthly period of the year relative to the 
reference period , May to June. Stata 8.0 statistical software (release 8.0 , 2003; 
Statacorp , College Station , Texas) was used for all analyses. 
Basic regression model 
The basic univariate timing-of-birth 'model ' was: 
• MS risk depends on month of birth Model (1) 
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the month (of birth) factor being a categorical variable comprising six periods , January 
to February ... November to December, (May to June being the reference period , 
IRR=1.0). 
Other univariate effects on MS risk-sex and birthplace 
Because preliminary prevalence estimates in Chapter 6 have indicated direct effects on 
MS risk per se by both sex and birthplace state (or survey area, see Chapter 5) , 
negative binomial regression was conducted to estimate MS incidence rates for each of 
these factors, sex and birthplace, irrespective of any temporal birth patterns. 
The factor birthplace was considered a categorical variable comprising the five states: 
QLD, WA, NSW/ACT, SA and TAS (refer to map in Chapter 5, Figure 5.2); IRRs were 
derived for the four states, QLD, WA, SA and TAS , relative to the most-highly 
populated state, NSW/ACT, as reference (IRR=1.0). 
For the factor sex, IRRs were calculated for females relative to males as the reference 
category (IRR=1.0). 
These univariate regression models were thus: 
• MS risk depends on sex Model (2) 
(reference=males, IRR=1 .0) , and 
• MS risk depends on birthplace (state) Model (3) 
birthplace comprising five states , QLD, WA, NSW/ACT, SA and TAS as indicator 
variables (reference=NSW/ACT; IRR=1 .0) . 
Decade of birth within 1920 to 1950 
A further univariate analysis was conducted to check the 1920 to 1950 year-of-birth 
data restriction period chosen for analysis . Although such restriction is a method of 
controlling confounding [1 ], it was still possible that MS risk was varying within the 
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chosen 1920 to 1950 year-of-birth range. Three 'decades', 1920 to 1929, 1930 to 1940 
and 1941 to 1950, were therefore considered as categories of the decade factor 
(reference=1930 to 1940) to check this possibility, using the following model : 
• MS risk depends on decade (of birth) within 1920 to 1950 Model (4) 
decade comprising 1920 to 1929, 1930 to 1940 and 1941 to 1950 (calendar) years of 
birth (reference category=1930 to 1940; IRR=1.0) 
7.2.4 Effects of other possible factors on timing-of-birth pattern 
Subgroup analyses 
Regression analyses of timing of birth using model (1) were initially conducted 
separately for each state region of birth, OLD, WA, NSW/ACT, SA and TAS , in an 
attempt to investigate any regional variation in a temporal birth pattern (i.e. research 
question 2). Separate timing-of-birth regression analyses were also conducted for each 
sex, because some characteristics of MS are known to differ by gender. For example, 
males often show differences in clinical course of disease and in disease severity and 
prognosis compared with females [665]. Sample size for each birthplace and each sex 
was quite low in these analyses, particularly for the smaller states (refer to Table 6.15, 
Section 6.3.1 ). 
Multivariate analyses 
Modelling MS risk by multiple negative binomial regression was then undertaken to 
investigate the possible effects of other main factors-particularly sex and birthplace--
on a timing-of-birth pattern. That is, the basic regression model (1) was employed and 
the additional factors added to the model. The advantage of this technique over 
subgroup analyses was that the effects of several factors could be considered at the 
same time , without compromising the overall sample size [1 ]. In particular, the possible 
effects of the additional factors as confounders of any observed seasonal pattern of 
birth could be determined , as well as their potentially important effects as mod ifiers of 
any such pattern. 
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Possible confounders 
A confounding variable may be described as 'a variable of little immediate interest that 
is correlated with the risk ( or exposure) factor and is independently related to the 
outcome variable of interest' [666]. The following factors were first added to the basic 
MS-risk regression model (1) comprising just the main study exposure (risk) factor, 
month of birth, to determine any large effects on the two-monthly IRRs that might 
indicate possible confounding of observed results by those factors: 
• sex (two categories, reference=males) 
• birthplace (five states, OLD, WA, NSW/ACT, SA and TAS, as indicator variables; 
reference= N SW/ ACT). 
The full multivariate regression model, including these possible confounders as 
covariates, was then as follows: 
• MS risk depends on month of birth, sex and birthplace Model (5) 
IRR values obtained were adjusted for each of the other factors, or covariates, in the 
model. For example, the IRR values for the two-monthly periods were adjusted for both 
sex and birthplace. Importantly, by comparing the unadjusted IRRs in the univariate 
models (1 ), (2) and (3) with the adjusted IRRs in model (5) and determining the extent 
of each difference in IRR value, it could be judged whether the additional factors were 
confounding any timing-of-birth pattern. 
Also, decade of birth within the restricted 1920 to 1950 year-of-birth range was 
checked as another possible confounder of a seasonal birth pattern. The full 
multivariate regression model then was: 
• MS risk depends on month of birth , sex, birthplace and decade Model (6) 
Potential effect modifiers 
A further advantage of multivariate analysis was that statistical interactions between 
the factors could also be investigated. Such interaction between a factor and the risk 
exposure of interest (e.g. month of birth) on MS risk may indicate the presence of an 
important effect-measure modifier that might provide more information about the nature 
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of the actual study exposure factor [666]. For example, a statistical interaction between 
month of birth and birthplace, defined by a product-term month*birthplace added to a 
baseline regression model [1 ], may indicate that MS risk varied more widely between, 
say, summer- and winter-born persons when their birthplace was in higher-latitude TAS 
compared with lower-latitude OLD (research question hypothesis 2). 
Therefore, the following product terms were added, in turn, to a baseline model 
comprising the three factors month (of birth), sex and birthplace (model (5)) and the 
effects of each product term evaluated statistically: 
• month*sex 
• month *birthplace 
• birthplace *sex. 
The above three interactions were tested in turn by comparing the following three 
models, which included the above product terms, with the baseline main-effects model 
(5): 
• MS risk depends on month of birth, sex, birthplace and month*sex Model (7) 
• MS risk depends on month of birth, sex, birthplace and month*birthplace 
Model (8) 
• MS risk depends on month of birth , sex, birthplace and birthplace*sex 
Model (9) 
Chi-square likelihood ratio tests were used to evaluate the 'nested ' negative binomial 
models with and without each of these interactions-that is, models (7) , (8) or (9) 
compared with model (5)-in order to determine whether any of these interactions were 
statistically significant (p<0.05) and should be retained in the final model. 
Finally, the addition of a month*decade (of birth) product term was similarly tested to 
determine whether there was any significant effect modification by decade within the 
restricted 1920 to 1950 year-of-birth range chosen for analysis. For this check , the 
following model (10) was compared with the baseline main-effects model (6): 
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• MS risk depends on month of birth , sex, birthplace, decade and month *decade 
Model (10) 
It should be noted that the aim in this section was simply model specification rather 
than precise model fitting or prediction. That is, the main concern was which covariates 
and product terms were required , as confounders and effect modifiers, in a basic 
timing-of-birth model. In other words, the final model was required to provide only 
approximately valid summary estimates or trends for a few key relationships rather 
than (approximately) valid exposure-specific predictions of outcomes [1 ]. 
Regional seasonal UVR as independent risk factor 
Figure 7.1 illustrates the wide seasonal and regional variation in daily ambient effective 
UVR in Australia, ranging from 1.6 MED units per day in Hobart, TAS in July to 30.4 
MED per day in Perth , WA in January (data as monthly averages for the capitals of the 
states surveyed in 1981, from Table 7.1 ). An approximate six-month periodicity is 
evident between the maximum (summer) UVR period (>15 MED per day) in November 
to February and the minimum (winter) UVR period (<10 MED per day) in May to August 
in all states (Figure 7.1 ). 
Seasonal UVR Cycle for Australian State Capitals 
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Figure 7 .1: Monthly averages of daily total UVRett (MED) for Australian state 
capitals included in 1981 MS Survey, 1996 to 2000. (Data from P. Gies [pers. 
commn] and Gies et al., 1994 for Hobart [660].) 
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Because ambient UVR may be an important (maternal) exposure or risk factor acting 
around the time of birth of the offspring, this additional exposure factor was used , 
independently of month of birth, in regression models similar to those already 
described. Further, because ambient UVR may be acting even before the time of birth , 
for example, through maternal serum vitamin D levels, this UVR factor was able to be 
successively 'lagged' to represent various periods before birth; these separate UVR 
variables-one for each period before birth-could then be tested in regression 
analyses for effects on MS risk. 
A continuous regional-UVRett variable was generated from the monthly ambient UVR 
values of the state capital cities (Table 7.1) to represent the ambient UVR at the time 
(month) and place (state) of birth of each individual. Similar variables were then 
generated for various periods before birth , from one to nine months prior, by lagging 
the UVR values. That is, the UVRett monthly averages at birth were successively 
lagged a number of months so that they then expressed the ambient UVRett pertaining 
to a particular time before birth, for each individual and for each region of birth. For 
example, the continuous variable 'UV-6mth' (see Table 7.11, Section 7.3 .4) denoted 
the daily ambient UVRett level at six months prior to the birth month of each individual at 
each respective birthplace. Nine such (continuous) variables, representing one to nine 
months before the birth month of an individual , were generated and included in 
separate negative binomial regression models , as previously described for the 
categorical month-of-birth variable in model (1) (Section 7.2.3) . Different periods before 
birth could then be assessed for their ability to account for the observed variation in 
(lifetime) MS risk. 
7.3 Results 
7 .3.1 Month of birth and MS risk 
Figure 7.2 shows the MS-risk pattern by month of birth (two-monthly periods) 
expressed as the IRR for MS births , and 95% Cl , relative to the reference IRR (= 1.0) 
for the May to June period. All (male and female) MS cases born in Australia during the 
1920 to 1950 period (n=1,524 cases) , together with their corresponding by-month and 
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by-year reference-population denominators, have been used here in negative binomial 
regression model (1 ). 
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Figure 7.2: MS risk by month of birth (data for 1920 to 1950 Australia born; 
n=1,524 cases). 
IRRs for all of the other two-monthly periods compared with the May to June reference 
period were statistically significant (p<0.05; 95% Cl excluding the IRR value 1.0) , 
ind icating increased MS risk in any of these periods (ranging from 1.22 to 1.34 times) 
compared with the minimum-risk period in May to June. In particular, the November to 
December period showed a maximum and highly sign ificant (p<0.01) excess of MS 
births relative to those in May to June (shown in bold in Table 7.3). These resu lts 
indicate that the MS risk if born in the early summer months of November to December 
is significantly higher than the risk if born in the early winter months of May to June, by 
34% (IRR 1.34; 95% Cl 1.10, 1.63) (Table 7.3). 
300 
Table 7.3: IRRs and 95% confidence intervals for MS risk for two-monthly periods 
of birth in Australia (1920 to 1950 born; n=1,524 cases) 
Factor 
Month of birth 
Category (months) 
1 (January toFebruary) 
2 (March to April) 
3 (May to June) 
4 (July to August) 
IRR [95% Cl] 
1.24 [1.02, 1.52] 
1.23 [1.01, 1.51] 
1. 00 (Reference) 
1.24 [1.02, 1.51] 
5 (September to October) 1.23 [1.01 , 1.49] 
6 (November to 1.34 [1.10, 1.63] 
December) 
* IRR statistically significant (p<0 .05). 
** IRR statistically significant (p<0.01 ). 
p-value 
0.031* 
0.037* 
0.030* 
0.041 * 
0.003** 
7.3.2 Direct effects of sex and birthplace factors on MS risk 
Table 7.4 shows MS risk as IRR and 95% Cl for females compared with males, 
estimated using negative binomial regression model (2) (univariate analysis). MS risk 
for females, as IRR, was 2.28 times that for males , this difference being consistent with 
the general overall female to male prevalence ratios for MS of approximately two-fold 
[301] . 
MS risk for each birthplace state , estimated from model (3), is also shown in Table 7.4. 
All birthplace states except SA showed significantly different (p<0.01) IRRs from that of 
the reference state, NSW/ACT. Further, the results indicate increased MS risk with 
increase in latitude from QLD to TAS (Table 7.4 ). 
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Table 7.4: MS risk as IRR+ 95% Cl for univariate factors, sex and birthplace, from 
negative binomial regression models (2) and (3), respectively (data for 1920 to 
1950 Australia born) 
Factor 
Sex 
Birthplace state 
(latitude of 
capitalt 
Category 
Male 
Female 
OLD (27.5°S) 
WA (31.9°S) 
NSW/ACT (33.9°S) 
SA (34.9°S) 
TAS (42.9°S) 
# Latitude of state capital cities in parentheses. 
** IRR statistically significant (p<0 .01 ). 
IRR [95% Cl] 
1.00 (Reference) 
2.28 [2.03, 2.55] 
0.59 [0.51 , 0.69] 
0.76 [0.62, 0.92] 
1.00 (Reference) 
1.03 [0.88, 1.21] 
2.70 [2.06, 3.51] 
p-value 
<0.001 ** 
<0.001 ** 
0.005** 
0.723 
<0.001 ** 
This trend of increasing MS risk with southern latitude at birth is illustrated in Figure 7.3 , 
where the IRR estimates from Table 7.4 are shown regressed against mean latitude of 
the birthplace states. The figure indicates that this association with latitude at birth is 
adequately explained by a linear model (p=0.031 for linear regression of mean IRR on 
mean latitude of birthplace states). 
A latitude relationship of MS risk with birthplace is thus evident rather than simply with 
survey area. Importantly, the data in Table 7.4 and Figure 7.3 allow simple quantitative 
comparison of the IRR means for the birthplace states and confirm , as indicated by the 
prevalence ratios for OLD and TAS derived in Chapter 6 (see Section 6.3.2) , that 
overall MS risk if born in TAS is some 4. 6 times higher than if born in OLD. 
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Figure 7.3: MS risk (IRR estimates from Table 7.4) by latitude of birthplace state 
(mean latitude of state in decimal degrees south; 1920 to 1950 Australia born; 
n=1,524 cases). 
Decade of birth within 1920 to 1950 restricted range 
As a check of the 1920 to 1950 year-of-birth restriction period chosen for analysis (see 
Chapter 5, Section 5.3.3, Figure 5.12) , three decades within this period were 
investigated . MS risk was found to be significantly different in only the later-born 1941-
50 decade group compared with the central decade reference group (Table 7.5) , the 
IRR for this later-born decade group being less than 1.0. This result indicated that there 
were probably some as yet undiagnosed (and therefore not ascerta ined ) MS cases in 
this age group compared with the other two groups. However, th is was not unexpected 
given the result shown in Chapter 5 (see Section 5.3.3, Figure 5.11 ) for the mid-1940 to 
mid-1950 decade using the tota l survey sample. In that figure, the number of MS cases 
relative to the census population was visibly lower than in the two earl ier-born decades. 
Whether this lowered MS risk per se in the 1941- to 1950-born decade group might 
have any confounding effect on an observed timing-of-birth pattern will be considered 
in the following section . 
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Table 7.5: MS risk as IRR+ 95% Cl for the univariate factor, decade of birth, from 
negative binomial regression model (4) (data for 1920 to 1950 Australia born) 
Factor 
Decade of birth 
Category 
1 (1920-1929) 
2 (1930-1940) 
3 (1941-1950) 
** IRR statistically significant (p<0.01 ). 
IRR [95% Cl] p-value 
1.09 [0.95 , 1.24] 0.222 
1.00 (Reference) 
0.73 [0.64, 0.83] <0.001** 
7.3.3 Effects of other factors on timing-of-birth risk pattern-sex, 
birthplace and decade of birth 
Subgroup analyses-sex and birthplace 
MS risk (as IRR and 95% Cl, using negative binomial regression model (1 )) is shown 
by month of birth (two-monthly periods) for the sexes separately (n=456 and 1,068 for 
males and females, respectively) in Table 7.6. IRR estimates were statistically 
significant (p<0.05) only for females, four of the five test periods showing increased MS 
risk compared with the reference May to June period (Table 7.6). 
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Table 7.6: IRR+ 95% Cl for MS risk for two-monthly periods of birth in Australia 
(1920 to 1950 born) by sex (males, n=456; females, n=1,068) 
Month of 
birth 
Jan-Feb 
Mar-Apr 
May-Jun 
Jul-Aug 
Sep-Oct 
Nov-Dec 
Males 
IRR [95%CI] 
1.12 [0.80, 1.57] 
1.30 [0.94, 1.80] 
1.00 (Reference) 
1.05 [0.75, 1.47] 
1.05 [O. 75, 1.4 7] 
1 . 31 [ 0. 94, 1 . 81] 
* IRR statistically significant (p<0 .05) . 
Females 
p-value I RR [95%CI] p-value 
0.493 1.28 [1.02 , 1.61] 0.036* 
0.106 1.18 [0.94 , 1.49] 0.150 
1.00 (Reference) 
0.769 1.32 [1.05, 1.65] 0.016* 
0.785 1.30 [1.04, 1.63] 0.022* 
0.104 1.33 [1.06, 1.67] 0.013* 
MS risk by month of birth is shown separately by birthplace (state) in Australia in Table 
7.7. While most of the state regions showed at least some significantly increased IRRs 
relative to the May to June reference, confidence intervals were also wider due to the 
smaller sample sizes and , overall, the results were not interpretable as either a 
consistent or a predictably changing pattern. The lack of any meaningful pattern of MS 
births in these subgroup analyses is likely due to inadequate sample size . Instead , the 
effect of factors such as sex, birthplace and decade of birth on the temporal pattern of 
birth were investigated further by multivariate analysis , considered next. 
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Table 7.7: IRR + 95% Cl for MS risk for two-monthly periods of birth in Australia (1920 to 1950 born) by birthplace (states, QLD 
[n=216], WA [n=123], NSW/ACT [n=928], SA [n=197] and TAS [n=60]) 
Month of 
birth 
QLD (27 .5 °s)' WA (31.9 °S) 
IRR [95%CI] p IRR [95%CI] 
Jan-Feb 1.39 [0 .83, 2.32] 0.204 1.63 [0 .81 , 3.31] 
Mar-Apr 1.35 [0 .81 , 2.25] 0.248 1.70 [0 .84 , 3.41] 
May- Jun 1.00 (Reference) - 1.00 (Reference) 
Jul- Aug 1.00 [0 .58 , 1.72] 0.992 2.16 [1 .11 , 4 .21] 
Sep- Oct 1.43 [0 .86, 2.37] 0.168 1.34 [0 .65, 2.78] 
Nov- Dec 1.67 [1 .01 , 2.75] 0.045* 1.56 [0 .76 , 3.17] 
# Latitude of state capital cities in parentheses . 
* IRR statistically significant (p<0 .05 ). 
p 
0.172 
0.138 
-
0.024* 
0.425 
0.222 
NSW /ACT (33.9 °S) SA (34.9 °S) TAS (42.9 °S) 
IRR [95%CI] p IRR [95%CI] p IRR [95%CI] p 
0.99 [0 .76 , 1.27] 0.924 1.90 [1.05 , 3.43] 0.033* 2.81 [1.09 , 7.24] 0.032* 
1.09 [0 .85 , 1 .40] 0.506 1.68 [0 .93 , 3.06] 0.086 1.39 [0.48 , 4.07] 0.543 
1.00 (Reference) - 1.00 (Reference) - 1.00 (Reference) -
1.06 [0 .83 , 1 .36] 0.647 2.05 [1.15 , 3.64] 0.015* 1.56 [0.56 , 4 .35] 0.394 
1.07 [0 .84 , 1.37] 0.587 2.00 [1 .12, 3.56] 0.019* 0.91 [0.29 , 2.86] 0.875 
1.09 [0 .85 , 1 .40] 0.489 2.03 [1.14 , 3.61] 0.016* 2.09 [0 .78 , 5.58] 0.140 
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Multivariate analyses-month of birth, sex, birthplace and decade of birth 
Having shown in the previous section that the factors sex and birthplace, and decade , 
have a direct effect on MS risk , it was now important to consider whether these factors 
might confound the observed timing-of-birth pattern shown in Figure 7.2. At the same 
time , potentially important statistical interactions between the covariate factors could be 
investigated without compromising the available sample size. 
Possible confounders of timing-of-birth pattern 
The variables sex and birthplace were considered together with month in a 'full ' 
multivariate model (model (5)). Table 7.8 shows MS risk by month of birth (two-monthly 
periods), the IRR values now adjusted for the covariate factors , sex and birthplace. The 
unadjusted IRR values (model (1 ), Table 7.3), are given again here for direct 
comparison , as are those for sex and birthplace. The close similarity between the 
unadjusted and adjusted estimates of MS risk by month of birth (<1.5% change in IRRs 
adjusted for both sex and birthplace factors together) indicate that neither of these 
additional factors were confounding the timing-of-birth MS-risk pattern (Table 7.8) . 
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Table 7.8: MS risk as IRR + 95% Cl for month of birth, shown both unadjusted 
(model (1 )) and adjusted for both sex and birthplace state (model (5); data for 
1920 to 1950 Australia born) 
Factor 
Month 
of birth 
Sex 
Birthplace 
(state t 
Category Unadjusted IRR 
[95% Cl] 
Jan-Feb 
Mar-Apr 
May-Jun 
Jul-Aug 
Sep-Oct 
Nov-Dec 
Male 
Female 
OLD 
WA 
NSW/ACT 
SA 
TAS 
1.24 [1.02 , 1.52] 
1.23 [1.01 , 1.51] 
1.00 (Reference) 
1.24 [1.02, 1.51] 
1.23 [1 .01, 1.49] 
1.34 [1.10, 1.63] 
1.00 (Reference) 
2.28 [2.03, 2.55] 
0.59 [0.51 , 0.69] 
0.76 [0 .62 , 0.92] 
1.00 (Reference) 
1.03 [0 .88 , 1.21] 
2.70 [2 .06, 3.51] 
p-value Adjusted* IRR 
[95% Cl] 
0.031 
0.037 
0.030 
0.041 
0.003 
<0.001 
<0.001 
0.005 
0.723 
<0.001 
1.23 [1.02 , 1.48] 
1.23 [1.02 , 1.48] 
1.00 (Reference) 
1.23 [1.02 , 1.48] 
1.22 [1.01, 1.46] 
1.32 [1.10 , 1.58] 
1.00 (Reference) 
2.28 [2.04 , 2.55] 
0.59 [0.51 , 0.69] 
0. 76 [0.63 , 0.92] 
1.00 (Reference) 
1.03 [0.88 , 1.20] 
2.70 [2.07 , 3.51] 
# Birthplace states listed in order of increasing south latitude (see Tab le 7.4) 
p-value 
0.033 
0.031 
0.029 
0.039 
0.003 
<0.001 
<0.001 
0.004 
0.714 
<0.001 
* IRR adjusted for both other factors in multivariate model (5); for example , month of birth adjusted fo r both 
sex and birthplace 
The decade (of birth) group within the 1920 to 1950 year-of-birth range , when 
considered as another possible confounder of the timing-of-birth pattern , also did not 
influence MS risk by month of birth to any extent-I RRs adjusted for decade as well as 
sex and birthplace (model (6)) differed from unadjusted values by <1 .6% (Table 7.9). 
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Table 7.9: MS risk as IRR + 95% Cl for month of birth, shown both unadjusted 
(model (1 )) and adjusted for sex, birthplace and decade of birth (model (6); data 
for 1920 to 1950 Australia born) 
Factor Category Unadjusted IRR 
[95% Cl] 
Month Jan-Feb 1.24 [1.02, 1.52] 
of birth Mar-Apr 1.23[1.01, 1.51] 
May-Jun 1.00 (Reference) 
Jul-Aug 1.24 [1.02, 1.51] 
Sep-Oct 1.23 [1.01, 1.49] 
Nov-Dec 1.34 [1.10, 1.63] 
Sex Male 1.00 (Reference) 
Female 2.28 [2.03, 2.55] 
Birthplace QLD 0.59 [0.51 , 0.69] 
(state t WA 0.76 [0.62 , 0.92] 
NSW/ACT 1.00 (Reference) 
SA 1.03 [0.88 , 1.21] 
TAS 2.70 [2.06, 3.51] 
Decade of 1920-29 1.09 [0.95, 1.24] 
birth 1930-40 
1941-50 
1.00 (Reference) 
0. 73 [0.64, 0.83] 
p-value Adjusted* IRR 
[95% Cl] 
0.031 1.22 [1.01, 1.47] 
0.037 1.22 [1.02, 1.47] 
1.00 (Reference) 
0.030 1.23 [1.02, 1.47] 
0.041 1.22 [1.01, 1.46] 
0.003 1.32 [1.10, 1.58] 
1 . 00 (Reference) 
<0.001 2.27 [2.03 , 2.53] 
<0.001 0.60 [0.51, 0.69] 
0.005 0. 77 [0.64, 0.93] 
1. 00 (Reference) 
0.723 1.04 [0.89, 1.21] 
<0.001 2. 73 [2.10 , 3.55] 
0.222 1.06 [0.94 , 1.20] 
1. 00 (Reference) 
<0.001 0. 73 [0.64 , 0.82] 
# Birthplace states listed in order of increasing south latitude (see Table 7.4 ). 
p-value 
0.035 
0.033 
0.029 
0.036 
0.003 
<0.001 
<0.001 
0.006 
0.630 
<0.001 
0.347 
<0.001 
* IRR adjusted for all other factors in mu ltivariate model (6); e.g. month of birth adjusted for sex, birthp lace 
and decade of birth . 
This means that although birthplace, sex and decade would be necessary terms in a 
predictive regression model (because of independent effects of these factors on MS 
risk) , these covariates were not confounding the main timing-of-birth study factor. The 
adjusted model in Table 7.9 in graphical form (Figure 7.4) is therefore essentially 
similar to the unadjusted timing-of-birth model in Figure 7.2. This adjusted model thus 
indicates significantly increased MS risk , approximately 1.3-fold , if born in the early 
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summer November to December period compared with the lowest MS risk if born in the 
early winter May to June period. 
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Figure 7.4: MS risk by month of birth, adjusted for sex, birthplace and decade of 
birth (1920 to 1950 Australia born; n=1,524 cases). 
Potential interactions between month of birth, sex, birthplace and decade of birth 
The product terms month *sex and month*birthplace were each considered additional 
terms in the 'full ' main-effects model (5) , to determine whether any important 
modification of the timing-of-birth pattern by either factor was evident. However, chi-
square likelihood ratio tests of nested regression models with and without these terms 
showed that there was no sign ificant interaction between the factors month (of birth ) 
and sex, and none between month (of birth) and birthplace (Table 7.1 0). 
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Table 7.10: Multivariate modelling-results of statistical tests for interaction 
between factors in negative binomial regression analyses using nested models 
Baseline model New model and p-value# /significance 
and factors additional product terms of product term 
(5) Month of birth, sex, (7) month *sex 0.506 NS 
birthplace (8) month*birthplace 0.247 NS 
(9) sex*birthplace 0.066 NS 
(6) Month of birth, sex, (10) month*decade 0.687 NS 
birthplace, decade 
#p-value for chi-square likelihood ratio test of nested regression models with and without the additional 
product term ; e.g. baseline model (5) nested in models (7), (8) or (9) containing the additional product 
terms. 
The product term sex*birthplace was also considered an additional term in main-effects 
model (5). Again, chi-square likelihood ratio tests of nested regression models with and 
without this product term showed that there was no significant interaction between the 
factors birthplace and sex (Table 7.10) , so that this term could also be omitted from the 
final model. Similarly, addition of a month*decade product term to model (6) showed no 
significant modification of the month-of-birth effect by decade of birth within the data 
restriction range chosen (Table 7 .10). 
The results in Table 7.10 indicate that the observed overall month-of-birth pattern of 
birth relating to MS risk was not significantly different between males and females and , 
most importantly, did not appear to be significantly affected by the birthplace region of 
the cases. That is, there was no detectable effect modification of the timing-of-birth risk 
pattern by either birthplace or sex in these data. This means that the early summer 
(November to December) versus early winter (May to June) ratio of MS births (~1.3) did 
not appear to differ over the birthplace regions studied (research question 2). 
Resulting MS risk model for timing of birth 
A relatively simple , unadjusted , main-effects-only model with no significant interactions 
appears adequate to specify MS risk (as IRR) as dependent on timirig of birth , using 
these Australian data. This model (1) is shown in Figure 7.2. The model shows 
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minimum MS risk for births in the (reference) early winter May to June period and 
higher risk for births over the remainder of the year, the increased risk rising in the 
early summer November to December period to approximately 1.3 times that for early 
winter-born. 
This increase in risk appears to be additional to other direct effects on MS risk by the 
factors sex and birthplace. That is, while 
• MS risk overall is approximately 2.3 times higher for females than for males 
• MS risk overall is approximately 4.6 times higher if born in TAS than if born in 
QLD (Section 7.3.2, Table 7.4), 
there now appears to be a further risk, for either sex and regardless of where born in 
Australia , of some 1.3 times if born in November to December than if born in May to 
June. That is, 
• MS risk is approximately 1.3 times higher if born in the early summer months of 
November to December than if born in the early winter months of May to June 
(research question 1) 
• the November-to-December to May-to-June risk ratio (1.3) does not differ by 
birthplace (research question 2) or sex. 
7.3.4 Perinatal UVR as independent exposure factor 
Ambient (maternal) UVR at and before time of birth 
To examine possible associations between ambient UVR around the time of birth and 
MS, incidence of MS was modelled against perinatal ambient UVR as a continuous 
variable generated from monthly regional ambient UVRett values. Advantages of these 
quantitative UVR variables were that not only were they monthly (compared with the 
previous two-monthly periods) , but they comprised a regional (place of birth) as well as 
a seasonal (month of birth) component; that is , the monthly UVR values for each 
perinatal period differed for each (individual) birthplace (Table 7.1 and Figure 7.1 ). 
Ten different UVR variables , representing the birth month and one to nine months prior 
to birth for each individual, were tested in separate negative binomial regressions , in 
order to assess different periods at and before birth for possible associations between 
regional perinatal UVR and (lifetime) MS risk (Table 7.11 , IRRs unadjusted and 
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adjusted for age (year of birth) and sex by multivariate analysis as described in Section 
7.2.4) . 
There was no association between regional daily ambient UVR at the time of birth and 
subsequent risk of MS. Similarly, lags of one to four months before birth (late second to 
third trimesters) were not associated with MS risk. However, for lags of five to nine 
months (first to early second trimesters) there were significant inverse associations 
between prenatal regional ambient UVR levels and lifetime MS risk (unadjusted IRR 
ranging from 0.74 (95% Cl 0.63, 0.85) to 0.81 (95% Cl 0.7 , 0.94) ; p<0.01) (Table 7.11). 
The strongest associations between regional ambient UVR and MS risk were at seven 
and eight months before birth-this period before birth corresponds to the mid-period of 
the first trimester of gestation . By averaging the ambient UVR values for seven and 
eight months prior to birth , UVR values representing 'first trimester UVR' for each 
region could then be obtained and analysed similarly by negative binomial regression . 
The result was an IRR of 0.72 (95% Cl 0.62 , 0.84 ; p<0.001) (Table 7.11 ). Interpreted 
quantitatively, this means that for an increase in ambient UVRert exposure of 20 MEO 
units (approximately equivalent to the regional average increase in daily total effective 
UVR from winter to summer in Australia , Figure 7.1) during the first foetal trimester, MS 
risk decreased to 0. 72 of the reference (winter) risk level , or by approximately 28% . 
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Table 7.11: Risk of MS for regional ambient UVR at and before time of birth 
Ambient UVR (monthly Unadjusted 
regional, maternalf IRR [95% Cl] 
At birth UV birth 1.01 [0.87, 1.17] 
Time UV-1 mth 1.03 [0.89, 1.19] 
before -2mth 1.00 [0.86 , 1.16] 
birth -3mth 0. 94 [0. 81 , 1.1 0] 
(prenatal) -4mth 0.88 [0.76 , 1.02] 
-5mth 0.81 [0. 70, 0.94] 
-6mth 0. 77 [0.67, 0.90] 
-7mth 0. 7 4 [0.63, 0.85] 
-8mth 0. 7 4 [0.63, 0.85] 
-9mth 0.79 [0.68 , 0.92] 
p-value Adjusted IRR* 
[95% Cl] 
0.906 1.01 [0.88, 1.16] 
0.706 1.03 [0.90, 1.19] 
0.991 1.01 [0.88 , 1.16] 
0.448 0.96 [0.83 , 1.1 0] 
0.100 0.89 [0 . 78 , 1.03] 
0.007 0.83 [0 .72 , 0.95] 
0.001 0.78 [0.68 , 0.90] 
<0.001 0. 75 [0.65, 0.86] 
<0.001 0. 75 [0.65, 0.86] 
0.002 0.80 [0.70, 0.92] 
p-value 
0.851 
0.630 
0.894 
0.525 
0.117 
0.007 
0.001 
<0.001 
<0.001 
0.002 
UV 1st 
trimester# 
0. 72 [0.62, 0.84] <0.001 0. 73 [0.63, 0.84] <0.001 
+ Based on composite month and region-specific values for each individual (see Table 7.1) and expressed 
in units of 20 MED/day in order to gain meaningful IRR in terms of UVR difference between summer and 
winter (20 MED/day is approximate average difference between summer and winter UVR levels for 
Australian state regions , see Figure 7.1 ). 
# First trimester UVR variable obtained by averaging monthly values for seven and eight months prior to 
birth (in bold) . 
* IRR adjusted for age (year of birth) and sex . 
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Shape of association between first trimester UVR and MS risk 
The shape of the relationship between (inversed) first trimester UVR exposure and MS 
risk was then investigated in greater detail. The UVRett variable was considered a 
categorical variable of six levels of effective UVR (in units of MED per day) and each of 
the five lowest levels were compared with the highest (Table 7.12, IRRs adjusted for 
age [year of birth] and sex). The association was non-linear and suggested a UVR 
'threshold ' at 20 MED/day, the four UVR categories below this level showing 
significantly increased MS risk (p<0.01 , Table 7.12). That is , there was a particular 
increase in risk for UVR levels below a monthly average of 20 MED/day (Figure 7.5). 
Table 7.12: MS risk as IRR+ 95% Cl for six levels of regional ambient effective 
UVR during first trimester of gestation#. (Reference UVR level=highest) 
Factor Category Ambient IRR* [95% Cl] p-value 
UVRett (range, 
MED/day) 
UVR exposure Level 1 > 25 1.00 (Reference) 
(regional 2 20 - <25 1.36 [0.98, 1.86] 0.062 
ambient, 3 15 - <20 1.57[1.13, 2.17] 0.007 
maternal) 4 10 - <15 1.58 [1 .14, 2.19] 0.006 
5 5 - <10 1.61 [1 .17, 2.21] 0.003 
6 <5 1.86 [1 .33 , 2.59] <0 .001 
# First trimester UVR values obta ined by averag ing values for seven and eight months prior to birth. 
* IRR adjusted fo r age (yea r of birth ) and sex. 
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Figure 7.5: MS risk by regional ambient effective UVR level during first trimester 
of gestation (IRR + 95% Cl adjusted for age [year of birth] and sex, from Table 
7.5). (Arrow on inverse UVR axis indicates threshold at monthly average of 20 
MED/day for effect of first trimester UVR on MS risk.) 
Effects of other factors on first trimester UVR and MS risk 
Table 7.13 shows the association between first trimester UVR (as six categories of 
ambient exposure) and MS risk, both unadjusted and adjusted for sex, region of birth 
and decade of birth. A multivariate negative binomial regression model was used , 
similar to model (6) (see Methods, Section 7.2 .4) but with first trimester UVR as the 
main study factor instead of month (of birth). The association between first trimester 
UVR and MS persisted after adjustment for sex, birthplace region and decade of birth 
(Table 7.13); that is, these additional factors can again be discounted as possible 
confounders of the main UVR-MS association. Further, chi-square likelihood ratio tests 
of nested regression models , with and without additional product terms between first 
trimester UVR and the other factors in Table 7.13, confirmed that there was also no 
interaction between any of these factors and first trimester UVR. That is , there was no 
effect modification of the association between first trimester UVR and MS risk by these 
factors (p-values 0.71 and 0.80 for product terms with sex and birthplace , respectively). 
Thus, an inverse association between low UVR in the first trimester of gestation and 
increased risk of subsequent, post-birth MS has been demonstrated. 
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Table 7.13: MS risk as IRR + 95% Cl for six levels of regional ambient effective 
UVR during the first trimester of gestation, with and without other factors 
Factor Category Unadjusted IRR p-value 
[95% Cl] 
Ambient > 25 1.00 (Reference) 
UVRett 20 - <25 1.35 [0.97, 1.87] 0.071 
exposure 15 - <20 1.58 [1.14, 2.20] 0.007 
in 1st 10 - <15 1.58 [1.13, 2.20] 0.008 
trimester+ 5 - <10 1.62 [1.17, 2.23] 0.004 
(MED/d) <5 1.90 [1.35, 2.67] <0.001 
Sex Male 1.00 (Reference) 
Female 2.28 [2.03, 2.55] <0.001 
Birthplace QLD 0.59 [0.51 , 0.69] <0.001 
(statet WA 0.76 [0.62 , 0.92] 0.005 
NSW/ACT 1.00 (Reference) 
SA 1.03 [0.88, 1.21] 0.723 
TAS 2.70 [2.06, 3.51] <0.001 
Decade of 1920-29 1.09 [0.95, 1.24] 0.222 
birth 1930-40 
1941-50 
1.00 (Reference) 
0. 73 [0.64, 0.83] <0.001 
Adjusted IRR* p-value 
[95% Cl] 
1.00 (Reference) 
1 . 54 [ 1 .1 0, 2. 16] 0.013 
1.58 [1.12, 2.22] 0.009 
1.65 [1.17, 2.33] 0.004 
1.65 [1 .18, 2.29] 0.003 
1.67 [1.18, 2.37] 0.004 
1.00 (Reference) 
2.27 [2.03 , 2.53] <0.001 
0.60 [0.52 , 0. 70] <0.001 
0.85 [O. 70, 1.04] 0.113 
1.00 (Reference) 
1.10 [0.94, 1.29] 0.237 
2.71 [2.08 , 3.52] <0.001 
1.06 [0.94 , 1.20] 0.346 
1. 00 (Reference) 
0. 73 [0 .64 , 0.82] <0.001 
+ Ambient UVRett in first trimester based on composite month- and region-specific UVR values for each 
individual (see Table 7.1 ). 
# Birthplace states listed in order of increasing south latitude (see Table 7.4). 
* IRR adjusted for all other factors in a multivariate model ; for example , first trimester UVR adjusted for sex, 
birthplace region and decade of birth. 
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Relationship between first trimester UVR and timing-of-birth pattern 
Could low first trimester UVR now account for the observed timing of birth pattern? The 
relationship between the two exposure factors, prenatal first trimester UVR and month 
of birth, with regard to MS risk could be explored by testing nested multivariate 
negative binomial regression models similar to model (6) (see Methods, Section 7.2.4) 
with and without each of these factors. These results showed that after adjustment for 
prenatal UVR in the first trimester, there was no residual association between timing of 
birth and risk of MS. That is, once first trimester UVR was included in the model (as in 
Table 7.13), there was no improvement in model fit by also including month of birth 
(likelihood ratio chi2 for difference between models [5 d.f.] =3. 79; p=0.58). In contrast, 
region of birth remained significantly associated with risk of MS even after adjustment 
for UVR in the first trimester. 
Summing up, these results mean that the risk pattern of timing of birth found here in 
southern hemisphere Australia among MS cases appears to be accounted for by the 
month- and region-specific ambient UVR during the first trimester of foetal development. 
That is, lower average daily levels of ambient UVR during the first trimester of 
pregnancy predicted a higher subsequent risk of MS in the offspring independently of 
timing of birth. This suggests that ambient UVR prior to birth might be an important 
(maternal) exposure factor influencing subsequent MS risk of the offspring. 
The results also show that there was an independent, residual association between 
birthplace region and lifetime MS risk after adjustment for UVR in the first trimester. 
This means that not all of the regional variation in MS risk has been accounted for by 
the prenatal first-trimester-UVR factor. This suggests that postnatal UVR exposure in 
childhood or adolescence may be a further component cause of MS in later life ; that is , 
postnatal UVR exposure might also be important in reducing overall MS risk. 
7 .4 Discussion 
Timing-of-birth pattern 
The analyses reported in this chapter show a timing-of-birth pattern for MS risk in 
Australia (research question 1 ). The r'sk of developing MS post-birth is some 30% 
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higher (approximately 1.3 times) for Australians born in the southern hemisphere early 
summer period, November to December, than for those born in the early winter period, 
May to June. This pattern was also not different by sex or birthplace (state) within 
Australia (research question 2). 
A relatively simple model of timing-of-birth effects on lifetime MS risk was developed 
using data from the 1981 Australian MS Survey (see Chapter 5) on 1,524 MS cases 
born in Australia, by sex and state of birth for OLD, WA, NSW/ACT, SA and Hobart 
(TAS). These data were reconstructed into a longitudinal dataset spanning every (birth) 
month of every year over the chosen study period, 1920 to 1950, together with derived 
and adjusted reference-population denominator estimates (total n=2,468, 779; see 
Chapter 6). 
Strengths of this study include the ability to analyse data at the individual level (rather 
than the population level, as in Chapter 4 for other autoimmune disorders) and this was 
enabled for this chapter by the comprehensive and standardised case ascertainment of 
MS in Australia by the McLeod group's national survey in 1981 (see Chapter 5). 
Because this MS survey was also carried out on an Australian national census day, 
census totals were able to be used to derive appropriate reference-population 
denominators for the analyses in this chapter by employing supplementary births-
registration data to apportion the census totals into month- and region-of-birth data by 
(birth) year (see Chapter 6, Section 6.2.2). In addition , other (1976) census data on 
interstate migration were able to be accessed to allow this study to make a final 
adjustment of the population denominators to account for potential case losses to the 
unsurveyed states post-birth and up to the survey date in 1981 (see Chapter 6, Section 
6.2 .3). 
A further strength of the present study is the inclusion of individual birthplace region , 
rather than survey ( or residence) area , as an exposure factor in the final MS-frequency 
dataset. This factor has not often been emphasised in other timing-of-birth studies [324 , 
644] (although McDowell and colleagues (2010) have recently reported earlier MS 
onset for US veterans born in winter in US birthplaces wi th low solar radiation [667]). 
Place of birth , rather than place of (later) residence should therefore be an exposure 
that is more relevant and appropriate to the time of birth. 
Potential limitations include the assumptions necessarily made to derive the population 
denominators; however, these assumptions do not appear to be having major effects 
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on the final dataset, as discussed in Chapter 6 ( see Section 6.4 ). The restriction of the 
year-of-birth range to the 1920 to 1950 calendar-year period further allowed exclusion 
of the more significant 'survival' and 'diagnosis' sampling biases for the MS cases (see 
Chapter 5, Section 5.3.3) , as well as limitation of at least some of the 'assumption 
effects' for the reference-population denominators (see Chapter 6, Section 6.4 ). For 
example, potential measurement bias from differences in month-of-birth classification 
between cases and census-population 'controls ' could be minimised by exclusion of 
earlier years when delays between birth and registration were greatest (see Chapter 6, 
Section 6.4 ). In the present chapter, although MS risk was found to vary by decade 
within this restriction range, the finding that the factor decade was not confounding or 
interacting with the timing-of-birth pattern gave further confidence in the final sample 
used. 
The importance of maintaining adequate sample size was emphasised in this chapter 
in requiring two-monthly rather than monthly periods for analysis and during the 
attempted subgroup analyses in Section 7.2.4. Subsequent multivariate analysis 
allowed the effects of all principal factors to be considered at the same time while , 
importantly, not compromising statistical power. 
Multiple regression modelling further enabled investigation of possible confounders , 
including birthplace and sex, that may have been influencing the subtle temporal 
pattern. By multivariate analysis , both sex and birthplace were confirmed as 
contributory factors to MS risk per se, but adjustment for these factors made little 
difference to the MS-risk estimates for timing of birth . The lack of substantial difference 
between adjusted and unadjusted IRR values (i.e. <<10%) indicated that confounding 
of the timing-of-birth pattern by these factors was not occurring . Data on other possible 
confounders were not available , especially data on personal exposure to seasonally 
related factors (e.g. viruses, UVR), including those possibly acting during pregnancy. 
To summarise , independent effects of both sex and birthplace on MS risk in Austral ia 
have been confirmed in this study, together with a newly found timing-of-birth MS-risk 
pattern for the southern hemisphere. This appears to be the first recorded find ing of a 
timing-of-birth pattern for MS risk in the southern hemisphere and the present results 
are broadly consistent with those for MS in the northern hemisphere (with seasons 
reversed). The analyses for the 1920- to 1950-born cases show a significant excess 
risk for those born in the early summer months of November to December, compared 
with the risk for those born in early winter May to June. Indeed, all other birth periods 
320 
show excess MS risk compared to the early winter May to June period , but risk is 
highest-approximately 1.3 times-for births in the early summer November to 
December period. 
These results are comparable to those found in the northern hemisphere for MS from a 
much larger pooled sample of register data from four countries, Canada, UK, Denmark 
and Sweden (n=42,000 cases) [324]. In this northern hemisphere study, a significant 
deficit in MS births occurred in November and a significant excess 'peak' occurred in 
May (pattern reproduced here in Figure 7.6). For direct comparison, Figure 7.7 shows 
the resulting pattern from the data in this chapter when single months of birth rather 
than two-monthly periods of birth are used, and May is the single-month reference. In 
this analysis by month, November shows an increased I RR relative to May that is only 
of borderline significance (IRR 1.32; 95% Cl 1.00, 1.74; p=0.052) while December 
shows statistically significant (p<0.05) 'peak' excess MS risk (IRR 1.41; 95% Cl 1.07, 
1.86; p=0.014 ). Although the confidence intervals in this analysis by month are wider 
because of lower sample size (Figure 7.7), these results again suggest an overall 
pattern of minimum MS risk in the early winter months of May and June and increased 
risk for all birth months other than May to June, with greatest risk if born over the 
November to December (and particularly December) early summer period. 
While the analysis techniques in this chapter are necessarily different from those of 
Willer and colleagues, who show both a (November) deficit and a (May) excess MS risk 
compared with a baseline ('observed=expected') value of 1.0 (Figure 7.6) [324], the 
important comparison parameter is their overall May-born to November-born OR, which 
represents a '13% higher MS risk (95% Cl 5 to 22%) if born in May compared with 
November'. The results in this chapter show a 30% higher risk for those born in the 
corresponding months of November to December compared with May to June (Figure 
7.2) ; however, the 95% confidence interval of 10 to 63% for this ratio largely overlaps 
that of Willer and colleagues [324] , and this result is , therefore , not inconsistent with 
theirs. The months of maximum (peak) births and minimum (trough ) births also are 
remarkably similar, given that the November and May months are reversed for the 
southern hemisphere seasons. 
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Interestingly, Willer and colleagues ' data for the UK showed a significant deficit in 
December as well as in November (the same two months as shown in this chapter for 
excess births) , although their December deficit lost significance when corrected for 
multiple comparisons [324]. The mean IRR values shown in this chapter thus indicate 
an early summer versus early winter MS-risk pattern that is quite similar to that in the 
northern hemisphere, in effect size and in the approximately six months periodicity 
between the trough and peak months. 
Of note here, in a large southern hemisphere (QLD, Australia) study of schizophrenia 
that differentiated between southern hemisphere-born and northern hemisphere-born 
cases, a southern hemisphere season-of-birth pattern that similarly 'mirrored ' the 
northern hemisphere pattern was found [668]. 
In this chapter's southern hemisphere results for MS, there was no measurable effect 
modification of the association between timing of birth and MS risk by birthplace region 
(research question 2), as evidenced here by the lack of statistical interaction between 
birthplace and the timing-of-birth pattern. The effect size of this timing-of-birth pattern 
appears to be not significantly affected by birthplace state from QLD to TAS, even 
though this factor has a significant independent effect on MS risk. Intriguingly, therefore , 
the ratio of early summer to early winter risk in this pattern does not change with 
increase in southern latitude in Australia . Such interaction might have been expected 
from the northern hemisphere work on MS and , perhaps , from the seasonal UVR 
pattern in Australia (see Table 7.1 ). Willer and co-workers , using incident MS cases in 
Scotland , Canada and Scandinavia , also reported that the magnitude of the May to 
November ORs appeared to increase with regional prevalence and , by implication , with 
regional latitude, the May to November OR for Scotland being highest. However, as in 
Australia , the data within the latitudinal breadth of Canada failed to show any difference 
by ascertainment area, or by sex or decade of birth [324] . 
For schizophrenia also, a northern hemisphere meta-analysis of several season-of-
birth studies showed a small but significant positive correlation between latitude and 
the ORs for winter-spring versus summer-autumn births [639] . However, a southern 
hemisphere meta-analysis by the same study group did not show a consistent season-
of-birth association for schizophrenia in this region , these authors suggesting that 
southern hemisphere risk-modifying environmental factors 'may be weaker, less 
prevalent, less regular and/or may be modified by other confounding variables ' [640] . 
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The present results for southern hemisphere MS appear to fall somewhere between 
these two extremes-a timing-of-birth effect consistent with that found in the northern 
hemisphere has been shown , but the MS-risk ratio of maximum to minimum MS births 
(November-to-December born to May-to-June born) of around 1.3 appears to be 
unaffected over the latitude and prevalence range in Australia. 
It should be noted again that, in comparison with these other studies, the effect of 
region at birth has been measured here, whereas the northern hemisphere studies 
such as those of Willer et al. (2005) for MS and Davies et al. (2003) for schizophrenia 
have used the study site or ascertainment area of the study [324, 639]. The previous 
studies on latitude and MS prevalence in Australia by Hammond, McLeod and 
colleagues (the 'McLeod group') were also based on region of ascertainment (current 
residence) rather than birthplace [299, 301, 302, 304, 645, 650], as were results by van 
der Mei and colleagues on ambient UVR and MS prevalence in Australia that were 
based on the McLeod group's prevalence data [9]. However, the present study has 
further shown that a relatively high proportion of the 1981-surveyed MS cases (up to 
94%), and of the census (1976) population (up to 87%), still remained in their birthplace 
state in 1981 or 1976, respectively (see Chapter 6, Section 6.2.3). Therefore, major 
differences between the results here, using region of birth, and these other studies, 
using region of ascertainment, should perhaps not be expected for either prevalence or 
timing-of-birth patterns. 
Prenatal UVR and MS risk 
Is prenatal UVR a candidate component causal factor affecting MS risk early in life and 
resulting in a timing-of-birth pattern? As outlined in Section 7.1, the finding of a timing-
of-birth pattern in MS, now in both global hemispheres , strongly suggests a component 
causal factor acting very early in life. Evident also is that this component has a lengthy 
induction period (some 20 to 40 years before MS onset) , defined as the time between 
action of the factor and onset of disease [1 ]. 
A timing-of-birth pattern is simply a risk indicator (month of birth actual ly being proxy for 
the solar zenith angle affecting solar radiation and UVR [661]) and can result from 
environmental influences acting at any time around the time of birth , from conception to 
shortly after birth. Pre-birth influences, in particular, may be especially important to this 
type of disorder and may be mediated through vitamin D status [221 , 451 , 452 , 4 77, 
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484] (see Chapter 2) . Pregnancy is a vulnerable time for vitamin D deficiency because 
of increased physiological needs and reduced maternal outdoor activity [4 77 , 669] . 
A possible mechanism by which higher maternal levels of vitamin D might be protective 
for MS in offspring is through its immunomodulatory action , vitamin D enhancing 
regulatory T-cell function (see Chapter 2) . Another mechanism may be that in utero 
vitamin D deficiency affects foetal brain development; experimental data on animal 
foetal development indicate that cerebral white matter is responsive to vitamin D and 
that oligodendrocytes in the brain and spinal cord have VD Rs [383 , 4 79] ( see Chapter 
2). Further, maternal vitamin D depletion alters neurogenesis in the developing rat 
brain [485], with subsequent altered gene expression in adult life [482]. 
As reviewed in Chapter 2, recent genetic studies in humans have further implicated 
vitamin D by showing direct functional interaction with the major locus that determines 
susceptibility to MS [188]. This risk allele , moreover, has been shown to be associated 
with timing of birth of MS cases in Canada, Sweden and Norway, indicating that this 
gene-environment interaction occurs during gestation or shortly after birth [670]. 
Although human evidence pertaining to foetal development has been difficult to obtain , 
the body of related evidence to date has led some to recommend antenatal 
supplementation with vitamin D specifically to prevent MS [289 , 4 77]. 
Sayers and colleagues further emphasise that UVR is a relatively 'direct ' variable for 
examining maternal vitamin D effects on subsequent offspring health and may be 
validly considered a causal exposure for any health outcome affected by maternal 
vitamin D [661 ]. UVR itself has also been directly implicated in autoimmune 
mechanisms considered to be underlying initiation of MS disease without necessarily 
involving vitamin D (reviewed in Chapter 2) . 
In this chapter, regional and seasonal variation in ambient UVR during the first foetal 
trimester has been shown to account (inversely) for the observed variation in MS risk 
with month of birth . That is , when the two exposure factors , month of birth and first 
trimester UVR, were considered together in nested reg ress ion models, there was no 
residual association between timing of birth and risk of MS once first trimester UVR 
was accounted for (Section 7 .3.4 ). The timing-of-birth pattern found here has therefore 
now been linked , for the first time, to prenatal UVR during the f irst trimester of 
pregnancy (published as Staples et al. , 2010, Appendix 11 ). 
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The overall correspondence between these two exposure factors can be seen in Figure 
7.8, where the month-of-birth pattern of MS risk is shown together with the UVR pattern 
(on an inverse scale) lagged seven to eight months to represent the ambient UVR 
pertaining to the first trimester. Two annual cycles are shown (data repeated for the 
second cycle). In addition, for diagrammatic simplicity, lagged-UVR has been averaged 
over all regions (however, data for the individual regions were used in all regress ion 
modelling). This figure illustrates the broad similarity between the two exposure factors 
with respect to MS risk, and emphasises the possible temporal link between them. 
Figure 7.8 thus shows a specific in utero link to MS risk and suggests that the higher 
MS risk evident in the November-to-December born in the timing-of-birth pattern may 
be consequent to suboptimal maternal UVR exposure seven to eight months earlier 
during the first trimester of pregnancy; that is, in the preceding autumn to early winter. 
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Figure 7.8: MS risk by month of birth (two-monthly periods), shown together with 
monthly averages of daily ambient UVR in first trimester of gestation on an 
inverse scale. Time interval is two annual cycles. 
These results are consistent with the stronger maternal over paternal 'pa rent-of-origin' 
effect seen in familial MS [225, 226], and consistent also with Barker's 'foetal origins 
hypothesis' for subsequent human disease (see Chapter 2). The find ings add to other 
work showing that maternal exposure to ambient UVR during pregnancy might 
influence subsequent health in both human and animal offspring [484 , 671-673] . For 
example, in a NZ birth cohort, human infants whose mothers were exposed to peak 
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sunshine during the first trimester were significantly heavier at birth than infants whose 
mothers experienced trough levels of sunshine during the same trimester [673]. In the 
UK, maternal ambient UVB exposure in the third trimester has been positively related 
to bone mineral density and content at age nine years in children [674]. 
There is now growing interest in the role of maternal vitamin D deficiency in pregnancy 
and the development of CNS and immune disorders, particularly schizophrenia [484] , 
type 1 diabetes and other disorders [451, 452] (see Chapter 2). A recent study in the 
US of gestational vitamin D and risk of MS in offspring suggested that MS risk was 
lower among women born to mothers with high (fortified) milk or vitamin D intake during 
pregnancy [675] . Although active-vitamin D concentrations in the mother increase 
substantially during pregnancy, early foetal supplies are lower [669, 676] and directly 
dependent on the mother throughout gestation [677]. By the time of delivery, maternal 
and infant cord serum 25(OH)D concentrations are highly correlated [469] . However, 
much remains unknown, leading to large international variations in maternal vitamin D 
monitoring and supplementation during pregnancy [451, 678, 679]. 
It has been previously proposed [4 77] that maternal vitamin D deficiency, a problem for 
some dark-skinned women migrating to regions with low ambient UVR, such as the UK, 
might explain the increase of disease seen among second generation migrants in such 
locations [454]. The findings in this chapter are consistent with this explanation. 
Because season of birth has previously also been related to the clinical course and 
disease progression of MS [643, 644, 680], it is possible that early life exposures 
determine not only onset of disease but also resistance to the demyelinating process of 
MS; the mechanisms involved could include neurological or immunological factors. 
A strength of using prenatal UVR exposure in this study, further to those study 
strengths already discussed , is that it was a prospective exposure whose levels were 
heterogeneously distributed among the MS cases because of the large variation in 
UVR linked to month and region of birth across Australia (UVR levels do not change 
significantly year to year, even over decades, P. Gies , pers. commn). This quantitative 
exposure factor had both a seasonal and a regional component relating to the 
individual MS-case data; the UVR parameter was also by monthly, rather than two-
monthly, periods as was necessary for timing of birth , increasing analytic power and 
sensitivity. 
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However, the regional ambient UVR levels were not necessarily those experienced by 
each mother-a limitation was that this exposure factor could not take into account 
individual behaviour or skin pigmentation , nor could it account for concurrent dietary 
vitamin D intake. Nevertheless, as recently shown for a longitudinal birth cohort in the 
UK, ambient erythemal UVR levels during pregnancy can be validly used to indicate 
maternal vitamin D status , and ambient UVR can be used as an instrumental variable 
for causal analysis of subsequent vitamin D-dependent disorders in offspring [661 ]. 
Similarly to the timing-of-birth pattern, the inverse association between first trimester 
UVR and MS risk persisted after adjustment for region of birth , sex and decade of birth , 
and effect modification by these factors was also not present. However, other factors, 
such as nutrition or physical activity, that could be associated with prenatal exposure to 
UVR during pregnancy and that could also determine MS risk could not be similarly 
controlled for, even though these would likely obscure the observed patterns rather 
than create them. 
Importantly, both here and in the northern hemisphere CCSG MS study, the pattern of 
timing of birth was not smoothly sinusoidal but showed a few months of particularly 
altered risk of MS. This may suggest an underlying seasonal factor that is required to 
reach a threshold before effects can be measured [324] . Consistent with this , when 
different levels of first trimester UVR were examined in this chapter, a threshold effect 
was clearly observed; that is , risk was specifically increased in the lower levels of 
exposure, below a monthly average of 20 MED units per day. Interestingly, this 
threshold level is reached from November to February in Brisbane, OLD, but only in 
January in Hobart, TAS. 
Taken together, all of these results provide evidence that maternal UVR exposure 
and/or vitamin D status are likely to be a contributory determinant of MS and linked to a 
critical period in or close to the prenatal first trimester. Whether the critical foetal 
developmental period is as early as this (first trimester) is not clear-if the action of 
UVR is vitamin D mediated , a lag period would be involved for the production of vitam in 
D. Recent Australian work has shown a lag of one and a half months, for example, 
between higher ambient UVR levels and higher vitamin D concentrations at the 
population level [327]. This would equate to a critical period for vitam in D in the second 
trimester. First or second trimester vitamin D concentrations might be particularly 
important in the development of the CNS because during early embryon ic development, 
VD Rs are expressed in the neuroepithelium and later in the subventricular zone [4 79] . 
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Myelination occurs later; even in mid-gestation (19 to 24 weeks) cortical axonal tracts 
are not yet myelinated [681], with major myelination of several areas occurring as late 
as 29 to 39 weeks [682]. 
The in utero development of immune central tolerance occurs in the first trimester (see 
Chapter 1) and vitamin D has immunomodulating properties (see Chapter 2). The first 
trimester is also a sensitive period with regard to prenatal thymocyte differentiation , 
with animal studies showing that chemicals such as dioxin can alter this process, 
disrupt the development of central tolerance, and lead to increased auto-reactive 
peripheral T cells [683]. Further, indirect effects of vitamin D should be considered. For 
example, vitamin D can down-regulate the cytokine IL-6, an important mediator of the 
adverse effect of maternal infection during pregnancy on neural development in the 
foetus [400, 684, 685] . Further work to confirm timing of the observed effects during the 
prenatal period is now needed. 
The independent effect of region of birth on MS risk , as shown by the strong residual 
association with birthplace after adjusting for first trimester UVR (see Section 7.3 .4 ), is 
consistent with birthplace possibly acting as an indicator of postnatal exposure to UVR. 
Indeed , given that many Australians apparently remain in their birthplace region for 
many years (see Chapter 6) , this factor may be a good marker for postnatal sun 
exposure linked to long-term residence. 
Taken together, the results in this chapter indicate that the possible beneficial effect of 
UVR exposure may occur at more than one life stage; this can be illustrated using 
Goodin 's (2009) multi-stage causal cascade hypothesis for MS pathogenesis as a 
basis, wherein perinatal and postnatal factors suggested by the results in this chapter 
are shown highlighted in green in Figure 7.9. As this life-course causation model 
proposes for MS pathogenesis , a series of environmental factors seems most likely to 
precipitate eventual MS in genetically susceptible people , including vitam in D 
deficiency very early in life [229]. The low prenatal maternal UVR exposure found in 
this thesis to be associated with MS risk is consistent with this proposed 'very early 
environmental influence' with a significant 'maternal effect' near the time of birth . 
Infections, or other factors , may act subsequently in childhood or adolescence, while 
other as yet unidentified environmental factors may act prior to onset of MS symptoms 
[229] (see Chapter 3) ; the latter may now include lower postnatal UVR also (Figure 7.9). 
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Possible 'Causal Cascade' to MS Pathogenesis 
Conception 
Genetic 
.... 
factors 
,,,... 
Birth Childhood/adolescence ?Adulthood 
in utero? 
UVR / Vit. D 
Infections deficiency? .... .... ?Other ,,,... 
e.g. EBV? 
,,,... 
factors (1 st trimester?, 
autumn/winter) 
~----- Low postnatal UVR? __J 
(birthplace/residence) 
20-40yr 
..... 
MS 
,,,... 
Figure 7.9: Possible causal pathway leading to MS, showing timing of putative 
environmental factors. (Figure based on 'causal cascade' model of Goodin, 2009 
[229] [see Chapter 3, Figure 3.5] and results in this chapter.) 
7.5 Conclusions 
The finding of a timing-of-birth pattern among MS cases suggests that at some time 
during the perinatal period, a critical window of time may exist when an environmental 
factor that is also fluctuating seasonally may be acting to influence risk of MS onset 
later in life. Just when this critical period may exist, and for how long , cannot be 
determined directly from the timing of birth pattern , but the presence of such a pattern 
suggests an environmental factor, which is also seasonally fluctuating , acting during 
this critical developmental period. Symmetrical patterns for MS risk in both global 
hemispheres now reinforce this suggestion and indicate a need for further detailed 
analysis of possible underlying exposures and mechanisms. 
Additional independent analyses undertaken with first trimester UVR in this chapter 
underline that prenatal UVR, and particularly first trimester UVR, is a poss ible 
candidate as an early life , component causal , environmental factor in the pathogenesis 
of MS. Regional ambient levels of first trimester UVR accounted for the timing-of-birth 
pattern found in Australia but not for the total variation in MS risk ; contributory low 
postnatal levels of UVR/vitamin D in the birth and/or residence region may be indicated 
by results in this chapter. The action of first trimester UVR may be mediated through 
lack of vitamin D during autumn and early winter, consistent with accumulating 
evidence for the importance of vitamin D during the prenatal period . 
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Low prenatal ambient UVR exposure, perhaps mediated by vitamin D deficiency, thus 
appears to be a good candidate for the early life determinant (indicated by timing of 
birth) in MS aetiology in Australia , and low postnatal UVR exposure may also be 
important (see Figure 7.9). 
7.6 Postscript 
Chapters 5 to 7 have examined a timing-of-birth pattern in MS in Australia using a 
longitudinal dataset constructed from the available MS case survey conducted in 1981. 
Associations between timing of birth, prenatal (maternal) ambient UVR exposure , 
region of birth and MS risk have been shown and a putative determinant of MS 
identified and discussed. 
The next chapter, Chapter 8, will investigate another possible influence on MS 
pathogenesis that may act subsequently to low prenatal UVR exposure (see Figure 7.9) 
and increase ( or decrease) MS risk to ultimately produce sufficient cause to precipitate 
MS [1 , 6, 189]. In Chapter 8, the possible role of childhood infections in MS will be 
investigated by independent analysis of birth order and sibling relationships in MS 
cases , using the original individual-level 1981 Australian MS survey (unit-record) case 
data . 
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CHAPTER 8 
ORDER OF BIRTH AND MS RISK IN AUSTRALIA: ANALYSIS OF BIRTH ORDER 
OF MS CASES AS POSSIBLE EVIDENCE FOR EFFECTS OF CHILDHOOD 
INFECTIONS ON MS RISK 
8.1 Introduction 
As outlined in Chapter 1, MS is a chronic inflammatory demyelinating disorder in which 
the immune system is activated to attack the white matter of the CNS, leading to 
severe disability. Despite numerous population studies, MS aetiology is unknown but is 
thought to be a complex, multifactorial interplay of both genetic and environmental 
factors [186, 189, 193] (see Chapters 2 and 3). Temporal changes in MS incidence in 
many parts of the world suggest significant environmental influences on MS causation, 
as do also geographic latitude gradients in prevalence or incidence, and seasonal 
variation. The relatively high rate of non-concordance between monozygotic twins, at 
least 60%, further emphasises the probable environmental contribution to MS aetiology 
[196, 202] (see Chapter 2). 
MS is generally believed to be an immune-mediated disorder (see Chapter 1 ); however, 
the sequence of environmental events that initiates the disorder remains largely 
unknown [150] . A possible 'cascade' model of MS causation in terms of timing of 
different factors has been proposed by Goodin (2009) [229] , in which a lack of vitamin 
D around the time of birth has been postulated as one factor. Consistent with this , 
Chapters 5 to 7 of this thesis have presented evidence that environmental UVR at or 
before birth may explain the timing-of-birth cycles in MS now evident in both northern 
and southern hemispheres. 
However, other strong evidence points to other environmental factors also being 
implicated in MS aetiology, particularly infectious agents . Infections may act to trigger 
the autoimmune processes leading to either initial disease onset or to ongoing 
recurrences, particularly for the most common type of MS showing a relapsing-
remitting clinical pattern [487, 490]. Alternatively, and paradoxically, childhood 
infections may protect against subsequent autoimmune disease such as MS [524]. In 
this case, the timing of such infections appears to be crucial to subsequent effects on 
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MS onset. That is, when infection has been found to be protective for such disease, it 
has often occurred early in childhood [3]. A later-than-normal exposure to an otherwise 
common infectious agent, such as a virus, may predispose the child or adolescent to 
subsequent MS [487, 545] (see Chapter 3). 
Birth-order and family-size studies can be used to measure the timing and intensity of 
early life exposure to childhood infections, particularly for a late-onset disease such as 
MS, when recall of past infections would be unreliable. The fact that childhood 
infections are often asymptomatic may also preclude their accurate measurement. 
Sibship structure of the case families, in terms of birth order of the case in relation to 
the total sibship size, can be used as a surrogate, or proxy, measure of timing and 
degree of exposure of childhood infections. For example, early birth order (i.e. being 
one of the older siblings in the sibship) and/or small family size are considered to 
lessen and delay exposure to the hypothesised infectious agents from early childhood 
to a later age [556, 686], thereby possibly increasing subsequent MS risk. 
However, evidence from birth-order studies for MS is conflicting; most of the previous 
studies have also been conducted in the northern hemisphere. An early birth-order 
pattern in cases , suggesting a lack of early infectious exposure, has been found by 
some [687-690], while others have found a late birth-order pattern [691 , 692]. Hernan 
and colleagues (2001) found an excess of first-born MS cases (i.e. first born had higher 
MS risk) only in larger families (four or more siblings) in a large nested case-control 
study [616], while several other studies found no evidence of any association between 
birth order and MS risk [686 , 693-700]. 
A more recent large longitudinal cohort study by the CCSG also concluded 'no support 
for the (hygiene) hypothesis that having older siblings protects against MS' [554]-that 
is , no support for an early birth-order effect in MS cases . In that study, an opposite, 
slightly higher MS risk was shown if born in a later birth-order position , for sibships 
greater in size than seven siblings (i.e. a late birth-order effect in MS cases in larger 
sibships). However, this result was deemed by this research group to be 'more likely 
due to a cohort effect resulting from increasing MS incidence' rather than being any 
real effect. Another large population-based cohort study of MS in Denmark also found 
no association with the number of older siblings or any other sibship characteristic 
[556]. 
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In one of the few southern hemisphere studies , MS risk in relation to the number of 
younger siblings, rather than birth-order position, was investigated in TAS , Australia. In 
this case-control study, a protective effect of longer exposure to a greater number of 
younger infant siblings, independent of birth order, was shown-adjusted ORs 0.57 (95% 
Cl 0.33, 0.98), 0.40 (0.19, 0.92), and 0.12 (0.02 , 0.88)-for, respectively, 1-<3, 3-<5 
and > 5 infant-years contact, compared with <1 infant-year, in the first six years of life 
[553]. However, in a large case-control study of both younger and older siblings in 
Sweden, a protective effect of having siblings per se was reported. The ORs for 
developing MS for people with siblings , compared with those with none, were 0.80 (95% 
Cl 0.70, 0.92) for three or more younger siblings , and 0.83 (0.72 , 0.96) for three or 
more older siblings [555] . Thus, the possible effect of older and/or younger siblings on 
subsequent MS risk is undecided, but these latter studies that include younger siblings 
may still suggest a protective effect of early microbial exposure by contact with both 
older and younger siblings, broadly consistent with the hygiene hypothesis (see 
Chapter 3). 
With regard to methodology, most previous birth-order studies can be categorised into 
two main types-those employing population controls (e.g. case-control studies 
matching for age and sex) and those studying cases only and employing theoretical 
techniques such as 'Greenwood-Yule'. This technique measures observed departures 
from an expected , random birth-order distribution per family size [701 , 702] and is the 
method used by many workers , including Sadovnick and colleagues for the CCSG 
group [554] . In this techn ique, the expected birth-order position of the MS case within a 
sibship of given size is calculated under the assumption of equal probability of the birth-
order positions (i .e. uniform distribution) ; the null hypothesis is that there is no 
relationship between birth-order position and occurrence of MS within the sibship [693]. 
A few studies, reviewed by Ahlgren and Andersen (2005) [693] , have used both 
techniques [686 , 690, 693 , 696-697, 700] ; all of these studies showed agreement 
between the two techniques (i.e. no association between birth order and MS risk) 
except for the study by Zilber et al. (1988)-this showed no associat ion by the 
Greenwood-Yule technique but an association between low (i .e. early) birth order and 
MS risk in the case-control study [690] . James (1984) also reviewed several earlier MS 
birth-order studies and the biases then inherent in the theoretical technique, pointing 
out that decreases in population family sizes over time would bias towards later birth-
order positions, if family (i.e. sibship) size was not controlled for when using the 
theoretical technique. He concluded that the unbiased early MS stud ies , mainly case-
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control studies, all showed an early birth-order effect in MS cases (i .e. earlier birth-
order position than expected) , consistent with the hygiene hypothesis [688 , 689]. 
As described in Chapter 5, the 1981 Australian MS Survey was a comprehensive 
population-based , cross-sectional data collection from identified MS patients in 
Australia on the national census day, 30 June 1981. This cases-only dataset comprised 
patients born in Australia or overseas between 1897 and 1969 (ages 12 to 84 years in 
1981 ). Therefore, theoretical techniques for birth-order analysis of MS cases were 
applicable in order to investigate the possibility that childhood infections played a part 
in MS aetiology in Australia. As in Chapters 5 to 7 of this thesis , the data were 
restricted to those MS cases born between 1920 and 1950 (inclusive) for analysis in 
order to minimise possible selection biases. 
In this chapter, birth-order position among the MS cases in the available dataset will be 
investigated , to determine whether a lack of early microbial exposure could apply. That 
is: Does MS occur more frequently in those exposed relatively less or later in life to 
common childhood infections because of being one of the older children in their sibship? 
The research question is: 
• Is there an early birth-order effect in Australian MS cases? 
That is, is there an association between birth-order position and MS risk? And , 
specifically , are earlier-born siblings (i.e. older children in the sibship) at higher MS risk? 
For example , are MS cases more likely to be born earlier in their sibships than would 
be expected by chance? That is, is there a shift in the mean birth-order position in MS 
cases compared with the expected , by chance , mean birth-order position of each 
sibship size? Further: 
• Are MS cases more likely to be in the first-born position than expected by 
chance? And/or less likely to be in the last-born position? 
Previous studies , both case-only and case-control , have varied widely in 
methodological rigour and many have suffered from small sample sizes . In addition , 
few of the previous studies (with the exception of Sadovn ick et al. , 2005 [554]) appear 
to have taken sufficient account of differing birth-order distributions among different-
sized sibships. That is , most of the case-only studies have given an estimate of mean 
birth order over all sibship sizes combined , without, for example , any weighting for 
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possible effects of sibship size, despite the importance of sibship size being recognised 
by some early workers in birth-order studies in other disease fields (e.g. Gregory, 1958 
[703]). 
In the present chapter, all analyses are conducted separately at first for each sibship 
size (usually up to 11, and sometimes up to 16, siblings in total) to account for possible 
differences in birth-order distributions. Both parametric and non-parametric tests are 
initially employed to analyse the birth-order position among MS cases. The first-born 
position, in particular, is also analysed independently to provide an additional birth-
order parameter. Next, to explore the effect of sibship size on birth order, these data 
are pooled over different-sized sibships, but only after taking account of possibly 
differing birth-order distributions for each sibship size; for the parametric tests, two 
different weighting models are employed to weight each sibship size before pooling. 
Finally, the independent results of all tests (including the last-born birth-order position) 
are compared and an attempt is made to interpret the relationships between the 
different parameters measured. 
8.2 Methods 
8.2.1 Source data 
As described in Chapter 5, a nationwide MS prevalence survey, coordinated by 
Professor J. McLeod, Discipline of Medicine, University of Sydney, was carried out on 
30 June 1981 to coincide with a national Australian census. MS cases were recorded 
by state; procedures for inclusion in the survey dataset were standardised by 
neurologists coordinating the survey. Clinical classification and validation of cases was 
described in Hammond, McLeod and colleagues ' various publications [301 , 646-648) 
(see Chapter 5). 
The unit-record MS-case dataset received from the McLeod research group was 
checked, cleaned and further verified by this candidate , as described in Chapter 5. Of 
the MS cases, 70% were Australia born , most of the remainder having been born in the 
UK and Ireland [304). The data were then restricted to those MS cases born between 
1920 and 1950 (inclusive) (see Section 5.3.3) . Importantly for this chapter, restriction of 
the year of birth to this three-decade period also achieved minimal variation in sibship 
336 
size over time-an assumption required for the theoretical analysis techn ique [556, 688, 
693] . That is , there was no significant difference in median sibship size over the three 
decades between 1920 and 1950 (p=0.052; Kruskall-Wallis non-parametric chi2 test). In 
addition , restriction to 1920- to 1950-born cases would have ensured that sibships 
were complete by the survey date in 1981 ( at least 30 years after birth of the index MS 
case) , a further requirement for this technique. 
Relevant demographic data variables for birth-order analysis of the MS cases included 
date of birth, sex, place in sibship (i.e. '1 ', '2', '3' ... =first born , second born , third born 
... ), sibship size (i.e. total number of siblings in the case family) , and whether the MS 
case was a twin . Single-child sibships (8.2% of cases) for which the theoretical 
technique is not applicable [693 , 703] were excluded from birth-order analysis (these 
cases being both 'first born ' and 'last born ' and providing no data for this analysis) . 
Twins (2 .5% of cases) were also necessarily excluded because a meaningful birth-
order position could not be assigned. 
The resulting unit-record dataset for birth-order analysis comprised 1,840 MS cases in 
sibships of two or more siblings who were born between 1920 and 1950 and present in 
Australia on 30 June 1981. These cases comprised 1,275 females and 565 males, and 
82% of the cases were of the relapsing-remitting clinical course type at onset. The 
average age of onset was 32.3 + 8.8 (s.d.) years. Thus , the 1,840 MS cases 
represented 1,840 sibships , each with a known total number of siblings in the sibship 
and the known order of birth of the MS case in the sibship . By tabulating birth order (of 
the case) by the total number of sibl ings in the sibship (=sibship size) as in Table 8.1, 
the data frequencies for the statistical analyses could be gained . The dataset fo r 
analysis thus comprised sibship sizes rang ing from two to 16 sibl ings in total ; MS cases 
in these sibships were born in birth-order pos itions rang ing from first to 15th , these 
birth-order positions being distributed among the sibsh ips in the frequencies shown in 
Table 8.1. 
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Table 8.1: Frequencies of birth-order positions of MS cases by sibship size (1981 MS Survey cases born 1920 to 1950; n=1,840) 
Sibship Order of birth (position in sibship) of MS case 
size 1 2 3 4 5 6 7 8 9 10 1 1 12 13 14 15 16 Total 
2 221 223 444 
3 184 174 143 501 
4 97 100 76 69 342 
5 43 40 51 42 39 215 
6 30 23 18 16 19 15 121 
7 13 15 8 10 8 12 22 88 
8 2 2 5 6 6 6 9 13 49 
9 1 0 3 4 3 6 0 3 2 22 
10 0 5 3 2 1 2 4 2 0 2 21 
1 1 2 0 1 3 1 0 1 2 2 2 4 18 
12 0 0 1 0 1 2 1 1 0 0 4 1 1 1 
13 0 1 0 0 0 1 0 1 0 0 1 0 0 4 
14 0 0 0 0 0 2 0 0 0 0 0 0 0 0 2 
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
16 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 2 
Total 593 583 309 152 78 46 37 22 4 5 9 1 0 0 1 0 1840 
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8.2.2 Statistical analysis 
Mean birth order 
The data consist of a number of sibships , each with an MS case born first , second , 
third ... , or last (i .e. any position up to the total number of siblings in the sibship). If 
there is no association between birth order and MS, the birth-order positions of the 
various MS cases in the sibships should be distributed randomly . A statistical test for 
an association between birth order and MS can be constructed by comparing the 
observed birth-order distribution with the expected birth-order distribution. 
For any particular sibship size , the mean birth-order position of the MS cases (mean 
birth order [MBO]) is calculated from the frequencies of each birth-order position in that 
sibship size. That is , for a sibship size s (=total number of sibl ings in the sibship ): 
s 
L J(x)x 
M BO,'v/SCASES = _x=-;---
L J(x) 
x= I 
where x=birth-order position of the cases 1, 2, 3 .. . s, and f (x)=frequency of each MS 
case with birth order x in that sibship size. The observed MBO may thus be less (i.e. 
cases are earlier born) , equal to , or more (i .e. cases are later born) than would be 
expected by chance . 
Analysis by sibship size 
The observed MBO was compared with an expected MBO for each sibship size , thus 
'conditioning on sibship size '. The tests were carried out separately over the sibship-
size range of two to 11 sibl ings (n=1 ,821 sibsh ips). Expected MBOs for a given sibsh ip 
size were calculated by assum ing , under the null hypothes is, an equa l shance of the 
MS case being born in any birth-order position in the sibsh ip (i. e. equal frequencies of 
each MS-case birth-order position in the sibship ). The observed distribution of MBO 
was then compared with the expected distribution using the central lim it theorem (CL T) 
[654]. 
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For example, for a sibship of four siblings, there are four birth-order positions and the 
expected MBO of the four birth-order positions-one, two, three and four-is 2.5 (Table 
8.2). This means that an MBO of 2.5 would be expected if the birth-order positions of 
all of the MS cases (of sibship size four) were randomly distributed. The variance of 
this expected birth-order distribution (Variance ExPo) is 1.25, which can be calculated 
from the general formula: 
Variance ExPo - ( 1) 
where s=total number of siblings in the sibship. For the example sibship of four 
siblings, the variance of the expected birth-order distribution is 15/12 (=1.25) (Table 
8.2). 
Comparing the observed sampling distribution of the means with the expected 
sampling distribution under the CL T, the test statistic, Z, follows a standard normal 
distribution and is given by: 
Z= Observed MBO - Expected MBO 
✓(Variance ExPo /n) 
(2) 
where n is the total number of cases of that sibship size. For example , for the sibship 
size of four siblings (n=342 sibships), the difference between the observed and 
expected MBO is 2.34 - 2.50 (= -0.16) , resulting in a negative Z-score of -2.61 (Table 
8.2) . This means that for this sibship size there was an observed 'shift ' in MS cases 
toward earlier birth-order position than expected. For the sibship size of eight siblings 
(n=49 sibships) , conversely, there was a positive Z-score of +3.58 and thus a shift 
toward later birth-order position than expected . 
The test statistic, Z, was calculated similarly for sibship sizes of up to 11 siblings , since 
the frequencies of sibships larger than this fell below the considered limit of accuracy 
(n=15) of the test [654] (Table 8.2). The 5% level of significance was used to assess 
each test statistic, Z-scores between +1 .96 being insignificant (two-tailed test) . 
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Table 8.2: Calculation of Z-scores for MBO of MS cases in sibships of two to 11 
siblings (n=1,821; calculated values shown to two decimal places only). (Sibship 
examples used in text shown in bold) 
Sibship Observed Expected Variance EXP□ Z-score Total cases of 
size (s) MBO MBO (equation 1) (equation 2) sibship size (n) 
2 1.50 1.5 0.25 +0.09 444 
3 1.91 2.0 0.67 -2.24 501 
4 2.34 2.5 1.25 -2.61 342 
5 2.97 3.0 2.00 -0.29 215 
6 3.13 3.5 2.92 -2.37 121 
7 4.24 4.0 4.00 +1.12 88 
8 5.67 4.5 5.25 +3.58 49 
9 5.41 5.0 6.67 +0.74 22 
10 5.14 5.5 8.25 -0.57 21 
1 1 7.06 6.0 10.00 +1.42 18 
12 8.27 6.5 Statistical limit of test* 1 1 
13 6.75 7.0 4 
14 6.00 7.5 2 
15 8.0 0 
16 12.50 8.5 2 
* Frequencies less than 15 are below the generally considered limit of accuracy of the Z-test [654] . 
Pooled sibship sizes using two weighting models 
The statistics for sibship sizes between two and 11 siblings (inclusive) were then 
pooled by weighting the {Observed MBO - Expected MBO} difference (=delta , a), for 
each sibship size , to take account of differing distributions for each sized sibship . Two 
models for a were considered. 
In model (1 ), the {Observed MBO - Expected MBO} difference (=01 ) was assumed to 
be the same for each sibship size . In this model , the weight for each sibship size was 
given simply by the reciprocal of the expected birth-order variance : 
1 / Variance ExPo Model(1) 
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In model (2) the difference, ch, was allowed to vary linearly with sibship size , s, thus: 
Observed MBO - Expected MBO 
s 
The weight for each a2 for each sibship size was then given by: 
s2 / Variance ExPo Model (2) 
For each model, the overall, weighted difference between observed and expected MBO 
was then converted to a Z-score given by: 
z Weighted estimate of a 
1 /✓( 2. weights) 
for comparison with a standard normal distribution , as previous_ly. 
As for the individual sibship-size calculations, only those sibships with frequencies of at 
least n=15 (Table 8.2) were considered to be within the limits of accuracy of the test; 
therefore , sibship sizes of up to 11 siblings only were pooled . 
Median birth order-non-parametric sign test 
Analysis by sibship size 
A second method used for testing for birth-order differences was a non-parametric sign 
test. This test required no assumptions about the birth-order distributions over the 
different sibship sizes. In the test , for each sibship size , the number of cases where the 
birth order was above , or below, the expected median birth-order position was 
determined. The null hypothesis here predicted an equal number of cases above and 
below the median , assuming an equal chance of be ing born in a higher or lower 
position than the median birth-order position. 
For example, for the three-siblings sibship size (Table 8.1 ), where the expected med ian 
birth order is 2.0, there are more MS cases (=184) born below the expected median 
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than above (= 143); this would result in a lower observed median birth order than would 
be expected by chance. 
Because cases where the observed birth order was equal to this median did not 
contribute to the test (='ties', where difference between observed and expected 
medians was zero), the total frequencies first needed to be adjusted to exclude these 
cases. For the sibship of three siblings, the 17 4 cases of observed birth order of 2.0 
exactly equal the expected birth order (Table 8.1 ); the adjusted n for this sibship size is 
then 327 (=501 - 17 4 ). 
The remaining cases were then either higher or lower than the median , and the number 
of 'positives' (=frequencies of cases above the median birth order) for each sibship size 
constituted a sample from a binomial distribution with n samples; the probability of 
being higher than the mean was 0.5 under the null hypothesis [654] . The null 
hypothesis could then be evaluated using the test statistic, Z+ , which followed a 
standard normal distribution providing that n was sufficiently large [654]. 
The test statistic, Z+, for a given sibship was given by: 
D - (n/2) 
✓(n/4) 
where D is the total number of cases with birth position above the median order, and n 
is the adjusted total number of cases with this sibship size . Sibship sizes up to 11 
siblings (i.e. where n >15) could be evaluated individually by this technique. 
Pooled sibship sizes 
With this non-parametric technique , the 'positives ' frequencies of a// sibships up to 16 
siblings could simply be pooled prior to calculating the test statistic, thus using all of the 
available case data in the pooled groups. 
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First-born fraction 
Analysis by sibship size 
As another way of investigating birth order of the MS cases and to support the findings 
so far, the specific 'first-born effect' among these cases was investigated by the 
parametric CL T technique as used for MBO, again initially stratifying by sibship size . In 
these tests , 'first-born ' MS cases were compared with 'non-first-born ' (i .e. with the 
remaining birth-order categories in each sized sibship ). Again , as for MBO, the null 
hypothesis was that there was an equal chance of the MS case being born in any birth-
order position in the sibship, the expected mean probability of being 'first born ', for 
each sibship size , s, being given by 1 /s. The expected proportion , or fraction , of first-
born cases was then calculated assuming a mean of 1 /s , and variance: 
1(1-1 /s) 
s 
Denoting the 'fraction of first-born cases ' as FFb, the test statistic, ZF, could be 
calculated , using the CL T under the same assumptions as previously for MBO: 
Observed FFb - Expected FFb 
✓(Variance ExPo / n) 
where n is the total number of cases with this sibship size . The Z-score was then 
compared against the standard normal distribution as previously. 
For example , for the sibship of four siblings again , the fraction of first born to non-first 
born , FFb, is given by 97/342 (Table 8.1) (=0.28), wh ich is greater than the expected 
fraction of 0.25 , thereby resulting in a positive Z-score . A pos itive Z-score here 
indicates that there is an excess of f irst-born MS cases , re lative to non-first born, in that 
sibship size. For the sibship of eight sibli ngs, the FFb is 2/49 (Tab le 8.1) (=0.04), wh ich 
is less than the expected fraction , 0.1 25 , result ing in a negative Z-score and ind icati ng 
a deficit of first-born MS cases in th is sibsh ip size . 
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Pooled sibship sizes 
Pooling of sibship sizes up to 11 siblings was again carried out using two different 
weighting models. Model (1) was similar to that previously used for MBO. That is , the 
difference between Observed FFb and Expected FFb (o1) was assumed to be the same 
for each sibship size. Model (2) assumed that the difference between Observed FFb 
and Expected FFb (o2) increased with family size , s, thus: 
s (Observed FFb - Expected FFb) 
The weight for each o2 for each sibship size (s) was then given by: 
1 / s2 Variance ExPo Model (2) 
Interrelationships between parameters 
The second analysis , specifically on first-born probability rather than mean or median 
birth-order positions , allowed later comparison of 'first-born ' effects in particular, versus 
the more general 'early-born ' effects investigated in the preceding subsections. That is , 
an excess of first born may be found to be consistent with a general early-born effect in 
some sibship sizes , supporting and adding to the overall birth-order information . In 
addition , subsequent independent analyses for the 'last-born ' birth-order position were 
also included ; these are detailed in Results , Section 8.3.3. 
MS Excel 2000 software was used for all statistica l analyses . 
8.3 Results 
8.3.1 Birth order-shifts in observed distributions 
Mean birth order 
Table 8.3 shows observed MBO and expected MBO, together with Z-scores ind icating 
negative shifts (i.e. observed MBO < expected MBO) and positive sh ifts (i .e . observed 
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MBO > expected MBO) in birth order, by sibship size over the range two to 11 siblings 
(n=1,821). 
Negative birth-order shifts (i.e. shifts toward earlier birth order of MS cases) were 
evident more often in the smaller-sized sibships; these were statistically significant for 
sibships of three, four and six siblings at the 5% level. Positive birth-order shifts (i.e. 
shifts toward later birth order of MS cases) were evident more often in the larger 
sibships of at least seven siblings, the sibship size of eight siblings reaching statistical 
significance (Figure 8.1 ). 
Table 8.3: Observed MBO and expected MBO, together with 2-scores and p-
values, for MS cases in sibships of two to 11 siblings, indicating significant 
shifts in birth order, by sibship size 
Sibship 
size 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 1 
Total 
Observed 
MBO# 
1.50 
1.92 
2.34 
2.97 
3.13 
4.24 
5.67 
5.41 
5.14 
7.06 
Expected 
MBO 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
5.0 
5.5 
6.0 
2-score# 
for shift 
+0.09 
-2.24 
-2.61 
-0.29 
-2.37 
+1.12 
+3.58 
+0.74 
-0.57 
+1.42 
#Observed MBO and Z-score each shown to two decimal places only . 
*Significant shift at p<0.05 . 
**Significant shift at p<0 .01 . 
p-value n 
0.928 444 
0.025* 501 
0.009** 342 
0.772 215 
0.018* 121 
0.263 88 
<0.001 ** 49 
0.459 22 
0.569 21 
0.156 18 
1821 
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Figure 8.1: Shifts, as Z-scores, in MBO of MS cases in sibships of two to 11 
siblings. 
Pooled sibships 
Pooling results over all sibship sizes from two to 11 siblings (n=1,821 sibships) gave 
non-significant or marginally significant shifts towards earlier birth order, depending on 
which weighting model was used for pooling (Table 8.4 ). That is , there appeared to be 
an overall trend toward earlier birth order of the MS cases in their sibships compared 
with expected ; however, this was only of borderline significance. 
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Table 8.4: Shifts in MBO of MS cases for pooled sibships overall (two to 11 
siblings, n=1,821 ), together with pooled smaller sibships (two to six siblings, 
n=1,623) and larger sibships (seven to 11 siblings, n=198), using two weighting 
models 
Pooled sibships Weighting model (1) 
(n, % of tested sibships) Z-score# 
Overall 2-11 (1821 , 100.0%) -1.84 
Smaller 2-6 (1623 , 89.1 %) -2 .19 
Larger 7-11 (198 , 10.9%) +2 .97 
#z -score shown to two decimal places only . 
*Significant shift at p<0.05 . 
**Significant shift at p<0 .01 . 
p-value 
0.067 
0.029* 
0.003** 
Weighting model (2) 
Z-score# p-value 
-1.95 0.051 
-3.04 0.002** 
+3.02 0.002** 
When smaller sibships of two to six siblings were pooled (89.1 % of tested sibships) and 
tested separately from larger sibships of seven or more siblings (10 .9% of sibships) , 
significant birth-order shifts in opposite directions resulted. In smaller sibships (two to 
six siblings ; n=1 ,623 sibships) there was a significant shift in birth order of MS cases 
towards the earlier-born sibship positions, while in larger sibships (seven to 11 siblings; 
n=198 sibships) , there was a statistically significant shift in birth order of MS cases 
towards the later-born positions (Table 8.4 ). 
Median birth order 
The non-parametric sign-test method also showed several negative birth-order sh ifts in 
the smaller sibship sizes , the three- and four-person sibships being stat istically 
significant and the six-person sibship approach ing significance (Table 8.5, sibship sizes 
tested separately up to 11-person sibships). The larger sibships aga in showed mainly 
positive birth-order shifts (Figure 8.2) , the eight-person sibship reach ing sign ificance at 
the 1 % level. 
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Table 8.5: Non-parametric sign test for differences between medians, and 
resulting Z-scores and p-values for birth order of MS cases, by sibship size 
(n=1,602). (Frequencies in italics have been adjusted for ties) 
Sibship Expected 
size median BO 
2 1.5 
3 2.0 
4 2.5 
5 3.0 
6 3.5 
7 4.0 
8 4.5 
9 5.0 
10 5.5 
1 1 6.0 
12 6.5 
13 7.0 
14 7.5 
15 8.0 
16 8.5 
Total 
Number +ve 
differences 
223 
143 
145 
81 
50 
42 
34 
1 1 
10 
1 1 
7 
2 
0 
0 
2 
#z -score shown to two decimal places only. 
*Significant shift at p<0 .05 . 
**Significant sh ift at p<0.01. 
Z-score# p-value 
+0.09 0.928 
-2.27 0.023* 
-2.81 0.005** 
-0.16 0.873 
-1.91 0.056 
+0.68 0.497 
+2.71 0.007** 
+0.69 0.490 
-0.22 0.826 
+0.94 0.347 
n (adjusted 
for ties) 
444 
327 
342 
164 
121 
78 
49 
19 
21 
18 
1 1 
4 
2 
0 
2 
1602 
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Figure 8.2: Shifts, as Z-scores, in median birth order of MS cases in sibships of 
two to 16 siblings (non-parametric test; n=1,602). (Statistically significant results 
of overall pooling of two to 16 siblings also indicated.) 
Pooled sibships 
Pooling over the entire range of two- to 16-person sibships (adjusted n=1,602 sibships) 
showed a statistically significant overall shift towards earlier birth order for MS cases 
(Table 8.6 and Figure 8.2). Separate pooling for smaller sibships (two to six siblings; 
adjusted n=1,398 [87.3% of tested sibships]) and larger sibships (seven to 16 siblings; 
adjusted n=204 [12.7% of sibships]) again showed significant birth-order shifts in 
opposite directions-towards lower (i.e. earlier) birth order in smaller sibships and 
towards higher (i.e. later) birth order in large sibships (Table 8.6) . Using this non-
parametric test , the early-born effect in smaller sibships was considerably stronger than 
the late-born effect in large sibships, resulting in an overall statistically significant early 
birth-order shift for the whole range of two- to 16-person sibsh ips. 
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Table 8.6: Overall shift in median birth order for MS cases in pooled sibships of 
two to 16 siblings (n=1,602 sibships), and shifts in median birth order for pooled 
smaller sibships (two to six siblings, n=1,398 sibships) and larger sibships 
(seven to 16 siblings, n=204 sibships), using the non-parametric sign test 
Pooled sibships 
(n t, % of tested sibships) 
Overall 2-16 (1 ,602, 100.0%) 
Smaller 2-6 (1 ,398, 87.3%) 
Larger 7-16 (204 , 12.7%) 
#z -score shown to two decimal places only . 
t n adjusted for ties . 
*Sign ificant sh ift at p<0.05 . 
**Sign ificant sh ift at p<0 .01 . 
2-score# p-value 
-2.00 0.046* 
-3.05 0.002** 
+2 .38 0.017* 
Comparison of parametric and non-parametric tests for birth-order shifts 
Each of the pooled results for shifts in birth order, by both parametric and non-
parametric tests , are shown together in Figure 8.3 , where it can be seen that the three 
techniques delivered similar birth-order shifts in both effect size and direction . The non-
parametric test was also able to use all of the available sibship data (i .e. up to and 
including sibships of 16 siblings). 
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Figure 8.3: Results of all techniques for birth-order shifts in MS cases, for all-
sized sibships (two to 11 [MBO] or two to 16 siblings [median birth order]); 
smaller sibships (two to six siblings [87 to 89% of tested sibships]); and larger 
sibships (seven to 11 or seven to 16 siblings [11 to 13% of tested sibships]). The 
figure compares the MBOs calculated using the CL T with two weighting models 
for pooling separate sibships (Mean [1] and Mean [2]) and the median birth order 
model calculated using a non-parametric sign test with 'positive' frequencies 
pooled before testing (Median). 
8.3.2 First-born fraction-excess or deficit 
Observed and expected first-born fractions (FFb) by sibship size , together with Z-
scores for the differences, and their corresponding p-values , are given in Table 8. 7. 
Here, a positive Z-score indicates an excess of first-born MS cases compared with the 
remaining sibship positions , because the observed FFb is greater than expected by 
chance. Similarly, a negative Z-score indicates a deficit of first born compared with the 
remaining birth-order positions for MS cases. 
A significant excess in first-born MS cases was evident for the six-person sibship; 
however, other sibship sizes with positive Z-scores (e.g. three- and four-person 
sibships) only approached significance at the 5% level. Deficits in first-born cases 
featured mainly in the larger sibships, although these again only approached 
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significance at the 5% level (e.g. eight- and 10-person sibships) (Table 8.7 and Figure 
8.4). 
Table 8.7: Observed and expected first-born fractions (FFb), together with Z-
scores and p-values, for MS cases in sibships of two to 11 siblings (n=1,821 ), 
indicating significant excesses and deficits in FFb, by sibship size 
Sibship Number 
size first born 
2 221 
3 184 
4 97 
5 43 
6 30 
7 13 
8 2 
9 1 
10 0 
1 1 2 
Total 
Observed 
FFb# 
0.50 
0.37 
0.28 
0.20 
0.25 
0.15 
0.04 
0.05 
0.00 
0.11 
#FFb and Z-score shown to two decimal places only . 
*Significant at p<0 .05 . 
Expected Z-score# p-value n 
FFb# 
0.50 -0.09 0.928 444 
0.33 +1.61 0.107 501 
0.25 +1.44 0.150 342 
0.20 0.00 1.000 215 
0.17 +2.40 0.016* 121 
0.14 +0.13 0.897 88 
0.12 -1.78 0.075 49 
0.11 -0.98 0.327 22 
0.10 -1.53 0.126 21 
0.09 +0.30 0.764 18 
1821 
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Figure 8.4: Excesses and deficits (as positive or negative Z-scores) of first-born 
MS cases, by sibship size (n=1,821 ). 
Pooled sibships 
Pooling over all sibship sizes from two to 11 siblings (n=1 ,821 sibships) gave positive 
Z-scores indicating overall first-born excesses among MS cases but these were non-
significant using either weighting model (1) or (2) (Table 8.8). 
Pooling separately for smaller and larger sibships using the previous pool-size 'cut-offs ', 
again suggested differences in opposite directions, although here the suggested deficit 
in the 'large' sibships pool (n=198 [10.9% of tested sibships]) was non-significant. 
Conversely, the two- to six-sibling pool (n=1 ,623 [89 .1 % of sibships]) showed a 
statistically significant excess in first-born MS cases, using we ighting model (1 ) (Table 
8.8). 
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Table 8.8 Excesses and deficits in first-born MS cases in overall pooled sibships 
(two to 11 siblings, n=1,821 ), together with pooled smaller sibships (two to six 
siblings, n=1,623) and larger sibships (seven to 11 siblings, n=198), using two 
weighting models 
Pooled sibships 
(n, % of tested sibships) 
Overall 2-11 (1821 , 100.0%) 
Smaller 2-6 (1623, 89.1 %) 
Larger 7-11 (198, 10.9%) 
#z-score shown to two decimal places only . 
*Significant at p<0 .05 . 
Weighting model (1) 
Z-score# p-value 
+1.37 0.171 
+2.28 0.023* 
-1.58 0.114 
Weighting model (2) 
Z-score# p-value 
+1.42 0.156 
+1.70 0.089 
-1.45 0.147 
Summing up, for the entire two- to 11-person sibship pool, a trend toward an overall 
excess of first-born MS cases is evident; this rr1ay be consistent with an overall 'early-
born' effect seen by the tests for mean and median birth order in preceding subsections, 
and is discussed further in the next sub-section. However, restricting the pool-size to 
two- to six-person sibships-this representing the bulk (89.1 %) of the total number of 
sibships-showed that there was a just significant excess of first-born MS cases in this 
pool (average Z-score from both weighting models= +1 .99 , p=0.04 7). 
Synthesis of results 
A comparison of pooled-data Z-scores of the two main analyses of the sibship 
characteristics of the MS cases can be used to summarise all of these findings for the 
sibships overall and for the 'smaller' and 'larger' sibships separately (Table 8.9). The Z-
scores for the individual MBO analyses using different weighting models and for the 
median birth order have been averaged for this purpose. Z-scores for the two weighting 
models used for the first-born fraction pools have also been averaged . 
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Table 8.9: Summary Z-scores for birth-order measures for MS cases in pooled 
overall and different-sized sibships, obtained by two independent measurement 
parameters-mean or median birth order and first-born fraction (Z-scores 
significant at 5% level shown in bold) 
All sibships 
(2+ siblings) 
Birth order -1 . 93 
(Median/MBO) 
First-born fraction +1.40 
(FFb) 
Smaller sibships 
(two to six siblings) 
Larger sibships 
(7+ siblings) 
[87 to 89% of sibships] [11 to 13% of sibships] 
-2.76 +2.79 
Early birth order Late birth order? 
+1.99 -1 .57 
Excess first born 
For all sibships pooled , the two parameters in Table 8.9 show a consistent pattern for 
MS cases. There is a trend towards an overall excess of first-born MS cases , 
consistent with an overall trend towards earlier birth order in these cases. That is, 
despite neither of these trends achieving statistical significance when all-sized sibships 
are pooled , there appears to be an overall trend toward MS cases being born either 
first , or at least earlier than expected in the sibship. Thus , in terms of MS risk , there 
appears to be a possible overall trend towards earlier-born people (in their sibsh ip) 
having higher MS risk. 
Restriction by sibship size 
However, clearer results in the same respective directions are gained by restricting the 
sibship sizes to the smaller, more numerous sibships of just two to six siblings. Here, 
there is a clear birth-order shift towards earlier birth-order positions in MS cases , 
together with an excess of MS cases born first in their sibsh ip, both of these 
parameters being statistically significant (indicated in bo ld in Table 8.9). The 
magnitudes of the balded Z-scores in Table 8.9 can also be directly compared with 
each other; a comparison shows that the 'early-born ' effect in two- to six-person 
sibships is statistically stronger than the 'first-born ' effect. Th is may ind icate that a 
heightened risk of MS extends beyond the first born in the family. 
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Summing up, the 'overall' trend in Table 8.9 is thus similar to that in the restricted 
sibship-size pool (i.e. two- to six-person sibships) for both of the measured parameters, 
mean/median birth order and first-born fraction, but this trend appears to be weakened 
because of the presence in the dataset of the larger, less numerous sibships acting in 
the opposite direction. Whether these effects suggested in the larger sibships are real , 
or possibly confounded by other factors, will be discussed in Section 8.4. 
8.3.3 Additional measurement parameters 
As independent data for 'last born' were also available in the dataset and because 
these might further support the results so far, additional analyses for the 'last-born' 
fraction, and for the 'first-born relative to last-born' fractions, were conducted. These 
supplementary tests are shown henceforth only for the restricted two- to six-person 
sibship pool, because in these tests this group constitutes 89 to 94.5% of all sibships 
(Table 8.10). 
Last-born fraction 
The fraction of last-born (Flb) MS cases was calculated for each sibship size in exactly 
the same way as for the first-born fraction, with 'last born' being compared with 'non-
last born' (i .e. with the remaining birth-order categories in each sized sibship ). The 
expected fraction of last born in each sibship was the same as that for first born . For 
the example sibship of four siblings, the Flb was 69/342 (see Table 8.1) (=0.20), which 
was less than the expected fraction of 0.25, thus resulting in a negative Z-score and 
indicating a deficit of last-born MS cases in this sibship size. 
It can be seen that when information from these two independently derived parameters 
is considered together, both an excess of first-born MS cases (Section 8.2.2) and a 
deficit of last-born cases in the same sibship is possible , as in the four-person sibship 
example. 
Pooling of sibship sizes up to six-person sibships was then carried out using two 
weighting models as for the first-born analyses. Results showed a significant deficit in 
last-born MS cases for these pooled sibships using either weighting model (average Z-
score -2.55, p=0.011; n=1,623 sibships). Considered together with the first-born results , 
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this means that there is now both a significant excess of first born and a deficit of last 
born in this main sibship-size pool (89.1 % of the total 1,821 sibships in the testable two 
to 11 sibship-size range). 
Relative fraction-first born to last born 
As a final supporting but still independent approach , the fraction of first born relative to 
last born (FFb2) could be calculated . In this analysis , the fraction of first-born MS cases 
was compared directly with the fraction of last-born cases, excluding all other cases 
from the analysis. Here, the null hypothesis was that there was an equal chance of 
being born either first or last in those sibships where the case was born in one of these 
two positions. 
The observed fraction of first-born cases relative to last-born cases , FFb2, for each 
sibship size , could again be tested using the CL T, the test statistic, ZF2, being given by: 
ZF2= Observed FFb2 - _Expected FFb2 
✓(Variance ExPo / n) 
where the expected fraction of cases had a mean of 0.5, and variance 0.5 (1 - 0.5)= 
0.25. The value n was now an adjusted value , sibships with neither a first-born or last-
born case being excluded . For the example four-sibling size , there were 166 (n= 97 + 
69) sibships where the MS case was either first- or last-born (see Table 8.1 ); the FFb2 
was 97/69 (=0.584) , which is greater than the expected 0.5 , resulting in a positive Z-
score and indicating a significant excess of first-born relative to last-born MS cases in 
this sibship size. 
As in the preceding analyses , the two- to six-person sibships were then poo led . As all 
cases that were neither first nor last born were excluded from th is ana lys is, every 
remaining case had an equal chance of be ing f irst or last born under the null 
hypothesis , regardless of sibship size . Therefore, the data were ab le to be poo led prior 
to the final CL T analysis and no assumption mode ls were requ ired . A second 
advantage of this analysis was that all ava ilable sibsh ip sizes cou ld be included in the 
pooled analysis-that is , all sibsh ips where the MS case was born first or last-wh ich 
included up to 12-person sibsh ips (see Tab le 8.1) (n=1 , 126 sibsh ips). 
358 
Results from this analysis for the two- to six-person sibship pool were stronger than for 
the independent first-born fraction and showed a highly significant relative excess of 
first born (Z-score +2.64, p=0.008; n=1,064 sibships). Further, the two- to six-person 
sibship pool of 1,064 sibships in this analysis represented 94 .5% of the total number of 
sibships in which the MS case was born either first or last. 
8.3.4 Birth order and MS risk-collation of all analyses 
All of these measures for the two- to six-person sibships can now be considered 
together (Table 8.1 O); the various effect sizes are indicated by the Z-score magnitudes. 
Table 8.10: Summary Z-scores for birth-order measures for MS cases in pooled 
two- to six-person sibships, obtained by four independent measurement 
parameters 
Test parameter 
Birth order 
(median/MBO) 
First-born fraction (FFb) 
Last-born fraction (Flb) 
First born to last born 
relative fraction (FFb2) 
# % of sibships in testable pool . 
*Significant at p<0 .05 . 
**Significant at p<0 .01 . 
Z-score (p-value) 
-2.76 (0.006)** 
+1.99 (0 .04 7)* 
-2 .55 (0.011 )* 
+2.64 (0.008)** 
Interpretation of 
test 
Early birth order 
Excess first born 
Deficit last born 
Excess first born 
( relative last born) 
In summary, the results show all of the following in MS cases : 
• an early birth-order shift 
• excess first born 
• a deficit in last born 
% 
sibships# 
87-89.1 
89 .1 
89.1 
94.5 
• excess first born relative to last born (where MS case either first or last born). 
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All of these shifts or differences were compared with that expected by chance . Each of 
these measured parameters constitute and contribute to an overall 'early-born ' effect 
evident in MS cases, particularly in these two- to six-person MS-case sibships (87 to 
94.5% of testable sibships). 
8.4 Discussion 
An association between birth order and MS risk that is dependent on sibship size has 
been shown by these analyses. In smaller sibships (up to a total of six siblings) , shifts 
in mean , or median, birth order of the index MS case towards being earlier born than 
expected are evident. In larger (7+) sibships, birth-order shifts of the MS case towards 
being later born than expected appear evident. 
These differences with sibship size were seen most readily by considering the smaller 
sibships, forming around 90% of the available sibships data , separately from the larger 
sibships and then averaging the (weighted) Z-scores for each sibship-size pool. By this 
means, the most numerous two- to six-siblings group showed a distinct early-born 
birth-order effect for MS cases , while the much less numerous 7+ siblings group 
showed a significant late-born effect. If all sibship sizes were considered together in a 
single (2+ siblings) pool , the overall effect was generally consistent with that for the 
two- to six-person sibships , though weaker. 
The two- to six-person sibships further showed a significant excess of, in particular, 
first-born MS cases , using an additional test parameter that was independent of the 
mean (or median) birth-order parameter. This result supported the early-birth-order 
shift for this major group of sibships . 
In addition , the two- to six-person sibships showed an independent, highly sign ificant 
excess of first born measured relat ive to last-born MS cases , as we ll as a sign ificant 
deficit of last-born MS cases by yet another independent test parameter. Together, al l 
of these results strongly suggest a significant, non-random , early-born effect in MS 
cases that is different from that of the general population as expected by chance . That 
is , the results suggest higher MS risk if born first or early in the sibsh ip and lower risk if 
born later or last, for most sibships . 
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This result for the majority of the sibships is consistent with shifts towards early birth 
order in some earlier work on MS cases [555, 616, 687-690] and may support the 
hygiene hypothesis concept of a lack of early infectious (or other microbial) exposure 
contributing to subsequent MS risk (see Chapter 3). 
Conversely, the shifts toward later-born cases for the less numerous sibships of seven 
or more are consistent with the (opposite) findings in the large Canadian study of 
Sadovnick and colleagues specifically for 7+ siblings [554]. Is the late-born effect in 
only 7+ -person sibships real? A confounding factor which might contribute to this 
finding is parental age at birth of the MS case. That is, if MS risk is associated with 
maternal (or paternal) age at birth, the chance of an MS case being born later in the 
sibship would be increased. Parental age was not adjusted for in this study; however, 
average maternal age in the two main sibship-size groups differed by less than four 
years (mean maternal age for two- to six-person and 7+ -person sibships was, 
respectively, 28.4 + 5.8 and 32.0 + 7.2 [s.d.] years). Further, whereas Antonovsky and 
co-workers reported a significantly higher percentage of MS patients born to mothers 
aged 40 or more years (but not 30 or more years) compared with controls in a small 
study [704], and Montgomery and colleagues reported an effect with paternal, rather 
than maternal, age in their Swedish case-control study [555], subsequent larger 
longitudinal studies in Denmark and Canada did not find any association between 
maternal or paternal age at birth and MS risk [556 , 705]. 
The late-born MS-case effect for 7+ siblings , found in both the Canadian study and the 
present study, if real, is also not inconsistent with the findings of younger infant siblings 
being protective for MS, independent of birth order, as found in the case-control study 
in TAS, Australia [553]. That is, if later birth order can be 'equated ' with fewer younger 
siblings (as might generally be the case) , then both of these parameters could 
conceivably result in higher MS risk. The findings of Montgomery and colleagues of 
protective effects of higher number of siblings (both older and younger) and of having a 
twin [555] are further broadly consistent here with this more general interpretation of 
the hygiene hypothesis-that is , that siblings per se in early childhood may be 
protective for MS risk. 
Alternatively, the late-born trends in just the larger sibships found here and in Canada 
may be due to a period-of-birth cohort effect resulting from increasing MS incidence 
over time, as suggested by Sadovnick and colleagues for similar results in their study 
[554]. That is, if incidence increases and/or age of onset of MS decreases over time, 
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the chance of becoming an MS case would be higher in those born later in the study 
period. In the present dataset the period between first born and last born of the largest 
sibships-for example, for those with 10 to 15 siblings-may span some 20 to 30 years 
(assuming a two-year spacing between siblings) , allowing ample time for such a cohort 
effect. However, it is also worth noting that if a period-of-birth cohort effect exists in the 
data, it will have weakened the overall results. Indeed , if the cohort effect is strong 
enough to produce a spurious result in the 7+ -siblings group, it may also be masking 
an even stronger effect in the two- to six-siblings group. Interestingly, the shift toward 
later birth order in the 7+ group was present only in females (subgroup analysis data by 
sex not shown), whereas both males and females exhibited the shift to earlier birth 
order in the two- to six-person sibships; this may, however, be due to inadequate 
sample size for the 7+ male group. 
Certainly, the early birth order result in MS cases for the majority of sibship sizes, up to 
six siblings, appears to be the strongest and most consistent finding in the present 
study, and is probably also the most relevant , given that family sizes of more than six 
children are now so rare as to be of less population health significance. The result 
suggests that infection(s) may be acting protectively during early childhood to reduce 
subsequent MS risk. 
Strengths of the present study include the relatively large, comprehensive, population-
based survey of clinically identified MS patients in most regions of Australia on the 
national census day, 30 June 1981 , comprising sibship sizes up to 16 siblings. 
Restriction of the data in the final sample to year of birth between 1920 and 1950 
(inclusive) then not only minimised likely selection biases of the cross-sectional survey 
(see Chapter 5) , but, importantly, also limited possible effects of changes in sibship 
size over time. Thus, this fundamental requirement of the theoretical analysis technique 
was fulfilled , together with the certainty that the sibships would most likely have been 
complete by the time of survey. The results should also have not been affected by the 
children in the sibships attending day-care facil ities and thereby being exposed earl ier 
to infections, since an older pre-1950-born dataset of cases was used . 
While the theoretical 'observed versus expected ' analysis technique for a cases-only 
dataset (rather than comparison with controls) has undoubtedly been misused in the 
past in some studies, the stringent use here by first conditioning (or stratifying) on 
sibship size, as used also by Sadovnick and co-workers [554], avoided major error. 
Then, for the parametric tests in the present study, weighting of these sibship sizes by 
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two different 'extreme-case' assumption models, to take account of different 
distributions for each sibship size, was carried out before any of the sibships were 
pooled. This does not appear to have been done by any previous such studies 
(Sadovnick and colleagues do not describe how they obtained their pooled value for 
seven or more siblings) [554]. 
While the correct weighting to be applied is unknown-that is, whether the difference 
between 'observed' and 'expected' varies linearly or not at all with sibship size-the 
answer is probably 'somewhere in between'. In fact , the Z-score results by these two 
weighting methods were not dissimilar and in most cases could finally be averaged 
together with results of additional non-parametric tests that did not require such 
assumptions and that further enabled all-sized sibships to be included (see Section 
8.3.2). Moreover, four different, independent test parameters were able to be employed 
in the present analyses, particularly for the more numerous smaller sibships. Because 
the final results of these parameters were consistent, being in the same expected 
direction, the overall result was strengthened. 
Limitations include the available cases-only dataset, for which only the theoretical 
analysis technique was possible; suitable population controls may have enabled a 
case-control study to be attempted for comparison . (Sibling controls are not suitable for 
even theoretical analysis as their birth-order position is 'conditioned ' by that of the 
index MS case.) Sibling ages and inter-birth intervals of the sibships were also 
unavailable ; these might have enabled any period-of-birth effects to have been more 
easily determined. 
MS cases born elsewhere than Australia were also included in the present analysis to 
retain sufficient sample size (as other workers , including Sadovnick et al. , 2005 [554], 
also appear to have done). However, subsequent analyses for just Australia-born MS 
cases showed similar birth-order shifts to those presented here for the smaller (up to 
six siblings) and larger (7+) sibship pools (data not shown ). Further, the included 
migrants mostly from the UK and Ireland came from similarly-developed countries in 
terms of hygiene and early infectious exposure . 
Summing up, MS risk in terms of birth-order position appears to depend on sibship size 
(i.e. whether <7 or > 7 siblings) in these Australian data , but the strongest and most 
relevant result for most sibships (two to six siblings) is that an earlier birth-order 
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position (i .e. being one of the older siblings in the sibship) increases subsequent MS 
risk. This is consistent with the broadest form of the hygiene hypothesis, which posits 
that there is a lack of microbial exposure early in childhood for the older, earlier-born 
siblings in a sibship, and that this lack of beneficial immune stimulation predisposes 
toward subsequent autoimmune disease such as MS, as detailed in Chapter 3. 
8.5 Conclusion 
MS risk in Australia appears to be associated with birth-order position. That is, in most 
sibship sizes-up to six siblings in total-MS cases appear more likely to be born in an 
earlier birth-order position than expected by chance (i.e. be an older sibling in the 
sibship than expected) . This may suggest the protective action of infectious or other 
microbial agents early in childhood (as one causal component in a multi-causal model) 
to ultimately prevent later MS disease onset. 
364 
CHAPTER 9 
KEY FINDINGS AND IMPLICATIONS FOR FUTURE RESEARCH AND 
POPULATION HEAL TH POLICY 
9.1 Introduction 
The aim of this thesis was to extend knowledge on key environmental risk factors for 
MS in Australia , and to relate this to some other organ-specific autoimmune disorders , 
including type 1 diabetes and RA, for which the specific aetiology is also presently 
unknown . The key findings for MS here emphasise the importance of timing of these 
putative factors in the period before disease onset, and support and extend northern 
hemisphere findings on both timing and possible nature of these factors. 
The timing-of-birth pattern found at the individual level in MS cases (see Chapters 5 to 
7) indicates a possible factor acting near the time of birth , consistent with northern 
hemisphere findings for reciprocal seasons. Importantly, for the first time , this factor 
may be possibly identified as low ambient UVR acting in the prenatal period and most 
critically in the first foetal trimester (see Chapter 7) . These findings for UVR and MS are 
further supported by a finding , at the population level , of an inverse association 
between regional ambient UVR and prevalence of autoimmune type 1 diabetes with in 
Australia (see Chapter 4 ). 
In addition , the independently determined birth-order pattern found at the individual 
level in MS cases (see Chapter 8) suggests a second environmental factor in the pre-
onset period of MS that may be possibly identified as lack of infection (s) or other 
microbial exposure early in childhood. This finding is consistent with the pred ict ions of 
the hygiene hypothesis and aga in emphasises the importance of timing of such factors . 
Thus, interaction of these suggested protective factors with genes, with each other and 
with subsequent unidentified factors , may constitute an important part of a sequential 
'causal cascade ' of determinants acting over the life course and leading to eventua l 
onset of MS. These findings constitute new or extended knowledge on the sequential 
timing and nature of environmental factors influencing MS and , perhaps , other 
autoimmune disorders. 
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Data and level of evidence 
Secondary analyses of existing datasets are a well-established methodology for 
addressing important research questions that would otherwise be expensive , time-
consuming and difficult to answer directly, particularly for long-latency and/or rare 
disease conditions such as MS [10 , 11 ]. Some challenges in the use of the two existing 
datasets analysed in this thesis have been discussed in preceding chapters , together 
with methods of overcoming these limitations. For example , a year-of-birth-restricted 
longitudinal study dataset, incorporating population denominators , was able to be 
constructed from the existing 1981 Australian MS Survey to optimise the data for 
analysis of the major exposure factors , including regional ambient UVR (see Chapters 
6 to 7). A complete comparison of timing of birth , gender and region-of-birth between 
MS cases and the relevant Australian reference population was then achievable from 
the original cross-sectional survey data, rather than simply a disease prevalence study 
(see Chapter 7) . Such secondary analyses can contribute to intellectual advancement 
by building on previously known findings and thereby creating new knowledge ; the 
findings can further be generalised from these existing representative , national 
datasets to the broad Australian population. 
1995 National Health Survey 
Good supporting documentation and statistical advice for use of this comprehensive 
national Australian health interview (cross-sectional) survey, and a high response rate 
achieved by the ABS, made this dataset reliable for valid secondary analysis of the 
immune disorders chosen , particularly for type 1 diabetes (see Chapter 4 ). Because 
this was necessarily an ecological analysis , focus ing on factors that are re levant and 
variable at the individual level , causal findings are not possible ; however, associations 
found between exposures (latitude , ambient UVR) and disease outcomes at the 
population level may inform other research . Potential confounders not measurable here, 
such as infections, climate , temperature and diet, and poss ible interactions between , 
also warrant consideration at the ind ividual level in future studies of type 1 diabetes. 
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1981 Australian MS Survey 
Chapters 5 to 8 were based on an existing proprietary dataset comprising individual-
level , original data from the comprehensive survey of MS cases in Australia by 
Professor J. McLeod's University of Sydney research group. This national, population-
based, clinical and epidemiological survey was conducted on 30 June 1981 , the date 
chosen to conveniently coincide with an ABS national Census of Population and 
Housing (see Chapter 5) for application of population denominators. This unique 
southern hemisphere MS survey was based on nationally standardised ascertainment 
and careful validation of MS-case diagnoses (see Chapter 5). 
As for the 1995 National Health Survey, the relative genetic homogeneity and access 
to national health care in Australia, as well as the well-coordinated nature of the survey, 
contributed to the overall validity and usefulness of this MS dataset. Several frequently 
cited and internationally recognised publications on the epidemiology of MS in Australia 
by this research group resulted between 1987 and 2011 , based on this dataset (see 
Chapter 5) , suggesting that these data were a reliable and comprehensive source of 
information on Australian MS cases for the purposes of this thesis. 
A particular strength of this thesis study lay in the extension of the initial timing-of-birth 
analysis to explore regional ambient prenatal UVR as a more direct, and independent, 
risk exposure factor at the individual level (see Chapter 7) . Thus, prenatal UVR was a 
prospective exposure whose levels were heterogeneously distributed among the MS 
cases because of the large variation in UVR linked to month and region of birth across 
Australia. While the regional ambient UVR levels were not necessarily those 
experienced by each mother, it has recently been shown that ambient erythemal UVR 
levels during pregnancy can be validly used to indicate maternal vitamin D status , and 
that ambient UVR can be used as an instrumental variable for causal analys is of 
subsequent vitamin O-dependent disorders in offspring (see Chapter 7). Thus , potential 
new knowledge of MS aetiology was ga ined from this extended ana lysis, and the 
possible public health importance of the prenatal period for prevention of MS now 
warrants further confirmatory study. 
For the birth-order analyses (see Chapter 8), the 1981 MS Survey dataset was used in 
its original unit-record , cross-sectional , cases-on ly form , and ana lyses included only 
those born between 1920 and 1950, as for timing-of-birth analys is. Because population 
controls with sibship information were unavailable for this study, a theoretical 'observed 
367 
versus expected' analysis technique, as used by some previous studies , was the only 
method applicable here. Importantly, in this thesis study, potential error due to differing 
birth-order distributions with total sibship size was able to be avoided by taking sibship 
size into account (see Chapter 8). Thus , while the findings need confirmation , this 
thesis study was able to improve on several previous theoretical birth-order analyses , 
the findings from which have lacked consistency. 
In synopsis, although pre-existing datasets designed for other purposes have been 
utilised in this thesis , important indications of the timing and possible nature of some 
environmental determinants influencing autoimmune disorders such as MS have been 
achieved. By analysis of such existing quality datasets, an epidemiological 'bird's eye 
view' can be gained of trends that future primary studies can now examine [11 ]. The 
secondary analyses in this thesis provide a first evaluation of the given research 
questions, that may set priorities for subsequent in-depth studies. Further work to test 
these indications or trends, using data from specifically designed prospective cohort 
and RCT studies (as considered in the following section), is now needed. 
9.2 Key findings of this thesis and implications for future 
research 
9.2.1 Latitude, UVR and type 1 diabetes prevalence 
The finding of an association between southern latitude and type 1 diabetes prevalence 
over the north-south breadth of Australia for the first time (see Chapter 4) is now 
consistent with similar gradients for such autoimmune disorders in the northern 
hemisphere. The further finding in Chapter 4 that this latitude gradient was accounted 
for by an inverse regional ambient UVR gradient over Australia (published as Staples 
et al. , 2003, Appendix I) is also consistent with that found previously for MS in Australia 
(see Chapter 2). This finding supports the specific prediction that autoimmune diseases 
other than MS, such as type 1 diabetes, should show latitude and/or UVR gradients 
similar to those seen for MS if these immune disorders are similarly influenced by UVR 
exposure [5] . The likelihood of ambient UVR, and/or vitamin D, being an influential 
environmental factor for organ-specific autoimmune disorders generally has been 
strengthened by the finding of an inverse ambient UVR gradient of type 1 diabetes 
prevalence in Australia. 
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These findings have implications for understanding the possible environmental causes 
for the observed global distribution of such autoimmune disorders. That is, lack of solar 
UVR exposure, perhaps mediated through vitamin D deficiency, may be a contributing 
factor (in both hemispheres) to the observed geographic disease gradients as well as 
to the increase in incidence of such disease over time (see Chapter 2). Using summary 
estimates at the population level, the present findings can only be hypothesis 
generating but should inform future studies on aetiology of type 1 diabetes and other 
autoimmune disorders. For example, it would be important to establish whether there is 
a seasonal timing-of-birth risk pattern at the individual level in such disorders in the 
southern hemisphere, and whether this might be related to regional ambient UVR20 . 
This may indicate whether a factor such as UVR might be influencing disease risk 
around the time of birth, and possibly when, in particular, the most critical period might 
be. 
9.2.2 Prenatal UVR and timing-of-birth risk pattern_ in MS cases 
The findings in Chapter 7 have extended the existing knowledge for MS. A timing-of-
birth risk pattern has been shown, at the individual level, for the first time in MS cases 
born in Australia (cases as sampled nationally in 1981 ). Importantly, this pattern also 
mirrors seasonally that seen for MS in the northern hemisphere (see Chapter 7), 
extending existing knowledge to other geographic regions and supporting the concept 
that an important environmental determinant of MS is 'time-locked ', globally, to the 
period around birth. A 30% increased MS risk was evident in those born in November 
to December (southern hemisphere early summer) compared with those born in May to 
June (early winter) (see Chapter 7). This indicates an environmental factor acting close 
to the time of birth and modifying the risk of later adult onset of MS. 
Most importantly, this timing-of-birth risk pattern in Australia has been shown for the 
first time to be fully accounted for by the regional (state) and seasonal ambient UVR 
levels specific to the prenatal period seven to eight months before birth (see Chapter 7) . 
That is, reduced ambient UVR in the first trimester of gestation appears to be 
associated with subsequent higher risk of MS post-birth. Thus , not only is the timing-of-
20 Elliott and colleagues ' study on incidence of type 1 diabetes in Austral ian children , conducted 
subsequently to this thesis study, resulted in equivocal findings , including a bi-directiona l association 
between regional ambient UVR and type 1 diabetes incidence that was dependent on popu lation density, 
and no season-of-birth pattern [351 ]. 
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birth risk pattern in MS cases found in this thesis now suggested to be linked to 
ambient UVR as a candidate disease determinant, but the particular time window for 
the main effects on MS risk is proposed to be prenatal and during the first trimester of 
gestation. This possibly critical prenatal timing is new information for MS and for 
autoimmune disease generally (published as Staples et al., 2010, Appendix II). The 
result further supports the UVR hypothesis of McMichael and Hall (1997) and 
contributes an answer to their subsequent (2001) question: 'Does UVR act early in life?' 
[5, 6]. 
Prenatal UVR-possible prevention of MS? 
This new finding suggests that ambient UVR prior to birth, and particularly during the 
first foetal trimester, might be an important (maternal) exposure factor influencing 
subsequent MS risk in the offspring. That is, lower average daily levels of ambient UVR 
during the first trimester of gestation, rather than simply the proxy factor of when MS 
cases are born during the year, now predict a higher subsequent risk of MS. Or, more 
simply, lack of UVR during this 'critical window' of time during foetal development 
appears to be associated with increased MS risk later in life. Thus, as explored in 
Chapter 7 (see Figure 7.8), a temporal link between the timing-of-birth risk pattern and 
ambient UVR levels seven to eight months before birth is suggested by the work in this 
thesis. The higher MS risk evident in the proxy exposure of November to December-
born MS cases may in fact result from the more direct exposure factor of low maternal 
ambient UVR exposure during the first trimester of gestation. 
These findings can on ly be hypothesis generating, given the nature of the case data 
utilised and the assumptions required in constructing the longitudinal study dataset 
(see Chapter 6). However, the finding , if confirmed , is an important one , with real 
possibilities for having an effect on prevention of MS, and perhaps also other 
autoimmune disorders. For example , a prospective cohort study could examine both 
personal and ambient individual sun exposure levels before , during and after 
pregnancy, and their possible effects on reducing subsequent MS risk in offspring . 
However, a long follow-up period (>20 years because of adult MS onset) and very 
large cohort numbers (because of low MS incidence) would be required , making this 
strategy challenging for MS (but perhaps feasible for type 1 diabetes , with earlier-age 
onset and higher incidence). Use of a high-risk group such as first-degree relatives of 
MS cases might aid such future MS studies. 
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An alternative, or an additional measure together with sun exposure, would be to 
investigate vitamin D supplementation in pregnancy and beyond, because vitamin D 
appears to protect against all three autoimmune disorders, MS, type 1 diabetes and RA 
(see Chapter 2) , particularly when administered early in life for MS and diabetes. 
Ideally, such studies would be RCTs, even though long follow-up times would still be 
required for MS. Such studies might only be feasible where, for example, large 
population-based centralised medical records are available, as in countries with 
universal health care where parents and their offspring can be readily tracked. In 
addition, the efficiency of identifying benefits of vitamin D supplementation might be 
increased by selecting for the presence of the vitamin 0-regulated MS-susceptibility 
a 11 e I e H LA-0 RB 1 * 1 5 [214]. 
The further finding that region of birth was still associated strongly with MS risk after 
accounting for either month of birth or first trimester UVR suggests that postnatal UVR 
exposure is also important in reducing overall MS risk. Given that many Australians 
apparently remain in their birthplace region for many years (see Chapter 6), this factor 
(birthplace) may be a good marker for postnatal sun exposure linked to long-term 
residence. Safe UVR exposure , or vitamin D supplementation , may thus be required 
into adulthood and future trials should also include this. 
9.2.3 Birth-order pattern in MS cases 
Using a stringent theoretical analysis technique, a tendency towards MS cases being 
one of the older siblings in their sibships has been shown in MS cases at the individual 
level in these Australian data (cases as sampled nationally in 1981 ), particularly in 
sibship sizes up to six siblings. MS cases also tended to be more likely to be first born 
and less likely to be last born in these sibships (see Chapter 8). Consistent with the 
hygiene hypothesis (Chapter 3) , this means that MS cases may have been exposed 
less frequently , and/or later, to protective , immune-boosting , common childhood 
infections or other microbial exposure than their younger siblings early in life. This lack 
of early microbial exposure may have contributed to their subsequent MS risk (perhaps 
by combination with late exposure to EBV) (see Chapter 3) . 
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Possible prevention of MS by early microbial exposure? 
In view of conflicting results in other birth-order studies (see Chapter 8) , these results 
need further confirmation. For example, specific infections have not been identified 
here, but the timing of likely microbial exposure has been indicated. Future studies 
should attempt to measure actual exposure to specific infections (including serology) 
and the timing ( onset age) of these, prospectively if possible and with population 
controls , together with the proxy factor of birth order. Further, if general microbial 
exposure is important rather than, or together with , actual infections (see Chapter 3) , 
factors affecting degree of microbial contact, such as day-care attendance, residential 
density, rural areas, exposure to farm animals and pets should also be considered. 
Other factors possibly confounding microbial exposure , such as SES or diet, should 
also be taken into account. 
Nevertheless, this thesis has suggested a possible candidate environmental factor for 
MS that may be acting protectively in a specific time (i.e . age) window. The main 
conclusion of this section of the thesis is that MS risk appears ·to be modifiable by this 
early childhood factor that may be related to common infections or general microbial 
exposure at this time. Thus , a non-sterile early environment and increased contact with 
older children may be advantageous for preventing such autoimmune disease. 
Importantly, this factor may also be interacting , sequentially, with other identified (or as 
yet unidentified) factors in an overall multi-causal 'cascade' for eventual disease onset, 
considered next. 
9.2.4 Proposed causal sequence for MS 
A possible sequential 'causal cascade' of MS determinants, comprising the novel 
findings in this thesis and based on Goodin 's (2009) [229] visualisation of a life-course 
approach (see Chapters 3 and 7) , is presented in Figure 9.1. Th is diagrammatic model 
encapsulates the timing of the two major candidate environmental factors suggested to 
be influential for MS risk in this thesis and now includes the period before birth , as we ll 
as the possibility of protective infections early in childhood. That is, th is thes is model 
proposes: 
• lack of UVR and/or vitamin D near birth , but particularly in the first trimester of 
gestation 
• possible lack of common infections or microbial exposure early in childhood , 
372 
as influential in determining subsequent risk of MS. 
Both of these proposed timings-pre-birth and early childhood-are consistent with 
evidence from age-related migration studies , of early exposure to major determinants 
in modifying MS risk-that is, before mid-adolescence (see Chapters 2 and 3). Both 
factors are also linked plausibly with necessary priming of the developing immune 
system for the establishment of immunological self-tolerance and prevention of 
autoimmune disease (see Chapter 1 ). Importantly, the proposed prenatal timing of the 
first critical factor is consistent with accumulating evidence for effects of foetal 
development on subsequent adult disease (see Chapters 2 and 7). Moreover, these 
thesis findings support the idea of an overall sequence of early life and later factors 
influencing subsequent MS [6]. 
Such a diagrammatic model further posits biological interaction between sequential 
factors in causation of such disease, as inherent in Rothman and Greenland's 
'component cause' model (see Chapters 2 and 3). That is , each component factor is 
necessary but not sufficient to cause disease, each factor interacting biologically with 
prior factors to modify subsequent MS risk [1 ]. Consistent with this concept, MS-
susceptibility gene loci have recently been shown to interact with later-in-life 
environmental factors such as vitamin D status [188 , 706], and synergistically with low 
infant sibling exposure [707] or late EBV infection (as IM) [569 , 708]. These studies 
indicate that both vitamin D status and hygiene hypothesis-related factors can modify 
functional effects of genes in MS. 
Still later in the life course , environmental factors can also interact with each other. 
Mechanisms for synergistic interactions between vitamin D and other environmental 
factors have been proposed in MS and other autoimmune diseases-for example, 
vitamin D modulating the subsequent effect of viral infections such as EBV in MS [8 , 
709-711] and , vice versa , herpesviruses such as EBV poss ibly underm ining the 
protective functions of vitamin D [712] . Still other, later (adult) exposures such as 
smoking seem to contribute further to adverse effects of vitam in D deficiency in MS 
patients [580] , and to upper respiratory tract infections that poss ibly trigger MS 
relapses (see Chapter 3) . 
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Possible Causal Cascade to MS Pathogenesis 
Conception !First trimeste Birth 
1. UVR and ,, 
Genetic /or vitamin D 
factors deficiency 
Findings: 1. MS cases are more often born in 
November to December (early summer) 
in Australia and are potentially 
deficient in ambient UVR exposure 
in their first foetal trimester (Chapter 7) 
... 
.... 
Ea riv childhood I / Adolescence 
2.Lack and/or 
of early late exposure 
infections (EBV?) 
3. Low postnatal UVR? 
2. Australian MS cases are more often 
early born in their sibships (and thus 
may lack sufficient early microbial 
exposure) (Chapter 8) 
3. MS cases are more often born in higher latitude (lower UVR) regions of Australia 
(perhaps receiving less UVR also postnatally) (Chapter 7) 
4. (supporting finding) Similar to MS, type 1 diabetes prevalence shows (positive) latitude 
and (inverse) ambient UVR gradients over Australia at the population level 
(suggesting UVR as factor for autoimmune disease but not timing) (Chapter 4) 
?Adulthood 20- 40yr 
... 
?Other 
... 
MS 
.... 
factors 
.... 
j 
Figure 9.1: Adaptation of the diagrammatic 'causal cascade' model of Goodin (2009) (229] for MS, showing possible life-course 
timing (not to scale) of sequential environmental factors as identified in this thesis and based on findings (balded) shown. 
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Recent RCT evidence demonstrates an improved child response to viral infection with 
higher vitamin D administration [713], showing that early life deficiency in vitamin D can 
restrict the innate and adaptive immune responses essential to a healthy, protective but 
self-tolerant, immune system (see Chapter 1 ). Further, lack of such viral or non-specific 
microbial exposure in early life may interact both qualitatively and quantitatively with 
subsequent immune response to EBV (see Chapter 3) , this hygiene hypothesis 
mechanism potentially increasing MS risk through late EBV infection (Figure 9.1 ). 
Summing up, the prenatal period now appears to be a possible critical period for 
environmental modification of MS risk. Second, a further specific critical period is 
indicated for MS in early childhood. Overall, interaction between the factors in these 
and other life-course periods most likely occurs, the specific factors converging to 
eventually cause autoimmune disease such as MS. 
9.3 Population health implications for MS and other 
autoimmune disorders 
From a population health viewpoint, if such a life-course causation sequence for MS 
(Figure 9.1) is true and all factors are 'necessary but not sufficient', then only one 
environmental factor need be modified to have a significant effect on MS risk [1 ]. The 
easiest, and perhaps most influential factor in terms of effects on later disease because 
of its early prenatal timing [714], is early life exposure to ambient UVR and/or vitamin D. 
Postnatal infections or other microbial exposure are less predictable , less amenable to 
manipulation , and can be causal or protective for the same disorders depending on 
conditions and specific timing (see Chapter 3). 
Chapters 2 and 7 have reviewed the accumulating evidence for the role of sunlight 
exposure and vitamin D status during pregnancy in determining subsequent risk of 
autoimmune disease in the offspring . Lack of vitamin D, in particular, in early life is 
plausible as a candidate determinant for autoimmune disease, as evidenced by effects 
on early brain development and the establishment of central immunological self-
tolerance (see Chapter 2). Moreover, many other conditions and long-latency diseases 
are now also known to be linked to vitamin D deficiency, such as several types of 
cancer, cardiovascular disease, type 2 diabetes, as well as some infections. Indeed , as 
proposed by some reviewers , the evident efficacy (Chapter 2) , safety and 
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inexpensiveness of vitamin D supplementation may be reason enough to begin such 
supplementation without first completing lengthy, stringent clinical trials , particularly 
during pregnancy and childhood [289 , 4 77]. 
Population health policy for healthy sun exposure in Australia 
Exposure to UVR in sunlight is necessary for most vitamin D requirements in humans, 
little being derived from diet in most populations. However, there must be caution for 
recommendations for sunlight exposure in countries like Australia and NZ with the 
highest skin cancer rates in the world [450]. Current population health guidelines in 
Australia now attempt to balance healthy sun exposure with sun-avoidance or sun-
screening advice that depends on time of day, time of year and location ('SunSmart' 
guidelines, 2009, revised 2006/2007 by the Australian and New Zealand Bone and 
Mineral Society; Osteoporosis Australia; the Australasian College of Dermatologists; 
and the Cancer Council of Australia21 . The following times are advised for exposure 'of 
face , arms and hands to maintain healthy levels of vitamin D': 
• 'a few minutes on most days in summer' throughout Australia , before 10 am 
and after 3 pm 
• two to three hours per week during [the winter months of] June to July in 
Sydney, Canberra and Perth (mid-latitude Australia) 
• two to three hours per week during May to August in Adelaide , Melbourne and 
Hobart (southern Australia) . 
These times and places are when and where the forecasted UV Index is likely to be 
below the accepted crit ical (for skin damage) value of 3. Vitamin D supplementation is 
suggested 'on doctor's advice' only for particular population groups: 
• dark-skinned people 
• those who cover their skin for religious or cultural purposes 
• elderly, house-bound and institutionalised people 
• babies (especially breast-fed ) and infants of vitam in D-deficient mothers 
• patients with osteoporosis . 
However, Stalgis-Bilinski and co-workers , in the ir recent Austral ian study of personal 
sunlight exposure required for optimal vitamin D synthesis , ind icate that there are few 
opportunities (i.e. within 30 minutes and with recommended body exposure) to 
2 1 Guidelines accessed at http://www.cancer.org .au/cancersmartl ifesty le/SunSmartNitaminD.htm ). 
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synthesise 1000 IU of vitamin D during times when the UV Index is less than 3, even 
for fair-skinned individuals [715]. Therefore , vitamin D supplementation may be 
required for more individuals and specific target groups than presently recommended , 
in order to achieve satisfactory vitamin D levels without incurring skin damage. 
Most importantly, the emphasis in these SunSmart guidelines is not particularly 
directed towards pregnant women, or women planning to become pregnant, whether 
for careful sun exposure or for vitamin D supplementation. Results from this thesis 
suggest a required minimum monthly average of 20 MED units of ambient UVR per day 
in pregnancy to reduce offspring MS risk; this is achievable from November to February 
in Brisbane, OLD (latitude 27.5°S), but only in midsummer January in Hobart, TAS 
(latitude 42.9°S) (see Chapter 7). Pregnant women also are sometimes advised by 
health professionals to avoid the sun because of intensified pigment changes causing 
irregular skin darkening. Further, screening for vitamin D deficiency in pregnant women 
is currently conducted only for 'at-risk' groups and not routinely in Australia [716]. 
The results in this thesis indicate the first trimester as possibly critical for receiving 
sufficient ambient UVR, suggesting a period up to mid-pregnancy that may be 
important for having sufficient serum vitamin D (given a lag of about one and a half 
months from higher ambient UVR levels to higher serum vitamin D levels at the 
population level in Australia , see Chapter 7) . Therefore , in light of these results , 
population health guidelines for vitamin D supplementation should perhaps specifically 
include pregnant women , or all women of child-bearing age, as a special target group. 
In conclusion , prevention strategies for MS and other autoimmune disorders might 
emulate the public health campaigns to reduce the incidence of foetal neural tube 
defects, such as spina bifida , in Australia and elsewhere [717] . This highly successful 
campaign to raise public awareness in health professionals and women of child-
bearing age recommends (and heavily advertises) pre-pregnancy (i.e. pen-
conceptional) as well as pregnancy vitamin supplements containing high levels of folic 
acid (e.g. 'Elevit ' by Bayer, Australia , http ://www.elevit.com .au/preparing-for-
pregnancy) , because these birth defects associated with low dietary folate levels also 
occur very early in pregnancy, by mid-first trimester. Peri-conceptional vitamin D 
supplementation for prevention of autoimmune and other disease could be similarly 
promoted safely to possibly reduce the rates of long-latency autoimrnune and other 
disorders in offspring. Perhaps, like the folic acid success story, primary prevention of 
autoimmune and many other disorders by early pregnancy vitamin D supplementation 
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could become one of the 10 best public health achievements of the next decade, as 
folic acid fortification and promotion became over the last decade in the US [718] . 
9.4 Conclusions 
Similar to MS, type 1 diabetes prevalence shows (positive) latitude and (inverse) 
regional ambient UVR gradients over Australia at the population level. 
At the individual level , aetiology of MS in Australia appears to be influenced by both 
perinatal and early childhood environmental factors , including low prenatal ambient 
UVR levels linked with a pattern of increased MS risk in early summer-born people , 
and a possible lack of early childhood infections. 
These findings for MS, in particular, provide new population-based evidence beyond 
timing-of-birth risk patterns to indicate that the prenatal period may be critical but also 
suitable for intervention , and that vitamin D supplements for prevention of this , and 
possibly other, autoimmune disorders might need to be considered during early in utero 
development. 
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Ecologic Analysis of Some Immune-Related Disorders, Including Type 1 
Diabetes, in Australia : Latitude, Regional Ultraviolet Radiation, and Disease 
Prevalence 
Judith A. Staples, Anne-Louise Ponsonby, Lynette L-Y. Lim, and Anthony J. McMichael 
National Center for Epidemiology and Population Health , The Australian National University, Canberra, Australian Capital Territory, Australia 
The apparent immune-suppressive effect of ultraviolet radiation (UVR) has suggested that this 
environmental exposure may influence the development of immune-related disorders. Self-reported 
prevalence rates of type 1 diabetes mellitus , rheumatoid arthritis (RA), eczema/dermatitis, and 
asthma, from the 1995 Australian National Health Survey, were therefore examined by latitude and 
ambient level of UVR. A positive association of type 1 diabetes mellitus prevalence was found with 
both increasing southern latitude of residence (r = 0.77; p = 0.026) and decreasing regional annual 
ambient UVR (r = - 0.80; p = 0.018); a 3-fold increase in prevalence from the northernmost region 
to the southernmost region was evident. In contrast, asthma correlated negatively with latitude (r = 
- 0 .72; p = 0.04 6), although the change in asthma prevalence from the north to the south of 
Australia was only 0.7-fold. For both RA and eczema/dermatitis, there were no statistically signifi-
cant associations between latitude/UVR and disease prevalence. These ecologic data provide some 
support for a previously proposed beneficial effect of UVR on T -helper I- mediated autoimmune 
disorders such as type 1 diabetes. The inverse association of type 1 diabetes prevalence with UVR is 
consistent with that previously reported for another autoimmune disease, multiple sclerosis, in 
Australia, and also with type 1 diabetes latitudinal gradients in the Northern Hemisphere. The 
finding also accords with photoimmunologic evidence of UVR-induced immunosuppression and 
may suggest a beneficial effect of UVR in reducing the incidence of such autoimmune conditions. 
In light of this study, analytic epidemiologic studies investigating risk of immune disorders in rela-
tion to personal UVR exposure in humans are required. Key words: asthma, Australia, autoimmune 
disease, ecologic analysis, eczema/dermatitis, immune disorders , latitude , rheumatoid arthritis , 
type 1 diabetes , ultraviolet radiation. Environ Health Perspect 111 :518- 523 (2 003 ). 
doi:10.1289/ehp.5941 available via http://dx.doi.org/[Online 19 D ecember 2002] 
Autoimmune diseases such as type 1 diabetes 
me ll itus, multiple scle ro s is (MS), and 
rheumatoid arthriti (RA) are immune sys-
tem disorders that hare common features of 
self-reactive T cells and the presence of auto-
antibodies; as a group they affect some 5% of 
the population (Davidso n and Diamond 
2001). Although their precise etiologies are 
unknown , these autoimmune disorders are 
generally agreed to reflect interactions of 
polygenic traits with various ill-defined 
environmenta l factors (Ca ntorn a 2000; 
Dahlquist 1998; Hayes et al . 1997; Karges et 
al. 1995 ; Weinshenker 1996). Descrip tive 
epidemiology may further elucidate the role 
of environmental factors in the etiology of 
the autoimmune diseases MS, type l di a-
be tes, and RA , as well as other immune-
re la ted disturbances such as a thma and 
eczema/ dermatitis. 
MS , type 1 diabetes , and, to a lesser 
extent, RA in the Northern Hemisphere , 
particularly in Western Europe and orth 
America, display a latitudinal gradient in di -
ease frequency, with the prevalence of these 
disorders increasing at hi gh er latitudes 
(Cantorna 2000; D ERIG 1988; Hayes et al. 
1997; Karvonen et al. 1993). MS exhibits a 
similar prevalence gradient in the Southern 
Hemisphere, in Australia and New Zealand 
(Hammond et al. 2000; Mi ller et al. 1990). 
In Australia, however, where the opportun ity 
exists to s tud y gradients in rates across a 
large-area population th at is less ethnical ly 
and genetically di ve rse than across Europe, 
analyses for other immune-related disorders 
have not been done previously. 
Ultraviolet radiation (UVR) reaching the 
ea rth 's surface varies inversely with latitude; 
UVR is thus a prominent latitude-related 
environmental factor. Recent photoimmuno-
logic work shows that UVR downregulates 
cellular immunity (Dam ian et al. 1998; Kelly 
et al. 1998), attenuating T-helper (Th) 1 T-
cell-mediated immune responses (Clydesdale 
et al. 2001). These responses are thought to be 
significantly involved in some autoimmune 
disorders uch as MS , type 1 diabetes, and RA 
(Mackay 2000). UVR might therefore be 
expected to be beneficial for these di orders. 
Few auto immune or other immune-related 
disorders, however, have been assessed ecolog-
ically with respect to UVR. A notable excep-
tion for the Southern Hemisphere is a recent 
analys is of MS in Australia, where the regional 
variation in MS prevalence was strongly 
inversely associated with ambient UVR level 
(r = -0 .91; p = 0.01) (van der Mei et al. 
2001) . This finding supports the possibility of 
UV R being a protective modulator of 
immune and autoimmune processes involved 
in the et iolo gy of such immune disorders 
(McMichael and Hall 1997) . Type 1 diabetes 
and RA were therefore chosen for eco logic 
analysis to determine whe ther these disorders 
showed enviro nmental gradients simi lar to 
those observed for MS in Australia. 
By downregulating T hl -mediated immu-
ni ty, UVR has been thought to effect a shift 
from Th 1- to Th2-medi a ted p rocesses 
(Clydesdale et al. 200 1). Th2 cells are respon-
sible for immedi ate-type hypen,ensitivity to 
allergens such as dust mites; UVR may thus 
have the potential to exacerbate allergic disease 
(Selgrade et al. 1997). However, recent work 
has cast doubt on the mutual antagonism of 
T h 1 and T h2 cyrokine express ion, particularly 
in huma ns (Davidson and Diamond 2001; 
Mackay 2000; Platts-Mi lls 2002; Platts-Mills 
e t a l. 2001). U ltraviolet B, particularly 
through interleukin 10, can inhib it both Th l-
and T h2-mediated immune responses in mice 
(Garssen et al. 1999). In children, asthma can 
coexist wi th T h I- type disorders such as type 1 
diabetes, RA, and celiac disease, suggesting a 
common environmental influence (Kero et al. 
2001). A recent randomized controlled trial in 
the United Kingdom on adult atopic eczema 
has shown UVR, particularly narrow-band 
ultraviolet B, to also have a beneficial effect 
(Reynolds et al. 2001). Eczema/dermatitis, 
together with asthma, were therefore chosen 
to be similarly analyzed for regional prevalence 
gradients to compare with any associations 
evident for type 1 diabetes and RA. 
We have examined the association between 
latitude and prevalence of the immune-related 
disorders type 1 diabete s mellitis , RA , 
eczema/dermatitis, and asthma in Australia, a 
country with a relatively genetically homoge-
neous population. We further considered 
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regional differences in ambient UVR to exam-
ine possible associations between regional and 
seasonal UVR levels and the prevalence of 
these immune disorders in Australia. 
Methods 
Prevalence data source. The 1995 Australian 
National Health Survey (NHS) was con-
ducted by the Australian Bureau of Statistics 
(ABS) during the 12-monch period from 
January 1995 to January 1996. Approximately 
54,000 people from all states and territories 
and across all age groups provided information 
about their own health status. Residents of a 
stratified, mulcistage area, random sample of 
23,800 private households and households in 
nonprivace dwellings were interviewed in per-
son by ABS interviewers; persons within each 
state/territory had a known, and in the main 
equal, chance of selection. Residents of hospi-
tals and ocher institutions were excluded, 
however, and the Northern Territory ( T) 
sample was predominantly urban . Responses 
were received from 91.5% of households and 
97% of people from these households fully 
completed questionnaires. Quarterly popula-
tion estimates were used by ABS for scandard-
izatio n, and prevalence rate estimates were 
adjusted for household size (ABS 1995a). 
The survey interviewers recorded infor-
mation on recent illness and/ or long-term 
conditions, as reported by respondents. 
Specific questioning about conditions, includ-
ing diabetes, arthritis, and asthma, was fol-
lowed by action-based questions on recent 
visits to hospitals or health professionals. 
Information on medication usage , including 
insulin and medications for asthma, arthritis, 
and allergies, was also elicited (ABS 19956). 
Disease condition were classified by the 
International Classification of Diseases, 9th 
Revision (cited by ABS 1995a) , categories. 
Information recorded in the survey was not 
medically verified, however. 
For chis study we used summary-data 
prevalence estimates for four immune-related 
disorders from the published survey results 
(ABS 1995c). We compared the age- and 
sex-standardized prevalence rares of type 1 
diabetes, RA, eczema/dermatitis, and asthma, 
per 1,000 population , over the eight major 
state and territory regions of Australia, as 
listed in Table 1. 
Latitude and ultraviolet radiation. The 
latitude of the regional capital city (decimal 
degrees south; Geoscience Australia mapping 
agency) was used for each region (Table 1). 
Three UVR measures were examined, each 
relating to the Australian UV index (Lemus-
Deschamps et al. 1999) and expressed in milli-
watts per square meter (where 1 UV index 
unit= 25 mW/m2). The measures were, for 
each regional capital, an arithmetic mean of 
12 monthly UV index averages, each monthly 
Articles Latitude, UVR, and immune disorders 
average calculated from single, daily (at local 
solar noon), eryrhemally weighted clear-sky 
UV index values derived from ozone data over 
the period 1979-199 3 (Lem us-Deschamps L. 
Personal communication), a midwinter mini-
mum O une) solar-noon UVR value, and a 
midsummer maximum Oanuary) solar-noon 
UVR value (Table 1). 
Statistical analysis. To account for the 
NHS sampling variability between regions, we 
calculated approximate standard errors (SEs) 
for each regional prevalence estimate, as out-
lined in Appendix H and "Technical Note: 
Sampling Variability" in the respective ABS 
publications (ABS 1995a, 1995c). The 
approximate SEs were calculated from SEs for 
the corresponding numerator estimates shown 
in Table 2, as listed by ABS for each region 
(ABS 1995a, 1995c). Age-standardization fac-
tors for the different regions were also applied, 
as recommended in the same Technical ore, 
and the final SEs for the prevalence rates cal-
culated (Table 2). The reciprocal of che vari-
ance of each prevalence race was then used to 
weight the relationships to account for differ-
ing sample sizes in the regions. 
Associations between the environmental 
variables and the immune disorder prevalence 
races were examined by variance-weighted 
lease-squares regression of the prevalence rate 
estimates versus, first, the latitude values of 
the regional capital cities, and second, the 
three UVR measures for each of the regional 
capitals. The magnitude of change in disease 
prevalence rates over the north-south range 
was compared by substituting latitude values 
for Darwin and Hobart into the regression 
equations. The statistical program Seara 7. 0 
(Seara Corporation, College Station, Texas, 
USA) was used for regression analyses. 
Table 1. Australian state and territory regions and approximate latitude ranges; regional capitals and their 
latitudes (decimal degrees south) shown together with midsummer (January) and midwinter (June) solar-
noon UVRa for each regional capital. 
State/territory Latitude range Regional Latitude of Midsummer UVR Midwinter UVR 
region for region (degrees) capital capital (degrees) (mW/m2) (mW/m2) 
Northern Territory 11-26 Darwin 12A5 339.5 205.9 
Queensland 10-29 Brisbane 27.47 332.4 103.9 
Western Australia 14-35 Perth 31 .95 326.1 82 .9 
New South Wales 28-37 Sydney 33.87 306.1 66.5 
South Australia 26-38 Adelaide 34.93 303.4 60.7 
Australian Capital Territory 35-35.5 Canberra 35.30 302.7 55.7 
Victoria 34-39 Melbourne 37 .82 287.6 48.6 
Tasmania 41-43.5 Hobart 42.88 256.7 31.4 
8UVR data are monthly averages calculated from daily (at local solar noon) erythemally weighted clear-sky UV Index values derived from ozone data over the period 1979-1 993 (courtesy of L. Lemus-Deschamps, Bureau of Meteorology Research 
Center, Australia) and expressed as mW/m2. 
Table 2. Regional immune disorder (excluding MS) prevalence ratesa (shaded lines with SEb in parentheses) 
together with numerator data on which SE estimates were based . 
State/ Type 1 Rheumatoid Eczema/ Regional 
territory diabetes arthritis dermatitis Asthma population 
Northern Territory 
No. cases 200 1,500 2,900 17,200 145,300 
Prevalence 2.9 (1.80) 18.2 (5.56) 19.2 (4.43) 127.2(13.11) 
Queensland 
No. cases 10,500 82,100 96,900 438,000 3,277,800 
Prevalence 3.2 (0 .62) 25.7 (1.34) 29.5 (1.40) 132.6 (2.51) 
Western Australia 
No. cases 6,900 49,000 82,400 201,500 1 .732,400 
Prevalence 4.2 (0.79) 29.8 (1. 66) 47 .1 (1.90) 115.2 (2. 76) 
New South Wales 
No. cases 26,300 170.700 181 ,900 633.700 6,120,500 
Prevalence 4.2 (0.56) 27.3 (1.24) 29.8 (1 .30) 103.9 (2.10) 
South Australia 
No. cases 8,300 41 ,900 73,000 163,500 1,474,800 
Prevalence 5.4 (0. 63) 26.8(1 .15) 50.3 ( 1.55) 1 P.4 (2.16) 
Australian Capital Territory 
No. cases 1,100 5,600 14,400 35,500 304,900 
Prevalence 4.6 (0. 99) 21 .4 (1. 65) 45.5 (3.98) 111.9 (2.65) 
Victoria 
No. cases 23,800 106,400 171,500 501 ,500 4,503,100 
Prevalence 5.2 (0.50) 23.2 (0.88) 38.2 (1 07) 111 . 8 ( 1 . 63) 
Tasmania 
No. cases 2,100 19,100 20.700 48,800 473,600 
Prevalence 4.5(1 .14) 39.5 (2.38) 44.0 (2.53) 102.1 (3. 48) 
8 Rate per 1,000, age- and sex-standardized to the 1995/1996 Austral ian population. Data from ABS ( 1995c). bApproximate 
SE calculated from ABS-provided SE for numerator (ABS 1995a, 1995c). 
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Because the use of capital city latitudes 
may not have been represe ntative of the 
regional population distribution , particularly 
for larger regions with the capital at either a 
northern or southern extreme of the region 
rather than medially placed, a sensitivity analy-
sis was carried out to test the effect of using an 
alternative latitude value midway between the 
two main population centers in these regions. 
Results were then compared with chose 
obtained from the regional capitals. 
Results 
Lati tude and immune dis orders . The 
relationships between latitude of the regional 
capitals and immune disorder prevalence are 
shown in Figure 1 as regression lines fitted to 
the prevalence estimates; 95 % confidence 
intervals (Cis) are also shown, and these indi-
cate, reciprocally, the relative weighting applied 
co each estimate in the regress ion analysis. 
Prevalence of type 1 diabetes was positively 
correlated with latitude (Pearson r = 0.77; p = 
0.026), with the prevalence increasing 2.97-
fold over the north-south latitude gradient. 
Asthma prevalence , on the ocher hand , was 
inversely correlated with latitude (Pearson r = 
- 0. 72; p = 0.04 6) , with the prevalence rate 
decreasing 0. 7-fold , i.e., by approximately one-
chird, over the same latitude range. Although 
both eczema/dermatitis and, to a much lesser 
extent, RA showed trends of increasing preva-
lence with increasing latitude, these were not 
statistically significant (F igure 1). 
Sensitivity analysis. In four of the eight 
region s, Western Australia (WA), South 
Australia (SA), Victoria (VIC), and Australian 
Capital Territory (ACT), at least 70% of the 
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state or territory populations resided in the 
capital metropolitan area (ABS census data 
1991 / l 996, not shown). Among the remain-
ing regions in which the population was more 
dispersed outside of the capital, only NT and 
Queensland (QLD) were also both of wide 
latitudinal range and had capitals located 
noncentrally in terms of the regional latitude 
range, thus potentially biasing the associations 
markedly. 
The effect on the initial associations of 
using alternative latitude values midway 
between the two main population centers, 
Darwin and Alice Springs, for NT (i .e., lati-
tude 18.08 degrees south), and Brisbane and 
Townsvi lle for QLD (i.e . , latitude 23.36 
degrees south), was to strengthen the statistical 
significance of the associations for type 1 dia-
betes , asthma, and eczema/dermatitis when 
one or both midway latitudes were substi-
tuted. For example, for type 1 diabetes and 
asthma, the statistical significance of the asso-
ciations was raised maximally [from p = 0.026 
top= 0.010 for diabetes (r = 0.77 to 0.84), 
and from p = 0.046 top = 0.013 (r = -0.72 to 
- 0.82) for asthma] when midway latitudes 
were used for both regions. Boch approaches 
unavoidably entail some exposure misclassifi-
cation for dispersed regional popula tions . 
Whereas the latter (midway latitude) approach 
may lead co better estimation of the correla-
tion , by using the capital latitude values for 
type 1 diabetes and asthma as we have done 
(Table 1), the estimate was somewhat biased 
coward the null hypothesis of no association 
and thu s coward underestimation of r. 
Similarly, for eczema/dermatitis the statistical 
significa nce was raised maximally [from p = 
:so Asthma 
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Figure 1. Assoc iations between latitude and prevalence per 1,000 (open circle) of type 1 diabetes, asthma, 
eczema/dermatitis, and RA. 95% Cls of prevalence estimates shown as error bars; solid lines denote sta-
tistically signifi cant asso ci ation, p < 0.05; dotted lines denote nonsignificant trend . 
0.206 top = 0.1 74 (r = 0.50 to 0.54)] when 
only the QLD latitude was altered, but chis 
was still nonsignificant at the 5% level. For 
RA, on the ocher hand , using both midway 
latitudes gave maximal change, bur the statisti-
cal significance of the observed trend was low-
ered [from p = 0.727 top= 0.795 (r = 0.15 to 
0 .11)] . In summary, the use of the regional-
capital latitude values rather than latitude val-
ues of the midway points did not airer the 
overall conclusions of whether the observed 
associations were statistically significant at the 
5% level. 
Ultraviolet radiation and immune disor-
ders. In light of the sensitivity analysis, UVR 
values for the regional capitals were used. A 
solar-noon, clear-sky measure of ambient UVR 
was chosen because midday, or noontime , 
exposure to the maximal UVR level in sunlight 
in Australia suppresses the systemic immune 
response in humans (Hersey er al. 1983) . 
T ype 1 diabetes prevalence was inversely corre-
lated with regional average solar-noon UVR 
(Pearson r = - 0.80; p = 0.018) , whereas asthma 
prevalence was positivel y correlated with 
regional average solar-noon UVR (Pearson r = 
0.73; p =- 0.040) (F igure 2). Eczema/dermatitis 
and RA prevalence showed inverse trends with 
average solar-noon UVR, but these were not 
significant (Ta ble 3). The prevalence of 
asthma was positively correlated with either 
average or midwinter so lar-noon UVR but not 
midsummer UVR. Although type 1 diabetes 
prevalence was inverse ly correlated with all 
three ambient UVR meas ures, it was more 
closely correl ated with ave rage or midwinter 
so lar-noon UVR than with midsummer UVR 
(Table 3) . 
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Figure 2. Assoc iations between regional average 
ambient so lar-noon UVR and prevalence per 1,000 
(open circle) of type 1 diabetes and asthma . 95% 
Cls of preva lence estim ates shown as error bars. 
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Discussion. Using summary age- and sex-
standardized data on self-reported prevalence 
of immune disorders from the ABS 1995 
HS, strong gradients in type 1 diabetes 
prevalence with latitude and a lso, inversely, 
with UVR were observed. The magnitude of 
change for type 1 diabetes in Australia was an 
approx im ately 3-fo ld increase in prevalence 
from the northernmost region, NT, to the 
southernmost region, Tasmania (TAS). 
These ecologic data provide support for a 
previously proposed beneficial effect of UVR 
on autoimmune disorders such as type 1 dia-
betes (McMichael and Hall 1997) . In con-
trast to type l diabetes, asthma correlated 
negatively with latitude and positively with 
regional annual or midwinter UVR, but the 
magnitude of change for asthma prevalence 
from the north to south of Australia was only 
0. 7- fold. For both RA and eczema/dermati-
tis, there were no statistically significant asso-
ciations between latitude/UVR and disease 
prevalence. 
A strength of this ecologic analysis derives 
from the relative genetic homogeneity of the 
Australian population (McLeod et al. 1994) 
and relative uniformity also in the standard of 
national heal ch care. A further advantage is 
the wide latitude range and the resulting wide 
range of ambient UVR levels over the 
Australian continent. A high total response 
rate to the survey was achieved by the ABS 
over all regions. 
One potential source of (probably ran-
dom) error, however, lies in the self-reported, 
nonverified nature of the data, which could 
have resulted in some misclassification of dis-
ease conditions. This is particularl y so for 
eczema/dermatitis, the classification of which 
appears to have been based largely on medica-
tion usage; there were no direct dis ase-s pecific 
questions on eczema (ABS 19956). The classi-
fication eczema is often used as an umbrella 
term encompassing various dry, itchy skin 
conditions (McNally et al. 2000); dermatitis 
similarly can include contact dermatitis. Also 
the eczema/dermatitis category in rhe NHS 
included hear eczema and sunburn (A BS 
1995a), leading to possible regional differences 
in prevalence. In addition, although arthritis 
was allocated four specific questions, misclassi-
fica rio n berwee n rheumatoid a rrh ri r is, 
osteoarthritis, and general arthritic or rheuma-
tism conditions could have occurred. Type 1 
diabetes, on the other hand, was classified on 
the basis of 24 direct questions for diabetes 
and insulin usage, including duration of use, 
both past and future expected use, and age at 
first use (ABS 19956). The relative validity of 
classification of type 1 diabetes, a serious dis-
ease requiring specific treatment, should there-
fore have been more regionally consistent. 
Exposure misclassification at the ecologic 
(i.e., state or territory) level compared with 
the individual level could have occurred 
because actual personal UVR exposure 
depends on both behavior in relation to the 
sun (i.e., whether sun avoidant or taking sun 
protection measures) and on regional ambient 
UVR. For example, regional UVR would not 
have been a good measure of personal sun 
exposure among sun-avoidant people, and if 
the proportion of such people in each local 
population varied markedly, then population-
leve l exposure assessment would be biased. In 
fact, the proportion was small and did not 
vary substantia ll y by region [percentage 
recording "don't go out in sun" was 3.4% for 
T , 2.0% for QLD, and 2.3% for TAS (ABS 
l 995c)]. For most individuals , however, per-
sonal UVR exposure varies between 5 and 
15% of daily total ambient UVR (Gies et al. 
1999). Ambient UVR levels thus may provide 
a reasonable measure of average personal sun 
exposure at the population level. 
Another possible source of measurement 
error-using capital city latitudes and UVR 
values as representative of each region-was 
shown by sensitivity analysis nor to signifi-
cantly bias the results even for the two 
regions having the most noncentral capitals 
and the widest latitude range, QLD and NT. 
However, we considered only current resi-
dence and could not take into account the 
co ntribution of prior residence areas, or the 
timing of the critical UVR exposure, which 
may have occurred earlier in life, or even 
possible migration after disease initiation, as 
prevalence rather than incidence data were 
used. In addition, we could not control for 
latitude when examining the relationships 
between the immune disorders and UVR 
because of collinearity between UVR and 
latitude. 
Table 3. Correlations between immune disorder prevalence and regional UVA levels in the 1995 NHS .a,b 
Prevalence Regional solar-noon UVR 
of disorder Average Midwinter Midsummer 
Type 1 diabetes -0 80 (0.018)* -0.77 (0.024)* -0.72 (0 045)* 
Eczema/dermatitis -047 (0 243) -0.49 (0.2 15) -034 (0412) 
RA -0.08 (0.845) -0.06 (0 880) -0.12 (0.774) 
Asthma 0.73 (0.040)* 0.72 (0 .044)* 0.68 (0.060) 
8 Pearson correlation coefficients (correlations based on the eight Austral ian state/territory regions) between immune dis-
order prevalence and solar-noon UVR, for each type of immune disorder and three different measures of UV Index val-
ues-average over year, midwinter minimum , and midsummer maximum . hp-Values in parentheses . Stre ngth of 
association examined by variance-weighted least-squares regression . * Statistic ally significar.t association, p < 0.05. 
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Potential ecologic confounders include 
other possible causal factors for immune-
related disorders that vary with latitude or 
UVR; for example, regional infection patterns 
that may be associated with climatic differ-
ences. Infectious agents have been linked to 
the etiology of immune disorders, including 
diabetes (Dahlquist 1998; EURODIAB 
2000; Kamradt and Mirchison 2001; Nork.ins 
and Lem mark 2001 ), RA (Albert and Inman 
1999; £bringer and Wilson 2000; Wilson et 
al. 2000), and asthma (Blasi et al. 2001). A 
lack of infections in early life may also 
adversely affect immune development-the 
so-called hygiene hypothesis (Bach 2002). A 
second important ecologic factor to consider 
for asthma is that there are marked regional 
differences in allergen levels. For example, an 
11-fold higher level of mean house dust mite 
allergen (Der p 1) concentration in homes in 
Sydney, ew Sou rh Wales (low lari rude, 
warm and more humid) compared with TAS 
(higher latitude, cool and dry) (Couper et al. 
1998) may contribute to the inverse latitude 
gradient for asthma. Other confounding fac-
tors could include environmental temperature 
and dietary differences (Dahlquist 1998). 
These potential confounders warrant more 
detailed consideration in future research. 
There may also be interaction between some 
of these environmental exposures, for exam-
ple , infection and nutritional factors 
(Haverkos 1997) . However, it is not possible 
to determine such interactions in ecologic 
analyses, as there is a lac k of data on joint 
environmental exposures at the individual 
leve l (Ponso nby et al. 2002). 
UVR has an inverse, or lack of, associa-
tion with the immune-related disorders ana-
lyzed except for asthma, which showed a 
positive association between prevalence and 
UVR. We are uncertain of the significance of 
this finding, particularly as the prevalence 
increase over the UVR range was only low. 
UVR-induced Th2 upregularion is one possi-
6 i l i ry, bur UV R can also suppress Th2 
responses (Garssen er al. 1999). In addition, 
the contribution of regional allergen levels to 
ast hm a prevalence could be important. 
Furthermore, much of asthma at the popula-
tion level may be nonallergic (Pearce er al. 
1999), with Th2 mechanisms nor involved. 
The stronger association found between 
latitude and rype I diabetes prevalence in 
Australia is consistent with similar incidence 
gradients found in Western Europe and 
orth America (DERIG 1988; Karges er al. 
1995; Karvonen er al. 1993) and also within 
China (Yang er al. 1998). The corresponding 
inverse association between UVR levels in 
Australia and ty pe 1 diabetes prevalence 
is aiso consisrerr with previous photo-
immunologic work showing that ultraviolet B 
irradiation has systemic as well as local 
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immunosuppress ive effects in humans and 
animals (Clydesdale er al. 200 l ; Duthie er al. 
1999; Garssen er al. 1999; Sleijffers er al. 
2001), as does also ulrrav ioler A irradiation 
( ghiem er al. 2001). UVR exposure may be 
protective against Th 1-mediared disorders 
such as type I diabetes by downregularing 
Th l autoimmune responses by several 
different immunoregulatory mechanisms 
(Clydesdale er al. 2001; Duthie er al. 1999; 
Ponsonby er al. 2002). 
One of these possible mechanisms for 
downregularion involves UVR-induced vita-
min D. Thus, rhe proposed protective role of 
UVR for autoimmune rype 1 diabetes may 
act through its imporranc role in vitamin D 
synthesis in rhe skin. Some 90% of plasma 
vitamin D in humans is produced endoge-
nously via skin exposure to UVR in sunshine 
(Norris 2001) and particularly so in Australia 
where foods are nor genera lly fortified with 
vitamin D (Mason and Diamond 2001; 
Pasco er al. 2001). There a re also recent 
rep o rt s o f vi r a m i n D de fi c i e n c y i n so me 
Australian populations (Grove r and Morley 
2001 ), particularly in winter (McG rath er al. 
2001; Pasco er al. 200 I). For type 1 diabetes , 
rhis possible mechanism is consistent wirh 
recent reports of decreased risk of this disor-
der in offspring of mothers supplemented 
with cod liver oil in pregnancy (S tene er al. 
2000), and decreased incidence of type I dia-
betes in children supplemented with vitamin 
D in infancy (EURODIAB 1999; Hypponen 
er al. 2001). The Finnish birth cohort study 
reported a rare ratio of 0.12 (95% CI, 
0.03-0.51) for diagnosis of type 1 diabetes by 
adulthood comparing regular versus no vita-
min D suppl ementation in rhe first year of 
life (H ypponen er al. 2001). These studies 
suggest rhar vitamin D may prevent initiation 
of type l diabetes , and thus accord with rhe 
vitamin D-pro recrive hypo thesis proposed for 
rhis and other autoimmune disorders such as 
MS (Cantorna 2000; Hayes er al. 1997) . For 
MS this hypothesi s is consistent with the 
recent finding of a strong inverse gradient 
between ambient UVR levels and MS preva-
lence in another Australian eco logi c study 
(van der Mei er al. 2001). Our analogous 
finding for ambient UVR and type 1 diabetes 
in Australia supports rhe specific prediction 
rhar autoimmune di seases other than MS , 
such as type I diabetes , should show larirude 
and/or UVR gradients similar to those seen 
for MS if these immune disorders are influ-
enced by UVR exposure (McM ichael and 
Hall 1997). 
In conclusion, our ecologic analysis of 
data from the 1995 HS has demonstrated a 
regional gradient of type 1 diabetes prevalence 
within Australia that is inversely associated 
wirh regional UVR levels measured at local 
solar noon. The inverse association with UVR 
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is consistent with rhar found for another 
autoimmune disease, MS, in Australia and 
consistent with type 1 diabetes latitudinal gra-
dients seen in rhe orrhern Hemisphere. The 
finding is also consistent with photoimmuno-
logic evidence of UVR-induced immuno-
suppression and suggests a beneficial effect of 
UVR in prevencing both these autoimmune 
conditions. Analytic epidemiology studies 
invesrigaring risks of type 1 diabetes and other 
immune disorders in relation to personal 
UVR exposure in humans are now required 
(McMichael and Hall 2001). 
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Low maternal exposure to ultraviolet radiation in pregnancy, 
month of birth, and risk of multiple sclerosis in offspring: 
longitudinal analysis 
Judith Staples, student,1 Anne-Louise Ponsonby, professor,2 Lynette Lim, biostatistician1 
ABSTRACT 
Objectives To investigate the distribution of month of 
birth in people with multiple sclerosis in Australia. To use 
the large regional and seasonal variation in ambient 
ultraviolet radiation in Australia to explore the 
association between exposure to ultraviolet radiation 
during pregnancy and subsequent risk of multiple 
sclerosis in offspring. 
Design Data were gathered on birth month and year 
(1920-1950), sex, and state of birth for all patients 
surveyed in 1981 in Queensland, Western Australia, New 
South Wales (including Australian Capital Territory), 
South Australia, and Hobart (Tasmania). Population 
denominators were derived from the 1981 census and 
supplementary birth registration data. A variable for 
exposure to ambient ultraviolet radiation "at birth " was 
generated from monthly averages of daily total ambient 
ultraviolet radiation for each region. Negative binomial 
regression models were used to investigate exposure to 
ambient ultraviolet radiation at birth and at various 
intervals before birth. 
Setting Patient data from multiple sclerosis prevalence 
surveys carried out in 1981; 1981 Australian census 
(giving the total number of people born in Australia and 
still alive and living in Australia in 1981 by year of birth 
1920-50); supplementary Australian birth registration 
data covering the same birth years by month and state. 
Parti cipants 1524 patients with multiple sclerosis born in 
Australia 1920-50 from total population of 2 468 779. 
Main outcome meas ure Cumulative incidence rate of 
multiple sclerosis. 
Res ults There was a pattern of risk of multiple sclerosis 
with month of birth (adjusted incidence rate ratio 1.32, 
95% confidence interval 1.10 to 1.58, P<0.01, for those 
born in November-December compared with those born in 
May-June). This pattern mirrored that previously reported 
in the northern hemisphere. Region of birth was related to 
risk. After adjustment for region of birth and other factors, 
there was an inverse association between ambient 
ultraviolet radiation in the first trimester and risk of 
multiple sclerosis (with ~25 erythemal (skin reddening) 
dose units as reference (that is, adjusted incidence rate 
rati o=l.00), the rates were 1.54 (1.10 to 2.16) for 20-<25 
uni ts; 1.58 (1 .12 to 2.22) for 15-<20 units; 1.65 (1.17 to 
2. 33) fo r 10-<15 units; 1.65 (1.18 to 2.29) for 5-<10 units; 
and 1.67 (1.18 to 2.37) for <5 units). After adjustment for 
this exposure during early pregnancy, there was no 
residual association between month of birth and multiple 
sclerosis. 
Conclusion Region of birth and low maternal exposure to 
ultraviolet radiation in the first trimester are 
independently associated with subsequent risk of 
multiple sclerosis in offspring in Australia. 
INTRODUCTION 
Multiple sclerosis is a chronic demyelinating disorder 
that most commonly presents in the second to fourth 
decade of life. Studies of migrants indicate that risk is 
strongly associated with place of residence in early 
life. 1 In Australia2 and elsewhere,3 ·1 there is a latitudinal 
gradient with increasing prevalence of multiple sclero-
sis, or incidence of first demyelinating event, as one 
moves away from the equator. This latitudinal gradient 
seems environmentally related because the risk asso-
ciated with latitude alters if people move after birth.' 5 
A strong environmental candidate is the level of ambi-
ent regional ultraviolet radiation, acting either directly 
or through the generation of vitamin D.6 Higher expo-
sure to ultraviolet radiation,7 higher vitamin D intake,8 
and also higher serum vitamin D concentrations9 seem 
to be associated with a reduced risk of onset of multiple 
sclerosis. This evidence comes from both case-control 
and cohort studies and indicates that age of operation 
for such a protective effect might include both child-
hood and early adulthood. 6· 11 
Exposure to ultraviolet radiation in early life has not 
yet been formally examined but might be linked to 
exces risk of multiple sclerosis at birth through seaso-
nal deficiency in maternal vitamin D concentrations . 12 
A study of half siblings with multiple sclerosis has also 
shown that risk can be maternally mediated. 13 Preg-
nancy is a vulnerable time for vitamin D deficiency 
because of increased physiological needs and reduced 
maternal outdoor activity. 14 Experimental data on 
animal fetal development indicate that cerebral white 
matter is responsive to vitamin D and that oligoden-
drocytes in the brain and spinal cord have vitamin D 
receptors. 15 16 Furthermore, maternal vitamin D deple-
tion alters neurogenesis in the developing rat brain, 17 
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with subsequent altered gene expression in adult life. 18 
A recent genetic study in humans has further impli-
cated vitamin D as a strong environmental candidate 
by showing direct functional interaction with the major 
locus that determines susceptibility to multiple sclero 
sis. 19 Although human evidence pertaining to fetal 
development has been difficult to obtain, the body of 
related evidence to date has led some to recommend 
antenatal supplementation with vitamin D to prevent 
multiple sclerosis. 14 
As an indicator of possible perinatal environmental 
exposures, such as ultraviolet radiation, individual stu-
dies in the northern hemisphere have examined month 
of birth and risk of multiple sclerosis with varied 
results.20·24 A large recent pooled analysis of births in 
the northern hemisphere, however, showed an excess 
of multiple sclerosis among people born in May and a 
relative deficit among those born in November; these 
results were stronger in familial cases and suggested 
interactions between genes and environment that are 
related to climate and that might act during gestation or 
shortly after birth. 12 We examined month of birth and 
risk of multiple sclerosis in Australia.We used the large 
regional and seasonal variation in ambient ultraviolet 
radiation across the continent to investigate the asso-
ciation between exposure to ambient ultraviolet radia-
tion during pregnancy and risk of multiple sclerosis 
among the offspring. 
METHODS 
Case ascertainment 
We obtained data on the number of patients with mul-
tiple sclerosis born in Australia for each birth month of 
every (birth) year, 1920-50, by sex and state of birth for 
Queensland, Western Australia, New South Wales 
Table 1 I Monthly averages of daily ambient ultraviolet radiation in minimum erythemal dose 
units*, 1996-2000, for capital cities of Australian sta es included in 1981 multiple sclerosis 
survey (data provided by H P Gies, personal communication) (capital city latitudes shown in 
decimal degrees in parentheses) 
Brisbane (Qld) Perth 0NA) Sydney (NSW) Adelaide (SA) Hobartt (Tas) 
(27.5° S) (31.9° S) (33.9° S) (34.9° S) (42.9° S) 
January 24.7 30.4 22.2 28.1 20.4 
February 22.3 27.9 21.7 24.5 18.6 
March 19.0 18.9 16.2 13.7 12.4 
April 12.5 11.8 9.8 9.4 6.5 
May 8.6 7.1 5.6 5.2 3.7 
June 6.6 4.9 3.9 3.6 1.7 
July 7.5 5.4 4.1 3.7 1.6 
August 10.4 7.9 6.9 6.3 3.9 
-
-
-
September 14.6 12.1 10.4 10.0 7.0 
October 18.9 18.8 15.3 15.5 12.0 
November 22.7 23.8 19.1 21.5 15.7 
December 24.4 29.2 21.9 26.1 18.1 
Seasonal variation:j: 
Max:min 3.7 6.2 5.7 7.8 12.8 
*Minimum erythemal dose is measure of ultraviolet radiation exposure required to induce erythema or 
sunburn .28 
t1991 data.28 
:j:Seasonal variation as given by ratio of summer maximum to winter minimum ultraviolet rad iation . 
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(including Australian Capital Territory), South Austra-
lia, and Hobart (Tasmania) from prevalence surveys 
carried out in 1981.22526 In these surveys, cases were 
ascertained from hospital records, treating doctors, 
multiple sclerosis societies, records from the Depart-
ment of Veterans' Affairs, and the Australian Bureau of 
Statistics.2 In the Hobart region the State Chronic Care 
Hospital Register and Commonwealth Department of 
H ealth notifications were also used.26 All patients were 
interviewed and examined for verification of multiple 
sclerosis, except in New South Wales, where only 57% 
of the patients were interviewed and examined 
because of the large number of patients notified. 
Almost all of the remaining patients had been exam-
ined previously by a neurologist. 2 All patients in whom 
the diagnosis of multiple sclerosis was considered to be 
correct were classified clinically according to the diag-
nostic criteria of Rose et al. 27 
Analysis dataset 
We constructed a longitudinal dataset in frequency ( or 
count) format, spanning every (birth) month of every 
year over the chosen study period, 1920-50, from the 
original unit record cross sectional 1981 survey data. 
The constru_cted dataset comprised numerator data 
taken directly from the surveyed cases of multiple 
sclerosis in 1981, 2 together with reference population 
denominators (n=2 468 779) derived from the 1981 
Australian census (giving the number of people still 
alive and living in Australia in 1981 by year of birth 
and the proportion who were born in Australia) and 
supplementary data on 1920-50 births registered in 
Australia by month, year, and state provided by the 
Australian Bureau of Statistics. We adjusted denomi-
nators to account for the main sampling losses from 
surveyed to unsurveyed state regions between the 
time of birth and time of survey ( 1981 ). A restricted 
dataset of those people with multiple sclerosis born in 
Australia between 1920 and 1950 (inclusive) was cho-
sen to minimise problems arising from differential sur-
vival (for those born before 1920) or age of onset (for 
those born after 1950) from use of the whole year of 
birth range ( 189 7-1969) in the original cross sectional 
dataset. The resulting dataset of adjusted rates of multi-
ple sclerosis comprised numerator and denominator 
data by month and by year for 1524 people with multi-
ple sclerosis born in any of the five surveyed states dur-
ing this 1920-50 period. 
We generated a variable for exposure to ambient 
ultraviolet radiation at birth from monthly averages 
of daily total ambient effective ultraviolet radiation 
for each region ( table 1). 
Statistical analysis 
Our main outcome measure was the number of people 
with multiple sclerosis born in each month relative to 
the general population, expressed as a cumulative inci-
dence rate of multiple sclerosis. 
We used negative binomial regression models to 
provide an estimate of the incidence rate for each 
month of birth, expressed as an incidence rate ratio 
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for each time period relative to a single reference per-
iod. Because of the small case numbers for the month 
of birth analysis, we collapsed months into two 
monthly periods (fig 1) . May:June was the reference 
period because the average ambient ultraviolet radia-
tion was generally lowest then. 
To examine the associations between levels of ambi-
ent ultraviolet radiation and multiple sclerosis, we 
modelled ambient ultraviolet radiation as a continuous 
variable against incidence of multiple sclerosis. 
Monthly averages were lagged a number of months 
so that they then expressed the ambient ultraviolet 
radiation pertaining to a particular length of time 
before birth for each individual and for each region 
of birth. Nine such (continuous) variables, represent-
ing one to nine months before the birth month of an 
individual, were generated and included in separate 
negative binomial regression models (see table 2), as 
previously done for the categorical variable for period 
of birth. We thus assessed different gestational periods, 
in terms of the associated month and region specific 
levels of ultraviolet radiation, in relation to risk of mul-
tiple sclerosis. P values assessing effect modification 
were derived from likelihood ratio tests of nested 
regression models with and without the relevant inter-
action term. Analyses were conducted with Stata 8.0. 
RESULTS 
There was a large variation in average total daily ambi-
ent ultraviolet radiation, from 1.6 minimum erythemal 
dose units/ day in Hobart, Tasmania in July to 30.4 
units/ day in Perth, Western Australia in January. 
Overall, the seasonal variation in total daily ambient 
ultraviolet radiation increased with increasing latitude 
from Brisbane, Queensland at lowest south latitude to 
Hobart, Tasmania at highest latitude (table 1). 
For year of birth from 1920 to 1950, we identified 
1524 cases in the prevalence study from a denominator 
population of 2 468 779. As expected from the pre-
vious Australian surveys,2 the incidence rate of multi-
ple sclerosis was higher among women than men 
(incidence rate ratio 2.28, 95% confidence interval 
2.03 to 2.55). There was also a latitudinal gradient in 
cumulative incidence rate by region of birth. 
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Fig 11 Risk of multiple sclerosis for each two month period of 
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southern hemisphere mid-winter and mid-summer, 
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Compared with the reference birth region, New 
South Wales/ Australian Capital Territory, the risk 
was lower for those born in Queensland (0.59, 0.51 to 
0.69) and higher for those born in Tasmania (2. 70, 2.06 
to 3.51). The capital cities of these northernmost and 
southernmost states are located at 27 .5° south and 42.9° 
south, respectively (table 1). 
Figure 1 shows the pattern of risk for multiple sclero-
sis for each two month period of birth, expressed as an 
incidence rate ratio for each period of birth relative to 
the reference incidence rate ratio ( 1.0) for May:June. 
The risk was 1.23-fold to 1.34-fold higher (P<0.05) 
for people born in all periods other than May:June; 
the highest magnitude of risk was for those born in 
the early summer months of November-December 
compared with the early winter months of May:June 
(1.34, 1.10 to 1.63; P<0.01 ). This pattern of month of 
birth persisted after adjustment for sex, age, and region 
of birth in Australia (1.32, 1.10 to 1.58; P<0.01, for 
November-December compared with May:June). We 
also examined whether the November-December to 
May:June risk ratio differed by region of birth; this 
ratio of around 1.3 was the same over the Queens-
land-Tasmania range, with no effect modification by 
region of birth (P=0.25). 
We then examined the role of prenatal exposure to 
ambient ultraviolet radiation. We found no association 
between daily ambient ultraviolet radiation at the time 
of birth and subsequent risk of multiple sclerosis 
(table 2). Similarly, lags of one to four months before 
birth (late second to third trimesters) were not infor-
mative. For lags of five to nine months (first to early 
second trimesters), however, there were inverse asso-
ciations between prenatal ambient ultraviolet radiation 
levels and multiple sclerosis (unadjusted incidence rate 
ratio ranging from 0.74 (0.63 to 0.85) to 0.81 (0.70 to 
0.94); P<0.01 ). Table 2 summarises these results and 
shows a strong inverse association for the first trimester 
(0. 72, 0.62 to 0.84), P<0.001 ). 
We examined the shape of the association between 
inversed first trimester exposure and risk of multiple 
sclerosis in greater detail by using six categories of 
ultraviolet radiation (in minimum erythemal dose 
units/ day, see table 1) and comparing each of the five 
lowest levels with the highest (table 3). The association 
was non-linear with a particular increase in risk for 
levels below a monthly average of 20 minimum erythe-
mal dose units/ day (fig 2). This "threshold" level is 
reached only in January in Hobart, Tasmania, but 
from ovember to February in Brisbane, Queensland. 
Table 3 also shows the increase in risk for women 
and people born at higher latitudes; the result for dec-
ade of birth, showing a deficit in more recently born 
affected people, probably reflects ascertainment 
because for some in this group onset of multiple sclero-
sis might not have occurred b the time of the 1981 
survey. The association between first trimester ultra-
violet radiation and multiple sclerosis persisted, how-
ever, after adjustment for region of birth and the other 
factors listed in table 3. 
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Table 21 Risk of multiple sclerosis as unadjusted and adjusted incidence rate ratio for 
ambient ultraviolet radiation at and before time of birth 
Ambient Unadjusted Adjustedt 
ultraviolet 
radiation* Rat io (95% Cl) P value Ratio (95% Cl) P value 
At birth 1.01 (0.87 to 1.17) 0.906 1.01 (0.88 to 1.16) 0.851 
Time before birth (months): 
1 1.03 (0.89 to 1.19) 0.706 1.03 (0.90 to 1.19) 0.630 
2 1.00 (0.86 to 1.16) 0.991 1.01 (0.88 to 1.16) 0.894 
3 0.94 (0.81 to 1.10) 0.448 0.96 (0.83 to 1.1 O) 0.525 
4 0.88 (0.76 to 1.02) 0.100 0.89 (0. 78 to 1.03) 0.117 
5 0.81 (0.70 to 0.94) 0.007 0.83 (0.72 to 0.95) 0.007 
6 0.77 (0.67 to 0.90) 0.001 0.78 (0.68 to 0.90) 0.001 
7 0.74 (0.63 to 0.85) <0.001 0.75 (0.65 to 0.86) <0.001 
8 0.74 (0.63 to 0.85) <0.001 0.75 (0.65 to 0.86) <0.001 
9 0.79 (0.68 to 0.92) 0.002 0.80 (0.70 to 0.92) 0.002 
First trimester 0.72 (0.62 to 0.84) <0.001 0.73 (0.63 to 0.84) <0.001 
* Based on composite month and region specific values for each individual (see table 1) and expressed in units 
of 20 minimum erythemal dose units/day to gain meaningful incidence rate ratio in terms of difference in 
minimum erythemal dose between summer and winter (20 minimum erythemal dose units / day is approximate 
average difference between summer and winter ultraviolet radiation levels for Australian state regions, table 1). 
First trimester ultraviolet rad iat ion variab le obta ined by averaging monthly values for seven and eight months 
before birth, for ea ch region . 
tAdjusted for age (year of birth) and sex. 
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We examined the association between prenatal 
exposure to ultraviolet radiation and risk of multiple 
sclerosis related to month of birth. Figure 3 shows the 
inverse relation between first trimester ultraviolet 
radiation and risk related to months of birth. That is, 
when we lagged the ultraviolet radiation values by 
seven to eight months, there was overall similarity 
between the two curves, such that inf ants experiencing 
low levels of ultraviolet radiation in the first trimester 
are associated with a higher risk of multiple sclerosis by 
birth month. 
After adjustment for ultraviolet radiation in the first 
trimester, we found no residual association between 
period of birth and risk of multiple sclerosis. That is , 
once we accounted for first trimester ultraviolet radia-
tion (as in table 3) there was no improvement in model 
fit by also including variation in period of birth (like-
lihood ratio x2 (5 dn =3. 79; P=0.58). In contrast, region 
of birth remained significantly associated with risk of 
multiple sclerosis even after adjustment for ultraviolet 
radiation in the first trimester (table 3). 
There was no effect modification of the association 
between ultraviolet radiation in the first trimester and 
multiple sclerosis by sex (P=0. 71 ) or region of birth 
(P=0.80). 
DISCUSSION 
In the southern hemisphere there is a relative excess of 
multiple sclerosis in people born in ovember-
December compared with the Mayjune reference 
minimum. This pattern is consistent with the pattern 
reported by Willer et al in their larger study in the 
northern hemisphere, 12 given that the seasons are 
reversed. Our results show a trough in multiple sclero-
sis in people born in Mayjune, when a protective 
effect is evident, compared with a peak in those born 
in November-December, thus mirroring the northern 
hemisphere pattern of a peak associated with May 
births and a deficit associated with November births. 
We found no interaction between this pattern and 
region of birth within Australia, nor with sex or decade 
of birth; this was also consistent with findings of Willer 
et al for region of ascertainment, sex, and decade of 
birth in Canada. 12 
The higher risk of multiple sclerosis for people born 
in November-December is consistent with these 
infants having experienced lower levels of ultraviolet 
radiation during the first trimester. In fact, the pattern 
of month of birth in the southern hemisphere was 
accounted for by the month and region specific ambi-
ent ultraviolet radiation during the first trimester- that 
is, the effect of month of birth did not persist after 
adjustment for first trimester ultraviolet radiation. 
Lower average daily levels of ambient ultraviolet 
radiation during the first trimester predicted a higher 
subsequent risk of multiple sclerosis independently of 
month of birth. This association was non-linear, with a 
particular increase in risk under the (monthly average) 
level of 20 units of minimum erythemal dose of daily 
ambient ultraviolet radiation. We have thus shown an 
inverse assoc;:iation between low ultraviolet radiation in 
the first trimester and increased risk of multiple sclero-
sis in the offspring. 
Strengths and weaknesses 
In this longitudinal study we used a prospective expo-
sure-prenatal ambient ultraviolet radiation- the 
levels of which were heterogeneously distributed 
among the study participants because of the large var-
iation in ultraviolet radiation linked to month and 
region of birth across Australia. A further strength is 
the standardised case ascertainment of multiple sclero-
sis from the national study in 1981, 2 even though this 
study was smaller than the extensive northern hemi-
sphere analysis by Willer et al 12 because of the much 
smaller population in Australia. 
We could not examine the vitamin D status of the 
fetus directly but instead chose the ambient ultraviolet 
radiation level experienced by the mother during 
gestation. This proxy has some limitations in that it 
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Fig 21 Risk of multiple sclerosis by average level of daily 
ambient ultraviolet radiation during first trimester. Incidence 
rate ratio adjusted for age (year of birth) and sex 
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Table 3 I Risk of multiple sclerosis as incidence rate ratio for six levels of ambient ultraviolet 
radiation during first trimester, with and without other factors 
Unadjusted Adjusted* 
Factor Rat io (95% Cl) P value Ratio (95% Cl) P value 
Ambient ultraviolet radiation exposure in first trimestert (minimum erythemal doses/day): 
~25 1.00 (reference) 1.00 (reference) 
20-<2 5 1.35 (0.97 to 1.87) 0.071 1.54 (1.10 to 2.16) 0.013 
15-<20 1.58 (1.14 to 2.20) 0.007 1.58 (1.12 to 2.22) 0.009 
10-<15 1.58 (1.13 to 2.20) 0.008 1.65 (1.17 to 2.33) 0.004 
5-<10 1.62 (1.17 to 2.23) 0.004 1.65 (1.18 to 2.29) 0.003 
<5 1.90 (1.35 to 2.67) <0.001 1.67 (1.18 to 2.37) 0.004 
Sex: 
Men 1.00 (reference) 1.00 (reference) 
Women 2.28 (2.03 to 2.55) <0.001 2.27 (2.03 to 2.53) <0.001 
Region of birth (latitude of capital city, degrees south): 
Queensland (27 .5°) 0.59 (0.51 to 0.69) <0 .001 
0.005 
0.60 (0.52 to 0.70) 
0.8 5 (0.70 to 1.04) 
1.00 (reference) 
<0.001 
0.113 Western Australia (31.9°) 
New South Wales/Australian 
Capital Territory (33 .9°) 
South Australia (34 .9°) 
Tasmania (42.9°) 
Decade of birth: 
1920-29 
1930-40 
1941 -50 
0.76 (0.62 to 0.92) 
1.00 (reference) 
1.03 (0.88 to 1.21) 
2.70 (2.06 to 3.51) 
1.09 (0.95 to 1.24) 
1.00 (reference) 
0.73 (0.64 to 0.83) 
0.723 
<0.001 
0.222 
<0.001 
1.10 (0.94 to 1.29) 
2.71 (2.08 to 3.52) 
1.06 (0.94 to 1.20) 
1.00 (reference) 
0.73 (0.64 to 0.82) 
0.237 
<0.001 
0.346 
<0.001 
*Adjusted for all other factors in mu ltivariate model-for example, ultraviolet radiat ion in first trimester adjusted 
for sex, region of birth, and decade of birth . 
tAmbient ultraviolet radiat ion in first trimester based on compos ite month and region spec ific values for each 
ind ividual (see table 1) . 
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does not take into account individual personal 
behaviour, concurrent dietary vitamin D intake, or 
skin pigmentation. These omissions, however, would 
probably obscure rather than create the patterns 
observed. Recent work by Sayers et al also indicates 
that ambient erythemal ultraviolet radiation levels dur-
ing pregnancy, even in a single location, can be used to 
indicate vitamin D status.29 Further work could con-
firm the timing of the observed effect of prenatal ultra-
violet radiation. 
Other considerations 
Prenatal exposure to ambient ultraviolet radiation dur-
ing the first trimester was probably not just a marker for 
postnatal exposure because the association had tem-
poral specificity and was not evident for exposure at 
the time of birth. Furthermore, the association was inde-
pendent of region of birth, a probable marker for post-
natal sun exposure correlated with long term residence. 
Here, and in the larger northern hemisphere 
analysis, 12 the pattern of month of birth was not 
smoothly sinusoidal but had a few months of particu-
larly altered risk of multiple sclerosis. This would sup-
port an underlying seasonal factor that was not altering 
smoothly throughout the year but was more evident in 
particular months or was a threshold biological effect 
of a continuous variable. Consistent with this, when we 
examined different levels of prenatal exposure to ultra-
violet radiation in the first trimester, we clearly 
observed that risk was specifically incr ased in the 
RESEARCH 
lower levels of exposure, below a monthly average of 
20 minimum erythemal dose units a day. We could 
not, however, control for other factors such as nutrition 
or physical activity that could be associated with pre-
natal exposure to ultraviolet radiation in the first trime-
ster and that could also determine risk of multiple 
sclerosis. In this setting, there is strong a priori evi-
dence that sun exposure or vitamin D, or both, is likely 
to be the central exposure6 and little a priori evidence 
for any other strong determinant of multiple sclerosis 
likely to be linked to maternal ambient ultraviolet 
radiation exposure during the first trimester. 
Maternal exposure and health of offspring 
This report adds to other work showing that maternal 
exposure to ambient ultraviolet radiation during preg-
nancy might influence subsequent health in the 
offspring.30-33 In a New Zealand birth cohort, infants 
whose mothers were exposed to peak sunshine during 
the first trimester were significantly heavier at birth 
than infants whose mothers experienced trough levels 
of sunshine during the same trimester.30 In the United 
Kingdom, maternal ambient ultraviolet B exposure in 
the third trimester has been positively related to bone 
mineral densi_ty and content at age 9 in offspring.34 
There is now growing interest in the role of maternal 
vitamin D deficiency in pregnancy and the develop-
ment of central nervous system and immune disorders, 
particularly schizophrenia, 33 type 1 diabetes, and other 
disorders.35 Although active vitamin D3 concentra-
tions in the mother increase substantially during preg-
nancy, early fetal supplies are lower36 and directly 
dependent on the mother. By the time of delivery, 
maternal and infant cord serum 25-hydroxyvitamin 
D3 concentrations are highly correlated.37 Unfortu-
nately, much remains unknown, leading to large inter-
national variations in maternal vitamin D monitoring 
and supplementation during pregnancy.353839 
A maternal effect operating antenatally would also 
be consistent with the stronger maternal than paternal 
"parent of origin" effect in familial multiple sclero 
sis. 1340 It has been previously proposed 14 that maternal 
vitamin D deficiency, a problem for some dark skinned 
women migrating to regions with low ambient ultra-
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WHAT IS ALREADY KNOWN ON THIS TOPIC 
In the northern hemisphere, there are more cases of multiple sclerosis in people born in May 
and fewer in those born in November 
Maternal exposure to ambient ultraviolet radiation in pregnancy can be used as an 
instrumental variable for vitamin D status during pregnancy 
Low vitamin D concentrations have been associated with a higher risk of multiple sclerosis 
WHAT THIS STUDY ADDS 
In Australia there is a reciprocal pattern of month of birth and risk of multiple sclerosis, with a 
higher risk for those born in November-December compared with May-June 
This pattern was accounted for by maternal exposure to ambient ultraviolet radiation in the 
first trimester 
Low maternal exposure to ultraviolet radiation in the first trimester was inversely related to 
risk of multiple sclerosis in the offspring after adjustment for either month of birth or place of 
birth 
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violet radiation, such as the UK, might explain the 
increase in incidence of disease seen among second 
generation migrants in such locations.41 Our findings 
are consistent with this explanation. Because season of 
birth has previously also been related to the clinical 
course of multiple sclerosis,42·44 it is possible that 
early life exposures determine not only onset of disease 
but also resistance to the demyelinating process of mul-
tiple sclerosis. The mechanisms involved could 
include neurological or immunological factors . Ultra-
violet radiation exposure during the first trimester 
would be expected to specifically influence vitamin D 
concentrations up to early in the second trimester, 
given that vitamin D has a half life of one to two 
months. 45 In recent Australian work, higher levels of 
ambient ultraviolet radiation were associated with 
higher vitamin D concentrations at the population 
level with a lag of one and a half months. 46 
Possible mechanisms 
First trimester vitamin D concentrations might be par-
ticularly important in the development of the central 
nervous system because during early embryonic 
development, vitamin D receptors are expressed in 
the neuroepithelium and later in the subventricular 
zone. 15 Myelination occurs later; even in mid-gestation 
( 19-24 weeks) cortical axonal tracts are not yet 
myelinated,47 with major myelination of several areas 
occurring as late as 29-39 weeks.48 In addition, the in 
utero development of immune central tolerance occurs 
in the first trimester and vitamin D has immunomodu-
lating properties. The first trimester is also a sensitive 
period with regard to prenatal thymocyte differentia-
tion, with animal studies showing that chemicals such 
as dioxin can alter this process, disrupt the develop-
ment of central tolerance, and lead to increased auto-
reactive peripheral T cells. 49 Furthermore, indirect 
effects of vitamin D should be considered. For exam-
ple, vitamin D can down-regulate interleukin 6, an 
important mediator of the adverse effect of maternal 
infection during pregnancy on neural development in 
the fetus. 50·52 
Prenatal and postnatal timing 
Our results do not indicate that the possible beneficial 
effect of ultraviolet radiation exposure is confined only 
to the prenatal period. The finding that both first trime-
ster ultraviolet radiation and region of birth were inde-
pendent predictors of risk of multiple sclerosis is 
consistent with birth region also acting as an indicator 
of postnatal exposure to ultraviolet radiation. Overall, 
epidemiological studies support a protective role for 
vitamin D in autoimmune disease, particularly in 
childhood and adolescence, and vitamin D supple-
mentation in early adulthood effectively reduces the 
risk of multiple sclerosis; therefore, supplementation 
of adolescents and young adults could be effectively 
used for prevention. 6 The findings here provide the 
first population based evidence beyond month of 
birth patterns to indicate that vitamin D supplementa-
tion for the prevention of multiple sclerosis might also 
need to be considered during in utero development. 1•1 
They are consistent with a multi-hit causal cascade for 
multiple sclerosis, with putative adverse environmen-
tal factors, such as low vitamin D concentrations, act-
ing at more than one stage of life. 53 
We gratefully acknowledge the assistance of J G McLeod, S R Hammond, 
and P Macaskill in providing case data and advice on the conduct of the 
origina l 1981 national multiple sclerosis survey. H P Gies, Australian 
Radiation Protection and Nuclear Safety Agency (ARPANSA). kindly 
provided the regional ultraviolet rad iation data for the Australian State 
capital cities for 1996-2000. We also thank A J McMichael and J G McLeod 
for their comments on the manuscript and H Raschella and A Pezic for 
literature review and manuscript preparation. 
Contributors: All authors were involved in the study design and analysis, 
participated in the preparation and writing of the manuscript, and 
approved the final version. JS is guarantor. 
Funding: The research was supported by an Austral ian National 
University (ANU) Graduate School scholarship and a supplementary 
scholarship from the National Centre for Ep1dem1ology and Popu lation 
Health, ANU, awarded to JS. 
Competing interests: All authors have completed the Unified Competing 
Interest form at www.icmje org/coi_d1sclosure.pdf (ava ilable on request 
from the correspond ing author) and declare that (1) JS, ALP, LL have no 
relationships with companies that might have an interest in the subm itted 
work in the previous 3 years; (3) their spouses, partners, or ch ildren have 
no financial relationsh ips that may be re levant to the submitted work; and 
(4) JS, ALP, LL have no non-financial interests that may be re levant o he 
submitted work. 
Ethical approva~ This study was approved by the human research eth ics 
committee, Austra lian National University 
Data sharing: No add1t1onal data avai lable. 
1 Dean G. Annual incidence, prevalence, and mortality of multiple 
sclerosis in white South-African -born and in white immigrants to 
South Africa. BM} 1967;ii :724-30. 
2 McLeod JG, Hammond SR, Hallpike JF. Ep idemiology of multiple 
sclerosis in Australia . With NSW and SA survey results. Med J Aust 
1994;160:117-22. 
3 Alter M. Epidemiology of multiple sclerosis in Israel. In: Alter M, 
Kurtzke JF, eds. The epidemiology of multiple sclerosis. Charles 
C Thomas, 1968:83-109. 
4 Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple 
sclerosis in US veterans: Ill. Migration and the risk of MS. Neurology 
1985;35:672-8. 
5 Hammond SR, English DR, McLeod JG. The age-range of risk of 
developing multiple sclerosis: evidence from a migrant population in 
Australia . Brain 2000;123:968-74. 
6 Ascherio A, Munger K. Epidemiology of multip le sclerosis: from risk 
factors to prevention. Semin Neurol 2008;28:17-28. 
7 Van der Mei IA, Pon son by AL, Dwyer T, Blizzard L, Simmons R, 
Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of 
multiple sclerosis: case-control study. BM} 2003;327:316. 
BMJ I ONLINE FIRST I bmj.com 
MJ I ONLINE FIRST I bmj.com 
8 Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, 
et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 
2004;62:60-5. 
9 Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-
hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 
2006;296:2832 -8. 
10 Islam T, Gauderman WJ, Cozen W, Mack TM. Child hood sun exposure 
influences risk of multiple sclerosis in monozygotic twins. Neurology 
2007;69:381 -8. 
11 Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in 
childhood and adolescence relate to MS risk above the Arctic Circle. / 
Neurol 2007;254:471-7. 
12 Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, 
Ebers GC. Timing of birth and risk of multiple sclerosis: population 
based study. BM} 2005;330:120. 
13 Ebers GC, Sadovnick AD, Dyment DA, Yee IML, Willer CJ, Risch N. 
Parent of origin effect in multiple sclerosis: observations in half 
siblings. Lancet 2004;363:1773-4. 
14 Chaudhuri A. Why we should offer routine vitamin D 
supplementation in pregnancy and childhood to prevent multiple 
sclerosis. Med Hypotheses 2005;64:608-18. 
15 Wion D, MacGrogan D, Neveu I, Jehan F, Houlgatte R, Brach et P. 1,25-
Dihydroxyvitamin 03 is a potent inducer of nerve growth factor 
synthesis./ Neurosci Res 1991 ;28:110-4. 
16 Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New 
clues about vitamin D functions in the nervous system. Trends 
Endocrinol Metab 2002;13:100-5. 
17 Cui X, McGrath JJ, Burne TH, Mackay-Sim A, Eyles OW. Maternal 
vitamin D depletion alters neurogenesis in the developing rat brain. 
Int} Dev Neurosci 2007;25:227-32. 
18 Eyles D, Almeras L, Benech P, Patatian A, Mackay-Sim A, McGrath J, 
et al. Developmental vitamin D deficiency alters the expression of 
genes encoding mitochondrial, cytoskeletal and synaptic proteins in 
the adult rat brain./ Steroid Biochem Mo/ Biol 2007;103:538-45. 
19 Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton S-
M, Dyment DA, et al. Expression of the multiple sclerosis-associated 
MHC class II allele HLA-DRB1 *1501 is regulated by vitamin D. PLoS 
Genet 2009;5:e1000369. 
20 Templer DI, Trent NH, Spencer DA, Trent A, Corgiat MD, 
Mortensen PB, et al. Season of birth in multiple sclerosis.Acta Neural 
Scand 1992;85:107-9. 
21 Wiberg M. Season of birth in multiple sclerosis in Sweden: 
replication of Denmark findings./ Orthomol Med 1994;9: 71-4. 
22 Sadovnick AD, Yee IM. Season of birth in multiple sclerosis. Acta 
Neural Scand 1994;89:190-1. 
23 Salemi G, Ragonese P, Arid on P, Reggio A, Nicoletti A, Buffa D, et al. ls 
season of birth associated with multiple sclerosis? Ada Neural 
Scand 2000;101:381-3. 
24 Torrey EF, Miller J, Rawlings R, Yolken RH. Seasonal birth patterns of 
neurological disorders. Neuroepidemiology 2000; 19:177-85. 
25 Hammond SR, de Wytt C, Maxwell IC, Landy PJ, English D, McLeod JG, 
et al. The epidemiology of multiple sclerosis in Queensland, 
Australia./ Neural Sci 1987;80:185-204. 
26 Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, 
English D, Holland JT, et al. The epidemiology of multiple sclerosis in 
three Australian cities: Perth, Newcastle and Hobart. Brain 
1988;111 :1 -25 . 
27 Rose AS, Ellison GW, Myers LW, Tourtellotte WW. Criteria for the 
clinical diagnosis of multiple sclerosis. Neurology 1976;26:20-2. 
28 Gies HP, Roy CR, Toomey S, Tomlinson D. The ARL solar UVR 
measurement network: calibration and results. SPIE 
1994;2282:274-284. 
29 Sayers A, Tilling K, Boucher BJ, Noonan K, Tobias JH. Predicting 
ambient ultraviolet from routine meteorological data; its potential 
use as an instrumental variable for vitamin D status in pregnancy in a 
longitudinal birth cohort in the UK. Int} Epidemiol 2009;38:1681-8. 
30 Tustin K, Gross J, Hayne H. Maternal exposure to first-trimester 
sunshine is associated with increased birth weight in human infants. 
Dev Psychobio/ 2004;45:221-30. 
RESEARCH 
31 Eyles OW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of 
the vitamin D receptor and 1 alpha-hydroxylase in human brain./ 
Chem Neuroanat 2005;29:21-30. 
32 Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F. Vitamin 03 and 
brain development. Neuroscience 2003; 118:641 -53 . 
33 McGrath JJ, Feron FP, Burne TH, Mackay-Sim A, Eyles OW. Vitamin 03-
implications for brain development./ Steroid Biochem Mo/ Biol 
2004;89-90:557-60. 
34 Java id MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, 
et al. Maternal vitamin D status during pregnancy and childhood 
bone mass at age 9 years: a longitudinal study. Lancet 
2006;367:36-43. 
3 5 Lucas RM, Ponsonby AL, Pasco JA, Morley R. Future health 
implications of prenatal and early-life vitamin D status. Nutr Rev 
2008;66:710-20. 
36 Delvin EE, Glorieux FH, Salle BL, David L, Varenne JP. Control of 
vitamin D metabolism in preterm infants: feta-maternal 
relationships. Arch Dis Child 1982;57:754-7. 
3 7 Maghbooli Z, Hossein-Nezhad A, Shafaei AR, Karimi F, Madani FS, 
Larijani B. Vitamin D status in mothers and their newborns in Iran. 
BMC Pregnancy Childbirth 2007;7:1. 
38 Munns C, Zacharin MR, Rodda CP, Batch JA, Morley R, Cranswick NE, 
et al. Prevention and treatment of infant and childhood vitamin D 
deficiency in Australia and New Zealand: a consensus statement. 
Med J Aust 2006;185:268-72. 
39 Vitamin D supplementation: recommendations for Canadian 
mothers and infants. Paediatr Child Health 2007;12:583-98. 
40 Herrera BM, Ramagopalan SV, Lincoln MR, Orton SM, Chao MJ, 
Sadovnick AD, et al. Parent-of-origin effects in multiple sclerosis: 
observations from avuncular pairs. Neurology 2008;71:799-803. 
41 Datta S, Alfaham M, Davies DP, Dunstan F, Woodhead S, Evans J, 
et al. Vitamin D deficiency in pregnant women from a non-European 
ethnic minority population-an interventional study. BJOG 
2002;109:905-8. 
42 Tremlett HL, Devonshire VA. Does the season or month of birth 
influence disease progression in multiple sclerosis? 
Neuroepidemiology 2006;26:195-8. 
43 Koch M, De Keyser J, Tremlett H. Timing of birth and disease 
progression in multiple sclerosis. Mutt Seier 2008;14:793-8. 
44 Sadovnick AD, Duquette P, Herrera B, Yee IM, Ebe rs GC. A timing-of-
birth effect on multiple sclerosis clinical phenotype. Neurology 
2007;69:60-2. 
45 Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D 
concentrations, and safety. Am J Clin Nutr 1999;69:842 -56. 
46 Tremlett H, van der Mei IA, Pittas F, Blizzard L, Paley G, Mesaros D, 
et al. Monthly ambient sunlight, infections and relapse rates in 
multiple sclerosis. Neuroepidemiology 2008;31:271-9. 
47 Jakovcevski I, Mo Z, Zecevic N. Down-regulation of the axonal 
polysialic acid-neural cell adhesion molecule expression coincides 
with the onset of myelination in the human fetal forebrain. 
Neuroscience 2007;149:328-37. 
48 Abe S, Takagi K, Yamamoto T, Okuhata Y, Kato T. Semiquantitative 
assessment of myelination using magnetic resonance imaging in 
normal fetal brains. Prenat Diagn 2004;24:352-7. 
49 Goga I RM Jr, Holladay SD. Perinatal TCDD exposure and the adult 
onset of autoimmune disease./ lmmunotoxico/ 2008; 5:413-8. 
SO Meyer U, Yee BK, Feld on J. The neurodevelopmental impact of 
prenatal infections at different times of pregnancy: the earlier the 
worse? Neuroscientist 2007; 13:241-56. 
51 Smith SE, Li J, Garbett K, Mimics K, Patterson PH. Maternal immune 
activation alters fetal brain development through interleukin-6. / 
Neurosci 2007;27:10695 -702. 
52 Correale J, Ysrraelit MC, Gaitan Ml. lmmunomodulatory effects of 
vitamin Din multiple sclerosis. Brain 2009;132:1146-60. 
53 Goodin OS. The causal cascade to multiple sclerosis: a model for 
multiple sclerosis pathogenesis. PLoS One 2009;4:e4565 . 
Accepted: 12 January 2010 
page 7 of 7 
